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Ten pa tients  w ith id io p a th ic  Parkinscn’ s disease (PD) (3 men and 7 women, group A) who 
had received no treatment fo r  the disease; 102 pa tien ts  w ith P0 (36 men and 66 women, group 8) 
who had undergone treatment and 45 healthy volunteers (15 men and 30 women, co n tro l group) were 
subject to  thy ro trop in-re leas ing  hormone (TRH) tes ts  and levodopa te s ts . In  group A basal 
plasma p ro la c tin  (PRL) leve ls  were s ig n if ic a n t ly  higher than in  the con tro ls  both before and 
during treatment. Peak plasma PRL leve ls  during TRH tes ts  were s ig n if ic a n t ly  h igher before 
treatment, but returned to the c o n tro l le ve ls  during treatment. Nadir plasma PRL le v e ls  during 
levodopa tes ts  were s ig n if ic a n t ly  increased before and during treatment. In  group В basal 
plasma thyro id -s tim u la ting  hormone (TSH) and PRL leve ls  were s ig n if ic a n t ly  h igher than 
in  the con tro l group. Peak plasma PRL leve ls  during TRH tes ts  and nad ir plasma PRL leve ls  
during levodopa tests were also s ig n if ic a n t ly  increased. The resu lts  s trong ly  suggest a 
disturbance o f p itu ita ry  hormone secretion due to  hypothalamic dysfunction in  PD pa tie n ts .
Keywords: Parkinson's disease, hypothalamus, TRH te s t, levodopa te s t
In t r o d u c t io n
Id iopathic Parkinson's disease (PD) is  a neuro-degenerative disease. 
I ts  princ ipa l c lin ic a l features are caused by dopaminergic d e f ic its  in  the 
n ig ro s tr ia ta l area. Besides, dopaminergic d e fic its  and morphological changes 
may occur in the hypothalamus /19, 23/, and reduction of noradrenaline /21, 
38/, serotonin /15, 38/, substance P /3 , 32, 41/ and somatostatin concentra­
tions /1 , 10/ in the brain have been reported in PD patients. Dopamine is
Abbreviations: PD: Parkinson's disease; TRH: thyro trop in-re leasing  hormone; PRL:
p ro la c tin ; TSH: thy ro id -s tim u la ting  hormone; GH: growth hormone; SD: standard devia tion
O ffp r in t requests should be sent to : Kozaburo Otake, Department o f In te rn a l Medicine, 
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one of the most notable neurotransmitters in  the hypothalamus, as i t  in h i­
b its  thyro id-stim ula ting  hormone (TSH) release /7 / ,  p ro lactin  (PRL) release 
/1 7 / and stimulates growth hormone (GH) release /6 / .  Since studies of 
the secretion of p itu ita ry  hormones in PD patients had produced incon­
s is te n t findings, we investigated the basal and stimulated plasma hormone 
leve ls  and the response pattern of TSH, PRL and GH to thyrotropin-releasing 
hormone (TRH) and levodopa in both untreated and treated PÜ patients to 
c la r i f y  hypothalamic dysfunction.
S u b jec ts
Ten patients w ith PD (3 men and 7 women, group A) who had received no treatment were 
examined tw ice, the f i r s t  tim e before treatment and the second time during each p a tie n t's  
p a r t ic u la r  levodopa treatment regimen. C lin ica l diagnosis o f PD was determined on the basis o f 
h is to ry ,  symptoms, neuro log ica l examination and b ra in  CT. The mean age in  group A was 
56.2+^7.18 years (mean ^s tanda rd  devia tion /SD /), and the mean Yahr score (an index ind ica ting  
s e v e rity  o f disease) was 1 .3 ^ 0 .5  (Table I ) .  A hundred and two patients w ith PD (36 men and 66 
women, group B) were examined during  each pa tie n t's  p a rt ic u la r  levodopa treatment regimen. The 
mean age o f the patients in  th is  group was 62.8^8.24 years, and the mean Yahr score was 2.8+^1.0. 
F o r ty - f iv e  contro l subjects (15 men and 30 women) were both neuro log ica lly  and endocrino- 
lo g ic a l ly  asymptomatic. The mean age o f the con tro l subjects was 58.4 _+ 4.75 years. Depression 
was ru le d  out fo r a l l  sub jects by means of the Hamilton Rating Scale fo r  Depression /25, 37/. 
Informed consent was obtained from a l l  subjects, and a l l  women in  th is  study were postmeno­
pausal.
Table I
C lin ic a l characte ris tics o f group A
No. Sex Age Severity of disease (Yahr)
Duration from 
onset ( in  years)
Total levodopa 
dose (gram)
1 M 52 I 0.7 25.2
2 F 65 I I 1.6 34.5
3 M 63 I I 1.2 29.1
4 F 42 I 0.5 18.3
5 M 58 I 0.8 38.4
6 F 61 I 0.9 21.6
7 F 59 I 0.7 28.8
8 F 54 I I 1.0 36.9
9 F 48 I 0.6 37.5
10 F 60 I 1.5 32.7
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Methods
The fo llow ing endocrinological te s ts  were performed.
A. TRH te s t : 500 ,ug synthetic TRH was administered by intravenous in je c tio n .
B. Levodopa te s t : 500 mg levodopa was administered o ra lly .
A l l  subjects underwent the tes ts  in  the morning a fte r  fas ting  overnight. Blood samples 
were drawn 30 min before administering TRH and levodopa, and a t 30 min in te rv a ls  the rea fte r 
fo r  2 h. Plasma was separated and stored a t -20 °C u n t i l  assayed. Two tes ts  were conducted not 
less than 4 days apart. Group A was tested before and during treatment (a t 15.2+^2.04 weeks) 
w ith a stable dosage o f levodopa combined w ith  benserazide. Group В was tested only once during 
treatment (a t 5.66+^4.14 years) w ith a stable dosage o f levodopa combined w ith  benserazide. 
Drugs fo r  treatment were la s t  taken in the evening before the te s ts . Delayed response o f plasma 
TSH during TRH tests  meant a TSH leve l less a t 30 min than a t 60 min /1 2 /. Paradoxical response 
o f plasma GH during TRH te s ts  was defined as d iffe rences > 5  ng/ml /27 /. Hyporesponse o f plasma 
GH during levodopa te s ts  was defined as d iffe rences < 5  ng/ml /3 3 /. Group В was subdivided ac­
cording to  severity o f disease (Yahr), duration from onset ( in  years) and to ta l levodopa 
dosage from in i t i a l  treatment ( in  grams). The se ve rity  o f PD was assessed according to  Hoehn 
and Yahr /1 6 /. Plasma TSH, PRL and GH le ve ls  were measured by commercially-available rad io ­
immunoassay k its  (Dainabot, lokyo, Japan). S ta t is t ic a l analysis was carried  out using the 
K ruska l-W allis  te s t.  Group data are presented as the mean+^SD, and P <  0.05 was considered to 
represent s ig n if ic a n t d iffe rence .
R e s u lts
Basal plasma TSH, PRL and GH levels
In group A the basal plasma TSH leve ls were s lig h tly  higher than 
those of the control group, while the basal plasma GH levels did not d if fe r  
appreciably from the control values. However, the basal plasma PRL levels 
were s ig n ific a n tly  increased before treatment. Elevated plasma PRL levels 
remained high during treatment. In group В the basal plasma TSH and PRL 
leve ls were s ig n if ic a n tly  higher than those of the controls (Table I I ) .
TRH test
In group A, delayed response of plasma TSH during TRH tests was found 
in  40% of the patients before treatment and in  10% during treatment. Peak 
plasma PRL levels during TRH tests were s ig n if ic a n tly  higher before tre a t­
ment but returned to the control levels during treatment (F ig. 1). Para­
doxical response of plasma GH during TRH tests  was recognized in  40% of the 
patients before treatment and in  20% during treatment. In group В delayed 
response of plasma TSH during TRH tests was found in 28%. Peak plasma PRL 
leve ls during TRH tests were s ig n if ic a n tly  higher than those of the contro ls.
Table I I
ON
Basal and stimulated plasma hormone leve ls  and response patterns o f groups A, В and contro ls
Controls Group A Group A Group В
(n=45) (before treatment, n=10) (during treatment, n=10) (n=102)
TSH basal 1.15 + 0.48 1.93 + 1.26 1.2 + 0.77 3.14 + 1.49a
(pU/ml) peak 10.8 + 2.29 9.92 + 4.2 9 .4 7+  3.58 11.6 + 5.42
TRH te s t PRL
(ng/ml)
basal
peak
8.53 + 3.18 
64.4 +13.1
21.8 + 7.85a 
109 + 33.2a
17.3 + 9.2a 
66.5 + 25 .4b
18.2 + 5.19a 
81.5 + 3 0 .4 a
GH basal 1.17 + 0.6 0.96 + 0.81 1.16 + 0.73 0.91 + 0.62
(ng/ml) peak 1.84 + 0.68 4.25 + 3.46 3.82 + 3.19 4.8 + 3.27a
PRL basal 9.22 + 2.58 22.5 + 5.07a 18.5 + 5.54a 20.5 + 4.65a
Levodopa (ng/ml) nadir 3.62 + 1.11 10.4 + 2.38a 9 .68+  3.72a 9.65 + 2.23a
te s t GH basal 1.25 + 0.56 1.02 + 0.52 0.96 + 0.67 1.06 + 0.79
(ng/ml) peak 9.26 + 2.56 6.62 + 3.64 8.09 + 3.01 9 .6 4+  5.63
delayed
response o f TSH 0% 40% 10% 28%
TRH te s t
paradoxical 
response o f GH
0% 40% 20% 25%
Levodopa
te s t
hyporesponse 
o f GH
04 604 40% 38%
Data are expressed as mean +_ SD; aP< 0.05: s ig n ific a n t d iffe rence between con tro ls  and groups A or B; bP-< 0.05: s ig n if ic a n t d i f f e r ­
ence between group A before treatment and group A during treatment
OTAKE e
t a
l.
PRL (ng/ml)
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F ig. 1. E ffe c t o f TRH on plasma PRL leve ls  in  group A and con tro ls . Data are expressed as mean 
±  SD; xs ig n if ic a n t d iffe rence between group A before treatment and group A during treatm ent; 
P<  0.05 was considered to  represent s ig n if ic a n t difference
Paradoxical response of plasma GH during TRH tests was recognized in  25% of 
the patients (Table I I ) .
Levodopa test
In group A nadir plasma PRL levels during levodopa tests were s ig ­
n if ic a n tly  higher both before and during treatment. Hyporesponse of plasma 
GH during levodopa tests was recognized in 60% of the patients before tre a t­
ment and in  40% during treatment. In group В nadir plasma PRL leve ls during 
levodopa tests were s ig n if ic a n tly  higher. Hyporesponse of plasma GH during 
levodopa tests was recognized in  38% of the patients (Table I I ) .
Correlation between c lin ic a l findings and plasma hormone levels
No corre la tion  was found between severity  of disease (Yahr), duration 
from onset ( in  years) or to ta l levodopa dosage from in i t ia l  treatment ( in
8 К .  ОТАКЕ e t  a l .
grams) vs. the fo llow ing: basal TSH leve ls ; basal PRL leve ls; basal GH 
le v e ls ; peak TSH leve ls during TRH tests; peak PRL levels during TRH tes ts ; 
peak GH levels during TRH tes ts ; nadir PRL leve ls during levodopa tes ts ; 
and peak GH levels during levodopa tests.
D iscuss ion
We found that in group A basal plasma TSH levels before treatment 
were s lig h t ly  elevated, whereas peak plasma TSH levels during TRH tests 
were normal. Delayed response of plasma TSH during TRH tests was recog­
nized in  40% of the patients before treatment in  group A. I t  has been re­
ported /4 , 13, 31/ tha t, in  untreated PD pa tien ts , basal plasma TSH levels 
are normal, and peak plasma TSH levels during TRH tests are e ither normal or 
lower than those of contro ls . Our findings corresponded with these reports 
regarding basal plasma TSH levels and peak plasma TSH levels during TRH 
te s ts , but when analyzing the response pattern of plasma TSH during TRH 
te s ts , we often found delayed responses in  PD patients. We have fa ile d  to 
f in d  such observation mentioned in  previous report.
I t  is  widely known that a s lig h t e levation in  basal plasma TSH leve ls 
/3 6 / and delayed response of plasma TSH during TRH tests ind ica te  the 
existence of hypothalamic lesion, and that th is  delayed response exh ib its  
peak leve ls between 60 min and 120 min /12, 39/. The present data suggest 
tha t decreases in TRH secretion may ex is t in  PD patients, although the 
mechanism for th is  phenomenon remains unclear.
As mentioned above, dopamine, noradrenaline, serotonin, substance P 
and somatostatin concentrations in the brain are lowered in PD pa tien ts . 
Reportedly, dopamine e ithe r in h ib its  /20/ or stimulates the secretion o f TRH 
/18, 24, 28/; therefore, i t s  effects on TRH secretion remain con trovers ia l. 
However, the secretion of TRH is  stimulated by noradrenaline or serotonin 
/9 , 22/, inh ib ited  by substance P or somatostatin /34, 40/, and regulated by 
many other neurotransmitters. Accordingly, i t  should be considered that 
complex changes in concentrations of many neurotransmitters may be re­
sponsible fo r any reductions in TRH secretion in  PD patients.
We found that in  group A basal plasma PRL levels and peak plasma PRL 
leve ls  during TRH tests were s ig n ific a n tly  elevated before treatment. I t  
has been reported /2 , 8, 42/ tha t, in untreated PD patients, basal plasma 
PRL leve ls  are e ither normal or higher than in  the controls, and tha t peak
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plasma PRL leve ls  during TRH tests  are normal or lower than the control 
values. Our find ings did not coincide with those in other reports regarding 
basal plasma PRL levels and peak plasma PRL leve ls during TRH tes ts . The 
reason for these differences is  unclear. Perhaps, the other studies included 
too few controls or the contro ls were not properly matched to PD patients 
by age and/or sex. I t  should be noted that PRL levels can be influenced by 
age and/or sex. The differences may also be a ttribu ted  to the differences 
in the conditions of patients and controls.
I t  is  widely known that PRL levels are p rim arily  regulated by in h ib it ­
ing factors such as dopamine, and that the dopamine concentration in  the 
hypothalamus decreases in PD patients. I f  so, elevations in basal plasma PRL 
levels and enhanced PRL response during TRH tests may result e ither from 
deficiencies in PRL-inhibiting factor or increases in the s e n s it iv ity  of 
lactotroph to TRH. Since the plasma PRL leve ls remained s ig n ific a n tly  high 
during treatment, the present study suggests tha t, although levodopa therapy 
greatly a llev ia ted  c lin ic a l symptoms, levodopa therapy alone may not be 
su ffic ie n t in  sustaining these favourable resu lts  in  view of the reduction 
of many neurotransmitters in PD patients. I t  is  thus suggested that elevated 
basal plasma PRL levels and enhanced PRL response during TRH tests resu lt 
from dopamine deficiency.
We found that in group A basal plasma GH leve ls were normal; para­
doxical response of plasma GH during TRH tests was recognized in 40% of pa­
tie n ts ; and hyporesponse of plasma GH during levodopa tests was recognized 
in 60% of patients before treatment.
I t  has been reported /13, 42/ tha t, in  untreated PD patients, basal 
plasma GH leve ls , like  the peak plasma GH leve ls during levodopa tes ts , are 
both normal. Our findings were sim ilar to these reports regarding basal 
plasma GH leve ls and peak plasma GH levels during levodopa tests. In analyz­
ing the response patterns of plasma GH during TRH tests and levodopa tes ts , 
however, we often observed paradoxical response of plasma GH during TRH 
tests and hyporesponse of plasma GH during levodopa tests. Paradoxical re­
sponse of plasma GH during TRH tests has been recognized in cases of acro­
megaly /29 /, depression /2 6 /, anorexia nervosa /27 /, renal fa ilu re  /14 /, 
severe liv e r  disease /33 /, insulin-dependent diabetes m ellitus /5 / ,  hypo­
thalamic tumors and Huntington's chorea /3 0 /. However, PD cases showing 
th is  feature were mentioned in  none of the c ited  reports.
The mechanism of paradoxical response of plasma GH during TRH tests  is  
thought to involve either the dysfunction of membrane receptors in GH-
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producing ce lls  at the p itu ita ry  locus or an a lte ra tion  in  some peptides at 
the hypothalamic locus /1 1 /. Such a lte ra tions  at the hypothalamic locus 
caused by a reduction in  dopamine may also be considered. Reduced response 
of plasma GH during levodopa tests may be a resu lt of the deficiency of 
GH-releasing hormone. I t  is  well known tha t GH is  stimulated by dopamine, 
serotonin and arginine, and that elevation of plasma GH induced by dopamine 
is  mediated by stim ulating GH-releasing hormone. Moreover, studies on obese 
and aged subjects have shown decreased peak plasma GH levels during levodopa 
te s ts .
In our study, however, reduced response of plasma GH during levodopa 
te s ts  in  group A was unrelated to obesity or gge, fo r the patients were well 
matched to controls by age and none of the subjects was obese. On the other 
hand, because dopamine concentration in the hypothalamus decreases in  PD pa­
t ie n ts ,  i t  is  suggested tha t reduced response of plasma GH during levodopa 
tes ts  is  a resu lt of th is  dopamine deficiency. Hyporesponse of plasma GH 
during levodopa tests was s t i l l  recognized in  40% of patients during tre a t­
ment in  group A, ind ica ting  that hyporesponse of plasma GH during levodopa 
te s ts  does not completely improve in PD patients during treatment. Some 
cases which showed abnormal responses during TRH tests or levodopa tests 
improved during treatment. This means tha t levodopa treatment a llev ia ted  
not only c lin ic a l symptoms but also hypothalamus-pituitary dysfunction.
In group B, basal plasma TSH levels and peak plasma PRL leve ls during 
TRH tests  were s ig n if ic a n tly  higher than the control values. This means that 
hypothalamic dysfunction may again increase in  some patients over the course 
of c l in ic a l treatment. The fact that not only dopamine but also several 
neurotransmitter systems were found to have decreased in the brains of PD 
pa tien ts  suggests that the effectiveness long-term supplementary levodopa 
therapy may be lim ited  in  the treatment of PD patients.
Moreover, i t  is  possible that plasma hormone levels were disturbed 
in  the early stages of PD, fo r we fa ile d  to find  any corre la tion  in  th is  
study between severity of PD and plasma hormone levels.
We conclude that in  PD patients the regulatory mechanism fo r secretion 
of TSH, PRL and GH is  disturbed in the hypothalamus. This dysfunction can be 
a llev ia ted  by treating  PD patients with levodopa.
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The a n te r io r p itu ita ry  hormone serum leve ls  o f 13 pa tients  of both sexes were examined 
fo r basal secretion and response to TRH-GnRH stim ulus before and a fte r parathyroidectomy. 
The pa tien ts  were su ffe rin g  from hyperparathyroidism o f parathyroid adenoma o r ig in .  A fte r the 
opoeration, the previously high serum calcium and low serum phosphate le ve ls  decreased 
(P <  0.001). The serum parathyroid hormone (PTH) concentration, too, decreased s ig n if ic a n t ly .  
A fte r surgery, the basal and s tim jla ted  secretion o f thy ro trop in  (TSH) showed a s ig n if ic a n t 
increase (P <  0.02 and P <  0.05, respective ly ). S ig n if ic a n t ly  higher p ro la c tin  (PRL) leve ls  
were measured a fte r  surgery in  those patients whose PRL leve ls  were normal both before and 
a fte r  the operation. No s ig n if ic a n t change was observed in  pa tients with hyperprolactinaemia. 
A fte r surgery an increased spontaneous growth hormone (GH) secretion was found, while  the 
basal lu te in iz in g  hormone (LH) and fo l l ic le - s t in u la t in g  hormone (FSH) secretions remained un­
changed. In  postmenopausal women the s tinu la ted  FSH secretion decreased ( P 0. 05) ,  while  the 
decrease o f the s tim jla te d  LH secretion was not s ig n if ic a n t.  The resu lts  suggest th a t ex tra ­
c e llu la r  calcium may modify the secretion o f ce rta in  adenohypophysis hormones and th e ir  
stim jlus-induced response.
Keywrds: P itu ita ry  hormones, hyperparathyroidism, serum calcium le v e l,  e ffe c t o f 
su rg ica l treatment
In t r o d u c t io n
The s ig n ifica n t ro le  of cytosolic free calcium ion in various c e llu la r  
a c t iv it ie s  and, especially in hormone secretion, was extensively inves­
tigated and the need for calcium in secretion was proved in several p e ri-
Abbreviations: FSH: fo l l ic le -s t im jla t in g  hormone, GH: growth hormone, GnRH: gonadotrop 
releasing hormone, LH: lu te in iz in g  hormone, PRL: p ro la c tin , PTH: parathyroid hormone, TRH: 
thyro trop in  releasing hormone, TSH: thyro tropin
O ffp r in t requests should be sent to : L. Kovács, H-1389 Budapest, P.0. Box 112, Hungary
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pheral hormones, such as aldosterone or in su lin  /21, 23/. As fa r as the p i­
tu ita ry  hormones are concerned, in tra ce llu la r calcium was proved to act as a 
p o s itive  mediator /4 , 5, 10, 12, 13, 17/. In recent years animal experiments 
/19, 20/ and human investigations have demonstrated /1 , 2, 6—9, 14, 15, 22/ 
tha t ex trace llu la r hypercalcaemia can in h ib it  the release of d iffe re n t p i­
tu ita ry  hormones. However, most of the human studies were lim ited to the in ­
ves tiga tion  of the change in  TSH /7—9, 15/, while the results of PRL, FSH, 
LH and GH release remained contradictory /1 , 2, 6, 14, 18, 22/. Our aim was 
to  study in  humans the e ffe c t of changes in  ex trace llu la r calcium leve ls  on 
the basal and stimulated secretion of p itu ita ry  hormones. The spontaneous 
and the releasing factors stimulated secretion of FSH, LH, TSH and PRL were 
measured before and a fte r surgery.
P a t ie n ts  and Methods
Thirteen pa tients (6 men and 7 women, aged between 15 and 76 years) w ith  diagnosed 
hyperparathyroidism induced by parathyroid adenoma were included. Serum to ta l calcium , serum 
phosphate, PTH concentrations, and GH, FSH, LH, PRL and TSH leve ls  were measured before and 
a f te r  TRH + GnRH adm in is tra tion , pre- and postoperative ly. Postoperatively, the in ve s tig a tion  
was genera lly  performed on the seventh day a fte r the operation. During the te s t,  medications 
th a t could in fluence calcium, phosphate or hormone le ve ls  were not given.
As TRH + GnRH stim ulus, res tin g  patients were given 0.2 mg TRH (Berlin-Chemie, B e rlin , 
GDR) and 0.1 mg LHRH (Fe rring , K ie l,  GFR) iv ,  a t 07.00 a.m. Blood samples were taken fo r 
measurement o f the hormone le ve ls  a t 0, 15, 30, 60 and 120 min (TSH was measured a t 0, 30 and 
60 m in ).
The measurement o f GH (RIA, In s t itu te  o f Nuclear Medicine, Hungarian Academy o f 
Sciences, Budapest, Hungary), FSH, LH TSH (DELFIA, Wallac Oy, Turku, F inland), PRL (RIA, In ­
s t i t u t e  Frederic O olio t-C urie , Budapest, Hungary), PTH (RIA, N ichols, San Tuan, USA) leve ls  
were evaluated by applying k i t s ,  while serum calcium and phosphate levels were measured by a 
c o lo r im e tr ic  method. Normal ranges o f serum calcium and phosphate levels are 2 .2-2 .6  mmol/1 
and 0 .7 -1 .6  mmol/1, respective ly .
The s ta t is t ic a l analyses were performed w ith  a Statgraphics 5.1 program package. 
A q u o tien t was constitu ted  from the in d iv id u a l basal pre - and postoperative values in  order to  
get normal d is tr ib u tio n . For the estimation o f p itu ita ry  responsiveness the next formula was 
used:
postoperative peak value—postoperative basal value 
preoperative peak value—preoperative basal value
To v e r ify  the normal o r non-normal d is tr ib u t io n  o f the ind iv idua l parameters, the 
skewness and ku rtos is  and th e ir  s ign ificance  were analysed.
In  case o f normal d is tr ib u t io n  Student's paired ta te s t was used. Mean^SD are shown. 
I f  the d is tr ib u t io n  was non-normal even a fte r transform ation, Wilcoxon signed-rank te s t was 
used ( fo r  analysing maximal responsiveness).
Pearson's or Spearman's co rre la tio n  method was used depending on the norm ality  o f the 
parameters.
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R e s u lts
The parathyroid adenoma of a l l  the patients involved were removed as 
shown by h is to log ica l examination.
A fter surgery the previously high serum calcium levels (3.08 _+ 0.27 
mmol/1) decreased and the previously low serum phosphate levels (0 .6 5 ^0 .0 9  
mmol/1) elevated (se calcium: 2 .08^0 .21  mmol/1, se phosphate: 0 .9 5 ^0 .2 6  
mmol/1); the change was highly s ig n ifica n t in  both cases (P <  0.001). The 
ind iv idua l serum calcium and phosphate values are shown in Table I .  The ab­
normal PTH levels were also reduced s ig n if ic a n tly  a fter the operation; 
before: 430 0 .7 4  pg/1; a fte r: 0.44 0 .2 1  pg/1 (P < 0 .0 1 ).
The changes of basal hormone values are shown in Table I I ,  and tha t of 
the stimulated values are presented in  Table I I I .
The basal and stimulated postoperative TSH levels showed s ig n if ic a n t 
increase. A fter the removal of the adenoma, stimulated PRL was also higher 
in  patients whose basal PRL levels were previously normal (less than 20 
pg/1). There was no difference between basal PRL levels before and a fte r 
surgery. No s ig n ifica n t changes were found in  patients with hyperp ro lacti- 
naemia (data are not shown). Neither the basal FSH and LH secretion in  both 
sexes, nor the stimulated FSH and LH release in  men changed a fte r surgery.
Table I
Ind iv idua l serum calcium and phosphate values
No.
Se Ca^+ before 
operation 
mmol/1
Se Ca^+ a fte r 
operation 
mmol/1
Se P^~ before 
operation 
mmol/1
Se a f te r  
operation 
mmol/1
1 3.20 1.90 0.70 0.50
2 3.05 2.30 0.50 0.80
3 3.30 2.15 0.50 0.90
4 2.80 2.40 0.70 1.00
5 3.50 1.60 0.60 0.70
6 2.90 2.30 0.60 0.90
7 3.40 2.00 0.60 0.80
8 3.50 2.00 0.70 1.30
9 2.90 2.00 0.80 1.10
10 2.80 1.90 0.70 1.20
11 3.10 2.00 0.60 1.10
12 2.70 2.05 0.70 1.40
13 2.90 2.10 0.80 0.70
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Table I I
Changes o f basal hormone secre tion a fte r  surgery
Ratio3 n Mean 95% conf. l im i t t P
TSH 13 2.39 1.37 3.42 2.96 X X
nPRLb 10 2.23 0.85 3.60 2.02 NS
GH 13 3.05 1.44 4.65 2.77 X X
fFSHc 4 1.19 0.87 1.51 1.91 NS
mFSHd 6 1.13 0.56 1.70 0.60 NS
fLHc 4 0.99 0.57 1.41 -0.10 NS
ntHd 6 2.01 0.33 4.36 1.12 NS
aRatio = postoperative basal va lues/preoperative basal values; 
bnPRL = normoprolactinaemic pa tients ; c f  = postmenopausal female 
pa tients; dm = male patients; **= P <  0.02; NS = non s ig n ifica n t 
(Student's paired ta te s t)
Table I I I
Changes o f p itu ita ry  responsiveness a f te r  surgery
Ratio3 n Median z score P
TSH 13 1.33 2.06 X
nPRLb 10 1.83 2.45 XX
fFSHc 4 0.50 2.01 X
mFSHd 6 0.80 0.21 NS
fLHc 4 0.61 1.64 NS
mLHd 6 0.79 0.62 NS
aRatio = postoperative peak values—postoperative 
basal values/preoperative peak values—preoperative 
basal values; bnPRl = normoprolactinemic patients; 
cf  = postmenopausal female p a tie n ts ; dm = male pa­
t ie n ts ;  *= P <  0.05; **= P -C 0.02; NS = non s ig ­
n if ic a n t  (Wilcoxon signed-rank te s t)
On the other hand, in  women after menopause the FSH responsiveness showed a 
s ig n if ic a n t decrease (P <  0.05), while the reduction of stimulated LH values 
was not s ig n ifica n t. S ta tis t ic a l evaluation was impossible because of the 
small number of f e r t i le  aged women. The basal GH secretion increased s ig ­
n if ic a n t ly  a fte r surgery (P < 0.02).
There was no apparent correlation between the decrease of calcium and 
PTH values and the basal and stimulated p itu ita ry  hormone secretion.
ADENOHYPOPHYSIS HORMONES IN  HYPERPARATHYREOIDISM 19
D is c u s s io n
In our study, the b io lo g ica lly  and s ta t is t ic a lly  s ig n if ic a n t decrease 
in  serum calcium and PTH levels and the increase in serum phosphate level 
could be a ttribu ted  to the successful removal of the adenoma inducing hyper­
parathyroidism. The p a ra lle l increase in  the basal and stimulated secretion 
of some anterior p itu ita ry  hormones underlines the modifying ro le  o f extra­
c e llu la r  calcium leve l. In human investiga tions, TSH response was studied 
most extensively; acute experimental hyper- and hypocalcaemia and other con­
d itions  with chronically altered calcium leve l change on the TSH response 
were also observed /7 —9, 15/. The resu lts  of the present study agree with 
those of the above examinations: in  patients with hypercalcaemia, both basal 
TSH secretion and i t s  reaction to TRH stim ulation decreased. The exact ex­
planation of th is  phenomenon is  not yet known, but there are several ex­
perimental data helping in  in te rp re ta tio n . I t  has been revealed th a t extra­
c e llu la r  hypercalcaemia can s ta b ilize  secretory granules in  p itu ita ry  ce lls  
/11/ and can stimulate dopamine release from hypothalamic c e lls ,  which, on 
the other hand, may in h ib it  the release of certain p itu ita ry  hormones. Con­
sequently, the administration of metoclopramid could partly  suspend the in ­
h ib it in g  e ffec t of hypercalcaemia on TSH release /15 /. I t  seems tha t the 
e ffec t of hypercalcaemia involves both in d ire c t and d irect in h ib it io n  of 
hormone release. As the referred studies and our examinations demonstrate, 
the a lte ra tion  in TSH secretion seems to be independent of negative feed­
back mechanism, since serum thyroxine and tri-iodo-thyron ine leve ls  do not 
a lte r .
However, the background of th is  observation has remained unclear; 
G ille t  et a l. /8 / presume that thyro id  s e n s it iv ity  increased by TSH or in ­
creased d is in tegra tion  of the thyroid hormone, even the re la tiv e  growth of 
the b io lo g ica lly  active form of TSH are a l l  possible in patients w ith  hyper­
calcaemia.
As to p ro lactin , the resu lts  of human tests are disputed /1 , 2, 6, 14, 
18, 22/, but most studies suggest an in h ib ito ry  e ffect of exogenic or endo­
genic hypercalcaemia on basal and TRH stimulated PRL secre tion . In the 
present study we obtained s im ila r resu lts : in  patients with normoprolacti- 
naemia the PRL secretion increased s ig n if ic a n tly  a fter surgery. On the other 
hand, in patients with hyperprolactinaemia we observed no s ig n ific a n t 
changes follow ing the operation. There is  no accepted explanation fo r th is  
observation yet; i t  may be supposed that the autonomous process resu lting  
in  hyperprolactinaemia is  more independent from calcium-regulation.
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There are only few data on changes of GH and gonadotrop hormone sec­
re tio n  in  human patients w ith  hypercalcaemia. In  a report of Veldhuis et a l.  
/2 2 /,  TRH + GnRH stim u la tion  tes t was performed a fte r  induction of acute exo­
genic hypercalcaemia by calcium infusion. These authors found that basal FSH 
and LH levels did not change in  healthy men, yet stimulated secretion was 
s ig n if ic a n tly  higher than in  the control subjects. We found no s ig n ifica n t 
changes in  male patients; however, in postmenopausal women higher stimulated 
gonadotrop hormone secretion was observed before operation ( i.e .  in hyper­
calcaemia), than a fte r surgery.
While GH values showed no s ign ifican t m odification in other studies in  
humans /22 /, we observed an increase in basal GH secretion following the de­
crease of the elevated serum calcium leve l.
In addition to the change of the e x tra ce llu la r calcium leve l, the e f­
fe c t of the decreased PTH secretion on the release of certain p itu ita ry  
hormones could also play a regulatory ro le . However, the partic ipa tion  of 
parathromone in the process was not proved e ithe r by our results or by other 
pub lica tions /8 , 9 /, in  s p ite  of the fact tha t an increase in PRL le ve l, 
induced by PTH infusion, was found in healthy subjects /16/.
We conclude tha t in  humans extrace llu la r calcium level can revers ib ly  
modify and regulate the secretion and s e n s it iv ity  of certain p itu ita ry  
hormones.
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Hypothyroidism is  known to  be associated w ith abnormalities of kidney fun c tion ; re­
ce n tly , low a t r ia l  n a tr iu re t ic  peptide (ANP) plasma leve ls  have been reported. Aim o f the study 
was to  asses ANP, sodium and water responsiveness to  an acute sa line load. Twelve pa tien ts  with 
established primary hypothyroidism and 9 con tro l subjects were studied. ANP was determined in 
plasma by RIA w ith ex trac tion , p r io r  to  and a fte r  the in fus ion  o f sa line , 500 m l/h fo r  4 hours. 
On a s im ila r  a lb e it l ib e ra l sodium d ie t hypothyroid pa tients  excreted less sodium and water 
(7 4 ^ 3 3  (SO) /jmol/min and 0.69 +_ 0.15 ml/min, respective ly) than con tro l sub jects (110 + 52 
^imol/min; P <  0.05 and 1 .0 6^0 .5 3  ml/min; P ^  0.025, respec tive ly ). However, the in fus ion  of 
sa line  resu lted  in  a 3 -fo ld  increase o f sodium output and more than 2 -fo ld  increase in  urine 
flow . The exaggerated responsiveness in  sodium excretion in  patients w ith hypothyroidism was 
associated w ith s ig n if ic a n t ly  decreased p re-in fus ion ANP plasma leve ls  (1 6 .1 ^ 1 1 .1  pg/ml vs. 
4 4 .4 ^1 4 .4  pg/ml; P 0.001) and also w ith sluggish response to  the volume expansion (+24% 
vs. + 48%). A s ig n if ic a n t co rre la tio n  was found between serum T4 leve ls  and plasma ANP con­
centra tions in  8 patients ( r  = 0.689; P <  0.05). Although hypothyroid pa tien ts  tend to  re ta in  
sodium on a l ib e ra l s a lt  d ie t ,  th e ir  kidney is  capable o f vigorously e lim ina ting  excess sodium 
when challenged w ith an acute sa line  load. This exaggerated responsiveness o f sodium excretion 
can be demonstrated in  sp ite  o f a sluggish response in  ANP. Subnormal ANP le ve ls  in  hypo­
thyroidism  are probably the re s u lt  o f thyro id  defic iency.
Keywords: A tr ia l n a tr iu re t ic  peptide, sodium excre tion, water excre tion, hypothyroidism
Abbreviations: ANP: a t r ia l  n a tr iu re t ic  peptide, RIA: radioimmunoassay, T4: thyroxin , 
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In tro d u c t io n
Hypothyroidism is  known to be associated w ith abnormal sodium and 
water metabolism. Body sodium was found to be increased /1 , 34/ and to d i­
m inish upon substitu tion therapy /26/. Various abnormalities of the renal 
handling of sodium and water recognized by early  c l in ic a l studies /15, 28, 
35 /, and confirmed by subsequent clearance and micropuncture experiments 
/10 , 25/. Recently, i t  has been shown by several investigators that plasma 
le ve ls  of a tr ia l n a tr iu re tic  peptide (ANP) are depressed in  hypothyroid pa­
t ie n ts  /39, 42/ and ra ts  /20 , 38/. Since the release of ANP from the cardiac 
myocytes may be altered in  various chronic sodium-retatining disorders, 
e .g ., renal fa ilu re  /33, 36 /, diabetes m ellitus /7 / ,  i t  seemed worth inves­
t ig a t in g  the effect of an acute saline load on ANP plasma levels and urinary 
sodium and water excretion in  patients with hypothyroidism.
P a t ie n ts  and Methods
Experiments were undertaken in  12 female patients ages 33 to  68 years w ith established 
hypothyroidism ; a l l  had elevated TSH and low T4 leve ls . Serum TSH was measured by a sens itive  
imnunoradiometric assay, and T4 by RIA. None of the pa tients had hypertension as defined by WHO 
c r i t e r ia  (>  160/93 mmHg, phase V. o f the Korotkoff sounds), and de ta iled  c l in ic a l and laborato­
ry  in ve s tig a tio n  excluded the p o s s ib i l i t y  of congestive heart fa i lu re  or any other diseases 
( re n a l,  hepatic, endocrine) th a t could have independently a ffected sodium homeostasis.
The contro l group consisted o f 9 females aged 33 to  59 years, who were free  o f c l in ic a l 
o r labo ra to ry  evidence o f any c irc u la to ry , renal, hepatic or endocrine disorders. Patients and 
c o n tro l subjects were hosp ita lized  a t the time of the study and received a balanced d ie t con­
ta in in g  d a ily  150 to 200 mmol o f  sodium. A ll gave informed consent to  the experiments.
A fte r having co llec ted  th e ir  24-hour urine, the pa tie n ts  and subjects remained re ­
cumbent fo r  30 min, at the end o f which blood pressure was taken 3 times w ith sphygmomanometer 
a t  2 min in te rva ls , and the pulse ra te  was determined. An indw e lling  cannula was then inserted 
in to  an antecubita l vein and blood was withdrawn fo r measurement o f ANP, sodium, potassium and 
c re a tin in e  concentrations. A fte r  vo id in g , a 4-hour in fus ion  o f physio log ica l sa line was started 
a t  a ra te  o f 500 ml/hour, a t the end o f which blood pressure and pulse ra te  were again mea­
sured, and blood sample taken fo r  ANP. The 4-hour urine was co llec ted  by spontaneous voiding.
For the determination o f  ANP, blood was withdrawn in to  c h il le d  EDTA tubes, centrifuged 
immediately and the plasma stored a t -20 °C u n t i l  assaying. E xtrac tion  was done using Sep-Pak 
C 18 ca rtridges , and radioimmunoassay was undertaken in  d up lica te , as described previously 
/3 0 / .  Serum and urine e lectrodes, and creatin ine concentration was determined by an auto- 
ana lyse r. S ta t is t ic a l analysis o f  the data was performed by using Student's jt - te s t  o f paired 
and unpaired samples as appropria te , and by co rre la tion  ana lys is  by the method o f least 
squares.
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R e s u lts
Relevant c l in ic a l and biochemical data of the patients and control 
subjects are shown in  Table I .  Hypothyroid patients had s ig n if ic a n tly  lower 
pulse rate and serum sodium leve l.
Table I I  demonstrates that patients with hypothyroidism had s ig n if­
ican tly  lower urine flow and sodium excretion compared with the control in ­
d iv iduals. During the infusion of 2000 ml saline urinary sodium excretion
Table I
C lin ic a l and laboratory data o f pa tients  w ith hypothyroidism and 
contro l subjects (mean ±  SD)
Patients
n=12
Control subjects 
n=9
Age (years) 48.2 (33--6 8 ) 44.6 (20 -5 0 )
Body weight (kg) 67.0 + 9.6* 64.1 + 9.1
Body height (cm) 160.3 + 5.6 158.7 + 6.1
Blood pressure (mmHg) 129/82 +. 17/10 125/79 + 16/8
Pulse ra te  (beats/m in) 67 + 12** 75 + 10
Serum sodium (mmol/1) 140.2 + 3.1* 145.3 + 3.7
Serum potassium (mmol/l) 4.2 + 0.9 4.4 + 0.4
Creatin ine clearance (ml/min) 94.41 + 9.6 98.3 + 7.1
*P <  0.05; **P-£ 0.01 compared w ith co n tro l subjects
Changes in  u rine
Table I I
flow  (V/min) and sodium excretion (Um„V) fo llow inq  the
infusion o f 2000 ml sa line fo r 4 hours in pa tients  w ith hypothyroidism and
contro l subjects (mean ±  SD)
Patients Control Subjects
n=12 n=9
V/min (ml/min)
Before in fus ion 0 .69+  0.15 1.06 + 0.53 0.001
A fte r in fus ion 1.62 + 0.61** 2.04 + 0.85* N.S.
UNaV (pmol/min)
Before in fus ion 74 + 33 110 +_ 52 0.05
A fte r in fus ion 228 + 87** 237 + 53** N.S.
*P.< 0.01; * * P <  0 .001 compared w ith before in fus ion  values
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ANP
pg/ml
8 0 -
60 -
40 -
20 -
o-J
C o n t r o l  s u b j e c t s  H y p o th y r o i d  p a t i e n ts
P< 0.001
F ig . 1. A t r ia l  n a tr iu re tic  peptide (ANP) plasma leve ls  before (open c irc le )  and a fte r  (s o lid  
c ir c le )  volume expansion w ith  2000 ml sa line  fo r 4 hours in  c o n tro l subjects and in  pa tients  
w ith  hypothyroidism. Mean +_ SE are ind ica ted ; asterisks denote le v e l o f s ign ificance o f changes 
w ith in  a group (**p  <  0.01; * p <  0.025)
was doubled in the contro l subjects, while a th reefo ld  increase was ob­
served in  the hypothyroid pa tien ts , whose mean sodium output thus approached 
th a t o f the control subjects. Urine flow was increased by saline infusion to 
about the same extent in the two groups.
Pre-infusion ANP le ve l in  the hypothyroid patients was s ig n if ic a n tly  
less than corresponding values of the control subjects (mean^SD) (16.1^11.0 
vs. 44 .4^14 .4  pg/ml; p •< 0.001), and i t  rose s ig n if ic a n tly  in response to 
volume expansion (p <  0.025), although to s ig n if ic a n tly  lower values than 
those observed in the con tro l subjects (post-infusion means, 20.0 +_ 14.3 vs. 
62.7 4^22.0 pg/ml; p <  0.001). Figure 1 shows ind iv idua l responses in  both 
groups.
In 8 patients with hypothyroidism pre-infusion ANP plasma concentra­
tio n  correlated s ig n if ic a n tly  w ith serum T4 level (F ig . 2 ), while there was 
somewhat weaker corre la tion  between serum T4 and post-infusion ANP con-
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ANP
nmol/1
F ig . 2. C orre la tion  between serum T4 le ve l and plasma concentration o f a t r ia l  n a tr iu re t ic  
peptide (ANP) in  patients w ith hypothyroidism
centration (г  = 0.600; N.S.) and no apparent re lationship between T4 levels 
and percent changes in the concentration of ANP in  response to volume ex­
pansion ( r  = -0.088; N .S.). Plasma ANP leve l correlated only weakly w ith the 
pulse rate ( r  = 0.360; N .S.). Also there was no corre lation between serum 
sodium concentration and plasma ANP level ( r  = 0.005; N.S.).
D iscuss ion
The present resu lts  confirm e a rlie r observations that hypothyroidism 
is  associated with various abnormalities of kidney function re su ltin g  in  a 
tendency to sodium and p a rtic u la r ly , to water retention /5 , 9, 15, 35/. 
Under steady-state conditions, our patients with hypothyroidism had s ig­
n if ic a n tly  lower urinary sodium and water excretion rates than the control 
subjects, although the two groups were given s im ila r d ie ts. The difference 
between the patients with hypothyroidism and the control subjects was par­
t ic u la r ly  prominent with respect to the urine flow rate, which is  in  agree-
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ment with the observation that free water formation is  impaired in hypo­
thyroid ism  /10, 25/. Water retention results in  hyponatraemia which could 
a lso be demonstrated in  our patients.
Impaired water excretion in hypothyroidism has been a ttribu ted  to in ­
appropriately high a n t id iu re tic  hormone (ADH) leve ls  /28, 32/, to decreased 
f lu id  delivery to the d is ta l d ilu ting  segment of the nephron /9 / and to 
o the r, less defined abnormalities of kidney function /1 7 /. AOH leve l was not 
measured in the present experiment, however, the observation that volume 
expansion resulted in  a more than twofold increase in  urine flow in  the 
hypothyroid patients, s im ila r  to that observed in  the control subjects in 
response to the same volume load, argues against the p o ss ib ility  that ex­
cessive ly high and not re a d ily  suppressible ADH leve ls /32/ would be re­
sponsible for chronic water retention and hyponatraemia in hypothyroidism.
Data concerning the excretion of sodium in  hypothyroidism are rather 
controvers ia l. Michael e t a l.  found that absolute and fractiona l excretion 
o f sodium was increased in  the hypothyroid ra ts  /25 /, while Capasso et a l.  ob­
served decreased excretion in  thyroidectomized ra ts  /4 /.  The patients with 
hypothyroidism studied by us also excreted s ig n if ic a n tly  less sodium than 
co n tro l subjects. Although both groups were instructed to avoid sodium at 
the table and they were given sim ilar hospital d ie ts , the p o s s ib ility  cannot 
be ru led out that there were differences in  s a lt  preference.
Several explanations have been provided fo r the sodium retention oc­
cu rrin g  in hypothyroidism. Thus Di Scala and Kinney /10 /, and Gibson et a l. 
/1 3 / suggested that enhanced proximal tubular reabsorption of sodium caused 
by diminished blood volume might be responsible fo r  observed abnormality of 
sodium and water excre tion . Capasso et a l. /4 / ,  on the other hand, thought 
th a t i t  was the increased in trarenal angiotensin I I  leve l which could have 
acted as a sodium re ta in in g  facto r. Whatever the underlying mechanism, i t  is  
c le a r tha t, despite the tendency for sodium re tention  under steady-state 
conditions, hypothyroid ra ts  respond with remarkable natriu res is  to the in ­
fus ion  of saline /1 8 /, s im ila r ly  to the patients observed by us. When chal­
lenged with an acute sa line  load, our patients exhib ited a 3-fo ld  increase in  
sodium excretion. Thus, taking together these data with the results of water 
excre tion , i t  may be concluded that acute volume regulatory responses are 
w e ll maintained in hypothyroidism; moreover, the pronounced n a tr iu re tic  and 
d iu re t ic  responses occur in  face of subnormal resting ANP levels and a 
slugghish responsiveness o f ANP release in these patients.
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Low plasma ANP concentration in patients with hypothyroidism has been 
reported by several /21, 39, 42/, although not a l l  investigators /22, 41/. 
Of the possible mechanism underlying th is  abnormality the frequent occur­
rence of pericard ia l effusion in hypothyroid patients has been suggested to 
be responsible for the low ANP levels found some of the patients /4 1 /; in 
fac t, increased a tr ia l pressure due to perica rd ia l effusion in hypothyroid 
patients /16/ may impede a tr ia l stretch which regarded to be the main s t i ­
mulus for ANP release /1 1 /. However, Weissel et a l.  /37/ found positive ANP 
level in hypothyroid patients.
A further p o s s ib ility  related to the cardiac abnormalities of hypo­
thyroidism that could explain low ANP levels in th is  disease is  bradycardia. 
Plasma ANP level depends on heart rate during v e n tr icu lo a tr ia l pacing /12 /, 
and Kohno et a l. /21 / found s ign ifican t corre la tion  between ANP concentra­
tion  and heart rate in patients with hyperthyroidism. In the present study 
there was only weak, s ta t is t ic a lly  not s ig n ifica n t corre la tion between pulse 
rate and resting ANP leve ls , thus i t  seems un like ly  that bradycardia would 
be the primary cause of low ANP concentration in hypothyroidism.
Since serum sodium concentration is  low in hypothyroidism /1 , 28/ and 
th is  could be demonstrated also in the present study, one might suggest that 
low ANP level be the resu lt of decreased serum concentration of sodium in 
these patients. The sodium ion has been incriminated as the p rinc ip le  s t i ­
mulus for ANP release /3 / ,  however, in a recent study elevation of plasma 
sodium concentration without volume expansion fa ile d  to a ffect ANP release 
/27 /. In the hypothyroid patients studied by us there was no corre la tion 
between serum sodium concentration and plasma ANP leve l.
F ina lly , i t  has been suggested that diminished thyroid hormone pro­
duction be responsible fo r the suppression of ANP in hypothyroidism /21, 
42/. This view is  supported by the observation of Ladenson et a l. /23/ show­
ing that the ANP messenger RNA in the myocardium is  reduced in hypothyroid 
rats and can be stimulated by the administration of thyroxine. Treatment of 
hypothyroid patients with thyroxine resulted in s ig n ifica n t increases in 
plasma ANP level /2 1 /, even in patients in whom in i t ia l  ANP concentration 
was not suppressed /4 1 /. The finding of a close corre la tion  between serum T4 
level and plasma ANP concentration in the study of Kohno et a l. /21 / and in 
the present experiments lends strong support to the view that thyro id hor­
mones are important modulators of ANP synthesis.
The most important find ing in the present study is  the demonstration 
of not only low plasma ANP levels but also of a diminished responsiveness of
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ANP in  patients with hypothyroidism. I t  is  well established that saline in ­
fusion enhances ANP release /21, 24, 40/; the rate of release, however, 
seems to depend on the actual sodium status, usually being high in  condi­
tio n s  associated with sodium retention /7 , 33, 36/. We also succeeded in 
demonstrating that ANP responsiveness depends on exchangeable sodium /8 /.  
Since body sodium has been shown to be increased in patients with hypo­
thyroidism  /1 ,34 /, one would expect an exaggerated ANP response to an acute 
colume expansion; however, th is  was not the case, the present increase of 
plasma ANP level in our patients following the infusion of saline attained 
only 24% compared with 48% observed in the control ind iv idua ls . We believe 
tha t defic ien t thyroid hormone production is  responsible also fo r th is  ab­
norm ality of ANP release in  hypothyroidism.
Although enhanced secretion of ANP is  regarded by most investigators 
as being instrumental in the renal elim ination of an acute saline load /2 , 
19, 24/, i t  seems that renal mechanism independent of ANP may be equal or 
even greater importance /29, 31/. Especially in  states of chronic sodium 
re ten tion , volume expansion may f a i l  to enhance ANP release, despite an in ­
crease in a tr ia l diameter /6 / .  In hypothyroid dogs, Zimmerman et a l . /43/ 
observed marked increases in  sodium excretion despite low ANP leve ls . In the 
present study hypothyroid patients responded with an even more vigorous 
enhancement of renal sodium excretion than did the control subjects to the 
same standardized volume load. Ihe fact that th is  occurred in  face of low 
res ting  and stimulated ANP leve ls and sluggish increase fo llow ing the saline 
in fus ion  indicates tha t, in  hypothyroidism, mechanism other than ANP release 
are mainly responsible fo r the elim ination of an acute sodium load.
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CHARACTERISTICS OF LONG QT WITH PERMANENT BRADYCARDIA
F. SOLTI, L. SZATMÁRY, T, VECSEY, E. BODOR, Z. SZABOLCS
Cardiovascular Surgical C lin ic , Semmelweis University Medical School,
Budapest, Hungary
(Received: December 1, 1993)
The study was aimed to  investiga te  the e lectrophysio log ica l p roperties  o f long QT 
syndrome associated w ith permanent bradycardia. The investigations were performed in  26 pa­
t ie n ts  su ffe rin g  from long QT duration (QTC — frequency adapted QT —: 484^34 ms) w ith per­
manent, marked bradycardia (heart ra te : 4 2 ^ 7  m in '* ). Adams Stokes syncopal a ttack appeared 
in  12 pa tien ts , while in  14 cases ve n tricu la r tachycardiac attack w ith syncope could be ob­
served (study group). As co n tro l served the data o f 30 pa tients su ffe rin g  from long lasting  
marked bradycardia (heart ra te : 44 j^7  min"^) w ith normal QT (QTC: 420 ^ 2 8  ms). Each patient 
was candidate fo r pacemaker im plantation. The fo llow ing  questions were studied: 1. The e ffec t 
o f heart ra te  on QT dura tion . The experiments were performed by e le c tr ic a l v e n tr ic u la r  s t i ­
mulation. 2. The e ffe c t o f sympathetic and parasympathetic — pharmacologic — blockade on QT 
tim e. The study was performed under e le c tr ic a l v e n tricu la r stim ulation  by adm in istra tion of 
propranolol and a tropine. 3. The dispersion o f QT time was studied by using e le c t r ic a l heart 
s tim u la tion  and 12 lead ECG recording.
E lectrophysio log ica l investiga tions were performed in  14 pa tients  w ith  long QT and 
permanent bradycardia. On augmentation o f the cycle length (bradycardia) the increase in  the 
QT duration was more — out o f a l l  proportion — expressed in  long QT. On pharmacologic sym­
pa the tic  blockade in  long QT syndrome the QT duration s ig n if ic a n t ly  d im inished. The QT 
dispersion was more expressed in  pa tients w ith prolonged QT in te rv a l and on bradycardia the 
QT dispersion fu rth e r increased s ig n if ic a n t ly .  The i r r i t a b i l i t y  o f the v e n tr ic le  was markedly 
augmented in  patients w ith  long QT and bradycardia. Appearance o f polymorphous ven tricu la r 
tachycardia could frequently  be observed and could be regu la rly  induced by e a rly  ven tricu la r 
e x tra s tim u li and bradycardia. The permanent bradycardia seems to  modify the e lectrophysio log­
ic a l cha ra c te ris tics  o f long QT and increase i t s  arrhythmogenic property. According to our 
study the la te  outcome o f long QT w ith bradycardia is  favourable by app lica tion  o f pacemaker 
im plantation (using higher pacing ra te ) and beta-blocker adm inistration.
Keywords: Long QT syndrome, dispersion o f the QT in te rv a l, bradycardia, heart rate-QT 
re la tio n sh ip , ve n tricu la r i r r i t a b i l i t y ,  sympathetic blockade
Abbreviations: LQTS: long QT syndrome, CL: cycle length, QT: QT in te rv a l,  QTC: frequen­
cy adapted QT in te rv a l, EP: e lectrophysio log ica l study, PMI: pacemaker im p lan ta tion , VERP: 
v e n tric u la r e ffe c tive  re fra c to ry  period, AERP: a t r ia l  e ffe c tiv e  re frac to ry  period
O ffp r in t requests should be sent to : F. S o lt i ,  Cardiovascular Surg ica l C lin ic ,  Semmel­
weis U n ive rs ity  Medical School, H-1122 Budapest, Városmajor u. 68, Hungary
0236-5286/94/fl' 4.00 ffl 1994 Akadémiai Kiadd, Budapest
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Introduction
The prolongation of the QT in terva l is  an important predictor of se­
rio u s  ventricu lar tachycardias. The long QT syndrome (LQTS) represents a 
spec ia l en tity  of arrhythmogenic property. Despite many c lin ic a l and ex­
perimental studies the pathomechanism of the ven tricu la r i r r i t a b i l i t y  in 
LQTS could not yet co rre c tly  be revealed. The association of LQTS with per­
manent bradycardia is  not a rare phenomenon /11, 13, 20, 23, 25/.
Scanty c lin ic a l observations and experimental data suggest that on 
bradycardia the arrhythmic propensity of LQTS can be modified /9 , 25/. This 
study was designed to investiga te  the effect of bradycardia on the arrhyth­
mogenic character and electrophysio logical characte ris tics  of LQTS. To study 
the long-term therapeutical e ffe c t of pacemaker implantation with adminis­
t r a t io n  of beta-blockers in  LQTS with bradycardia was the other objective of 
the study.
Patients and Methods
Twenty-six patients s u ffe r in g  from LQTS and permanent — marked — bradycardia could be 
e n ro lle d  in  the study (study po p u la tio n ). Exclusion c r i t e r ia  were: 1. Serious accompanying 
h e a rt disease (coronary a rte ry  disease, cardiomyopathy, congenita l o r acquired va lvu la r heart 
d isease ). 2. Progressive cerebrovascular disease, renal or hepatic in su ffic ie n cy . A l l  pa tients 
were re fe rre d  to our c l in ic  fo r  pacemaker implantation i . e .  to  determine the proper therapy. 
The most important c l in ic a l data o f  the study group were summarized in  lab ié  I .
To compare the experim ental and c l in ic a l resu lts  the adequate data o f 30 pa tien ts  suf­
fe r in g  from marked long -las ting  bradycardia (contro l group) served as co n tro l, each pa tien t was 
cand idate  fo r pacemaker im p la n ta tio n . The exclusion c r i te r ia  in  se lec tion  o f pa tients  were the 
same as those in  the study group. The c l in ic a l ch a rac te ris tics  o f the con tro l group were de­
p ic te d  in  lab ié  I I .
The patients o f the two groups were quite well-matched fo r  age, sex d is tr ib u t io n  and 
h e a rt ra te . I t  was remarkable th a t  in  the study group the appearance o f major v e n tricu la r 
arrhythm ias was frequent, demonstrating the propensity fo r  v e n tric u la r  i r r i t a b i l i t y  in  LQTS 
w ith  bradycardia. There was — as could be expected — great d iffe rence  in  the QT between the 
two groups.
The QT in te rva l was measured from the onset of QRS to  the end o f T wave a t ECG paper 
reco rd ing  speed 50 mm-s”  ^ and the  average of three consecutive beats was taken. The end o f T 
wave was defined as return to  the TP base lin e . When U wave in te rrup ted  the T wave before 
re tu rn  to  base lin e , the QI in te rv a l was measured to the nad ir o f the curve between 1 and U 
waves /1 4 /.
The frequency adapted QT (QTC) was determined by using the Bazett's  fo rim la  /2 / .  Long 
QT du ra tio n  was recognized when QTC was markedly prolonged: QTC more than 460 ms. The e ffe c t o f 
h e a rt ra te  on QT in te rva l was s tud ied  in  24 patients; in  14 cases from the study group and in  
10 p a tie n ts  from the con tro l group. Ihe study was performed before the pacemaker im plantation 
to  s e le c t the proper pacemaker frequency ra te . The QT time was measured by using d iffe re n t 
pacing — driv ing — cycle length  (600—1100 ms).
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Table I
from permanent bradycardia associated w ith Iona
QT duration
Patients (N): 26
Age (years): 28 + 6 (range 12—42)
Sex (male/female): 16/11
Heart ra te  (beats, min"^): 42 + 6.8 (36-59)
QTC (ms): 484 + 34 (470-510)
QT (ms): 630 + 48 (560-690)
Accompanying diseases
Hypertension: 1
Diabetes m e llitu s : 1
Genesis o f bradvcardia
Sick sinus syndrome: 1
2nd-3rd degree AV block: 
S ick sinus syndroma
18
w ith AV block: 7
In d ica tion  fo r pacemaker im plantation
Adams Stokes syncopal
a ttack :
V en tricu la r tachycardiac
12
attack w ith syncope: 14
Type o f LQTS
Congenital long QT: 2
Acquired — sporadic — QT : 24
For inves tiga tion  the e ffe c t o f sympathetic-parasympathetic in te ractions on the QT 
pharmacologic sympathetic and parasympathetic blockade was performed in  26 pa tien ts ; in  16 from 
the study group and 10 from the con tro l group. To avoid the d is turb ing e ffe c t o f the sym­
pa the tic  and parasympathetic blockade on the heart cycle  length, the inves tiga tion  was per­
formed under v e n tric u la r e le c tr ic a l stim ulation using constant — 800 ms — pacing-driv ing- 
cycle . For parasympathetic blockade atropine was administered: 0.04 mg-kg"-*- in travenously. 
For sympahetic blockade propranolol was applied: 0.2 mg-kg-  ^ in  intravenous in je c tio n .
The QT dispersion was determined in  16 pa tien ts  during e le c tr ic a l v e n tricu la r heart 
s tim u la tion  by using d if fe re n t  pacing-driving-cycle length ( in  8 pa tients w ith LQTS and in  8 
ones from the con tro l group). The QT dispersion was defined as the d iffe rence between the 
maximum and minimum QT in te rv a ls  measured on the standard 12 lead ECG. Normal value: 48;+20 ms 
/6 , 9, 15/.
E lectrophysiologic study (EP) was performed in  14 pa tients su ffe ring  from LQTS and 
lon g -la s tin g  bradycardia w ith  appearance o f polymorphous v e n tricu la r tachycardiac a ttack. The 
EP consisted o f programmed e le c tr ic a l stim ulation o f the heart and recording endocavital ECG 
trac ings  ( in traca rd iac  electrograms from the His bundle region, high and low r ig h t  atrium  and 
d if fe re n t area o f the r ig h t  v e n tr ic le ) .  For e le c tr ic a l stim ula tion  a programmable d ig ita l  
s tim ula to r (Medtronic 5325) was used. To induce v e n tric u la r  tachycardia s ing le  and double 
v e n tric u la r e x tra s tim u li were applied. For s ta t is t ic a l analyses o f the data the Student's 
j t - te s t  fo r unpaired and paired data was applied.
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Table I I
C lin ic a l ch a ra c te r is tic s  o f pa tients su ffe ring  from
permanent bradvcardia
Patients (N) : 30
Age (years): 35 + 5 (range: 13—55)
Sex (m ale/female): 18/12
Heart ra te  (beats, min- ^ ): 44 + 7 (36-59)
QTC (ms): 420 + 28 (380-440)
QT (ms): 484 + 30 (450-520)
Accompanying diseases
Hypertension: 2
Emphysema : 1
Diabetes m e llitu s : 1
Genesis o f bradycardia
Sick sinus syndrome: 3
2nd-3rd degree AV block: 16
Sick sinus syndrome w ith
AV block: 11
Ind ica tion  fo r  pacemaker implantation
Adams Stokes syncopal a ttack: 20
Permanent bradycardia: 9
Brady-tachycardia : 1
R e s u lts
The QT in te rva l was regu la rly  langer in LQTS than in  the contro l group 
at d iffe re n t pacing rates. On bradycardia (long driv ing cycle), although the 
QT increased in both groups, however, the QT prolongation on bradycardia was 
s ig n if ic a n t ly  more pronounced in  LQTS. In tachycardia the difference in  QT 
between the two groups proved s ta t is t ic a lly  non s ig n ifica n t. On bradycardia 
the d ifference became d e fin ite ly  marked and s ta t is t ic a lly  highly s ig n ific a n t 
(F ig . 1).
On a pharmacologic parasympathetic blockade — atropine administra­
t io n  — there was no s ig n if ic a n t change in  the QT using constant pacing 
ra te . At propranolol adm inistration — sympathetic blockade — in  normal 
cases (contro l group) the QT did not change s ig n ific a n tly  -- at constant 
pacing rate — while in  LQTS s ig n if ic a n tly  shortened (Fig. 2).
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F ig . 1. The e ffe c t o f heart ra te  (pacing cycle length) on QT in  normal pa tien ts  and in  LQTS. 
□ : pa tients  w ith normal QT (mean values and SD) ; ■: pa tien ts  w ith LQTS (mean values and SD). 
Mean values were compared w ith  unpaired ta te s t. NS: p >  0.05; +: p <  0.05; ++: p <  0.01;
+++: p <  0.001
Pacing cycle length 800 ms
F ig . 2. The re s u lt o f parasympathetic (atropine) and sympathetic (propranolol) pharmacological 
blockade on QT in  normal pa tie n ts  and in  LQTS. □ :  mean values and SD o f p a tie n ts  w ith  normal 
QT; • :  mean values and SD o f pa tients  w ith LQTS. The in i t i a l  — basal — values were compared 
— by using paired t_-test — w ith those a fte r  a tropine or propranolol adm in is tra tion
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F ig . 3. The dispersion o f QT in  normal patients and in  LOTS: the e ffe c t o f the increase in  
pacing cycle length on QT d isp e rs io n . □ : mean values and SD o f patients w ith normal QT ; 
•  : mean values and SD o f p a tie n ts  w ith  LQTS. Paired data ta te s t was applied to  compare the 
values in  700 ms cyc le  length with those in  1000 ms cycle length
The results of th is  investigation suggest that in LQTS sympathetic 
ove ra c tiv ity  can be supposed. The dispersion of the QT in  LQTS was in ­
creased already under normal heart rate (normal pacing ra te ) . The d i f ­
ference between the minimum and maximum QT time was 40 ms in average in 
normal cases and i t  was 90 ms in LQTS. I t  was also in te resting , that on 
bradycardia the QT dispersion markedly fu rther augmented in LQTS, while in 
normal cases did not change s ig n ifica n tly  (F ig . 3 ).
In LQTS with bradycardia we could frequently observe the appearance 
of ventricu lar i r r i t a b i l i t y .  In 14 cases of 26 patients recurrent poly­
morphous ventricu lar tachycardiac attacks could be detected. The resu lts  
o f the EP furnished fu rth e r data about the arrhythmic propensity fo r the 
heart in LQTS with bradycardia. Sustained (mostly of torsade de pointes 
type) ventricular tachycardia could be induced by early single or double 
ex tras tim u li in 14 pa tien ts  from 16 cases. I t  is  also worth fo r mentioning 
th a t the QT related ve n tr icu la r effective re frac to ry  period (VERP) was very 
sho rt; VERP/QT: 0 .5 2 ^ 0 .0 7  (normal value according to our measurements in 
pa tien ts  with normal QT is :  0 .6 4 ^ 0 .0 8 ) . There was not any s ig n ifica n t
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difference from the normal values concerning the other electrophysiological 
parameters (VERP, AERP, AV conduction time, AV node Wenckebach po in ts). As 
treatment of LQTS with bradycardia, each patient was implanted with pace­
maker using comparatively high pacing rate: 75-85 pro minute and received 
beta blocker, too. Two patients received dual chamber pacemaker and two 
other ones were implanted with rate responsive pacemaker using ven tricu la r 
pacing mode.
The late outcome was very favourable (fo llow -up: 10-60 months). No 
syncopal attack or appearance of ventricu lar tachycardia could be revealed 
a fte r  the pacemaker implantation. Only in two patients could occasionally 
ven tricu la r couplets be detected.
D iscussion
The LQTS represents a well-recognized, but poorly understood syndrome. 
The LQTS has two types: 1. Congenital, fa m ilia r LQTS. 2. Acquired -- spora­
d ic  — LQTS. The fa m ilia r LQTS can be divided in  two subgroups: LQTS with 
/13 / and without /21, 27/ deaf-mutism. The cha rac te ris tic  recurrent v e n tr i­
cular tachyarrhythmias accompaniyng the LQTS attracted the in te rest of many 
c lin ic ia n s  and physicians. The d iffe ren t c l in ic a l and experimental studies 
furnished quite divergent data about the pathogenesis and mechanisms of 
ven tricu la r tachycardias in LQTS, but the arrhythmogenic property of QT 
prolongation received general acceptance. Among the numerous theories to ex­
p la in  the arrhythmogenic propensity for the heart (ven tric le ) of LQTS two 
seem to be essentia l: 1. Some experimental data and c lin ic a l observations 
suggest that a sympathetic imbalance, u n ila te ra l change in the sympathetic 
tone of the heart (lower than normal r ig h t sympathetic a c tiv ity )  can fre ­
quently be revealed in LQTS /16, 22, 28/. 2. The results of other studies 
seem to prove that an exaggerated dispersion of ven tricu la r refractoriness a 
non-uniform and delayed recovery of repolarization represents one of the 
most important reason fo r ventricu lar i r r i t a b i l i t y  in  LQTS /4 , 9, 18, 23/. 
The results of th is  study indicate that both of the two mechanisms can be 
involved in the genesis of ventricu lar polymorphous tachycardia in  LQTS.
There are many studies dealing with the e ffec t of parasympathetic and 
sympathetic blockade on QT. The majority of investigators agree that on 
parasympathetic blockade the QT has not changed remarkable /1 , 5, 24/. Our 
present data prove that on atropine administration the QT w i l l  not change
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ne ithe r in LQTS nor in  normal cases i f  the heart rate remains constant 
(using constant pacing ra te ). Concerning the e ffec t of sympathetic blockade 
on QT divergent data e x is t. In some studies a l i t t l e  shortening of QT could 
be detected on beta-receptor adm inistration /8 , 10, 19/. Other investigato rs 
found a small prolongation of QT on beta-receptor blockade /1 , 26/. No com­
prehensive study could be found dealing with the e ffec t of sympathetic 
blockade on QT at constant heart rate in  normal patients and in  LQTS. Ac­
cording to our investigation the QT w i l l  s ig n ific a n tly  shorten on sympathe­
t i c  blockade in LQTS. This find ing supports the assumption of a sympathetic 
ove ra c tiv ity  in LQTS.
Inhomogeneous ven tricu la r repo lariza tion  is  postulated as one of the 
reason of QT prolongation in  LQTS. The widened dispersion of QT in  LQTS can 
be reconcilated with th is  theory. We also could detect markedly greater 
dispersion of QT in LQTS, confirming the data of Linker et a l.  /1 5 /. I t  
should be emphasized that the dispersion of QT s ig n ific a n tly , very remark­
able augments on bradycardia in  LQTS.
According to our study the bradycardia w i l l  modify the charac te ris tics  
o f LQTS and w il l  increase the arrhythmic propensity fo r the v e n tr ic le . On 
bradycardia in LQTS an exaggerated QT prolongation could be revealed in  our 
study. The dispersion of ven tricu la r repo lariza tion  also markedly increased 
on bradycardia. The appearance of polymorphous ventricu lar tachycardia was 
very frequent in LQTS associated with permanent bradycardia. We also could 
re g u la rly  induce ven tricu la r tachycardiac attack by ventricu lar ex tras tim u li 
in  LQTS with bradycardia. The advent of pacemaker therapy and the adminis­
t ra t io n  of beta-blockers s ig n if ic a n tly  improved the prognosis of LQTS. The 
beta-blocker therapy was comparatively early applied in the treatment of 
LQTS. The results were quite divergent; in  some cases the therapeutical re­
s u lt  was good, while in  other ones the treatment proved to be in e ffe c tive . 
A prerequ is ite  of a successful treatment of LQTS is  to prevent the develop­
ment of bradycardia. On beta-blocker adm inistration the heart ra te  slows 
down. The combination of beta-receptor blocking agents with pacemaker im­
p lan ta tion  resulted much be tte r therapeutical e ffec t /3 , 7, 11, 12, 20, 25/. 
According to our experiences the la te  outcome of LQTS with bradycardia is  
very favourable by using pacemaker implantation with administration of beta- 
receptor blocker. I t  is  advisable to determine the proper pacing ra te  before 
the pacemaker implantation. Generally quite high pacing rate (75-85) is  ne­
cessary to shorten s ig n if ic a n tly  the QT duration. Because of the very ex­
pressed ventricu lar i r r i t a b i l i t y  in LQTS associated with bradycardia the 
therapy should early be started.
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C o n c lu s io n s , C l in ic a l  im p lic a t io n
The results of th is  study with data of c lin ic a l observations allow us 
to make some conclusions concerning the characteris tics of LQTS.
1. The association of permanent bradycardia with LQTS represents a 
subset group of LQTS.
2. The bradycardia markedly increases the ventricu lar i r r i t a b i l i t y  in
LQTS.
3. The dispersion of ventricu lar repolarization further increases on 
bradycardia in LQTS.
4. The augmentation of the QT on bradycardia is  more — pathological­
ly  — expressed in LQTS.
5. The sympathetic blockade results a s ign ifican t shortening of QT 
duration in  LQTS.
6. Inhomogeneous ventricu lar refractoriness and sympathetic overac­
t iv i t y  have a part in  the arrhythmogenic property of the heart in  LQTS.
7. The late outcome of LQTS with permanent bradycardia is  favourable 
by using pacemaker implantation (with higher pacing rate) and beta-receptor 
adm inistration.
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ANALYSIS OF RE-ENTRY MECHANISM IN  A PATIENT 
WITH CONCEALED WOLEF-PARKINSON-WHITE SYNDROM:
G. VERESS
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(Received: February 15, 1994)
This report deals w ith a pa tient with concealed W olff—Parkinson—White syndrome in 
whom both narrow and wide QRS tachycardias were observed. The sinultaneous occurrence of 
various QRS morphology during supraventricular tachycardia resu lts  in  a challenging diagnosic 
ECG problem. The cycle length during tachycardia w ith le f t  bundle branch block was longer than 
the cycle length during narrow QRS supraventricular tachycardia and w ith functiona l r ig h t 
bundle-branch block. E lectrophysiologic studies revealed an increased V-A conduction time 
during tachycardia with le f t  bundle branch block. These studies suggested the presence o f a 
concealed le ft-s id e d  anomalous pathway. D iffe re n tia tio n  between in tra -  and extranodal re-entry 
and therapeutic m odalities are also discussed.
Keywords: Concealed anomalous pathway, A-V rec iproca l tachycardia, retrograde conduc­
tio n  time, aberrant in tra v e n tr ic u la r  conduction
In t r o d u c t io n
A trioven tricu la r re-entry tachycardias can occur w ith in  the AV node or 
using the normal pathway and an extranodal pathway /8 / .  In the absence of 
delta wave in  sinus rhythm paroxysmal supraventricular tachycardia (SVT) 
mostly due to re-entry w ith in the AV node. However there are cases in which 
anomalous pathway (bundle of Kent) capable of only retrograde conduction and 
therefore concealed on the surface electrocardiogram, id est delta wave is  
not present /3 , 5, 7, 12—17, 20/. Increase in cycle length of SVT during 
development of functional bundle branch block could be helpfu l fo r making
Abbreviations: SVT = supraventricular tachycardia, EPS = e lectrophysio log ic  study, 
W.-P.-W. syndrome = Wolf—Parkinson—White syndrome, HRA = high r ig h t a t r ia l  electrogram, 
HBE = His bundle electrogram, SNRT = sinus node recovery time, PES = premature ex tras tim ilus
O ffp r in t requests should be sent to : G. Veress, 8230 Balatonfüred, Gyógy té r  2, Hungary
0236-5286/94/# 4.00 © 1994 Akadémiai Kiadó, Budapest
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the diagnosis of concealed extranodal anomalous pathway /2 / .  D iffe ren tia tion  
between AV-nodal re-entry and re-entry via an accessory pathway is  based on 
electrocardiographic, electrophysio logic and c lin ic a l observation and has 
both diagnostic and therapeutic implications /1 2 /. We report herein the 
find ings  of a patient whose ECG during sinus rhythm showed no evidence of 
preexc ita tion  and during tachycardia the wide QRS configuration suggested 
the existence of ven tricu la r tachycardia. Electrophysiologic study (EPS) was 
h e lp fu l fo r establishing the diagnosis of concealed W olff—Parkinson—White 
(W.-P.-W.) syndrome.
Case re p o r t
The patient was a 31-year o ld  male without any evidence o f organic heart disease. He 
had su ffe red  serious recurrent tachycardia fo r 6 weeks. ECG recording between the a ttacks have 
shown sinus rhythm with normal P-Q in te rv a l (0.16 s) and a QRS duration o f 0.08 s , without 
d e lta  waves (F ig . 1). Before h o s p ita l admission episodes o f SVT become more frequent and 
la s t in g  fo r  several hours. During tachycardia e ith e r narrow QRS or r ig h t  (RBBB) o r l e f t  bundle 
branch b lock (LB8B) con figura tion  o f the QRS complex could be observed. Because o f d if fe re n t ia l 
d ia g n os tic  d if f ic u lt ie s  and fa i lu re  o f drug therapy (proprano lo l, D igoxin, verapamil) the pa­
t ie n t  was referred to EPS.
Method
EPS was performed a fte r  informed consent was obtained. Cardioactive drugs were d is ­
continued 48 hours p rio r the study. M u ltipo la r electrode catheters were inserted percutaneously 
through femoral veins and advanced under fluoroscopic con tro l to  positions in  the r ig h t  atrium 
and AV-junction to record His bundle electrogram (HBE) /1 9 /. Both o f a t r ia l  and ve n tricu la r 
e le c t r ic a l stim ulation were performed. Anterograde and retrograde conduction in te rv a ls  were 
recorded during sinus rhythm and during induced SVT. Surface ECG leads ( I ,  I I ,  I I I ) ,  high r ig h t 
a t r ia l  electrograms (HRA) and HBE were recorded simultaneously w ith a paper speed o f 50 and 
100 mm/s. The a t r ia l  s tim u li consisted o f rectangular impulses o f 2.0 ms duration and a t twice 
d ia s to l ic  threshold. For cardiac s tim ula tion  B iotronic UHS-20 e le c tro s tirru la to r was used.
R e s u lts
During sinus rhythm HBE revealed normal conduction in te rva ls  proximal- 
ly  and d is ta lly  to the His bundle (А-H in te rva l: 70 ms and H-V in te rva l: 
50 ms, respectively). A tr ia l pacing from d iffe re n t sides fa ile d  to demon­
s tra te  delta wave due to preexcitation. Sinus node recovery time (SNRT) 
and i t s  corrected value were w ith in  normal range; 1140 ms and 320 ms, re-
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F ig . 1. V. GY., 31 years o ld  male. Twelve leads electrocardiogram (ECG). Sinus rhythm and 
normal (0.16 s) P-Q in te rv a l.  QRS also is  normal, there is  no evidence o f p reexc ita tion .
Paper speed is  25 mm/s
spectively. during incremental high a tr ia l pacing А-H in te rva l increased 
from 70 ms to 200 ms, while H-V in te rva l and QRS width remained unchanged. 
During incremental ven tricu la r pacing (90-150/min) ve n tricu lo a tria l re tro ­
grade conduction time was fixed (V-A in te rva l: 190 ms).
During a tr ia l extrastimulus testing the follow ing electrophysiologic 
responses were observed: at sinus rhythm an early a t r ia l extrastimulus (PES) 
with a coupling in te rva l between 600-440 ms conducted with a prolongation of 
А-H in te rva l and with narrow QRS complex. A PES with a coupling in te rva l of 
420 ms resulted in r ig h t bundle branch (RBBB) configuration but w ithout an
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F ig . 2. During sinus rhythm a PES w ith a coupling in te rv a l o f 380 ms resu lted LBBB. QRS was 
fo llow ed by a t r i a l  echo beat (Ä ). HRA = high r ig h t  atrium , HBE = His bundle electrogram.
Paper speed is  50 mm/s
a t r ia l  echo beat. A PES with a coupling in te rva l of 380 ms conducted with 
200 ms of А-H in te rva l and resulted in le f t  bundle branch block (LBBB) con­
fig u ra tio n . Concomitantly a tr ia l echo beat (Ä) was demonstrated (F ig . 2). 
During sinus rhythm a PES with a coupling in te rva l of 340 ms e lic ite d  sus­
tained SVT. During SVT the R-R cycle length was 300 ms with a RBBB configu­
ra tio n  (Fig. 3). Paroxysmal loss of functiona l RBBB during tachycardia 
resulted not any change in  R-R in te rva l and retrograde V-A conduction time 
(F ig . 4 ). Several episodes of functional LBBB were observed during induced 
paroxismal SVT. The cycle length and V-A conduction time during tachycardia
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F ig , 3. PES w ith  a coupling in te rv a l o f 340 ms in i t ia te s  SVT w ith functional RBBB. ECG leads 
I ,  I I ,  I I I ,  HRA and HBE. Paper speed is  50 mm/s
I  *»0 mrn/sec
А —^L-А—Д—J—L-J—i_Jl— 
и  f
Fig. 4. Sudden loss o f RBBB con figura tion during SVT. Note th a t cycle length o f tachycardia and 
retrograde conduction time (VA) do not change a fte r  morphologic a lte ra tio n  of QRS configura­
t io n . ECG leads I ,  I I ,  I I I ,  HRA and HBE. Paper speed is  50 mm/s
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F ig . 5, Occurrence o f LBB during SVT suggesting l e f t  free  w a ll accessory pathway. Note tha t 
cyc le  length o f SVT and VA conduction time increased from 300 ms to  330 ms and from 120 ms to 
190 ms, respective ly . ECG leads I ,  I I ,  I I I ,  HRA and HBE. Paper speed is  50 mm/s, than 100 mm/s
w ith  LBBB were 330 ms and 190 ms, respectively (F ig. 5). The SVT could be 
repeatedly terminated w ith PES, but spontaneous termination of the tachy­
cardias could also demonstrated (Fig. 6). A fte r administration of quinidine, 
verapamil therapy only non-sustained form of SVT could be induced (F ig . 7). 
The sustained tachycardia has subsequently been e ffec tive ly  prevented with 
the above-mentioned medication.
D iscuss ion
Occurrence of SVT w ith  functional BBB resu lts  in a challenging diag­
no s tic  problem. Re-entry tachycardias are invo lv ing the AV node alone or as­
sociated with an accessory bypass conduction in  the appearance of preex­
c ita t io n  (W.-P.-W. syndrome) /1 , 2, 4, 3, 12, 13, 17, 22/. I f  delta wave is  
present in  the ECG trac ing , recorded during sinus rhythm, of a patien t with 
SVT, the tachycardia usually related to the partic ipa tion  of an anomalous
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F ig , 6. Spontaneous term ination o f SVT w ith functiona l LBB8. ECG leads I ,  I I ,  I I I ,  HRA and HBE.
Paper speed is  100 nrn/s
pathway. In the absence of delta wave in  sinus rhythm SVT is  based regu la rly  
on re-entry w ith in the AV-node. However in many patients the SVT is  re lated 
to an accessory pathway which conducts only in  retrograde (VA) d ire c tio n , 
therefore concealed on surface electrocardiogram. EPS is  helpful in  d i f ­
fe ren tia tion  between in tra -  and extranodal re-entry tachycardias and has as 
diagnostic as therapeutic value.
In our presented case the presence of concealed anomalous pathway was 
suggested by the follow ing:
1. On 12 leads surface electrocardiogram there was not any evidence of 
preexcitation (normal P-R in te rva l, or delta wave),
2. a t r ia l pacing from multiple sides fa ile d  to e l ic i t  delta wave due 
to preexcita tion ,
3. at increasing rates of ventricu lar stim ulation the retrograde con­
duction time (VA in te rva l) remained constant (190 ms), /11/,
4. during SVT with LBBB pattern increase in  R-R in terva l and VA-in ter- 
val could be observed from 300 ms to 330 ms and from 120 ms to 190 ms, re­
spectively.
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F ig . 7. A fte r adm in istra tion o f quin id ine, verapamil therapy only non-sustained from o f SVT 
could be in it ia te d  w ith  PES. ECG leads I ,  I I ,  I I I ,  HRA and HBE. Paper speed is  50 mm/s
A ll of the above electrophysiologic features could be detected in  our 
case suggesting the presence of a concealed accessory pathway in  the le f t  
free  wall of the heart (Fig. 8). The fo llow ing electrocardiographic and 
c l in ic a l  features seem to exclude the diagnosis of AV-junctional re-entry 
tachycardia with aberrant ventricu lar conduction:
1. During PES we could not demonstrate dual pathway AV-nodal function 
curves, which are very characteristic fo r the mechanism of re-entry in  the 
AV-node.
2. During tachycardia with AV-node re -en try the retrograde P( Á) mostly 
located in  R(V). In our case P waves occurred a fte r QRS and were negative in
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F ig . 8. Schematic representation o f mechanism o f re -en try  tachycardia w ith narrow QRS, w ith 
RBBB and LBBB con figura tion . Measurement o f anterograde and retrograde conduction in te rv a ls  are 
presented. Note th a t during SVT w ith LBBB con figura tion  the expansion o f re -e n try  cycle in  
suggested by the increased VA conduction time and the increased cycle length o f SVT
lead standard I .  A negative P wave in lead I  during SVT can be detected in 
tachycardias with retrograde bypass tra c t conduction but not in  patients 
with AV-nodal re-entry tachycardia /4 / .  Unfortunately, we did not notice 
th is  important electrocardiographic sign e a r lie r  but re trospective ly with 
the help of intracardiac recordings negative P wave on standard lead of I 
could be suggested (F ig. 5).
3. Association of functional BBB w ith AV-junctional re-entry tachy­
cardia is  rare (8.0%), while the incidence of BBB in concealed W.-P.-W. 
syndrome is  more frequent (66.0%) /12 /.
4. The high rate of SVT in  our presented case also suggested the 
existence of concealed W.-P.-W. syndrome. The average rate of SVT invo lv ing 
a concealed accessory pathway is  faster than of AV-nodal re-entry tachy­
cardia.
5. Taking in to  consideration the age, sex, no evidence of heart 
disease can be supposed that concealed Kent bundle was responsible in  our 
patient fo r the recurrent SVT.
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C l in ic a l  im p lic a t io n s
Knowledge about the exact mechanism of a supraventricular tachycardia 
w ith  wide QRS is  extremely important fo r treatment and prevention of the 
arrhythmia. In a given patient with wide QRS tachycardia we must establish 
the orig ine of the tachycardia. In our presented case several e lectrocardio­
graphic and electrophysio logic characteristics o f the tachycardia excluded 
the existence of ve n tr icu la r tachycardia. There was no evidence of a t r io ­
ven tricu la r d issocia tion , capture, fusion beats and H-potentials preceeded 
V waves during tachycardia.
Further d if fe re n t ia l diagnostic p o s s ib ilit ie s  are the follow ings: SVT 
w ith  preexistent BBB, AV-junctional re-entry tachycardia with aberrant ven­
t r ic u la r  conduction, W.-P.-W. syndrome with antidrom tachycardia and con­
cealed W.-P.-W. syndrome with functional BBB during tachycardia. The diag­
nosis of a concealed accessory pathway can be supposed i f  the increase of 
cycle length during the tachycardia associated w ith the appearance of func­
t io n a l BBB /2 , 11/. The location of concealed anomalous pathway can be sus­
pected ip s ila te ra l to the BBB configuration ( le f t  or r ig h t) . The demonstra­
t io n  and explanation o f th is  can be seen in  our case in  Figure 8. Occurrence 
of RBBB had no e ffe c t on cycle length and retrograde VA conduction time 
during SVT. However the cycle length and VA conduction time during SVT with 
LBBB were longer than during SVT with a normal QRS complex or with RBBB. The 
presence of LBBB during tachycardia necessitates the supposition tha t the 
anterograde ven tricu la r activa tion  w il l  f i r s t  pass through the r ig h t ven­
t r ic le  and than slowly by in traventricu la r conduction reach the concealed 
bypass tra c t in the le f t  ven tric le . I t  is  obvious that the slower ventricu­
la r  conduction lengthens the re-entry c ir c u it  therefore tachycardia cycle 
length and retrograde VA conduction w il l  be prolonged. Therapeutic approach 
o f SVT with concealed accessory pathway might be d iffe ren t from those w ith 
junc tiona l re-entry tachycardias. The adm inistration of drugs depressing the 
AV-node (beta-blockers, verapamil) allows a given extrastimulus to cause 
greater AV-node delay which delay potentiates the concealed retrograde con­
duction through anomalous pathway because i t  is  given more time for recovery 
from antegrade concealed penetration. Thus drugs, as procainamid, quin id ine, 
amiodarone should be used in  these circumstances which depress anterograde 
pathway conduction and lik e ly  prolong retrograde refractoriness of the 
concealed accessory pathway, therefore preventing of maintenance of re ­
entrant SVT /21 /.
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In patients with drug-resistant tachycardias due to the above-men­
tioned mechanism, invasive diagnostic methods such as endocardial mapping and 
surgical intervention should be considered /18 /. A curative therapeutic a l­
te rnative  to surgery has recently offered the catheter ablation method. 
Ablation of these accessory pathways can be achieved by app lica tion  of 
catheter induced radiofrequency current with high efficacy and safe /7 , 9 /. 
The exact loca liza tion  of the accessory pathway is  the most important pre­
requ is ite  fo r a successful catheter ablation and surgical in tervention  
/6 , 9 /.
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PATHOPHYSIOLOGICAL ASPECTS OF THE PROTECTIVE EFFECT 
OF MAGNES IOM IN MYOCARDIAL INFARCTION (REVIEW)
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Intravenous adm in is tra tion o f magnesium has proved to  have b e n e fic ia l e ffe c t in  acute 
myocardial in fa rc tio n . Magnesium seems to  act at d if fe re n t le ve ls  of the cardiovascular system. 
Of the greatest importance is  the d ire c t influence o f Mg^+ on the cardiomyocyte which includes: 
reduction of cytoplasmatic calcium overload, pro tection o f mitochondria against calcium in f lu x , 
and dim inution o f c e llu la r  potassium, magnesium and ATP dep le tion. By means o f these e ffe c ts , 
or by i t s  d ire c t action on myocardium, Mg^+ in h ib its  the o rig in  o f p o s tin fa rc tio n a l dys­
rhythmias. Furthermore, magnesium reduces a fterload by decrease in  vascular resistance, and 
improves coronary flow.
The mechanism underlying the p ro tective  e ffe c t o f magnesium remains complex and poorly 
understood. Nevertheless, Mg^+ therapy is  e ffe c tive , undemanding, and easy to  procure. Ex- 
pectably, intravenous adm in is tra tion  o f Mg^+ may become a rou tine  part o f myocardial p ro tection 
in  acute myocardial in fa rc tio n .
Keywords: Magnesium, myocardial in fa rc tio n , myocardial protection
In tro d u c t io n
Contemporary cardiology continues to expand therapeutic approaches to 
reduce the extent of damage caused by myocardial in fa rc tion  (M I). Besides 
invasive interventions a good number of pharmacological preparations are 
used, e.g. beta blockers, asp irin , and trombolytics /19 /. In the la s t decade 
Mg^ + has been frequently used as a therapeutic agent against MI. However, 
the f i r s t  experimental data on protective e ffe c t of Mg^+ against myocardial 
in fa rc tion  have been achieved several decades ago /9 / and protective e ffect 
of magnesium on the cardiovascular system has been em pirica lly u t i l is e d  over 
the las t 50 years /13 /.
Abbreviation: MI : myocardial in fa rc tio n
O ffp rin ts  requests should be sent to : Fedor Simko, Department o f Pathophysiology, 
Faculty of Medicine, Komensky U n ive rs ity , Sasinkova 4, 813 72 B ra tis lava , Slovak Republic
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Surveys presenting several controlled c lin ic a l t r ia ls  /29, 43/ suggest 
p o s itive  effect of intravenously applied Mg^+ during MI. Ionized magnesium 
was shown to reduce the incidence of dysrhythmias /1 , 34, 38, 41/ and car­
diac shock /34 /. Rassmussen e t a l.  /34 /, Smith /41 / and Shechter et a l.  /38/ 
observed a substantial decrease in m orta lity  in magnesium treated groups in 
comparison to placebo-treated groups. However, a comparison between these 
t r ia ls  is  made d i f f ic u l t  because of d iffe re n t doses of magnesium administer­
ed, d iffe re n t duration of therapy and lack of uniform ity of the c r ite r ia .
The LIMIT-II t r ia l  (the second Leicester Intravenous Magnesium In te r­
ventiona l t r ia l )  represent by fa r the largest experience with magnesium in 
acute MI /51/. This sing le-centre study randomised 2300 patients w ith sus­
pected acute MI to receive intravenous MgSO^  with 8 mmol given as a bolus 
over 5 min and then 65 mmol given as an infusion over 24 h, or a matching 
placebo infusion. At 28 days, the re la tive  reduction of m orta lity  was 24% in 
magnesium-treated group in  comparison to placebo-treated group and incidence 
o f le f t  ventricu lar fa ilu re  was decreased in  25% /51 /. The benefic ia l e ffec t 
o f intravenous Mg^ + treatment l ie s  probably in the acute phase. However, the 
b e n e fit attained here was not lo s t during the follow ing year /33 /.
Despite these undoubtedly promising c lin ic a l data the mechanism of 
magnesium protective e ffe c t fo r MI is  s t i l l  unclear and remains a top ic of 
contraversy /44/.
C o m p a rtm e n ta liz a tio n  o f  Mg^+ in  th e  body under p h y s io lo g ic a l c o n d it io n s  and
in  th e  course o f MI
Magnesium is  the second most prevalent ion ic  species of the in tra ­
c e llu la r  m ilieu. Out of i t s  to ta l content in  the human body 60% is  w ith in 
the bone matrix, 39% in  the in tra c e llu la r space and only 1% is  ex trace llu la r 
/4 6 /. I t s  concentration in  the myocardial c e ll is  about 17 mM/kg of the 
c e llu la r  f lu id  /30 /. A major fraction  of ce llu la r magnesium is  presumably 
present as Mg complexes such as adenosine triphosphate /АТР/ and other 
adenosine nucleotides. Because most of the adenosine nucleotides are sup­
posed to be associated w ith  the m yofib rils , con trac tile  proteins represent 
the richest ce llu la r compartment of bound magnesium /30 /. However, fo r the 
m a jo rity  of biochemical processes the level of free ionised magnesium (Mg +) 
is  decisive. The in tra c e llu la r  concentration of Mg^+ is  about 1.0 mM /49 /.
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E xtrace llu la r magnesium concentration under physiological conditions 
lie s  between 0.75 and 1.2 mM/1 /8 / .  In the course of acute MI, a rapid in ­
crease of serum magnesium concentration takes place at the onset. Very 
quickly i t  is  decreased to below normal values, and w ith in  36-48 h the serum 
magnesium concentration reaches normal values again /17, 29/.
The early magnesaemia increase, which appears before the creatinkinase 
increases, is  probably caused by elim ination of magnesium from the ischaemic 
myocardium /1 7 /. Immediately a fte r the onset of in fa rc tion  ATP is  s p l i t ,  
magnesium is  released from the ATP complex and as a resu lt cytoplasmatic 
magnesium ion concentration increases trans ien tly  /18 /. The increase in the 
concentration gradient of Mg^+ across the cardiomyocyte membrane and the 
deterioration of the sarcolemma by ischaemia may both be responsible fo r 
leakage of magnesium ions from the cardiac tissue /1 8 /. This assumption is  
supported by the find ing of decreased magnesium concentration in the myo­
cardium of patients who died of ischaemic heart disease /14 /.
The subsequent decrease of Mg^ + serum concentration is  supposed to be 
caused by postin fa rc tiona l sympathetic s tim ula tion . The increased sympathe­
t ic  tone stimulates postin farctiona l d iuresis which possibly resu lts in  the 
loss of magnesium in  the urine /17/ and augments lip o ly s is  with subsequent 
binding of magnesium with free fa tty  acids in  adipocytes /15 /. Hypomagne- 
saemia is  not spec ific  fo r postin farctional sympathicotonia, but also occurs 
during other types of stress /4 /.
The return of Mg^+ to normal levels is  l ik e ly  mediated by the kidney 
which represents the main regulator of magnesium homeostasis. Excretion of 
magnesium responds d ire c tly  to the load presented to the kidney-high serum 
magnesium levels lead to diminished renal tubular reabsorption and vice 
versa /24 /.
The p h y s io lo g ic  r o le  o f  magnesium in  th e  card iom yocyte
Both in tra -  and extrace llu la r magnesium partic ipa te  in many processes 
w ithin cardiomyocyte including contraction, enzyme activa tion  and ion 
transport processes /30, 39, 49/, while in teractions of Mg^+ with Ca^+ and 
K+ are supposed to be of greatest physiological importance.
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Magnesium—calcium In teractions
Mg^+ antagonizes the e ffe c t of Ca^+ ions at d iffe re n t leve ls of the 
heart muscle c e ll. Mg^+ in h ib its  the slow calcium channel, sometimes con­
sidered to be the decisive component of the calcium-antagonistic e ffe c t of 
Mg^+. This e ffect is  more pronounced when the channel is  activated /49 /. 
Mg^+ has, however, a re la t iv e ly  low a f f in ity  to the calcium channel and 
causes only a mild blockade /23 /. Mg^ + is  by three to five  orders of magni­
tude less potent than the organic Ca^+ channel blockers, e.g. verapamil or 
n itrend ip ine  /5 / but, compared to these compounds, a d is tin c t advantage of 
Mg^+ is  i t s  broad spectral e ffec ts  i t  has on volatage-, receptor- and leak- 
oparated membrane channels /5 / .  I t  seems therefore, that Mgz+ in  i t s  phy­
s io lo g ic a l concentration may have a ro le  as a non-specific natural cardiac 
and vascular blocker of the slow calcium channel /20 /.
The level of in tra c e llu la r  Ca^+ is  also influenced through in te rac­
tio n s  between magnesium and the sarcoplasmic reticulum /SR/. Mg + is  the 
cofactor of SR Ca^+-ATPase /10 / and a normal level of ce llu la r Mg^+ is  es­
s e n tia l fo r the a c tiv ity  of th is  enzyme, so perm itting active uptake of Caz+ 
w ith  the subsequent re laxation  /4 9 /. Magnesium also blocks calcium induced 
calcium release by in h ib it io n  of propagation of th is  process along the in ­
t ra c e llu la r  network of the cardiomyocyte's  sarcoplasmic reticulum /16 /.
Besides regulation of the cytoplasmatic Ca^+ concentration, Mg^+ in ­
fluences the cardiomyocite' s calcium action in  several other ways. Mg + was 
shown to reduce the uptake of Ca^+ by mitochondria, which would be d e le te r i­
ous to oxidative phosphorylation /20 /. Moreover, free magnesium ions par­
t ic ip a te  in modulating tension development in  cardiac tissue. A p lausible 
mechanism may be the in te rac tion  of Mg^+ and Ca^+ ions on the non-specific 
s ite s  of troponin C, which constitutes a locus of d irect competition between 
ions o f calcium and magnesium at the leve l of the con tractile  proteins /31 /. 
The f in a l level of conformation changes on troponin C, and thus also the 
degree of derepression of actino-myosin interactions on which contraction 
in te n s ity  depends, may be determined by the re la tion  of Ca^+ to Mg^+ ion 
concentrations during systole /2 4 /.
E ffec ts  of magnesium on potassium metabolism
There is a good evidence suggesting that Mg^ + and K+ metabolism is  
c lose ly  linked. I t  was, e .g ., shown that an increased magnesium concentra-
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tion  in the perfusion f lu id  prevented potassium release from the iso la ted 
myocardium /40 /. I t  was also revealed that in  some patients with hypoka- 
laemia the reple tion of potassium alone fa ile d  to normalize the serum po­
tassium leve l. This potassium-refractory hypokalaemia is  caused by conco­
mitant magnesium deficiency, and can be corrected with magnesium supple­
mentation /4 7 /. The re la tive  representation of Mg2+ and K+ in lymphocytes 
may be a prognostic factor of dysrhythmia development /2 / and m orta lity  /3 / 
in patients with acute MI.
The mechanism of Mg2+ and K+ in teraction  in  the cardiomyocyte is  not 
fu l ly  understood. Although Mg2+ acts as Na+-K+-ATPase cofactor /4 2 /, the 
d e f ic it  of th is  ion does not seem to s ig n if ic a n tly  a ffect enzyme a c t iv ity  
/11, 39/. Of greater importance seems to be that Mg2+ may determine the 
level of ce llu la r K+ by acting on potassium channels. Several of the K+ 
channels exh ib it inward re c tif ic a tio n , i .e .  they allow K+ to pass more 
read ily  in the inward d irection  than in the outward direction /2 5 /. I t  ap­
pears that th is  inward re c tif ic a tio n  may be caused by internal Mg2+ blocking 
the outward movement of K+ through these channels. In the absence of mag­
nesium, transport in  both d irections takes place at the same in tens ity  /2 5 /.
P a s s ib le  mechanisms o f  My2+ b e n e f ic ia l  e f f e c t  d u rin g  MI
Mg2+ protective e ffec t w ith in  the cardiomyocyte
I t  is  not clear and needs further study, which of the above-mentioned 
mechanisms might resu lt in  protection against MI /44 /. However, knowing the 
mechanism of deleterious e ffec t of ischaemia i t  is  supposed that during MI 
Mg + may reduce cytoplasmatic calcium overload and protect the mitochondria 
against calcium in flu x  /52 /. Intravenous application of magnesium is  sup­
posed to prevent ce llu la r depletion of Mg2+ /8 , 18/. Through obstructing e f­
fect upon the potassium channel Mg2+ might help to lower the potassium loss 
/49 /. Moreover, magnesium is  necessary fo r Mg-ATP regeneration /18 / and 
decreases high-energy phosphate depletion during MI /8 /.
Antiarrhythmic action of magnesium
The antiarrhythmic e ffec t of magnesium i f  one of i ts  e a rlie s t c l in ­
ic a lly  u t il iz e d  properties /13 /. Already in  the s ix tie s  the treatment with
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K+-Mg^+ asparaginic acid was shown to reduce the incidence of dysrhythmias 
in  patients with various cardiovascular diseases /6 , 7 /. Magnesium reduces 
the incidence of supraventricular /35/ as well as the p o te n tia lly  le tha l 
dysrhythmias that occur during acute MI /1 , 41/. Elevation of ex trace llu la r 
magnesium levels prolong conduction time and the refractory period in  a tr ia  
and AV node /33 /. On the other hand, decreased levels of e x tra ce llu la r Mg + 
shorten the e ffec tive  re fracto ry  period, but lengthen the re la tive  re frac ­
to ry  period, thereby increasing the vu ln e ra b ility  of the ven tric les to  f ib ­
r i l la t io n  /45 /. The antiarrhythmic properties of Mg^ + depend heavily on the 
concentration of other ions, p a rticu la rly  of potassium /45/ and are mediated 
e ith e r by a d irect e ffe c t of magnesium on myocardium, or by i t s  calcium- 
antagonistic a ffec t and in te raction  with potassium /46/.
E ffec ts  of Mg^ + on systematic and coronary c ircu la tio n
A number of authors believe that m o rta lity  reduction as a re s u lt of 
intravenous administration of Mg^+ in MI is  not a resu lt of i ts  an tia rrhy th ­
mic e ffe c t because dysrhythmias a fter in fa rc tio n  are successfully affected 
by aimed antiarrhythmic therapy /38, 44/. Larger importance is  a ttr ib u te d  to 
the pos itive  haemodynamic e ffec t of magnesium including an in h ib it io n  of the 
myogenic, basal and hormonal-induced tone of vascular smooth muscule in  the 
la rge vessels, a rte rio les  and venules in  a l l  regional vasculatures so fa r 
examined /2 / .  This action is  supposed to be determined by Mg + a b i l i t y  to 
in h ib i t  the slow calcium channel /2 / and/or by stimulation of prostacyclin 
release /28 /. The next e ffe c t is  a decreased blood pressure as a re su lt of 
the peripheral a r te r ia l resistance while the c o n tra c tility  and the fre ­
quency of the heart are not affected /36 /. Magnesium has also an advantage­
ous e ffe c t on coronary c ircu la tio n . I t  in h ib its  tonic contraction of corona­
ry  spasm as a consequence of physical load /22 / or hyperventilation /27 / as 
observed in patients with variant angina pectoris . Reduction of a fterload 
and improvement of coronary blood flow may both improve the re la tionsh ip  
between oxygen supply and consumption during MI /36 /.
The main ro le of the Mg^ + protective e ffe c t during acute MI seems to 
be determined by i ts  d ire c t action on the cardiomyocyte /51, 52/. Reducing 
a fte rlo a d , improvement of coronary flow and lim ita tio n  of dysrhythmias are 
also o f importance /3 3 /. The presumed antiaggregation /12/ and anticoagula­
t io n  po ten tia l /33/ of Mg + may play a supportive ro le.
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Q uestions to  be answered
In  connection with intravenous administration of Mg^+ during MI 
several questions s t i l l  remain unanswered:
— Should Mg^ + be administered in suspected acute MI only in  cases of 
evident hypomagnaesemia, or in every case (since serum levels of Mg + do not 
re f le c t the in tra c e llu la r  concentration of th is  ion) /29, 37, 47/?
— Is  the therapy's goal to normalize serum Mg^ + levels, or to  prevent 
i t s  postin fa rc tiona l decrease or to achieve i t s  s lig h t increase to  above 
normal values /50/?
— faking in to  account that hypomagnaesemia is  considered a r is k  
facto r fo r sudden death /32 /, m orta lity  in  ischaemic heart disease /1 4 /, as 
well as in  other cardiovascular diseases /3 7 /, should determination of mag­
nesium level and i t s  theraputic correction become part of a routine diag­
nostic and therapeutic practice /47 /, especia lly in patients w ith cardio­
vascular diseases /37/?
The mechanism of protective e ffec t of magnesium is  complex, poorly 
understood and thus more or less hypothetical at the present time. Again i t  
appears that we are facing the old problem of not understanding the mecha­
nisms of action of an administered drug. However, the c lin ic a l resu lts  of 
venous application of magnesium are very promising. Moreover, Mg + therapy 
is  simple, inexpensive, of lim ited side e ffec ts  and non-apparent po ten tia l 
to in te rac t with other drugs. These indisputable preferences enable the use 
of th is  substance fo r a broad spectrum of therapeutic care /26, 29, 41, 52/. 
The mentioned facts suggest that venous administration of magnesium may 
become a routine part of myocardial protection in  acute in fa rc tion  in  the 
near fu tu re .
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The authors studied the d is tr ib u tio n  o f the paracetamol conjugation in  a Hungarian 
population (53 adu lt Caucasian persons). The data ind ica ted  tha t the excretion o f paracetamol 
glucuronide and sulphate were not normally d is tr ib u te d . B imodality were apparent in  both con­
jugation pathways: 15.1% of subjects was re la t iv e ly  extensive glucuronidators, and the 24.5% of 
subjects was extensive sulphatators. Monitoring the ra t io s  of various urinary paracetamol 
conjugates/paracetamol may be useful as a to o l fo r determ ining the glucuronide and sulphate 
conjugation capacity in  humans.
Keywords: Paracetamol, HPLC, glucuronidation, su lpha ta tion , conjugation capac ity , drug 
conjugation
In t r o d u c t io n
Paracetamol (acetaminophen) is  excreted as glucuronide (55 to  60% of 
the dose administered) and sulphate (35% of the dose administered) conjugate 
from the human body and only a very small amount undergoes the oxidative 
metabolic route via the cytochrome P-450 system leading to formation of a 
reactive intermediary, the N-hydroxy-N-acetyl-4-aminophenol conjugated then 
with glutathione. Trace amounts of conjugates with cystein and mercapturic
Abbreviations: UDGPT — Uridinediphosphoglucuronosyi transferase, PST — phenyl 
sulphatetransferase, M/P — metabolite/paracetamol r a t io ,  P — paracetamol, G, S — glucuronide 
and sulphate conjugated paracetamol
O ffp r in t requests should be sent to : K. Róna, Haynal Imre University o f Health Sciences 
1st Department o f Medicine, D iv is ion  o f C lin ic a l Pharmacology, H-1389 Budapest, P.0. Box 112, 
Hungary
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acid conjugates can also be detected. Only 3% of the administered parace­
tamol dose is  excreted unchanged. Paracetamol is  therefore a good te s t agent 
fo r  studies in phase I I  (conjugative) metabolism /2 /.
Uridinediphosphoglucuronosyl transferase (UDGPT) is  readily inducible 
by phénobarbital and methylcholantrene type enzyme inducers, but th is  holds 
not true in the case of sulphate conjugation. The conjugation capacity of 
the ind iv idua l can be characterized by the metabolite/paracetamol ra tio  
(M /P), the ra tio  being 18 fo r glucuronide and 12 fo r sulphate conjugates in 
healthy volunteers /3 / .  Phenytoin or rifam p ic in  pretreatment resu lts  in  an 
increase to 41 and 35, respectively, in  the ra tio  of the glucuronide fo r­
mation. Smoking of 40 cigarettes a day leads to an induction in  a glucuro­
nide formation equivalent to rifam picin adm inistration, but only to a m ini­
mal induction of sulphate conjugation. There was a 17% increase in  para­
cetamol glucuronidation in volunteers on a 10-day Brussels sprouts and 
cabbage d ie t compared to controls and no s ig n ifica n t change in  sulphate 
conjugation /12 /.
The two key transferases in  paracetamol conjugation d if fe r  in  lo c a liz ­
a tio n , too, UDGPT being prevalent in the endoplasmic reticulum /4 /  and 
sulphatetransferase (PST) in  the cytosol of hepatic ce lls  /5 /.
There is  a s ig n ifica n t decline in  sulphate conjugation w ithout any 
change in glucuronide formation in patients suffering from Parkinson's 
disease and various motoric function losses /1 7 /. Similar resu lts  were ob­
ta ined from a population of patients with rheumatoid arthrosis. A weak-S- 
carboxymethyl-cysteine sulphoxidation may be responsible fo r th is  pheno­
menon .
However there is  no difference in paracetamol conjugation in  G ilb e rt 's  
disease compared to healthy controls /2 0 /. The b iliru b in  conjugation is  im­
paired in  G ilb e rt's  disease and th is  may imply a possible existence of 
various UDPGT isozymes /3 / .  Paracetamol h a lf l i f e  is  increased and the 
glucuronide and sulphate conjugation rates are diminished in  acute and 
chronic l iv e r  diseases /5 / .  There is  an increase in glucuronide conjugation 
in  obese patients /1 / .
Glucuronidation is  increased by 75%, the oxidation by 88% in  pregnant 
women without any change in sulphate conjugation /9 /.  Anticonceptives have 
s im ila r effects /4 / .
Age seems to play no major role in  the sulphatation capacity but there 
is  a 23% decline in  glucuronide formation capacity in the population above 
the age of 80 years compared to the population of the age of 20 /10 /.
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Glucuronidation is  absent or in e ff ic ie n t in  newborn babies and young children 
/1 3 /, paracetamol ha lf l i f e  is  also prolonged, and the main metabolic route 
is  sulphate conjugation. This finding is ,  however, disputed /6 / .
Sulphate conjugation of paracetamol is  a saturable process. The l i ­
m iting factor is  the sulphate pool available /8 / .  The rapid sulphate con­
jugation rate drops to ha lf a c t iv ity  a fte r 4 h, glucuronidation reaches i t s  
steady-state level a fte r 6 h /13 /.
The in te rind iv idua l and in tere thn ic differences of paracetamol con­
jugation and the genetic background (tw in studies) confirmed the monogenetic 
regulation of the UDGPT and PST a c t iv it ie s  in  man /4, 18, 21/. A 300% in te r-  
ind iv idua l difference in  paracetamol glucuronide and sulphate conjugate fo r­
mation was demonstrated in  twins /11 /. The differences were grater in  mono­
zygote twins h inting at the dominant impact of environmental facto rs  over 
the genetic ones. On the contrary, in  another study there were no s ig n if ­
icant differences in the metabolic pattern of paracetamol between twins of 
the Venda tr ib e  liv in g  in  South A frica and in  Europe /15, 16/. S ig n ifica n t 
in te rin d iv id u a l differences in UDGPT /4 / and PST a c tiv it ie s  /21 / were also 
reported. The urinary M/P ra tio  had 27% RSD according to Bock /2 / ,  while 
th is  value was only 14% when repeated on the same subject.
The controversies in the data generated by previous studies motivated 
us to carry out a study on paracetamol glucuronide and sulphate conjugation 
capacity d is tr ib u tio n  in a Hungarian population.
We have developed a liq u id  chromatographic method /14/ fo r  deter­
mination of paracetamol and i ts  glucuronide and sulphate conjugates from 
urine. A fter oral paracetamol adm inistration we determined f i r s t  the excret­
ed unchanged (" fre e ") paracetamol (P), then the enzyme-pretreated samples 
were fu rthe r analysed for the glucuronide (G)- and sulphate (S)-conjugated 
paracetamol. The G/P and S/P ra tios  were calculated as representative values 
fo r ind iv idua l conjugation capacity.
S u b je c ts  and M ethods
A fte r g iv ing  th e ir  informed consent 53 healthy volunteers (mean age 37.5 +_14.3, 38 
women and 15 men) pa rtic ipa ted  in  the study. A l l  o f them were nonsmokers. The sub jects swallow­
ed 500 mg paracetamol (1 ta b le t o f Rubophen, Chinoin Chemical Works, Budapest, Hungary) w ith  
1 d l tap water while fas ting  in  the morning, and co lle c te d  th e ir  urine fo r the consecutive B h. 
These u rine  samples were stored a t -20 °C u n t i l  fu rth e r analysed.
The unchanged ( " fre e ")  paracetamol was determined in  the f i r s t  step by l iq u id  chromato­
graphy ( in te rn a l standard: 3-acetaminophenol). The u rine  samples were pretreated w ith  beta-
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glucuronidase and the " to ta l"  ( fre e  and conjugated) paracetamol was determined in  the second 
s tep . This method detects, beside the "free" paracetamol, the glucuronide- and su lphate- 
conjugated paracetamol a f te r  the beta-glucuronidase/sulphatase cleavage.
The paracetamol content o f  the glucuronide (G) and sulphate (S) conjugate was c a lc u la t­
ed from the paracetamol (P) measured by subtraction and a metabolite/paracetamol (M/P) ra t io  
was formed. The "free " (unconjugated) paracetamol was extrac ted  by adding 50 pg 3-acetmino- 
phenol in te rn a l standard (1 mg/ml) to  1 ml o f urine sample and adjusting i t s  pH to  10 w ith  
0.25 M sodium hydroxide. A fte r  add ition  o f 8 ml e thy lace ta te  the samples were shaken mechan­
ic a l ly  fo r  10 min. The upper la y e r was separated, f i l t e r e d  through 1 PS phaseseparator (What­
man), and dried under n itrogen  stream. The dry residues were made up in  100 p i  o f methanol:wa- 
te r  (3 :7 , v /v ) mixture: 20 p i  volumes were in jected.
The " to ta l"  paracetamol was extracted by adding 1 ml o f 0.2 M (pH = 5) acetate b u ffe r 
and 50 p i  o f beta-glucuronidase/arylsulphatase or only beta-glucuronidase (Serva) and 500 pg o f 
3-acetaminophenol in te rn a l standard to  1 ml of urine sample. A fte r  mechanic shake the samples 
were incubated in a 37 °C water bath fo r 2 h. The pH o f the samples was adjusted to  10 w ith 
1 ml o f 0.25 M sodium hydroxide a fte r  the incubation pe riod . 8 ml of ethyl-acetate was added 
fo llow ed by a 10 min shaking and the separation o f the upper la ye r. The upper layer was f i l ­
te red  through 1 PS phaseseparator (Whatman) and dried under n itrogen stream. The residues were 
made up in  1000 p i  o f methanol : water (3:7 , v /v) m ixture; 20 u l volumes were in je c te d . Beckman 
HOB pump, Labor HIM 308 UV de tecto r, Rheodyne 7125 in je c to r  w ith  20 p i  loop and Shimadzu 
C-R6A in teg ra to r constitu ted  the l iq u id  chromatographic system. Separation was ca rrie d  out a t 
room temperature on Spherisorb-5-ODS (250x4.6 mm I .D . ,  Chrompack) column. The mobile phase was 
methanol:water (3:7 , v /v ) m ix tu re , the flow speed was 1 m l/m in. The monitoring wavelength was 
254 nm.
The excreted amounts of free paracetamol (P ), i t s  glucuronide (G) and 
sulphate (S) conjugates in  proportion to the dose administered (500 mg) are 
shown on Table I .  The G/P ra tios are shown in  Fig. 1. The cumulative f re ­
quencies of the S/P ra tio s  are represented in  F ig . 2.
The normal d is tr ib u tio n  pattern of the M/P ra tios  could be re jected 
both in  the case of G/P and S/P ratios (95% confidence in terva l, goodness of 
f i t  tes t 5.1 4.2 S.D. fo r  G/P and 15.7 jh 14.5 S.D. for S/P, x^ = 33.18 fo r 
G/P and 38.62 fo r S/P). The population could be divided into two d is t in c t 
populations by the antimode of the cumulative M/P ra tio  frequencies (Table
R esults
Table I
Eight hour urine-excrected paracetamol conjugates in  healthy 
volunteers (n=53)
Free paracetamol Paracetamol
glucuronide
(dose%)
Paracetamol
sulphate
(dose%)(dose^)
mean (x) 
+ S.D.
2.98
2.47
7.74
7.3
21.67
13.76
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Na of cases 
N */.
Cumulative frequency 
*/.
F ig . 1. The d is tr ib u tio n  pattern  o f G/P
I I ) .  The "normal conjugator" population has a G/P ra tio  <. 8 and and S/P 
ra tio  <  18, while the "intensive conjugators" have a G/P ra tio  >  8 and an 
S/P ra tio  >  18 (Table I I I ) .
The corre la tion coe ffic ie n t between G/P and S/P was 0.379. We found 
2 normal sulphate conjugators out of the 8 intensive glucuronidators and 7 
normal glucuronidators out of the 13 intensive sulphate conjugators.
No corre lation was found between age and conjugator capacity (M/P). 
The corre la tion  co e ffic ie n t was 0.020 fo r G/P and 0.091 fo r S/P.
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No. of cases 
N • /.
Cumulative frequency 
•/.
F ig , 2. The d is tr ib u tio n  pa ttern  o f S/P
D iscussion
With regard to the chromatographic charac te ris tics  of the ana ly tica l 
method for the investiga tion  of paracetamol conjugation elaborated by us we 
re fe r  to  our previous papers /14 /.
We demonstrate in  F ig. 3 a chromatogram showing the separation of 
4-acetaminophenol (paracetamol) from 3-acetaminophenol ( in te rna l standard) 
and 2-acetaminophenol. The separation factor ( a )  of the in terna l standard 
and paracetamol was 2.59. The typ ica l blank (A) and an after-treatment (B) 
urine  sample extract chromatogram is  shown in  F ig . 4.
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Table I I
D is tr ib u tio n  o f paracetamol coniuqation in  the Hungarian adu lt 
population (n=53)
Glucuronide conjugation Sulptste conjugation
G/P < 8 G/P >  8 S/P< 8 S/P>• 0
n % n % n % n %
No. of
cases 45 84.9 8 15.1 40 75.5 13 24.5
(n=53)
Men 12 80 3 20 12 80 3 20
(n=15)
Women 33 86.8 5 13.2 28 73.7 10 26.3
P — paracetamol; G — glucuronide conjugated paracetamol; S — s u l­
phate conjugated paracetamol
Table I I I
Coniuqation capacity o f the Hungarian population (n=53) according to  sex
M/P + S.D.
Total population "NC" phenotype "IC " phenotype
Glucuronidation (G/P) 
Men 
Women
Significance
6.1 + 6.1 
4.6 + 3.1 
t  = 1.106 (N.S.)
3.6 + 2.3
3.7 + 1.9
t  = 0.194 (N.S.)
16.3 + 6.1 
11.1 + 2.7 
t  = 1.678 (N.S.)
Sulphatation (S/P) 
Men 13.3 + 7.9 9.9 + 4.1 26.6 + 3.9
Women 16.7 + 16.4 9.8 + 3.3 35.9 + 22.7
S ignificance t  = 0.785 (N.S.) t  = 0.021 (N.S.) t  = 0.686 (N.S.)
M/P — metabolite/paracetamol
There is  a corre la tion  ( r  = 0.B4) between the paracetamol clearance 
and the volume of the collected urine /7 / .  We investigated only those urine 
samples the collected volume of which was between 150 and 800 ml. We did not 
find  a corre la tion  between the M/P ra tios  under these circumstances ( r  = 
= 0.107) and th is  is  in  good accordance with the results of Bock e t a l.  /2 /. 
The urinary pH did not influence the resu lts  obtained.
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F ig . 3 . Chromatographic separations o f acetaminophenols. Chromatographie conditions in  the te x t
The effect of smoking was not taken in to  account, fo r a l l  our volun- 
te reers  were nonsmokers.
There was no co rre la tio n  between the glucuronide (G/P) and sulphate 
(S/P) conjugation, what can be explained on grounds of d iffe re n t loca liza ­
t io n ,  in d u c ib ility  and other biochemical differences between the two trans­
ferases /4 , 21/. Both M/P d is tribu tions  contradict the normal d is trib u tio n  
2
p a t t e r n  (X - t e s t ,  95% p r o b a b i l i t y  le v e l ) .
The variation c o e ffic ie n t fo r G/P was 82.7% ( xjhS.D. = 5 .08^4 .2 ) and 
fo r S/P 91.5% (x+  S.D, = 15.7 +_ 14.5). These data allow the d is tinc tion  be­
tween two phenotypes w ith regard to glucuronidation and sulphatation w ith in 
the population. 15.1% were extensive glucuronidators and 24.5% were exten­
sive sulphate conjugators in  the Hungarian population studied. Age and 
gender had no s ign ifican t e ffe c t on phenotype (p >  0.05, N.S.).
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F ig . A. Chromatograms o f u rine  extrac ts  (A) blank w ith the in te rn a l standard, (B) ty p ic a l 
sample. Chromatographic conditions in  the te x t
The gene frequences fo r UDGPT were p = 0.612, q = 0.388 and for PST 
p = 0.506, q = 0.494 (calculated according to the Hardy—Weinberg law).
The glucuronide formation and sulphatation play a key role in  the "end 
phase" of drug metabolism. The insuffic iency of the monogenically deter­
mined UDPGT and PST a c t iv it ie s  is  manifested in  G ilbert's  syndrome, C rig le r— 
Najjar's disease, certa in  chronic neurologic disease states (e .g .: Parkinson's 
disease) and rheumatoid a r th r i t is  /17, 18, 20/. Paracetamol is  a suitable 
test agent fo r conjugation capacity determinations /19 /.
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A sem i-longitudinal study o f the cholestero l p ro file s  a t various stages o f pregnancy 
was conducted. The study involved 49 pregnant women who showed no physical signs o f obesity, 
were ne ither hypertensive nor d iab e tic , and had a mean age o f 2 4 .7 ^4 .5  (mean+^SD). The re ­
s u lts  showed a progressive increase in  the serum to ta l and high-density lip o p ro te in  (HDL) 
cho lestero l leve ls from 4 .0 2 ^0 .3 9  mmol/L (meanjfSD) and 1 .81^0 .15  mmol/L, resp e c tive ly , a t 
3 months, to  5 .5 9^0 .5 1  mmol/L and 2 .4 6^0 .1 8  mmol/ in  the n in th  month o f pregnancy. These 
represent a 39^11% and a 35^+10% increase in  to ta l and HDL cho lestero l, resp e c tive ly , over 
the 3-month le ve l. The le ve ls  o f to ta l and HDL cho lestero l however decreased to  4 .08 j^0 .40  
mmol/L and 1 .8 9 ^ 0 .1 7  mmol/L, respective ly , a month a fte r  de live ry . The most s ig n if ic a n t 
(P <  0.05) month to  month increase was recorded between the 6th and the 7th month fo r  both 
to ta l and HDL cho leste ro l. The proportion o f HDL cho lestero l remained f a i r l y  constant at 
43^3  to 45^4% throughout the period o f pregnancy covered, and one month a fte r  d e live ry . 
This suggests a proportiona l increase in  a l l  lip o p ro te in  fra c tio n s . I t  is  concluded th a t the 
observed changes are normal physio log ica l events.
Keywords: Pregnant women, gestational ages, to ta l cho les te ro l, HDL cho lestero l
In t r o d u c t io n
Plasma lip id s  are associated with macromolecular complexes known as 
lipopro te ins. Total cholesterol is  a measure of the cholesterol content of 
a l l  lipoprote ins. Because the cholesterol composition of lipopro te ins  is  
fa ir ly  constant, the cholesterol content of the various lipopro te ins is  
often used as a measure of th e ir concentration in  the plasma /2 / .
Abbreviations: HDL — High Density L ipoprote in , LDL — Low Density L ipopro te in , 
VLDL — Very Low Density L ipoprote in
O ffp r in t requests should be sent to : A. E. Udoh, Department o f Chemical Pathology, 
U n ivers ity  o f Calabar, Calabar, N igeria
0236-5286/94/# 4.00 © 1994 Akadémiai Kiadő, Budapest
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Changes in plasma cholesterol may be due to disease /8 , 10, 11/, d ie t 
/6 , 12/, age and other physiological changes involving abnormalities of sex 
hormones /9 /.  Pathological chances in cholesterol levels usually involve the 
lowering of HDL cholestero l leve l and increases in  to ta l,  low density lip o ­
p ro te in  (LDL), and very low density lipopro te in  (VLDL) cholesterol /3 / .  Such 
changes are known to co rre la te  positive ly  w ith the development of severe, 
and premature atherosclerosis /4 , 7/ and coronary heart disease /5 / .
Pregnancy is  a s tre ss fu l physiological state during which hormonal 
changes are induced. Some of the involved hormones a ffec t l ip id  metabolism 
/1 5 /.  The aim of th is  study is  to determine the serum cholesterol p ro f ile  of 
some Nigerian women at d if fe re n t stages of pregnancy in  a sem i-longitudinal 
manner and to compare the HDL/total cholesterol ra tio  at each stage. A l­
though cholesterol leve ls  in  some pregnant women had e a rlie r been carried 
out /1 3 /, to our knowledge, no longitud inal study has been conducted on 
Nigerian women.
We believe that the findings in th is  study w i l l  enable the c lin ic ia n  
to  d iffe re n tia te  between l ip id  changes due to pregnancy per se and those due 
to  possible complications of pregnancy or other diseases which may occur 
during pregnancy.
P re g n a n t women and Methods
Subjects : The fo llow ing  c r i t e r ia  were used fo r  the se lec tion  of subjects fo r  the study. 
Blood pressure: S y s to lic  120 mmHg or less 
D ia s to lic  70 mmHg or less 
Fasting blood glucose — 3 .3 .-4 .5  rnmol/L.
Urine glucose: N i l l  
Age: 22—30 years
Habitus: Lean — no tendency to  obesity.
No previous h is tory o f diabetes or hypertension. There was however no con tro l on d ie t.
The study was s ta rted  w ith  28 pregnant women who reported at the M aternity C lin ic  o f 
the U n ive rs ity  of Calabar Teaching Hospital w ith 3 month o ld  pregnancies. More subjects were 
incorporated in to  the study a t  gesta tiona l ages o f 4, 5 and 6 months, respective ly , a t which 
tim e the number o f p a rtic ip a n ts  rose to  49. A ll subjects remained in  the study to  the end had 
normal d e live ries .
Sample co lle c tio n  and analysis
Fasting blood samples were co llected  once a month during v is i ts  to  the c l in ic .  Samples 
were a lso collected from the same subjects in  the postnata l c l in ic  one month a fte r  d e live ry . 
Sera separated from the samples so collected were analysed fo r  to ta l and HDL cho lestero l 
w ith in  24 h.
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Tota l and HOL cholesterol estimation
Cholesterol estimation was performed according to  the method o f Bachorick e t a l.  /1 / .  
For to ta l cholestero l 0.10 ml o f serum was extracted w ith  2.4 ml o f chloroform/methanol 
(2:1 v /v ) .  1.0 ml o f the supernatant from the ex trac t was mixed w ith 0.06 ml o f 2.5% fe r r ic  
ch lo ride  and 1.0 ml o f g la c ia l ace tic  acid. Two m i l l i l i t r e s  o f concentrated sulphuric were then 
added and thoroughly mixed. The re su ltin g  coloured so lu tio n  was examined a t 550 nm in  a 
Shimadzu UV 120-02 spectrophotometer.
Two standards (2.5 mmol/L and 5 mmol/L) and Sigma co n tro l sera (normal and abnormal 
range) were analysed along w ith  the te s t samples. The absorbance o f standards was used to  c a l­
cu la te  the values o f the te s t and con tro ls .
H0L cholestero l
This fra c tio n  was separated from the other lip o p ro te in s  by the Heparin manganous ch lo ­
r id e  method described by Burnstein and Samaille /2 / .  The supernatant, which contained the HDL, 
was analysed fo r  HDL cho lestero l as described above fo r to ta l cho lestero l except th a t instead 
o f 0.1 m l, 0.2 ml o f the supernatant was extracted w ith chloroform/methanol (2:1 v /v ) .
S ta t is t ic a l analysis
The s ign ificance  o f changes in  l ip id  p ro f ile  a t various ages o f gestation was assessed 
by the one-factor analysis o f variance while the s ign ificance  o f d ifferences between any two 
ages o f gestation was assessed by Student’ s ta te s t.
R esu lts
The resu lt of the pre-test screening fo r a l l  subjects is  shown in
Table I .
Table I
Results o f p re -test screening o f subjects
Parameter Value
Blood Pressure: sys to lic 117 + 2+ mmHg
d ia s to lic 67 +_ 4 mmHg
Fasting Blood Glucose 3.65 +_ 0.23 mmol/1
Mean age 24.7 ^ 4 .5  years
"TTean + SD
Cholesterol p ro file
A p lo t of the mean serum to ta l and HDL cholesterol levels of p a r t i­
c ipa ting  . subjects against gestational age is  shown in Fig. 1. The graph
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Fig. 1
shows a progressive increase in  both the to ta l and HDL cholesterol levels 
throughout the period of pregnancy studied. The highest monthly increases in 
both to ta l and HOL cholesterol levels occurred between the 6th and the 7th 
months. The ninth-month leve ls  of to ta l and HDL cholesterol was 5 .50^0 .51  
and 2.46 +_ 0.18, respectively (Table I I ) .  These levels were by 39^+11% and 
35 +_ 10%, respectively, higher than the three-month leve ls. The proportion 
o f HDL cholesterol to to ta l cholesterol remained between 43 +_ 3% and 45 +_ 4% 
throughout pregnancy (Table I ) .  One month a fte r delivery the leve ls of both 
to ta l  and HDL cholesterol decreased s ig n if ic a n tly  (P <. 0.05) versus the 
ninth-month levels and were s im ila r to those obtained in  the third-month of 
pregnancy (Fig. 1). The percentage of HDL to to ta l cholesterol was, however, 
not s ig n if ic a n tly  altered (P >  0.05) a month a fte r delivery.
This study has shown that the leve ls of both serum to ta l and HDL 
cho leste ro l increased w ith the age of pregnancy but the ra tio  of HDL cho­
le s te ro l to to ta l cholesterol remained constant. The constancy of the 
total/HDL cholesterol ra t io  may be an important d iffe re n tia tin g  fac to r be­
tween pathological and non-pathological increase in  cholesterol leve ls , for
D iscuss ion
Table I I
Serum to ta l and HDL cholestero l leve ls at d iffe re n t ages o f gestation
Gestational age: months Per cent
Parameters
measured 3 4 5 6 7 8 9
**
increase 
9th month
vs
3rd month
post-
d e li­
very
** *
Total 4.02+ 4.25 4.47 4.84 5.35 5.51 5.59 4.08
cholesterol + + + + + + + p+ i 0.05 39 + 11 + P > 0.05
(mmol/1) 0.39 0.44 0.49 0.32 0.52 0.55 0.51 0.40
HDL 1.81 1.89 2.03 2.08 2.32 2.43 2.46 1.89
cholesterol + + + + + + + p <  0.05 35 + 10 + P >  0.05
(mmol/l) 0.16 0.18 0.20 0.20 0.19 0.19 0.18 0.17
HDL
cholestero l 
as % o f 
to ta l
cholesterol
45 + 4 44 + 3 45 + 3 43 + 3 44 + 4 44 + 3 44 + 3 p >  0.05 46 + 4 ? >  0.05
n = 28 31 41 49 41 28 29 18
4*S ignificance o f d iffe rence between 9th and 3rd months leve ls ; ***S ign ificance o f d iffe rence between post-de livery and 3rd month 
leve ls ; mean _+ SD
- j40
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pathological increase in  cholesterol leve l is  always accompanied by a de­
crease in  HDL cholestero l: to ta l cholesterol ra t io  /3 , 7 /. An e a r lie r  study 
on d iabetic  patients under treatment showed that even when the serum to ta l 
cho lestero l levels were w ith in  the normal range, the HDL cholesterol leve ls 
were s ig n ific a n tly  reduced /1 4 /.
An increase in  cholestero l leve l at the f u l l  term of pregnancy was re­
ported by Taylor et a l.  /1 3 /, who a ttribu ted  the increase to  hormonal 
changes. I t  had also e a r lie r  been observed that women on estrogen had in ­
creased HDL cholesterol and reduced LDL cholesterol /15 /. However, women who 
combine estrogen w ith progestins as ora l contraceptives have normal leve ls 
o f HDL and LDL cho lestero l, while those on progestins alone have reduced HDL 
cho lestero l /15 /. In our study no s ig n ifica n t change (P >  0.05) in  the HDL 
cho lestero l fraction  was observed. This may be due to the fac t th a t both 
estrogens and progestins are increased during pregnancy, thus, creating  a 
s im ila r  s itua tion  to those of the women who combine estrogen and progestins 
as contraceptives /1 5 /.
We suspect that the increase in  cholesterol level during pregnancy may 
be important fo r the su rv iva l of the fe tus, fo r the female sex hormones, 
such as estrogens and progestins, which are increased during pregnancy are 
formed from cholesterol. The cholesterol increase may therefore serve to 
meet the requirements fo r these hormones which are essential fo r fetoplacen­
ta l  well-being. The observed cholesterol changes should therefore be seen as 
a normal physiological event. I t  should also be noted that the normal leve ls 
o f cholesterol in  pregnant women would depend on the age of pregnancy and 
may r is e  up to a leve l exceeding by 39 +_ 11% the levels of the non-pregnant 
women.
A c k n o w l e d g e m e n t :  The authors are g ra te fu l to  Professor Alan M ello rs  o f the 
Department o f Chemistry and Biochemistry o f the U n ive rs ity  o f Guelph fo r donating the Sigma 
L ip id  Control sera used in  th is  study.
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New immunoactive therap ies, plasmapheresis, intravenous ste ro id  pulse in fu s io n  and 
intravenous immunoglobulins were examined fo r e ffica cy  on the basis of large ca su is tic s  o f 
myasthenia g rav is . The best re s u lts  were achieved w ith  combination o f these procedures. In ­
d ications o f the new methods: ( i )  resp ira to ry c r is is  o f any character (myasthenic, ch o line rg ic  
or mixed o s c il la t in g  c r is is ) ;  ( i i )  the patients ' preparation fo r thymectomy; ( i i i ) post­
thymectomy therapy aimed a t improving the patients co n d itio n , a t avoiding relapses, a t shor­
tening the time o f s te ro id  therapy and at repressing ch o lin e rg ic  drug therapy; ( iv )  pa tien ts  
o f o ld  age in  c ris is -p rone  s ta te . — The new methods, together w ith thymectomy, s te ro id  
therapy and immunosuppression, represent a very e f f ic ie n t  and promising new way toward modern 
therapy o f myasthenia g rav is .
Keywords: Myasthenia, immunoglobulin, plasmapheresis, pulsus s te ro id , thymectomy
In tro d u c t io n
Myasthenia gravis (MG), a disease characterized by disorder o f the 
transmission of neuromuscular s tim u li, has long been known as a c l in ic a l 
e n tity  /3 1 /. The disease has gained special importance in  the la s t three 
decades when MG became the f i r s t  neurological disease recognized and proved 
to be of autoimmune character /15—17/. There is  another important fa c t: MG 
often associates with other known or suspected immune or autoimmune d is -
Abbreviations: AChR: acetylcholine receptor, MG: myasthenia grav is , PEX: plasma ex­
change, PS: pulsus s te ro id  in fu s io n , IVIG: intravenous immunoglobulin, OSS: D is a b ility  Status 
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eases; such an association reached 20% in  the great casuistics published by 
one o f us /24 /, and th is  fac t in  i t s e l f  supports the theory o f immune or 
autoimmune pathogenesis o f MG from the c l in ic a l point of view. In  sp ite  of 
the fa c t that quite a few myasthenia syndromes or diseases s im ila r to  MG 
have been described in  the la s t decades /2 8 /, MG i ts e l f  became a valuable 
and heterogeneous arena o f immunological research, and especially th a t of 
therapeu tica l experiments. I t  can be considered a model disease in  many re­
la t io n s  of the question. So the re lated, mainly therapeutical experiments 
are o f p i lo t  character and may be va lid  in  other research areas, too.
The casuistics of ours — registered and followed up fo r 43 years — 
is  one of the greatest MG casuistics in  the lite ra tu re , elaborated in 
d e ta il concerning a l l  the possible points o f view. I t  is  also one of the 
greatest casuistics fo r thymectomies and thymomectomies /13, 24, 27, 30/. 
E x tirp a tio n  of the thymus gland or of thymoma, the possible to ta l or maximal 
thymectomy, can be considered the most useful and most valuable procedure in 
the therapy of MG. Steroid therapy in numerous forms and protocols also has 
long been used in MG therapy, as has been cytosta tic  immunosuppression in 
chronic cases and in relapsing forms of the disease, too /2 4 /. The views 
mentioned above have opened a way to such newer therapeutic p o s s ib il it ie s  
which essentia lly  improved the resu lts  of MG therapy, especially together or 
in  combination with thymectomy. So in  the la s t one and ha lf decades plasma­
pheresis, plasmaexchange, PEX /4 , 10, 14/, la te r high-dose intravenous
méthylprednisolone pulse in fus ion (PS) therapy /2 , 25/, s t i l l  more recently 
intravenous immunoglobulin (IVIG) therapy /5 , 9/ became very important 
procedures.
Our Department of Neurology can be considered the centre fo r  myas­
then ic  cases in th is  country; i t  is  used also by foreign patients, concern­
ing both diagnosis and therapy. A ll the above-listed modern immunoactive 
therapeutic  procedures and th e ir  combinations have been applied on a great 
number of patients (sometimes also with p i lo t  character); i t  seems to be 
worth while to give a summary of these modern single and combined therapies, 
and o f the results of th e ir  use. We mention here that there are th e o re tic a l­
ly  other modern therapeutical approaches: e.g. antigen manipulation (in
form, timespan and e ffic a c y ); change of the immune system p rio r to  antigen 
e f fe c t ;  creation of В c e lls  producing antibodies; suppression o f immune 
reaction  specific  fo r AChRs; change of in te rac tion  between T and В c e lls , 
f in a l ly ,  introduction of a n tiid io typ ic  or anticlonotypic reactions, i .e .  
ta rg e tin g  the antigen-specific T ce lls . A ll these theoretica l p o s s ib il it ie s  
\
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are s t i l l  in an experimental phase; they ce rta in ly  need a rather long period 
u n t il one or more of them w il l  be applied in  humans /1 , 3, 6, 7 /. This is  a 
fu rthe r reason fo r making available the resu lts  of our modern, well-known, 
proven and applicable therapeutical procedure which are based on our great 
casu istics.
C a s u is t ic s  and Methods
Diagnosis, observation, therapy and fo llow -up  o f the patients have been based on 43-year 
experiences o f one o f us. Meanwhile the view o f the disease changed considerably and the term 
o f myasthenia syndrome has been developed; the range o f diagnostic procedures widened and so 
d id  th a t o f the therapeutica l p o s s ib il it ie s  (except fo r thymectomy and ch o lin e rg ic  drug 
therapy).
We surveyed 1596 cases of MG, out o f whom 730 passed thymectomy or thymomectomy /13, 
24, 27, 30/. The age range o f the patients was very wide: 7y-91y, the m ajority being 35y-60y, 
(x = 49.9y, cr = 6.29, a2 = 39.6). The age of p a tie n ts , however, has hardly any in fluence  on the 
in d ica tio n  o f the therapy. S im ila r ly , the sex r a t io  has no importance (female—male: 2 .7 :2 ) ; i t  
tended to  be equalized over the age o f 55 years.
The greatest experience — a few hundred p a tie n ts , more than five  hundred treatment — 
was gained w ith PEX, which was introduced 6 years a f te r  the f i r s t  experiments in  the lite ra tu re  
and has been used by us ever since. — PS therapy, i . e .  500-2000 mg méthylprednisolone every 
second or th ird  day, was performed in  56 p a tie n ts , on 2-5 occasions in  each case. — The very 
expensive IVIG therapy was applied per se on ly  in  a few cases, fo r th is  method o f treatment 
used alone is  o f l i t t l e  value, though i t  is  extremely valuable in  contiination w ith  o ther active 
therapeutic procedures.
The therapeutica l protocol is  shown in  a fig u re  (F ig . 1) to  make the complicated, some­
times soph istica ted forms o f these therapeutica l combinations easier to understand. Maintenance 
therapy has frequently  been supplemented w ith  long-term azathioprine (Imuran) treatment 
(100-150 mg d a ily  or on a lte rna te  days), less frequen tly  w ith 100-150 mg levamisole (Decaris) 
weekly once and, very seldom, w ith inos ip lex  (Isoprinosine) or Cyclosporin-A (Sandimnun) 
therapy.
Although the immunotherapies recognized and introduced recently  are of 
great importance, thymectomy keeps on having i t s  central pos ition  in  the 
therapeutic plan of MG, a position tha t was occupied by th is  in tervention  
50 years ago. A ll the other therapeutical procedures serve the preparation of 
the patient fo r surgery, or can be considered supplementary therapies a fte r 
surgery i f  necessary; they are applied sometimes repeatedly, or as a main­
tenance therapy. Hence, a l l  other therapies must be considered in  th e ir  log­
ic a l re la tion  to thymectomy or thymomectomy. This complicated therapeutic 
strategy s t i l l  pointing in one d ire c tio n , sometimes even with feed back 
mechanism, is  shown in Fig. 2. The importance of individual decision ought 
to be stressed in a l l  these patterns, including, of course, the necessary 
actual changes, too. In spite of the complexity of the therapies lis te d
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C O R T I C O ­
S T E R O I D
T H E R A P Y
• LOW DOSE (10-20 mg/day) chronic maintaining therapy
•  HI GH DOSE (250-300 mg/day fo r 2 weeks )
•  "PU LSE ''-THERAPY (500-2000 mg in infusion every other day or 
every 5th day, 5 to 10 tim es)
•  " MA I N T A I N I N G "  PULSES (m onthly one procedure)
P L A S M A
E X C H A N G E
One-and-a-half plasma volume daily for 5 days ( in crisis)
One plasma volume every other day, 5 to 6 times
• Two volumes every other day, 4 times
• Combined w ith lymphoptasma exchange alternately (among 3 
plasma exchanges alternately 2 lymphoplasma exchanges, every 
other day )
•  Combined with steroid pulses alternately (every other day 
500-1000 mg steroid infusion)
•  Combined w ith intravenous immunoglobulin (alternately 
every other day 5 to 10 mg Intraglobin "F " Biotest)
• "M ain ta in ing" procedures (one and a half volume every second 
week or monthly)
F ig . 1. Therapeutic protocols in  myasthenia gravis
"Maintaining 
steroid pulses
Low-dose
steroid(LD)
I
"Reminding" 
PEX procedures
I
Chronic immunosuppression«,ч
Relapsing cases
Chronic Secondary
progressing cases generalized cases
THYMECTOMY
T reble
combination
Anticholinesterase 
drug th. (± )
( PEX +IVIG 
combination
Steroid "pulse" Plasma exchange Iv. immunglobulin PEX+SPT
therapy (PS) (PEX) therapy ( 1V1G ) combination
Ocular MG
Ant ichol i nesterase 
drug th. (+)
♦
Chronic progressing 
oculo-, bulboscelatal 
orsceletal MG
Anticholinesterase 
drug th .(± )
T
Acute fulminant 
bulbar MG
F ig . 2. Strategy fo r therapy fo r myasthenia gravis
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above, there is  no risk  of incom patib ility  when therapy is  changed or a new 
combination is  introduced.
Treatment w ith PEX ju s t as in  our previous studies — was performed by a running 
operative , automatic ce ll-separa to r o f Dideco-Vivacell type, in  general on a lte rna te  days or on 
every th ird  day ( in  maintenance therapy monthly or b im onth ly). The pattern of previous inves­
tig a tio n s  and th a t o f continuous con tro l were described elsewhere /10, 26/, and th is  pa tte rn  has 
been v a lid  fo r  combined therapies, too . No complications occurred in  th is  great the rapeu tica l 
se ries , and considerable s id e -e ffe c ts  (such as collapse or skin-phenomena) were ha rd ly  met. 
This may be a ttr ib u te d  to the ca re fu l previous inves tiga tions  and th e ir  correct eva lua tion . In 
eva lua tion , fo llow -up, and comparison o f the pa tien ts ' c l in ic a l status the DSS p o in t system 
/22 , 24/ was applied, which has been used recently by Kornfeld e t a l.  /11 / during the fo llow -up  
o f great apheresis casu is tics .
A considerable part o f the pa tien ts  were admitted in  resp ira to ry c r is is  or in  a c r is is -  
prone s ta te . These were treated according to  the complicated but well-elaborated ru le s  o f in ­
tensive care, including u t i l iz a t io n  o f "synaptic res tin g  process" and a l l  the other ways th a t 
can be used in  th is  important therapeutic strategy /18—21, 23, 25/. Patients in  severe con­
d it io n s  needed constant and ra tio n a l psychotherapy, i . e .  conversation during re g u la r ly  re ­
tu rn ing  v is i t s ,  followed by appropriate care and advices /2 9 /. A pos itive  and o p tim is t ic  s p i r i t  
o f the p a tie n t and the so lu tion  o f h is  depressive s ta te  seem to be important fo r  the function  
o f the immune system, too.
R e s u lts
The fie ld s  of ind ica tion  of modern immunosuppressive therapies re f le c t 
besides th e ir  growing bene fit, the increase in  therapeutical p o s s ib il it ie s .  
Preparation of patients fo r surgery has become safer and thymectomy has be­
come possible also in formerly inoperable cases. Thymectomy must be a plan­
ned operation which should be performed at the best time, a fte r correct pre­
paration of the patients, possibly ensuring th e ir  compliance and consent. 
Hence, thymectomy is  never an emergency operation. Some urgent operations 
have become possible due to the improvement of the patients' condition and 
the shortening of the preparation period. These therapies are especia lly  im­
portant, fo r the respiratory c r is is  or cris is-prone state rap id ly  ceases and 
thus the patient can soon be operated. I t  should not be forgotten th a t the 
myasthenic or cholinergic forms of resp ira tory c r is is , as well as the a l­
te rna ting , o sc illa tin g  manifestations of the c r is is  present a very d i f f i c u l t  
problem fo r intensive therapy /20, 21, 23, 25/. The therapies l is te d  above 
proved to be essential not only fo r the quick resolution of crises, but also 
fo r the avoidance of rather frequent complications of crises. Results of 
PEX + IVIG, i.e .  PEX + PS treatment, furthermore, that of treb le  combination 
fo r patients suffering from c r is is  or cris is-prone state, are shown in  
Fig. 3.
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Fig. 3. E ffe c t o f combined therapies in  myasthenia gravis
The results of even to ta l or maximal thymectomy may not be sa tis fac ­
to ry  and patients may require further active treatment. The combined thera­
pies have also had an important role in  the post-thymectomy therapeutic 
plan, e ither in one series or as maintenance therapy.
Recently, one encounter in a growing number of old patients, i .e .  
cases in which thymic surgery is  excluded, except in cases of v e r if ie d  
thymoma. Formerly, these patients were only treated by X-ray ir ra d ia tio n  of 
the thymic area in  add ition  to drug therapy. By now the therapeutical meth­
ods in  these cases have become richer. Consequently PEX treatment has been 
performed in old patien ts without any troub le . Furthermore, PS therapy has 
been well tolerated by the old patients, too, and th is  invervention has be­
come more e ff ic ie n t than long-term ste ro id  therapy, whose s ide -e ffects , 
inc lud ing osteoporosis, are considerable. Combined therapy has been found 
useful in cholinergic drug resistance, moreover, in cases when resistance 
and intolerance occurred together. PEX therapy may be applied cautiously in 
pregnant myasthenic pa tien ts , too, especia lly i f  lack of immunoglobulins 
can be eliminated by IVIG therapy. S ubstitu tion  of immunoglobulins is  im­
portant in  e lderly pa tien ts , too. — Modern immune therapies can be applied 
in  cases associated w ith other immune disorders. We have gained favourable 
experiences in MG + m u ltip le  sclerosis, MG + polymyositis and in  the Landry— 
G u illa in —Barré—Strohl syndrome.
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D is c u s s io n
The benefic ia l e ffect of PEX in  general lasts about one year. This 
period can be prolonged by ha lf a year, or one year by combination with 
other in terventions. I t  may be stated tha t no such important and e f f ic ie n t  
change has taken place in  the therapy of MG since the f i r s t  app lica tion  of 
Neostigmine and development of thymectomy as the introduction of immune 
therapies, especially in favourable combinations. Furthermore, there is  
hardly any neurological disorder or syndrome in  the therapy of which such an 
advance would have happened as in MG.
Introduction of PEX therapy in  the neurological practice was an event 
of considerable importance. Sorry, i t s  app lica tion  is  lim ited by i t s  very 
high expense. Kornfeld et a l. /11/ summarize 10-year experiences in  aphere- 
t ic  therapy carried out in  an apheretic centre in  a great number o f cases. 
M ajority of th e ir  patients were suffering  from neurological diseases, MG or 
Landry—G u illa in—Barre—Strohl syndrome. The authors mention the same con­
siderations in  MG practice as we did in  our previous studies /10, 26/, and 
in  the present one. The indications are: resp ira tory crises, grave exacerba­
tions res is tant to drug therapy, preparation fo r surgery, especia lly of pa­
tie n ts  suffering from respiratory defic iency, too, post-thymectomy tre a t­
ment, i f  cholinerg ic drug therapy and long-term azathioprine immunosuppres­
sion is  in s u ff ic ie n t, and, f in a lly ,  avoidening or shortening of a long-term 
stero id  treatment. In pure ocular MG, PEX therapy was not applied in  the 
mentioned casuistics e ithe r. Comparing th e ir  resu lts  with our previous ones 
/1 1 /, they stress that there was no s t r ic t  corre la tion between the duration 
of MG and the success of the therapy. Patients with AChR antibodies, on the 
other hand, respond to PEX therapy be tte r than seronegative pa tien ts . We 
fa ile d  to find  any corre la tion between the response of the patien ts to PEX 
and th e ir  antibody leve l. I t  can be considered that one of the great ad­
vantages of these complex therapies is  tha t the therapeutical response of 
also seronegative cases is  good, although immunoglobulins in these instances 
may be bound to a target-organ (muscle) and the c lin ic a l improvement can be 
ascribed only to the elim ination of c irc u la tin g  immune-complexes.
PS therapy, an intervention used fa r less frequently than PEX, was 
found successful when used alone /25/ and s t i l l  better in combination with 
PEX. In addition to i t s  e ffic iency , i t  has a fu rthe r important advantage: i t  
can pa rtly  or completely substitute the long-term steroid cure, thus de­
crease or even elim inate i t s  s ide -e ffec ts . We were surprised to  learn how
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w ell e lderly patients to lerated PS therapy. The e ffec t with combination w ith 
PEX was almost dramatic in  very serious and hardly treatable patien ts, too, 
even in  cris is-prone or res is tant cases.
IVIG therapy in  i t s e l f  was poorly e f f ic ie n t .  Considerable e ffe c t was 
observed, however, in  combination with e ith e r PEX or PS. A treb le  combina­
t io n , however, was performed only in very few cases, just as ultimum re - 
fugium. Advantage of IVIG treatment can be looked fo r in quick su bs titu tion  
of the immunoglobulins lo s t in  consequence of PEX therapy. This may be im­
portant in  old pa tien ts , in  cases with weakened organism, in patients w ith 
in te rcurren t disease or in  pregnancy.
In spite of the fa c t that previous l i te ra r y  data /12, 24/ unequivocal­
ly  proved that in  the cultured areas of the world MG did not depend on geo­
graphical, social or n u tr it io n a l factors, long-term research shows a slow 
increase in MG incidence. This fact should be attribu ted not only to the 
more improving diagnostic p o ss ib ilit ie s  of MG, but also to an apparent den­
s ity  of the disease both in childhood and in  older age. This includes, of 
course, an increased number of childhood myasthenic syndromes /8 / ,  as well 
as of the associated and provoked myasthenia syndromes /28/. The ra t io  of 
o r ig in a l, acquired MG — as an en tity  — has shown a modest increase.
We consider on the basis of the above-mentioned facts that a correct 
therapeutic plan should be elaborated fo r the very e ff ic ie n t, modern immuno­
therapies applicable in  the acquired forms of MG. For th is  purpose, th e ir  
ind ications should be considered p rim arily . So, respiratory c r is is  o f any 
k ind, especially o s c illa t in g  c r is is  characterized by myasthenic and cho lin ­
erg ic symptoms (e x is tin g  sometimes simultaneously), has been considered 
prime indication fo r combined therapy. These methods have been e f f ic ie n t ,  
even life -sav ing . Thymectomy or creation of i t s  conditions often need care­
fu l preparation. By routine use of these modern immunoactive therapies, 
operation became feasable even in  previously inoperable cases. Accordingly, 
the same is  va lid  also fo r the post-thymectomy period when the re s u lt of 
surgery is  poor, when drug therapy is  not sa tis fac to ry  on account o f re ­
sistance, intolerance or both, or when the duration of the long-term ste ro id  
therapy ought to be shortened. These therapies may be indicated in  associat­
ed diseases, in childhood, in old age, and sometimes in pregnancy, too. 
Double combination in  general should be planned in  each case in d iv id u a lly , 
on the basis of the duration, c lin ic a l form and therapeutical responsiveness 
of the disease. Omission of long-term ste ro id  therapy is  a special advant­
age. Complications p ra c tic a lly  do not occur i f  patients were prepared cor­
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re c tly . In such cases, furthermore, s ide-effects are less pronounced, occur 
very ra re ly , they do not r is k  the patient.
Hence, the therapeutic inventory of MG has been essen tia lly  enriched 
by the immunoreactive therapies, which — together with thymectomy, steroid 
and cytosta tic  treatment — s ig n ific a n tly  improved the l i fe -q u a li ty  of our 
patients, furthermore, they may open gate for new directions of research and 
promise further good resu lts  in  the near fu ture .
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HEPATOLOGY
POLYPHASIC AND PROTRACTED PATTERNS OF HEPATITIS A INFECTION:
A RETROSPECTIVE STUDY
A. L. KASSAS, L. TELEGDY, E. MÉHESFALVI, T. SZILÁGYI,
I .  MIHÁLY
3rd Department, Szent László Hospital, H-1097 Budapest, Gyáli út 5—7,
Hungary
(Received: June 14, 1994)
The present study was performed in  order to  evaluate the frequency and c l in ic a l 
features o f polyphasic and p ro tracted  forms o f HA in fe c tio n . Out of 297 adu lt HA patients ad­
m itted to  our hosp ita l, 12.5% and 8.4% were polyphasic and protracted, respective ly , in  c l in ­
ic a l course. 21.6% of the polyphasic patients had more than one relapses. The rates o f sympto­
matic relapse during the fo llow -up  o f the polyphasic and protracted HA in fe c tio ns  were 51% and 
56%, respective ly , One % o f a l l  HA pa tients presented a cho les ta tic  pa ttern . Three % of a l l  
the pa tients  had to  be readm itted fo r  hosp ita l treatment. The outcome o f disease was benign in 
a l l  HA pa tients, though, complete recovery sometimes needed s ix  months.
Keywords: H epatitis  A in fe c tio n , polyphasic, p ro tracted , cho les ta tic  patterns
In tro d u c t io n
Recently the incidence of hepatitis  A had decreased in  Hungary /7, 13/, 
ind ica ting  an increase in  susceptible population. HA is  usually a mild and 
s e lf- lim ite d  disease, but i t  may take a protracted, or polyphasic course 
/1 —6, 11/, especially in  adults. However, i t  remains generally benign; i t  
resolves in six months.
In the recent years a few reports of sporadic cases of pers is tently  
abnormal liv e r function with IgM anti-HAV, and chronic h is to log ica l changes 
in  HA patients have been documented /8—10/.
Abbreviations: HA: h e p a tit is ,  HAV: h e p a titis  A v iru s , anti-HAV IgM: h e p a tit is  A v irus  
antibody class M, HBV: h e p a tit is  В v iru s , HBsAg: h e p a tit is  В surface antigen, HBc Ic^l: hepa­
t i t i s  В core antibody class M, HCV: h e p a tit is  C v irus , anti-HCV IgG: h e p a tit is  C v iru s  antibody 
class G, CMV: cytomegalovirus, EBV: Epstein—Barr v irus
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The prevalence and the c lin ic a l features of polyphasic and protracted 
patterns in HA patients are evaluated re trospectively.
M a t e r ia l  and Methods
Patients: 297 adu lt HA pa tie n ts  were consecutively admitted to  the 3rd department of 
In te rn a l Medicine o f the Szent László Hospita l in  Budapest, from January 1988 to  September 
1993.
Demographic data and disease cha rac te ris tics  are shown in  Tables I ,  I I  and I I I .  Diag­
nosis was based on c l in ic a l fea tu res, laboratory find ings, and p o s itive  It^ l anti-HAV tes ts . 
A l l  the patients with a typ ica l course were negative to HBV, CMV and EBV. HCV IgG te s t was 
in troduced fo r exclusion o f HCV, as la te  as in  January 1990. There were no intravenous drug 
abusers, homosexuals, a lcoho lics among the pa tients, nor people who had undergone a recent 
blood transfusion or immunosuppression therapy; extrahepatic obstruction and drug-induced 
ic te ru s  were also excluded. L ive r function  tes ts  (ASAT, ALAT, ALP, GGT) were performed weekly 
du ring  the acute phase o f disease and monthly (3-5 weeks) during the fo llow-up period. The 
standard methods were used. Assay fo r anti-HAV IgM, HBsAg, HBc IgM were carried  out using 
Organon Teknika M icroelisa, Roche Cobas-core automated ELISA. Tests fo r HCV used Organon 
Teknika M icroelisa ( f i r s t  generation), Ortho, Abbott (second generation). CMV was investigated 
by Organon Teknika M icroelisa, B iowhittaker EIA. Tests fo r EBV were performed by immuno­
fluorescence methods. A l l  sera were stored a t -20 °C u n t i l  tested. We regarded the c l in ic a l 
course ty p ic a l when acute ic te r ic  period resolved w ith in  1-4 weeks, followed by permanent nor­
m a liza tion  o f ASAT, ALAT by the 12th week. The term "polyphasic course" was used to  HA patients 
who had a 2-10 times increase in  ASAT, ALAT w ith or w ithout e levation in  serum b il ir u b in  
le v e l a f te r  the early convalescence period. The term "protracted course" was used in  cases when 
the acute phase was severe and slow reso lu tion  in  l iv e r  function values lasted more than 12 
weeks. C holestatic pattern was applied to  patients who had a prolonged severe jaundice with 
p ru r itu s  accompanied by h igh ly  elevated ALP and a bad general sta te .
R es u lts
The 62 HA patients who showed an atypical course represented 20.9% of 
the admitted HA patients; o f these 37 (12.5%) showed a polyphasic, and 25 
(8.4%) a protracted c lin ic a l pattern.
Characteristics of polyphasic HA cases are illu s tra te d  in Tables I  
and I I .  Eight of these patients (21.6%) presented more than one relapse.
The average in te rva l between the early convalescence and the f i r s t  
relapse was five  weeks, and i t  was four weeks between the relapses.
We noted that during the relapses only 51% of polyphasic HA patients 
presented symptoms such as anorexia, and/or fatigue, ep igastric discomfort 
w ith  or without jaundice. Seven polyphasic HA patients were readmitted to 
the department for bed-rest and symptomatic treatment. Tables I ,  I I I  give 
the features and liv e r  function values of 25 protracted HA patients. Three
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Table I
C haracte ris tics o f typ ica l and a typ ica l patterns o f HA in fec tion
Typical Polyphasic P rotracted
course course course
No. o f pa tients 235 37 25
Men/Women ra t io 0.98 1.1 2.1
Age (years), mean (range) 27.8 (15-65) 22.8 (14-78) 27.9 (14 -4 8 )
Length o f acute phase 
mean (range), days
16 (4 -4 5 ) 17 (13-45) 29 (1 7 -9 5 )
Total length o f illn e s s  
mean (range), days 46 (27-60) 117 (67-186) 106 (79 -159)
No. o f readmitted patients 0 7 2
No. o f pa tients  who presented 
symptoms during follow-up 0 19 14
Table I I
Laboratory findings in  polyphasic cases
Acute phase Early
convalescence
phase
1st
relapse
2nd
relapse
ASAT* (U /l)
mean 670 88 267 320
(range) (99-2850) (16-310) (73-310) (81 -410)
ALAT** (U /l)
mean 1232 179 507 479
(range) (185-3790) (54-298) (137-1380) (188—1090)
Serum b il ir u b in * * *  
(mmol/1) 
mean 122 33 24.3 19
(range) (17.1-147) (1 7 .1 -7 8 ) (17.1-38) (1 7 .1 -2 5 )
*normal range < 3 7 ; **normal range <40 ; ***normal range <17.1
of them (1% of the to ta l HA patients) showed a cholestatic pattern , to ta l 
serum b il iru b in  ranged between 291 and 660 mmol/1. The c lin ic a l recovery and 
normalization of l iv e r  function tests of the HA patients with protracted 
course appeared at 3, 4, 3 and 6 months, 52%, 36%, 4% and 8%, respective ly . 
Fortéén of the protracted cases (56%) were symptomatic during the follow-up,
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Table I I I
Laboratory findings in  p ro tracted  HA cases
Acute phase Early
convalescence
phase
1st
follow-up
ASAT* (U /l)
mean 821 110 97
(range) (118-3400) (43-1250) (58-301)
ALAT** (U /l)
mean 1257 265 190
(range) (229-4600) (75-1436) (82-570)
Serum b i l i r u b in * * *  
(itmol/1) 
mean 159 46 27
(range) (42-660) (17 .1 -294 ) (17.1-126)
^normal range <  37; **normal range < 40; ***norm al range -<17.1
and two of them needed readmission to the department with symptoms s im ila r 
to  that seen during the acute-phase disease.
In general, the ove ra ll rate of rehosp ita liza tion  because of relapse 
was 3%.
Discussion
Many hypotheses have been suggested to explain the pathogenesis of re­
lapsing course of HA in fe c tio n , such as a supposed defect in cell-mediated 
immune mechanism, mutation in HAV, superimposed in fection  with other v ira l 
agents. Sjogren et a l.  /1 2 / isolated HAV from the stool of HA patien ts 
during the relapse by using immune electron microscopy and molecular hyb­
r id iz a t io n ; accordingly, HAV its e l f  seems to play a causative ro le  in  the 
aetio logy of relapsing h e p a titis  A. V i l la r i  e t a l.  /15/ found h is to lo g ica l 
changes of the liv e r  during the relapse phase of HA infection are s im ila r to 
other acute hepatitis  due to  v ira l agents.
Our findings have shown that polyphasic course occurs more often than 
i t  was previously suggested /2 , 6, 11, 14/, we did not find any d ifference 
in  mean age, sex, and mean duration of the f i r s t  attack between HA in  the
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polyphasic HA group and the typ ica l HA patients. Mean values of ASAT/ALAT 
during the relapses were three times higher than the values of the early 
convalescence phase, in contrast with serum b iliru b in  which was lower during 
the relapse than in  the early convalescence phase.
Age, underlying disease, and other predisposing factors have been ob­
served in protracted HA in fec tion . We did not find any prevalence of pre­
disposing factors in our patients with protracted course, except tha t these 
patients were seriously i l l  at the onset of the disease. The only laboratory 
sign of protracted disease was a low prothrombin rate (0.40 or le ss ), which 
may be a consequence of massive liv e r  c e ll necrosis.
The c lin ic a l features of the acute phase in polyphasic HA in fe c tio n  
were s im ila r to that of typ ica l HA in fec tion  without any sign that may be 
he lp fu l in predicting relapse.
Generally, a l l  a typical HA in fec tion  were benign in outcome, and the 
disease resolved e n tire ly  in complete recovery within six months.
In conclusion, HA in fection  may not be a short-course disease; i t  may 
take a severe, polyphasic, and slow-resolution course, therefore, i t  merits 
a care fu l, and s u ff ic ie n tly  long follow-up.
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LABORATORY
THE USE OF URINE PROTEIN 1 AS AN INDICATOR OF RENAL TUBULAR FUNCTION 
IN  TYPE I  (INSULIN-DEPENDENT) DIABETES
0. 0.  I .  AYATSE, J .  W. WRIGHT 
Department of Biochemistry, University of Surrey, Guildford, England
(Received: March 25, 1993)
One hundred male insulin-dependent d iabe tic  p a tie n ts , aged 16 to 85 (mean 51.9) 
years, w ith  albumin excre tion ranging from normal to  gross excess were examined fo r  glomerular 
and tubu la r functiona l a lte ra tio n s  by estimating u rin a ry  le ve ls  of albumin and in d ic a to r  pro­
te in s  o f tubular damage. Urine p ro te in  1 (UP1), a newly-discovered low-molecular weight alpha-2 
glycom icroglobulin, together w ith “ ^-m icroglobulin was used to  assess tubular fu n c tio n . 19% of 
the pa tien ts  showed increased albumin excretion w ith  normal leve ls  of tubular p ro te in s  (g lo ­
merular p ro te in u r ia ), 11% excreted only tubular p ro te ins  in  excess (tubular p ro te in u r ia ), while 
40% had a mixed pattern o f both increased albumin and tubu la r proteins (glom erulotubular or 
mixed p ro te in u ria ). 30% had normal albumin and tu b u la r p ro te in  excretion in  u rin e . UP1 was 
found to  be a more sens itive  ind ica to r o f tubular abnorm ality than <x^-microglobulin. I t  is  
concluded th a t, although glomerular changes may be responsible fo r the pro te inuria  seen in  most 
d iabe tics  (mixed p ro te in u r ia ), in  a small but s ig n if ic a n t proportion of d ia b e tics , tubu lar 
func tion a l a lte ra tio n  may occur before, or in  the absence o f ,  glomerular dysfunction, and may 
warn o f su b c lin ica l tubu lar abnormality. This fin d in g  may have a d irec t bearing on the devel­
opment and course o f progression o f d iabe tic  nephropathy, and may question the r e l i a b i l i t y  of 
the present prognostic in te rp re ta tio n  o f microalbuminuria.
Keywords: Urine p ro te in  1, p ro te inu ria , kidney disease, albuminuria, tubu la r dysfunc­
t io n , diabetes m e llitus
In t r o d u c t io n
Diabetic nephropathy has been id e n tif ie d  as a major cause of renal 
fa ilu re  in patients beginning therapy fo r end-stage renal disease. I t  has 
been estimated that about 30% of insulin-dependent diabetic m e llitu s  sub­
jec ts  w i l l  develop p ro te inuria  and progressive renal fa ilu re  on the average
O ffp r in t requests should be sent to : 0. 0 . I .  Ayatse, Department o f B iochem istry, 
College o f Medicine, U n ive rs ity  o f Calabar, PMB 1115 Calabar, Nigeria
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of 16 to 20 years a fte r onset of the disease /10 /. This is  because when 
d iabe tic  renal disease is  well established, as evidenced by c l in ic a l pro­
te in u ria  or albuminuria, attempts to modify the relentless progression of 
the disease have often fa ile d  /10/. The dominant role of d iabetic nephro­
pathy as a cause of death in  la te diabetes stresses the importance of study­
ing changes in the renal function of d iabetics.
Reports characterizing a much e a rlie r stage of diabetic renal disease, 
ca lled  microalbuminuria /2 0 /, have called a tten tion  to the early id e n t if ic a ­
tio n  and therapeutic in tervention, with a view to delaying the ra te  of 
progression to end-stage renal disease. The early  renal changes in  d iabetics 
can be glomerular or tubu lar. However, since d iabetic  kidney disease is  usu­
a l ly  c lin ic a lly  characterized by an increased urinary excretion of albumin 
(a generally accepted marker of glomerular malfunction), i t  has often been 
argued that diabetic nephropathy is  exclusively a glomerulopathy /17, 21/. 
In the las t decade, a growing body of evidence has been advanced which ap­
pear to ca ll fo r more studies on tubular involvement in diabetes. These 
studies indicate the presence of tubular p ro te inu ria  before c l in ic a l nephro­
pathy develops /11, 19/.
The present study reports the estimation of tubular involvement in 
d iabe tic  patients by assaying Urine Protein 1 (UP1), which is  an cij g lyco- 
m icroglobulin (Mr 21000) that was isolated from human patients w ith renal 
tubu lar dysfunction (Dakopatts, Denmark). I t  has been p a rtia lly  p u r if ie d , 
sequenced and characterized /8 , 12/. The o r ig in  and function of UP1 has not 
been fu l ly  ascertained but data suggest tha t i t  might be useful as a new 
marker of impaired tubular reabsorption /1 , 2, 7 /. Excretion of a .-M icro - 
g lobu lin  (Mr 33000) which has been widely used in  evaluating tubular func­
t io n , was also examined.
Urinary albumin excretion was used to monitor glomerular function . 
D iabetic metabolic contro l was assessed by the levels of red c e ll glyco­
sylated haemoglobin (HbA^c).
P a tie n ts  and M ethods
P atien ts
One hundred male insulin-dependent (type I )  d iabetes m ellitus pa tients , aged between 
16 and 85 (mean 51.9) years, w ith  albumin excretion ranging from normal to  overt a lbum inuria , 
were included in  our s tud ies . The patients supplied untimed early  morning urine and overn ight 
fa s t in g  blood samples. From a con tro l group consis ting  o f 50 male healthy vo lun teers, aged
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20 to  50 years, early  morning u rine  samples were obtained. None o f the pa tients  and con tro l 
subjects showed evidence o f u rinary  t ra c t  in fe c tio n . A l l  urine samples were stored a t -20 °C 
u n t i l  analyzed.
Assays
Red c e ll g lycosylated haemoglobin (HbA^c) was measured by electroendo-osmosis using the 
G lytrac™  System (Ciba-Corning L td ., Essex, U .K .). The between batch c o e ff ic ie n t o f va ria tio n  
o f the method was 4% a t HbA^c concentration o f 12%. Urinary albumin was measured by imnuno- 
tu rb id im e try  on a ce n trifu g a l analyser (Roche D iagnostics, Welwyn Garden C ity , H erts, U .K .). 
This method had an interassay va ria tio n  of 4.6% at albumin concentration o f 15 mg/L, and a 
recovery of 98.7%. For u rine  c rea tin ine  assay J a ffe 's  p ic r ic  acid reaction on a c e n trifu g a l 
analyser was used, a j  m icroglobulin  (ajM) and UP1 were measured by ra d ia l immjnodiffusion /14 / 
and ELISA /2 2 /, respective ly . S ta t is t ic a l evaluation was performed using Student's ta te s t.
R esu lts
Of the 100 patients studied 12 had gross prote inuria with urinary 
albumin >230 mg/L. A ll urinary proteins measured were expressed as ra t io  of 
prote in to creatin ine, as recommended by Barrat /5 / and Marshall and Albert 
/1 5 /: albumin to creatin ine (ACR), UP1 to creatin ine (UCR) and a-^ M to crea­
tin in e  (MCR). The upper lim its  of normal (mean +_ 2 SD) were for ACR 1.5 
mg/mmol, for UCR 30 jjg/mmol, and for MCR 1.2 mg/mmol creatin ine, above these 
leve ls exretion was considered abnormal. Patients with ACR > 2 . 5  mg/mmol 
creatin ine and a negative reaction to Albustix were c lass ified  as having 
microalbuminuria.
The diabetic population had red c e ll HbA^ levels of 9.9 jw 2.2% (range 
6.7 to 18.8%), and there was a s ign ifican t difference (p<L. 0.01) between the
Table I
C la ss ifica tio n  o f renal function o f d iabe tic  subjects'*
Urinary pro te in  
pattern
Type of 
pro te inuria
Renal function n
Normal albumin, Normal Normal 30
UP1 and a
Increased albumin, 
normal UP1 and a^M
Glomelurar Glomerular
dysfunction
19
Increased UP1 and Tubular Tubular dysfunction 11
ci^M, normal albumin
Increased albumin, 
UP1 and ajM
Glomerular 
and tubular
Glomerular and 
tubular dysfunction
40
*UP1 = Urine p ro te in  1; ctjM = a^-M icroglobulin
1 0 2 3 .  0 .  I .  AYATSE, 3 . W. WRIGHT
E g
l i-  e
O. "  
3 0 .
4и  E
i t
< r~
AO-.
30-
го-
i O '
о
120
100-
80-
60-
AO-
20-
a
5-
A-
3-
2
1-
0-
C±3 c b
t
c b  (± 1  L
b  Ù
ъ  и
rn
Ű
J ű L
Con. Norm. Tub. Glom. Mixed
F ig . 1. Urinary output o f albumin, a-pm icroglobulin (ajM) and Urine Protein 1 (UP1) re la tiv e  
to  c rea tin in e  in  con tro l sub jects and d iabetic pa tien ts . Con. = con tro l or healthy subjects 
(normal p ro te inu ria , n = 50); Norm. = d iabetic subjects w ith normal p ro te inu ria  (n = 30); 
Tub. = d iabetics w ith tubu lar p ro te in u r ia  (tubular dysfunction, n = 11); Glom. = d iabe tics  w ith 
glom erular pro te inu ira  (glom erular dysfunction, n = 19); Mixed = d iabetics w ith  glomerular and 
tu b u la r  p ro te inuria  (g lom erulotubular dysfunction, n = 40). Types o f p ro te inu ria  are as defined 
in  Table I .  Mean +_ SEM are indicated. ^D ifference vs. co n tro l: p<f 0.001
le ve ls  in normal subjects and diabetics. The corre la tion  between HbA^c and 
a l l  the low-molecular weight proteins was however poor.
The relationships between the albumin and the globulin proteins was 
estimated. Above ACR of 2.5 mg/mmol, there was a s ign ifican t corre la tion  be­
tween ACR and UCR ( r  = 0.71, p ^  0.001, n = 62) and between ACR and MCR 
( r  = 0.88, ? <  0.001), n = 62). This contrasted with the poor corre la tion  be­
tween ACR and UCR ( r  = 0.09, p < 0.6, n = 38) or ACR and MCR ( r  = 0.29, p<  0.4,
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n = 38) fo r ACR below 2.5 mg/mmol. A s ig n ifica n t correlation was however 
shown between the urinary globulin proteins ( r  = 0.91, p<. 0.001, n = 100).
The glomerular and tubular functions of the patients were character­
ized by the ra tios  ACR, UCR and MCR. Patients with ACR >2.5 mg/mmol were 
considered to have glomerular dysfunction, while those with increases in 
both MCR and UCR ( > 1 . 2  mg/mmol and 30 pg/mmol, respectively) were consi­
dered to have tubular impairment. Based on these urinary proteins, the renal 
function of the diabetic patients have been c lass ified  as shown in  Table I .
There was a good agreement (91%) between MCR and UCR. However, d is ­
cordant globulin values were noticed in  9 of the patients. Urine samples 
from these patients were fu rther examined using re tino l-b ind ing  protein 
(RBP), which is  a more sensitive plasma protein fo r tubular func tion . RBP 
was assayed by ELISA /3 / .  Using RBP, there was a 8/9 agreement w ith the 
trend as shown by UP1 in  contrast with the 2/9 agreement found w ith  a^M. 
UP1 may be more sensitive or re lia b le  in  detecting renal changes than a^M.
A ll the 12 patients with A lbustix -pos itive  urine showed glomerular and 
tubular (or mixed type) renal dysfunction. Data for the urinary p ro te in  ex­
cretion (mean +_ SEM) are shown in Fig. 1.
D iscu ss io n
We used urinary albumin, UP1 and a^M levels to assess glomerular and 
tubular involvement in  a cross-section of 100 diabetic patients. There was a 
good agreement between the newly discovered protein UP1 and ( r  = 0.91), 
ind ica ting  that UP1 is  a good monitor of renal function in th is  group of 
patients. However, when compared with RBP, the globulin "gold standard" fo r 
tubular function /6 , 16/, UP1 appeared to be more sensitive than a-^ M in  de­
tecting  tubular functional changes in d iabetics. This is  evidenced from the 
good corre la tion  between UP1 and RBP in  the nine samples with discordant UP1 
and oijM values. This s e n s it iv ity  of UP1 over a-^ M in monitoring renal func­
tio n  agrees with e a rlie r reports /2 , 4 /.
Eleven out of the 41 normoalbuminurics (albumin 2.5 mg/mmol) had in ­
creased urinary UP1 and a^M excretion (tubular pro te inuria ). This is  in 
agreement with observations by Rowe et a l.  /19 /, but at variance w ith  re­
ports of others /16, 20/, who used ß2 ' mi cro 9 l°b u lin  as indicator p ro te in  fo r 
renal function. This discrepancy may be due to the greater in s ta b i l i ty  of 
$ 2 -microglobulin vs. a^M and UP1 /1 , 14/, and the use of 24-h urine without
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a lka lin iza tio n  /20 /, which provided a longer period fo r the breakdown of $ 2 ~  
microglobulin in that study. In addition, increased ac id ity  of urine during 
periods of poor contro l o f diabetes might be expected to increase the l i a ­
b i l i t y  of ß2 -m icroglobulin and thus conceal obvious tubular abnormity.
There was a weak co rre la tion  between HbA^c and a^ M or UP1, ind ica ting  
the lack of re la tionsh ip  between renal impairment and the degree of g ly - 
caemic control as shown by glycosylated haemoglobin concentration. This may 
mean that, although metabolic derangements may have in itia te d  the néphro­
pathie events, the processes determining renal deterioration in the p ro te in ­
u r ic  stage are independent of glycaemia. Glomerular changes that occur 
during poor metabolic co n tro l, such as functiona l microangiopathy with in ­
creased f i l t r a t io n  pressure and/or increased porosity of the microvas- 
culature /19/, are not l ik e ly  to a ffect urinary excretion of small plasma 
prote ins since th e ir  glomerular permeability is  usually high /13 /. Also the 
generally fa ir ly  good metabolic control of the diabetics in th is  study 
(HbA-^c = 9.9 +_ 2 . 2 % )  may explain the fact tha t there was a very poor cor­
re la tio n  between urinary albumin and red c e ll HbA^.
Urinary excretion o f UP1 and a^ M was frequently increased in the group 
o f patients with increased albumin excretion. This may be due to two pos­
s ib i l i t ie s .  F irs t, i t  may indicate progressive renal damage advancing per­
haps through glomerular damage to involve the renal tubules. This would be 
consistent with the high urinary levels of small plasma proteins observed in  
a l l  patients with gross pro te inuria . Second, increased albumin in the u lt ra ­
f i l t r a t e  due to damaged glomeruli may saturate and in h ib it  the reabsorptive 
mechanisms of otherwise normal proximal tubules /13, 18/, and p rec ip ita te  
increased tubular prote ins and albuminuria.
This study has shown that in 11% of d iabe tic  patients, tubular pro­
te in u ria  (indicated by increased excretion of a^M and UP1) and hence tubular 
dysfunction, may, besides occurring early before the positive conventional 
A lbustix test, occur independently of glomerular change or microalbumin­
u r ia . This finding poses a number of questions. Do the tubular proteins oc­
curring  without albuminuria have any prognostic message? Does the presence 
o f tubular proteinuria render prognostic in te rp re ta tio n  of microalbuminuria 
unreliable? C learly, only long-term prospective studies (using purely tub­
u la r, glomerular and mixed type proteinuric d iabetics) can provide answers 
and give empirical evidence for the prognostic value of the estimation of 
tubular proteins in d iabe tics . However, the im plica tion  of tubular p ro te in ­
u ria  on the in te rp re ta tio n  of microalbuminuria seems obvious. F irs t,  low-
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molecular-weight (LMW) prote inuria is  an indication of proximal tubular mal­
function, which was previously regarded as a re la tiv e ly  la te  complication of 
diabetic renal disease /17, 20, 21/. Second, the in te rp re ta tion  of micro­
albuminuria usually depends on the assumption that tubular reabsorption is  
unimpaired and therefore microalbuminuria is  concluded to be a re fle c tio n  of 
a glomerular change. The present resu lt undermines th is  assumption because 
i t  arises from tubular lesion which may impair tubular reabsorption of a l­
bumin. This implies that microalbuminuria may be a less spec ific  indicator 
of glomerular changes in  diabetics than i t  was assumed.
Let us examine fu rthe r the implications of tubular prote inuria  in the 
prognosis and management of diabetic nephropathy. Consider two groups of 
patients: the one with normal and the other with dysfunctional proximal 
tubules; both have normal in i t ia l  glomerular function. Assume that both sub­
sequently develop s truc tu ra l and functional glomerular a lte ra tions . In the 
group with normal tubular function, albumin reabsorption would be e ff ic ie n t,  
therefore, u ltra s tru c tu ra l and functional glomerular changes may be correct­
ly  revealed by albumin excretion. Correct prognostic signals may be read 
with respect to the renal disease. This is  the group where current in te r­
pretation of albuminuria is  applicable. In the group with pre-existing 
proximal tubular dysfunction, there would be an inappropriately high albumin 
excretion in re la tion  to the level of glomerular a lte ra tio n . This would give 
wrong prognostic signals of the renal disease. The resu lt would be a poor 
corre la tion  between morphological changes in the kidney and renal function 
or the development of renal disease. I t  has been reported, fo r example, that 
whereas 30-40% of a l l  insulin-dependent diabetic patients w i l l  develop overt 
c lin ic a l nephropathy, 60-70% of the patients never develop c l in ic a l renal 
disease despite h is to log ica l evidence of glomerulosclerosis in nearly a l l  
patients a fter only a few years of the disease /9 / .  Patients with tubular 
dysfunction may show a d iffe re n t c lin ic a l course of renal disease from those 
without tubular abnormity. This resu lt therefore advises caution in  the in ­
terpre ta tion  of albuminuria in diabetics, especially when the h is tory of 
tubular function is  unknown.
The present study using the senstive LMW protein UP1, has shown the 
presence of tubular prote inuria  in diabetics without microalbuminuria. A l­
though i t  is  presumptious based on the available empirical data to conclude 
that the evaluation of tubular proteinuria can, at the present state of 
knowledge, improve the s e n s it iv ity  and s p e c if ic ity  of predicting renal 
desease in d iabetics, the evidence presented here raises questions that
1 0 6 3 .  0 .  I .  AYATSE, 3 . W. WRIGHT
challenge the s c ie n tif ic  premise on which both the prognostic signal and the 
in te rp re ta tio n  of microalbuminuria are based. Long-term prospective studies 
may provide data that would reveal the actual ro le  of tubular prote inuria  in 
the s e n s itiv ity  and s p e c if ic ity  of predicting overt d iabetic nephropathy.
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MITOTIC DELAY IN  PERIPHERAL BLOGO LYMPHOCYTES AND 
FIBROBLAST CULTORES OBTAINED FROM A CHILD 
WITH DOWN'S SYNDROME ANO f RIM A HEALTHY CHILD
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M ito tic  delay (MO) o ften  occurs in  c e lls  o f donors exposed in  vivo to genotoxic agents. 
To investiga te  in d iv id u a l s e n s it iv ity  w ith genetic background, author measured the 3-methyl- 
cholanthrene (MC)-induced MD in  cu ltured human skin f ib ro b la s ts  (FBs) and in  periphera l blood 
lymphocytes (PBLs) obtained from a 4-year-old pa tien t w ith  Down's disease. Samples from a 
10-year-old healthy sub ject served as con tro ls . Skin samples were obtained during su rg ica l in ­
te rven tion . The induced MO was calculated from the m ito t ic  index (MI) which was expressed in  
per cent o f the co n tro l; a t various times up to 18 h a f te r  treatment. Cells were trea ted  w ith 
10“ ^ , 10~^ and 1 0 "5  M MC (w ith  S-9 l iv e r  homogenate). At passage 10, the average MI L+SE) was 
8.32+_0.43%, and 7.85+^0.64% fo r the healthy and fo r the Down's FBs, respective ly ; and i t  was 
4.89 +_ 0.59%, and 4.92+^0.72% fo r the healthy and fo r  the Down's PBLs, respective ly . M0 was 
characterized as 50% MI o f con tro l (MO50) . The MD^ g values were the most expressed when c e lls  
were treated w ith IO '-’ M MC. No d iffe rence was found in  MD o f healthy and Down's fib ro b la s ts . 
For Down's lymphocytes, on the other hand, MD was approximately 30% longer than fo r  healthy 
c e lls .  This re su lt agrees w e ll the reported increased SCE and decreased DNA-repair data ob­
tained in  PBL o f Down pa tie n ts .
Keywords: Children, genotoxicology, ind iv idua l s e n s it iv ity ,  in  v it r o  3-m ethylchol- 
anthrene-treatment, r is k  assessment
In t r o d u c t io n
M ito tic  delay (MD), in general represented in  reduced p ro life ra tio n  
index at the time of standard sample preparation is  often observed in  pe­
riphera l blood lymphocytes (PBLs) of populations exposed to genotoxic agents 
/8 , 20/. Reduced p ro life ra tio n  index /5 / is  also often associated with de­
creased unsheduled DNA synthesis /9 , 20/. Ind iv idua l s e n s it iv ity  with a 
genetic background including DNA-repair capacity, influences the obtained
O ffp r in t requests should be sent to : 3. Major, Department o f Human Genotoxicology, 
National In s t itu te  o f Occupational Health, H-1450 Budapest, P.0. Box 22, Hungary
0236-5286/94/# 4.00 © 1994 Akadémiai Kiadó, Budapest
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data; i t  is  a current top ic  of genotoxicology monitoring. Patients with 
Down's disease are more sensitive  than healthy donors to in  v it ro  exposures 
when measured with SCE /1 0 /. Lambert et a l. /4 /  found decreased UV-induced 
DNA repa ir, and Agarwal et a l. /1 / reported decreased DNA polymerase ac­
t i v i t y  in patients with Down's syndrome. Therefore, investigation of ce lls  
obtained from patients w ith  Down's syndrome can help in a better understand­
ing of individual s e n s it iv ity  to genotoxic exposures.
Survival and MD a fte r  X, or ï  irra d ia tio n  was intensely studied in 
various type of ce lls  from healthy donors /7 , 17/ and from patients with 
a taxia  teleangiectasia /7 , 12, 16, 17, 21—23/ or with retinoblastoma /22 /. 
There is  an evidence of a re lationship between MD and DNA-lesions in  X-ray 
irra d ia te d  cells /2 , 16, 19/; and between MD and DNA repair /2 5 /. However, 
less attention has been paid to chemically induced MD. No information is  
ava ilab le  on induced MD in  ce lls  obtained from patients with Down's synd­
rome. The aim of th is  study was to investigate 3-methylcholanthrene (MC)- 
induced MD in cultured human skin fib rob lasts  (FBs) and PBLs. A healthy 
c h ild , and a patient w ith Down's disease were the donors.
Materials and Methods
C e ll cu ltu res
C e ll cultures were se t up as described elsewhere /1 0 /.  B r ie f ly ,  primary sk in  FBs o f a 
10-year-o ld  healthy c h ild , and a 4-year-old pa tien t w ith  Down's syndrome were cu ltu red  under 
standard conditions in  TC-199 medium (Flow) supplemented w ith  20% fe ta l c a lf  serum (Flow) on 
g lass coverslips in  P e tr i d ishes; c e l l  s tra ins  underwent fo r  20 passages. The sk in  samples were 
obtained during surg ica l in te rv e n tio n . MD studies were performed at passage 10, the passage in  
which the trisomy of the chromosome 21 was present. Peripheral blood lymphocytes were taken by 
venipuncture from the same donors, and cultured under standard conditions, fo r  68 h in  RPMI- 
1640 medium (Flow) supplemented w ith  20% fe ta l c a lf  serum (Flow), and 5pM phytohaemaggluti- 
nin-M (Bacto) in  s te r i le  g lass tubes.
Treatments and determination o f  MD
The MC (CAS Reg. No.: 56-49-5, Sigma) chosen fo r treatment was in  concentration 10*7, 
10- ^ and IO“ -’ M ( in  the presence o f S-9 l iv e r  homogenate). Lymphocyte cu ltures were trea ted  fo r 
10 min, 50 h a fte r the c u ltu re s  were set up, then the medium containing MC was washed ou t, and 
rep laced w ith fresh medium. FBs were treated 24 h a fte r  passage fo r  10 min, then the medium was 
changed.
Sample co llec tion  was taken a t 0 h, 0.5 h, 1 h and 2 h a fte r  treatment, then in  2 hours 
in te rv a ls ,  up to 18 h. The c e l ls  were then fixed  in  s itu ,  in  acetic acid:methanol, 3:1 (PBL 
then dropped onto s lid e s , and a i r  d rie d ); and stained w ith 5% Giemsa (F luka). MD was determined 
according to  Scott and Zam ptetti-Bosseler /16 /. Frequencies o f a l l  m ito tic  phases per 2000
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interphases were determined in  each sampling time, both fo r  FB and PBL. Mis in  the treated 
samples were ca lcu la ted as a ra t io  to  MI o f the untreated con tro l o f the given sampling time, 
and expressed in  % o f the co n tro l. MDjg ( i . e . ,  the d iffe rence  in  hours between the correspond­
ing two MI values a t 50% o f the con tro l) was calcu lated according to Scott and Zampetti—Bos­
se ler /1 0 /. S ignificances were determined by the t - te s t .
R e s u lts  and D is c u s s io n
At passage 10, the average MI (>SE) was 8.32^0.43%, and 7.85^0.64% 
for the healthy and fo r the Down's FB, respective ly; and i t  was 4 .89^0 .59 , 
and 4 .92^0 .72  fo r the healthy and for the Down's PBL, respectively. MI of 
the untreated controls as a function of sampling time is  demonstrated in 
Fig. 1. The difference was s ign ifican t neither between healthy and Down's 
lymphocytes, nor between healthy and Down's fib rob las ts . As expected, the 
mean MI fo r lymphocytes /3 / was s ig n ifica n tly  lower (P<0.01)  than MI fo r 
fib rob las ts .
Figure 2 shows MI in MC-treated ce lls  as % of the actual untreated 
contro l. However, 10  ^ M MC-treatment resulted in  no m ito tic  delay e ithe r in 
fib rob lasts  or in lymphocytes. In Fig. 2A resu lts  are presented on 10” ^ M 
MC-treated FBs. For healthy, and Down's FBs, MD was 12.0 h, and 11.0 h, re-
Fig. 1. M ito tic  index (%) fo r  the investigated untreated (con tro l) c e ll  cu ltu re s . Data 
represent the actual 100% m ito tic  index fo r the in ve s tig a tion  o f induced m io tic  delay a fte r  
3-methylcholanthrene treatm ent. ---- »  - Healthy skin f ib ro b la s ts ; — M — Down's skin f ib ro ­
b la s ts ; -  • Д  • -  Healthy blood lymphocytes; Down’ s blood lymphocytes
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F ig . 2. Demonstration o f m ito tic  delay (expressed as X o f the actual untreated co n tro l m ito tic  
index) in  3-methylcholanthrene (MC)-treated c e l l  cu ltu re s  (w ith  S-9 l iv e r  homogenate). MD5q 
( in d ica te d  as a bar) represents the m ito tic  delay a t 50% m ito tic  index o f the co n tro l. 
A) M ito t ic  delay in  10"é M MC-treated healthy and Down's fib ro b la s ts ; — ♦ —  Healthy skin
f ib r o b la s t s ; -----в -----Down's sk in  f ib ro b la s ts . B) M ito t ic  delay in  10- ^ M MC-treated healthy
and Down's fib ro b la s ts ; — ♦ —  Healthy skin f ib r o b la s t s ; -----► — Down's skin f ib ro b la s ts .
C) M ito t ic  delay in  10~5 M MC-treated healthy and Down's lymphocytes; —• —  Healthy blood 
lym phocytes;-----Ш- — Down's blood lymphocytes
spective ly ; MD^ g was 4.2 h, and 4.6 h, respective ly. The differences were 
not s ig n ifica n t. Mitoses were found in  each sampling time. Lymphocytes 
showed no measurable MD. MI values were over 50% of the contro l in  each 
sample. In Fig. 2B resu lts  are demonstrated on 10  ^ M MC-treated FBs. MD was
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13.0 h and 12.5 h; MD^ g was 9.8 h and 9.0 h fo r the contro l, and fo r Down's 
FBs, respectively. The differences were not s ig n ifica n t. No mitoses were 
found between 2 h and 6 h a fte r treatment. An "overshoot" was observed 14 h 
a fte r treatment, indicating synchronization of cultures /21 /. Results ob­
tained in  10 M MC-treated lymphocytes are presented in Fig. 2C. For tre a t­
ed healthy lymphocytes MD was 11.0 h and MD^ was 8.0 h. However, MD was 
15.5 h and MD^ g was 12.2 h in  the case of 10 M MC-treated Down's lympho­
cytes. The difference in MD^ g between healthy and Down's lymphocytes is  s ig ­
n if ic a n t 34.4% (P <  0.01). No mitoses were found 4-8 h a fte r treatment. The 
k ine tics  of the MI curves represent the m ito tic  phases. In the f i r s t  2-4 h 
a fte r treatment mainly telophases were observed. Prophases appeared 6-8 h 
a fte r treatment.
The ionizing radiation-induced MD was prolonged in human PBL, He-La, 
mouse lymphoma, and Chinese hamster ovary c e ll cultures /2 , 15, 16, 24, 25/. 
In FBs from patients with ataxia teleangiectasia, however, X-ray ir ra d ia tio n  
/7 , 21, 22/, and UV-light irra d ia tio n  reduced MD /12/. The prolongation or 
reduction of MD is  connected with the DNA-repair a c tiv ity  of the c e lls  /11, 
13, 18, 23/. DNA lesions remain open for a longer time in the case of a 
decreased DNA-repair capacity, thus, the prolonged DNA-repair plays a major 
ro le  in  the prolongation of MD /13, 14, 23/. In the case of a missing repair 
capacity as in  X-ray irrad ia ted  ataxia teleangiectasia FBs, no, or reduced 
MD was reported /6 / .
The present resu lts indicate that chemical mutagens can induce a 
measurably increased MD in  sensitive c e lls , in  accordance with the data on 
chemically induced SCE /10 /. Lymphocytes from the donor with Down's syndrome 
were more sensitive than fib rob las ts . The reported reduced DNA-repair capac­
i t y  in ce lls  with 21 trisomy /1 , 4/ can explain the results obtained in 
Down's lymphocytes.
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EXPERI MENTAL STUDY
TIME-COURSE CHANGES IN PANCREATIC LABORATORY AND 
MORPHOLOGIC PARAMETERS IN  TWO DIFFERENT ACUTE PANCREATITIS 
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The aim of th is  work was to  study in  ra ts  the temporal course o f laboratory parameters 
and morphologic features in  acute pancrea titis  induced by cholecystokinin octapeptide (CCK-8) 
or by a closed duodenal loop. P ancreatitis  was induced e ith e r w ith an overdose o f CCK-8 
(3 ж 75 >jg/kg a t 1 h in te rv a ls )  or by lig a tio n  of the duodenum on both sides of the b ilio -p a n - 
c re a tic  duct. The animals were examined a t 0, 2, 4, 8, 16 and 24 h a fte r  AP induction. In 
CCK-8-induced acute p a n c re a tit is , the pancreatic weight/body weight ra t io  (8.2 +_ 1.1 mg/g) and 
the amylase leve l (44.8 +_7 .5 x ltP  U/ml) were s ig n if ic a n tly  increased vs. the con tro ls  (4 .5 ^ 0 .8  
mg/g and 3.3;+0.2 x lCp У/m l, respective ly) 2 h a fte r the in te rve n tio n . The plasma CCK was s ig ­
n if ic a n t ly  increased a t 4 h (4.55 ;+1 .7  pM) and remained elevated the rea fte r. The tissue  ma- 
lonyldialdehyde concentration was s ig n if ic a n tly  elevated a t 8 h (0 .2 8 ^0 .07  pmol/mg pancreas) 
vs. the controls (0.20 +_0.02 pmol/mg pancreas). In closed duodenal loop-induced acute pan­
c r e a t i t is ,  the ra t io  pancreatic weight/body weight s te a d ily  increased during the study; i t  
reached i t s  maximum le ve l a t 24 h (7.1 +; 0.5 mg/g) vs. the sham-operated con tro l (4 .8+ ;0 .9  
mg/g). The serum amylase le v e l was s ig n if ic a n tly  elevated a t 2 h (47.1+^9.3x10^ U/m l), and 
then decreased s te a d ily . Plasma CCK values were s ig n if ic a n t ly  higher than the contro ls through­
out the study. A s ig n if ic a n t increase in  the tissue malonyldialdehyde concentration (0.94j+0.15 
/imol/mg vs. 0.20 + 0.01 pmol/mg pancreas) appeared a t 4 h. Our data ind ica te  th a t in  CCK-8-in- 
duced acute pancrea titis  the laboratory signs of panc re a titis  are most expressed at 4 h, where­
as the morphologic changes culm inate 8 h, fo llow ing the la s t CCK in je c tio n . In  closed duodenal 
loop-induced acute p a n c re a tit is , the h is to log ic  find ings showed a progressive de te rio ra tion . 
Endogenous CCK and oxygen-derived free  rad ica ls  seem to  play a ro le  in  the pathogenesis o f both 
types o f acute p a n c re a titis .
Keywords: Cholecystokinin-octapeptide, acute p a n c re a tit is , closed duodenal loop, tissue 
malonyldialdehyde, plasma cholecystokinin
Abbreviations: CCK-8 = cholecystokinin-octapeptide, CDL = closed duodenal loop,
AP = acute p a n c re a titis , MDA = malonyldialdehyde, pw/bw = pancreatic weight/body weight
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In t r o d u c t io n
The two main e tio lo g ica l factors in the development of human acute 
pancrea titis  (AP) are ch o le lith ia s is  and alcohol consumption /1 8 /. Accord­
ing to the theory most generally accepted at present, a secretory blockade 
(co loca liza tion  of the lysosomal enzymes and digestive proenzymes) resu lting  
in  an autolysis of the pancreas in both cases /18 /. Despite numerous expe­
rim ental and c lin ic a l re su lts , the pathomechanism of AP has not yet been es­
tablished in de ta il /2 , 8 /.
A number of recent studies have suggested that the loca l, and especi­
a l ly  the systemic e ffects of AP may be mediated in a common pathway (oxygen- 
derived free radicals, cytokine cascade), irrespective of the in it ia t in g  
stimulus /14, 17/. Sanfey et a l. /14/ demonstrated the pathogenetic ro le  of 
oxygen-derived free rad ica ls . Agents which act as scavengers have been found 
to  reduce the severity of experimental AP /12 /.
CCK has also been supected to play a role in the pathogenesis of va­
rious pancreatic disorders /2 1 /. In 1977, Lampel et a l. demonstrated that 
high doses of CCK-8 induce edematous AP in the ra t /6 /.  CCK-8 has been found 
to  worsen morbidity and m orta lity  in experimental AP caused by in traducta l 
in je c tio n  of b ile  sa lts  in  ra ts /5/ .  The lite ra tu re  is  poor in data are con­
cerning the pathogenetic ro le  of the endogenous plasma CCK leve l in  AP /19 /.
The aim of th is  study was to examine the biochemical and morphological 
a lte ra tions  in CCK-8-induced and b il ia ry  AP models in order to c la r i fy  the 
puta tive  roles of endogenous CCK and l ip id  peroxidation in  the pathogenesis 
of these pancreatitis models.
M a te r ia ls  and Methods
Male Wistar ra ts  weighing 280-330 g were used throughout. The animals were kept a t a 
constant room temperature (27 °C ), w ith  free access to  water and a standard labora to ry chow 
(LATI, Gödöllő, Hungary).
Experimental protocol
For both models, animals were segregated in to  6 groups, w ith 6 ra ts  in  each, and tre a t­
ed as lis te d  below.
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CCK-8-induced AP model
The animals received 75 pg/kg CCK-8 (synthesized by B. Penke, Department o f Medical 
Chemistry, Szeged) s .c . three times a t hourly in te rv a ls  /7 / .  Groups o f 6 ra ts  were s a c rific e d  
0, 2, 3, 8, 16 or 24 h fo llow ing  the la s t CCK-8 in je c t io n . Control animals (n = 6/group) re ­
ceived sa line  s.c,. and were sa c rifice d  at the same times.
CDL-induced AP
In ra ts  laparotomized under ether narcosis a CDL was crated by lig a tin g  the duodenum at 
two po in ts on e ithe r side o f the common b ile  duct on a p la s t ic  tube inserted in to  the duodenum 
/1 1 /. The blood supply to  the duodenal CDL was c a re fu lly  preserved. The CDL was 2 .0 -2 .5  cm in  
length. A fte r the procedure, the abdomen was closed. In  the con tro l ra ts , a m idline laparotomy 
was performed.
The ra ts  were k i l le d  by exsanguination through the abdominal aorta 0, 2, 4, 8, 16 or 
24 h a fte r  the lig a t io n  o f the duodenum (n = 6/groups). The pancreas was c a re fu lly  removed 
and weighed.
Assays
Serum samples were stored a t -20 °C fo r subsequent analysis o f amylase a c t iv i t ie s  by 
the Phadebas te s t method /3 /  and o f MDA a c t iv it ie s  according to  S la te r 's  method /1 6 /.
Plasma CCK-like b io a c t iv ity  was measured by the h ig h ly  s p e c ific  and sens itive  bioassay 
described by L iddle e t a l.  / 9 / .  CCK was extracted from 2 ml o f plasma by adsorption on octa- 
d e c y ls i ly ls i l ic a  cartridges (Sep-Pak, Waters Assoc.) and e lu ted in  ethanol and t r if lu o ro a c e tic  
acid. The quantita tion  o f CCK in  the extracts was based on i t s  a b i l i t y  to  release amylase from 
ra t  pancreatic ac in i prepared w ith  collagenase. The b io a c t iv ity  of CCK was compared w ith  a 
standard curve, and the re s u lts  were expressed in pM CCK-8 equivalents. The assay is  se ns itive  
even to  plasma leve ls  as low as 0.5 pM.
The development o f pancreatic edema was measured by comparing the pancreas weight ob­
tained immediately a fte r  the anim al's death (wet weight) w ith  th a t o f the same sample kept at 
150 °C fo r 48 h (dry weight) as described by Ohshio e t a l .  /1 3 /. The ra t io  pancreatic wet 
weight/body weight (pw/bw) was calcu lated in  each case.
H is to log ic  examination
A fragment o f the pancreas was fixed  overnight in  10% neutra l formaldehyde so lu tio n  fo r 
haematoxylin and eosin s ta in in g  and fo r h is to lo g ica l study by lig h t  microscopy. For e lectron  
microscopy, tissue samples were fixed  in  a modified Karnowsky's  solution (810 mOs), and the 
semithin sections were stained w ith  to lu id in e  blue. The sections were examined by a pa tho log is t 
who was unaware of the treatment m odalities, and the h is to lo g ic a l a lte ra tions were evaluated on 
a sem iquantitative score system, graded on a scale o f 0 -  ++++, as minimal to  maximal changes 
/2 3 /. Zero ind icated no change. +, ++ and +++ ind icated th a t about 25%, 50% and 75% o f the 
c e lls ,  respective ly , were a ffec ted , and ++++ indicated th a t p ra c tic a lly  a l l  the c e lls  were a f­
fected. For in t e r s t i t ia l  les ions the fo llow ing scoring system was applied: 0 = no change, 
+ -  m ild in t e r s t i t ia l  oedema, ++ = m ild in t e r s t i t ia l  oedema with inflammatory c e lls ,  and 
+++ = in t e r s t i t ia l  oedema w ith  haemorrhagic lesions.
S ta t is t ic a l analysis
Results were expressed as means +_ SEM. Experiments were evaluated s ta t is t ic a l ly  w ith  
Student's ta te s t fo r paired or unpaired values, as appropria te . P values < 0 .05  were accepted 
as s ig n if ic a n t.
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R es u lts
Results on the CCK-B model
75 p g / k g  of CCK-8 administered s.c. 3 times at hourly in te rva ls  s ig ­
n if ic a n t ly  increased the pancreatic weight and water content of the organ 
re la t iv e  to the contro ls . The ra tio  pw/bw was greatly increased a fte r  the 
induction of AP and reached its  peak 4 h a fte r  the last CCK-8 in jec tion  
(F ig . 1). After 4 h, the ra t io  pw/bw decreased continuously, and i t  had nor­
malized by 24 h (F ig. 1).
The serum amylase a c t iv ity  rose s tead ily  up to 24-fold by 4 h a fte r 
the la s t CCK-8 in je c tio n  (F ig . 2). I t  had' reached the control leve l by lő  h 
(F ig . 2).
The plasma CCK b io a c tiv ity  was s ig n if ic a n tly  increased at 4 h and re­
mained elevated thereafte r (F ig. 3).
The tissue MDA concentration was s l ig h t ly  but s ig n ifica n tly  elevated 
8 h (F ig . 4).
Macroscopic study of the pancreata in  the CCK-8-treated group revealed 
in t e r s t i t ia l  oedema. Microscopic examination demonstrated a moderate d iffuse 
parenchymal degeneration, including vacuolation and focal necrosis (dark 
c e lls )  w ithin the acinar ce lls . These morphological changes were most ex­
pressed (++ or +++) at 8 h and gradually decreased thereafter (Figs 5—7). 
The in te rs titiu m  remained v ir tu a lly  unchanged (grade: 0).
Results on the CDL model
Both the pancreatic weight and the pancreatic water content were in ­
creased a fter the ra ts w ith CDI AP. The ra t io  pw/bw was s ig n if ic a n tly  above 
the basal value at 2 h and increased continuously during the experiment; i t  
reached its  maximum leve l at 24 h (Fig. 8).
The serum amylase a c t iv ity  attained i t s  peak level at 2 h, and a fte r­
wards decreased continuously (F ig. 9).
The plasma CCK b io a c tiv ity  was s ig n if ic a n tly  increased 2 h a fte r  the 
onset of AP, and reached i t s  highest level at 4 h (Fig. 10).
The tissue concentration of MDA was 5 -fo ld  the control value at 4 h 
and then declined abruptly (F ig. 11).
On visual inspection, the pancreas seemed to be oedematous w ith oc­
casional haemorrhages. Microscopic examination revealed an acute inflam-
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F ig . 1. Ratio pancreatic weight/body weight (pw/bw) in  CCK-induced AP. Rats received 3 x 75 
pg/kg o f CCX-B a t 1 h in te rv a ls  (open c ir c le s ) ,  o r the same volume o f sa line  (c o n tro l cases: 
f i l l e d  c irc le s ) ;  they were sa c rifice d  a t the times indicated. The pancreatic wet weight and 
body weight were measured and the ra t io  pw/bw was ca lcu la ted. Means +_ SEM fo r  groups o f 6 ra ts  
are shown. "S ig n ific a n t d iffe rences from the contro l values (P <  0.05)
F ig . 2. Serum amylase a c t iv ity  in  CCK-induced AP. Rats received the same volumes o f CCK-8 
(open c irc le s )  or sa line ( f i l l e d  c irc le s )  as ind ica ted  in  F ig. 1, and were s a c r if ic e d  a t the 
times ind icated. Means _+ SEM fo r  groups o f 6 ra ts  are shown. "S ign ifican t d iffe rences  from the
con tro l values (P <  0.05)
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Time (h ) X+SEM
P<0.05
F ig . 3. Plasma CCK le ve ls  in  CCK-induced AP. Rats received the same amount of CCK-8 (open 
c irc le s )  or saline ( f i l l e d  c ir c le s )  as indicated in  F ig . 1, and were sacrificed at the times 
ind ica ted . Plasma CCK was measured by bioassay as described in  d e ta il in the te x t.  Means 
+_ SEM fo r groups of 6 ra ts  are shown. ^S ign ifican t d iffe rences  from the con tro l values
(P <  0.05)
Time (h ) X±SEM
P<0.05
F ig . 4, MPA a c t iv ity  in  CCK-induced AP. Rats received the same amount of CCK-8 (open c irc le s )  
o r sa line  ( f i l le d  c irc le s )  as ind ica ted  in Fig. 1, and were sa c rific e d  at the times ind ica ted . 
Means +_ SEM fo r groups o f 6 ra ts  are shown. ^S ig n ifica n t d iffe rences from the con tro l values
(P <  0.05)
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Tig- 5, L ight microscopy o f a con tro l ra t pancreas. Normal s truc tu re  of pancreas w ith  d is t in c t  
c e llu la r  ou tlines  and g lobu la r vesicu lar nucle i. The a p ica l cytoplasm contains f in e  granules 
(semithin section, to lu id in e  b lue , x40)
F ig . 6, In CCK-induced AP marked acinar c e ll vacuolation and foca l necroses — dark c e l ls  (D) — 
are v is ib le  a fte r  8 h (semithin section, to lu id in e  blue, x25)
1 2 4 T .  TAKÁCS e t  a l .
F ig , 7. In  CCK-induced AP vacuoles are missing a fte r  24 h, only some dark c e lls  are v is ib le  
(sem ith in section, to lu id in e  b lue , x40)
Time (h ) X SEM P 0.05
F ig . 8. Ratio pw/bw in  CDL-induced AP. Test animals (open c irc le s ) and con tro ls  ( f i l l e d  
c ir c le s )  were s u rg ica lly  prepared and sacrificed  as described in  d e ta il in  the te x t .  The 
pancreatic wet weight and body weight were measured and the ra tio  pw/bw was ca lcu la ted. 
Means +_ SEM fo r groups o f 6 ra ts  are shown. ^S ig n ific a n t d ifferences from the co n tro l values
(P C  0.05)
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F ig . 9, Serum amylase a c t iv ity  in  CDL-induced AP. Test animals (open c irc le s )  and co n tro ls  
( f i l l e d  c irc le s )  were s u rg ica lly  prepared and s a c r ific e d  as described in  d e ta il in  the te x t .  
Means +_ SEM fo r  groups o f 6 ra ts  are shown. ^S ig n ific a n t differences from the c o n tro l values
(P <  0.05)
Time (h ) X±SEM
P <0.05
F ig , 10, Plasma CCK leve ls  in  CDL-induced AP. Test animals (open c irc le s ) and co n tro ls  ( f i l l e d  
c irc le s )  were su rg ica lly  prepared and sa c rifice d  as described in  d e ta il in the te s t .  The plasma 
CCK was measured by bioassay. Means +_ SEM fo r groups o f 6 ra ts  are shown. *S ig n if ic a n t 
d ifferences from the con tro l values (P <  0.05)
1 2 6  T .  TAKÁCS e t  a l .
Time (h )  X+SEM
P <0.05
F ig . 11. MDA a c t iv ity  in  CDL-induced AP. Test animals (open c irc le s )  and con tro ls  ( f i l l e d  
c irc le s )  were su rg ica lly  prepared and sacrificed  as described in  d e ta il in  the te x t.  
Means +_ SEM fo r groups o f 6 r a ts  are shorn. ^S ig n ific a n t d iffe rences from the con tro l values
(P<  0.05)
F ig . 12. In CDL-induced AP enlarged in te r s t i t ia l  space w ith  d ila te d  blood vessels can be 
detected a fte r 8 h. The acinar c e l l  structure is  in ta c t (sem ith in  section, to lu id ine  b lue , x25)
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F ig . 13, In CDL-induced AP an acute haemorrhagic inflammation is  c le a rly  v is ib le  a f te r  24 h 
without les ion o f parenchymal c e lls  (sem ith in section, to lu id ine  blue, x40)
matory in f i l t r a t io n  in the in te rs tit iu m . Large amounts of f lu id , neutrophils 
and red blood ce lls  were seen to be leaking out of the vessels. These h is ­
to log ic  a lte ra tions already existed at 8 h (grade: +), and fu rther increased 
(grade: ++ - +++) during the experiment, resu lting  in acute haemorrhagic in ­
flammation by the end of the study (Figs 12—13). The acinar c e lls  remained 
nearly normal (grade: 0 - +) (F ig. 13).
Discussion
Because of the typ ica lly  rapid onset of c lin ic a l AP and the poor ac­
c e s s ib ility  of human pancreatic tissue, the pathophysiology of AP have 
examined mainly on experimental models of the disease /1 /.  Since 1977, when 
Lampel et a l. described CCK hyperstimulation-induced AP, th is  model has 
served as a prototype of oedematous pancrea titis  /6 /.  Another c l in ic a l ly  re­
levant and widely accepted model of experimental AP is  b ilia ry -ty p e  AP, in 
which the b iliopancreatic duct is  obstructed surgically with a simple l i ­
gation /1 / or through formation of a CDL /1 1 /.
\
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In both models, a blockade of exocytosis from acinar ce lls  at a time 
when the pancreatic enzyme synthesis is  unimpaired ("pancreastasis") is  the 
e a r lie s t intraacinar aberration. The pancreatic enzyme levels in  the blood 
r is e  abruptly, the acinar c e ll cytoplasm displays vacuoles containing d i­
gestive and lysosomal enzymes (in  CCK-induced pancreatitis) and focal in te r ­
s t i t i a l  haemorrhage appears ( in  b ilia ry -typ e  AP). In spite of the consider­
able number of pub lica tions concerning the pathomechanism of AP, there is  no 
ready explanation fo r  the common pathomechanism of the disease /1 /.
CCK and other gastro in testina l hormones have been supposed to p a r t i­
cipate in the pathophysiology of experimental AP /5 / .  Recent studies w ith 
sp e c ific  CCK receptor antagonists have demonstrated a marked protective e f­
fe c t of these agents ( i . e .  CR-1392, CR-1409 and L-364, L-718) in d iffe re n t AP 
models /10, 13, 24/. These results provided fu rth e r evidence on the ro le  of 
CCK in  AP. However, there are only few data on the plasma CCK leve l during 
the early phase of AP /19 , 22/.
Our data ind ica te  tha t in CCK-induced AP the laboratory signs ( ra t io  
pw/bw and serum amylase leve ls) are the most expressed at 4 h, and they are 
decreased at the end o f the study. In th is  model, the plasma CCK values were 
also s ig n ifica n tly  elevated at 4 h and remained so throughout the study. In 
sp ite  of the constantly elevated plasma CCK le v e l, the morphological signs 
o f AP were most marked at 8 h, and then diminished continuously. This in d i­
cates that the e levation of the plasma CCK in  th is  model may have been a 
consequence of the secretory blockade and a negative feedback mechanism. The 
lack of a corre lation between the plasma CCK le ve l and the morphologic signs 
o f AP demonstrates tha t the endogenous plasma CCK plays only a supportive 
ro le  in  the pathogenesis of oedematous AP.
In the b il ia ry  type of AP, the laboratory parameters of pancreatic in ­
flammation are already pronounced 2 h fo llow ing CDL formation. The r is e  in  
plasma CCK was quicker (a t 2 h) and more expressed than in CCK-induced AP. 
In th is  model, morphological signs started at 8 h in  the in te rs titiu m , and 
progressive haemorrhagic acute inflammation developed without marked acinar 
c e ll damage.
A number of data are available concerning the crucia l role of oxygen- 
derived free rad ica ls in  the development of experimental AP /4 , 15/. D irect 
increases in l ip id  peroxidation products and pro tective  effects of d iffe re n t 
scavengers ( i.e .  superoxide dismutase, dimethylsuphoxide and a llopu rino l) in  
AP models have been described /12/. In our study, the increase in  a l ip id  
peroxidation product (MDA) in the course of b i l ia r y  AP displays a strong
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corre la tion  with the laboratory signs of pancreatic inflammation, In CCK-in- 
duced AP, only a s lig h t but s ign ifican t increase in plasma MDA a c t iv ity  was 
found at 8 h. The s ig n ifica n t elevation of the plasma MDA a c t iv ity  as a re­
s u lt of the increase in  l ip id  peroxidation demonstrates that oxygen-derived 
free radicals may be involved in the pathogenesis of AP in both models.
In conclusion, our resu lts have proved that repeated adm inistration of 
CCK-8 causes only a mild oedematous, in te r s t i t ia l  type of AP. By the end of 
the study, the pancreatic architecture was to ta lly  restored. In b ilia ry -ty p e  
AP, however, the pancreatic h is to log ica l p icture progressively deteriorated 
and severe haemorrhagic signs developed. Besides the supportive ro le  of en­
dogenous CCK, other mechanisms (involving oxygen-derived free rad ica ls , for 
instance) seem to be involved in the process of acute pancreatic damage.
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PRESENT RESEARCH TRENDS IN  CANCER CHEMOTHERAPY
S. ECKHARDT
National In s titu te  of Oncology, Budapest, Hungary
(Received: September 23, 1994)
Those research trends which are cu rre n tly  in  the focus o f in te re s t of various research 
groups are summarized. The main tendency is  to  look fo r new molecular targets and to  synthesize 
new a n tit iim u r drugs. Moreover, new research concepts emerge out o f which d if fe re n t ia t io n  
induction, in h ib it io n  o f MDR and study o f apoptosis seem to  be promising. Among c l in ic a l  
approaches megachemotherapy, neoadjuvant treatment and progress in  supportive therapy are the 
main research d ire c tio n s . Last but not le a s t, qua lity  o f l i f e  issues o f the cancer pa tien t are 
o f p a rticu la r importance.
Keywords : Chemotherapy, new research trends, re d if fe re n t ia t io n , apoptosis, megatherapy, 
adjuvant therapy
Cancer chemotherapy is  a fa i r ly  new therapeutic modality of malignan­
cies. I ts  o rig in  goes back to World War I I  /3 / .  Since that time four periods 
can be distinguished in the development of drug selection (Table I )  /2 / .
Each period sets d iffe re n t objectives. The goals are sometimes very 
closely related to each other and are reviewed in  Table I I .
Recently, the revolutionary findings in  molecular biology have given 
an enormous push to the development of drug therapy. There are new targets 
as well as new agents. The targets in the cancer c e ll are numerous. The 
major trends are shown in  Table I I I  /7 /.
Based on these concepts, a series of investiga tiona l drugs have been 
produced. These are e ither analogues of ex is ting , e ffec tive  antitumour com­
pounds or completely new chemical structures.
Table IV shows a summary of those agents which are currently in  phase 
I  or I I  t r ia ls  /8 / .
O ffp rin t requests should be sent to : S. Eckhardt, National In s t itu te  o f Oncology, 
H-1122 Budapest, Ráth Gy. u. 7—9, Hungary
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Table I
H is to ry  o f cancer chemotherapy. Drug selection
Period Years Models used fo r  drug selection
Em pirical 1945-1959 Tissue cu ltures 
Transplantable rodent tumours
Rational 1960-1979 Nude mice, athymie mice, other 
xenografts
Complex 1980-1989 Human tumour c e ll lines 
Transgenic mice
Molecular 1990- In h ib it io n  o f gene a c t iv ity ,  
irnrnne b lo tt in g , PCR*
*PCR = Polymerase Chain Reaction
Table I I
Objectives o f cancer chemotherapy
Periods Objective
Em pirica l Antitumour e ffe c t:  remission induction, 
prolongation o f s u rv iva l, to le rab le  to ­
x ic i ty
Rational Curative e ffe c t o f sensitive  tumours, 
decreased to x ic ity
Complex Curative e ffe c t w ith  other therapeutic 
methods, less to x ic  drugs
Molecular Targeted chemotherapy o f genes, r e d if ­
fe re n tia tio n , improved qua lity  o f l i f e
The cytotoxic analogues were synthesized in order to possess less 
to x ic  substances w ith  a c t iv ity  equal or even larger with a borader tumour 
spectrum than the parent compound.
Since th is  goal was only pa rtly  achieved, many new drugs have also 
been produced to explore th e ir antineoplastic e ffec t. These are l is te d  in 
Table V /4 /.
These agents are s t i l l  subject to research. Nevertheless, some of them 
(e .g . taxanes) have new mechanisms of action. Accordingly, i t  can be ex­
pected that th e ir  c l in ic a l application might prove to be useful in  case 
th e ir  to x ic ity  can be overcome.
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Table I I I
New ta rge ts  fo r cancer chemotherapy
Level л Approach
DNA, RNA, histone, 
prote in synthesis
Topoisomerase in h ib ito rs , antisense 
molecules, a n tilig a se  a c t iv ity ,  e tc .
Gene a c t iv ity MDR*, a ltered oncogene and suppressor 
gene a c t iv ity  in h ib it io n
C e ll d iv is io n In h ib it io n  o f tu b u lin  assembly and 
m itosis
Organism Antim etastatic therapy
*W)R = Multidrug Resistance
Table IV
New cy to s ta tic  analogues in  phase I - I I  t r ia ls
Chemical Group New derivatives
Anthracyclines E p i-, id a -, iodo-, p ira - ,  hydroxyrubicine
Anthracenedions Mitoxantrone, Losoxantrone
Anthrapyrazoles Piroxantrone, BBR 2778
Oxazaphosphorines Ifosfam id, Trofosfamid, Mafosfamid
Vinca a lca lo ids Vindesine, V inorelbine
Camptothecins Topotecan, Irino tecan , In to p lic in
Platinum deriva tives Carbo-, ip ro - , oxo-, lobo-, amino-, cyclo-, 
ormaplatin
Nitrosoureas Fotemustin, cistemustin
Naphthylureas Suramin
Antimetabolites Trimetrexate, edatrexate, AZT, AZC, gém­
e i tab in  , 2-chloro-2-fluor-adenosine
There are also new concepts which have resulted in  progress of therapy 
of malignant diseases. The major research approaches are enumerated in 
Table VI.
What is  d if fe re n t ia t io n  induction? The assumption th a t a premalign ant or malignant c e ll 
might be reintegrated in to  i t s  normal environment instead o f i t s  k i l l in g  has been confirmed. 
For example, o ra l leukoplakias might be healed by re tin o ic  acid deriva tives /1 2 /. Those agents 
which are capable o f stim ulating  th is  " re d iffe re n tia tio n "  process are ca lled  "d if fe re n t ia t io n  
in d jce rs ". Many such substances e x is t.  Table V II l is t s  the most important re d if fe re n t ia t in g  
agents /1 6 /.
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Table V
Investiga tiona l antitumour drugs
Groups o f o r ig in Drugs
Taxanes Taxol, taxotere
Antiproteases Distamycin
Polyamine in h ib ito rs Deoxyspergualin, PT-523
Antilipases Crotaxin
Plant de riva tive s Ipomeanol, fla vo n ic  acid , e lag in in
Barbiturates Merbaron
A zirid ines Imexon
Chinons Chlorochinoxalin, ansamycin
Heavy metal complexes Titanium, Ruthenium complexes
Metal complexes Tellurates
Table VI
New concepts in  drug therapy
D iffe re n t ia t io n  induction (re d iffe re n tia tio n )
Enhancement o f apoptosis
In h ib it io n  o f MDR
P o te n tia tio n  o f drug e ffec t
Megatherapy, supportive drugs
Adjuvant (neoadjuvant) therapy
The mechanism o f ac tion  o f d iffe re n tia tio n  inducers is  not c lea r. At lea s t three d i f ­
fe re n t explanations e x is t :  (1 ) in fluence exerted upon c e l l  surface molecules, (2 ) enhancement 
o f  lig a se  type a c t iv ity ,  and (3 ) production of various enzymes responsible fo r  subce llu lar 
m etabolic a c t iv ity .
Another substan tia l research top ic  is  c e ll  death (apoptosis). Normally, there is  a 
balance between c e ll reproduction and c e ll loss. Such balance ex is ts  between new and dyeing 
cancer c e lls  as w e ll. Any e f f o r t  which is  d irected towards the enhancement o f c e l l  death, 
d is to r ts  th is  equ ilib rium . Consequently, i f  more malignant c e lls  disappear than the amount in  
which they are produced, the tumour is  in  a shrinking stage. The re s u lt may also be a complete 
tumour disappearance ("re g re ss io n ").
Several research ways exist fo r in fluencing ce llu la r metabolism and 
inducing apoptosis. Table V I I I  reviews certa in  avenues /14 /.
Basically, agents inducing apoptosis might be e ither molecules exert­
ing  a c tiv ity  se lec tive ly  against c e ll surface adhesion proteins (autocrine
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Table V II
R ed iffe ren tia tinq  agents
9 -c is -tra ns re tio n o ic acid Vitamin Dj
13 -c is -transre tino ic acid Tamoxifen
Eenretinid Bisacetamide derivatives
Tocopherol Phorbol derivatives
Table V II I
Apoptosis induction
Autocrine mechanisms Antiadhesion molecules (a n t i-  
adherrin, a n tile c tin s , a n ti-  
fib ro n e c tin , e tc .)
Paracrine mechanisms Antim etastatic therapy (bryo- 
s ta tin , e tc .)
or in tr in s ic  factors) or new chemical structures influencing c e l l  death 
(paracrine or ex trins ic  fa c to rs ). Some of them are increasing c e ll degradase 
a c tiv ity  by a series of various metabolic steps.
Great excitement was attached to the discovery that ce rta in  glyco­
proteins (P170 proteins) may accumulate in  tumour c e ll membranes, thus in ­
h ib it in g  drug uptake. As a re s u lt, the malignant c e ll becomes "re s is ta n t" 
to any cy tos ta tic  therapy. This phenomenon may manifest i t s e l f  p rim a rily  as 
a c e ll in b u ilt  property, o r, secondarily, a fte r a certain period o f tre a t­
ment. I t  represents a major obstacle to the d e fin itive  success o f cancer 
chemotherapy. At least a h a lf o f the existing drugs show th is  "m ultidrug 
resistance" (MDR). MDR is  an overexpression of three d iffe re n t genes, re­
su lting  in an excess of glycoproteins in the cancer c e ll embrane. MDR is  
probably the most important type of drug resistance /10/.
Any e f fo r t  aimed at overcoming resistance means a success in  therapy. 
Therefore, several agents w ith various mechanisms of action have been pro­
duced to in h ib it  MDR. These substances are shown in  Table IX.
Based upon pharmacokinetic data mainly published in  the la s t  decade 
the study of mechanism of action of several antitumour compounds has been 
renewed. Various substances have been found which are capable of increasing 
the concentration of d iffe re n t enzymes, thus, preparing the ta rge t fo r  an 
increased e ffec t of the cy tos ta tic  drug. These "potentiating" substances are
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Table IX
Agents in h ib itin g  MDR
Calcium channel blockers
Sporins
Camptothecins
Podophyllins
Verapamil, n ife d ip in , nomodipin, 
g u ld ip in , dexniguldip in
Cyclosporin, staurosporin 
CPT-11, irinothecan 
Etoposide, tenoposide
Table X
Poten tia ting  drugs under current 
c lin ic a l investiga tion
Drugs Malignancies
Leucovorin Colorectal cancer
Zidovudin Gastric cancer
Dipyridamol Breast cancer
A c iv ic in Head and neck cancer
non-cytotoxic drugs. As an example, in i t ia l l y  drug "potentia tion" was used 
to  enhance fluoropyrim idine a c tiv ity  by leucovorin. Table X demonstrates 
compounds possessing po ten tia ting  effect /13 /.
Actually, various antimetabolites and potentia ting  agents are under 
c l in ic a l  investigation in  d iffe re n t malignant tumours.
The dosage of estab lished  drugs has also been re investiga ted . The term "megatherapy" 
means very high doses o f e f fe c t iv e  antineoplastic drugs. This approach aims a t destroying 
—w ith  the aid o f large concentrations of cy tos ta tic  drugs — those tumour c e lls  which are 
in s e n s it iv e  to standard doses. Th is  procedure became possib le  because promising advances were 
made in  supportive therapy. The major resu lts  are l is te d  in  Table XI /9 , 11/.
Last but not le a s t, methods of adjuvant therapy has been re v is ite d  in  
the la te  eighties in  order to  find  an established place fo r cytotoxic tre a t­
ment w ithin the frame o f complex therapy. Metaanalysis showed tha t post­
operative adjuvant chemotherapy of premenopausal N+ breast cancer patient 
w ith  various antitumour drugs is  useful while postmenopausal women of the 
same category require postoperative hormonal treatment. Several malignancies 
were also objects o f successful postoperative adjuvant chemotherapy. Apart 
from th is  approach preoperative adjuvant chemotherapy was in it ia te d  to im-
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Table XI
Advances ln  supportive therapy
Type o f to x ic ity Therapeutic approach
Haemopoietic — BM-transplantation (heterologous, 
autologous)
— Progenitor c e l l  in fusion
— Growth fac to r therapy 
(H-EPO, G-CSF, GM-CSF, IL-3)
Antiemetic Antiserotonins (ondan-, tro p i- ,  
granisetron)
U roep ithe lia l MESNA
Cardiac WR-2721 ?
Antia llopecic Tellura tes ?
Antihepatic Thio l de riva tives  ?
Table X II
Adjuvant chemotherapy
Type Maligiancy
Preoperative (neoadjuvant) Oral cancer 
Laryngeal cancer 
Oesophageal cancer 
Osteosarcoma
Postoperative (data from 
metaanalysis)
— compulsory Premenopausal N“  breast cancer, 
Postmenopausal N“  breast cancer 
w ith hormones
Wilms tumours, neuroblastoma, 
rhabdomyosarcoma
— optional G astric carcinoma in  s itu  
Colorecta l cancer
prove the resu lts of surgical in tervention as w ell. Table XII is  a review of 
the most important research trends /1 /.
The methods of adjuvant therapy performed by immunological methods has 
not yielded any so lid  data. There is  s t i l l  a debate whether the adm inistra­
tio n  of immunostimulants in  colorecta l cancer or melatoma is  useful or not. 
C lin ica l investigations are in progress.
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In both experimental and c lin ic a l research, i t  is  the cancer pa tien t 
who is  in  the focus o f in te res t. He is  the su ffe ring  individual and i f  there 
is  no cure fo r him at least he can be re lieved from i t s  burdening or pa in fu l 
symptoms /5 / .  His qu a lity  o f l i f e  has to be insured by a l l  means. Every step 
in  research has to have the goal to assist him in  preserving th is  q u a lity . 
This e ffo r t  is  now in  the centre of in te res t o f dedicated researchers. I  am 
hopeful tha t we w i l l  be able to f u l f i l  th is  task in  the near fu tu re .
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THE ROLE OF CT IN  THE TREATMENT PLANNING OF RADIOTHERAPY 
OF MALIGNANT TUMOURS
E. KUHN
Department of Radiology, University Medical School of Pécs 
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The advantages o f and the information given by CT examinations in  the proper and v a lid  
treatment planning o f radiotherapy o f malignant tumours are discussed. Without in d iv id u a l and 
thoughtful app lica tion  o f CT before and during radiotherapy the chances o f cure are s ig ­
n if ic a n t ly  reduced. Radiotherapists nust be fa m ilia r w ith  th is  imaging method.
Keywords : CT, therapy planning, radiotherapy, malignant tumours
Survey
Our aim in  the radiotherapy of malignant tumours is  to decrease the 
number of clonogenic tumour ce lls  to such a leve l that the defence mecha­
nisms of the immune system can alone overcome them. This c r i t ic a l  number 
of clonogens is  supposed to be about 106 c e lls .  Continuous regression o f the 
tumour is  achieved by a complex process in it ia te d  by absorption of rad ia tion  
energy and produced by various biochemical, rad io- and tumourbiological as 
well as c e ll-k in e t ic  processes in  tumour during irrad ia tion . The amount of 
the da ily  dose fraction  administered, as well as the to ta l tumour dose, is  
of great importance, as is  the homogeneity of the dose d is tr ib u tio n  in  the 
tumour. The dose that is  thought to be e ffe c tive  in  k i l l in g  tumour c e lls  is  
usually associated with risks  to normal tissue damage thus the given dose 
should never exceed normal tissue tolerance. Unfortunately, i t  is  not pos­
sib le  to f u l f i l  completely th is  requirement. Healthy tissues and organs 
ly ing in the path of beams unavoidably receive a certain amount o f rad ia tion  
energy. I t  is  our aim to keep th is  amount o f rad ia tion  and the unnecessarily 
irrad ia ted volume of normal tissues as low as possible.
O ffp r in t requests should be sent to : E. Kuhn, Department of Radiology, U n ive rs ity  
Medical School, H-7641 Pécs, Ifjú sá g  u. 13, Hungary
0236-5286/94/fi' 4.00 © Akadémiai Kiadó, Budapest
142 E . KUHN
Just l ik e  the s a ilo r  navigating between S c il la  and Charybdis, there is  a narrow path 
fo r  the  rad io therap ist to  walk between the necessary dose to  reduce the rumtoer o f clonogens 
and the tolerance dose o f hea lthy tissues and organs. Th is  narrow path, which depends on 
va riou s  fac to rs , is  defined as therapeutic ra t io .
S im ila r ly  to  the s a ilo r ,  who must decide whether sea ling  is  reasonable or n o t, and how 
to  s a i l  and on which rou te , the radiotherapist must consider several circumstances w h ils t  
dec id ing  the ind ica tion  o f radiotherapy, v iz . whether radiotherapy is  indicated o r n o t. The 
parameters, how to  t re a t,  by which f ie ld  arrangement, by which radiation energy, dose f ra c ­
t io n s ,  dose d is tr ib u tio n , e tc . ,  these de ta ils  a ltoge the r are called treatment p lann ing.
The treatment planning contains a l l  the physical parameters which are 
needed to  ensure the homogeneous dose d is tr ib u tio n  in the target volume. The 
ta rg e t volume is  determined by the tumour volume together with a ce rta in  
amount o f a surrounding volume of apparently normal, healthy tissue . This 
la t t e r  contains tissue th a t is  po ten tia lly  infected by tumour c e lls  and a 
tissu e  free of microscopic lymphogenous progression. The amount of surround­
ing  tissue po ten tia lly  invaded depends on the size and h is to log ica l type of 
the tumour. Anaplastic tumours must be irra d ia te d  by larger fie ld s  than w e ll 
d iffe re n tia te d  ones. The target volume may also contain the regional lymph 
node area, e ither because métastasés are already present or the microscopic 
spread in to  the regional lymphatics is  h igh ly suspected. Obviously, the size 
and the shape of the volume to be irrad ia ted  varies s ig n ifica n tly  ju s t  as 
i t s  re lationship to adjacent organs of various rad iosensitiv ity  i .e .  to ­
lerance. I t  is  important to  irrad ia te  the ta rge t volume as homogeneously as 
possib le . This is  true fo r  a l l  daily administered treatment frac tions  even 
i f  tumours are f in a lly  inhomogeneously irra d ia te d . Such an inhomogeneous 
dose d is tribu tion  gives tumour regression more effective and reduces the 
volume of irradiated normal tissues. I t  is  w e ll known that oxygen tension in  
the c e lls  influences rad iosens itiv ity . The cen tra l part of the tumour con­
ta in s  various amounts o f hypoxic ce lls  which are more resistant than the 
w e ll oxygenated ones. At the periphery of the tumour the ce lls  are mostly 
w e ll oxygenated, thus cen tra l part needs higher dose for ce ll k i l l in g  than 
i t s  peripheral part. The size of irrad ia ted volume can thus be decreased 
step-by-step during the f in a l period of rad ia tion  therapy. This method of 
treatm ent, using shrinking fie ld s , improves the rate of tumour con tro l and 
decreases normal tissue damage. I t  is  obvious that treatment planning is  
performed not only before the s ta rt of the treatment, but also before any 
m odification that may be necessary during treatment.
I t  is  of great importance to accurately know the loca liza tion  and 
s ize  of the tumour as w e ll as i t s  re la tion  to the neighbouring organs. To 
develop a re a lis t ic  treatment plan, one must possess a transversal sketch
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Fig. 1. Pulmonary in f i l t r a t io n  was detected during check-up examination. The p a tie n t was 
symptomfree. The l e f t  border o f the V II thoracic vertebra shows l ig h t  moth-eaten destruction
from the body at the level of the tumour. P rior to the introduction o f CT i t  
was very d i f f ic u l t  to get transverse sections from the body. Treatment 
planning based on these drawings was not only lengthy but also o f low ac­
curacy /2 / .  Before the CT era i t  was impossible by any conventional ra d io l­
ogical method to demonstrate tumorous in f i l t r a t io n  of so ft tissues, early 
invasion of the bone (F ig. 1), and lymph node métastasés in  hidden s ites  
(F ig. 2 ). Data in  the lite ra tu re  /1 / as well as our early experiences in  
1981 w ith CT showed that treatment plans without the use of CT required mo­
d if ic a tio n  in  35-40% of the cases, because the size and invasion of the tu ­
mour had been underestimated. The underestimation of the target volume would 
have resulted in  an undertreatment of some of i t s  parts. The English l i ­
terature characterizes th is  s itua tion  as "geographic miss" /2 / ,  the resu lt 
of underestimation of the tumour bound with increased frequency of local 
recurrence. Owing to the use of CT in the evaluation of the tumour th is  type 
of recurrence has become rare, now i t  is  caused mostly by inaccurate patient 
set-up or by f ie ld  displacement during da ily  treatment.
The advantages of CT in  treatment planning are as fo llows:
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The a x ia l  scans o f th e  CT p ro v id e  c o r re c t  c ro s s -s e c t io n a l ( t r a n s ­
v e r s a l )  p ic tu re s  o f th e  body w ith  a l l  an a to m ica l d e t a i ls  and o f th e  tumour 
a t  th e  chosen le v e l .  T here  has been a debate  in  th e  l i t e r a t u r e  w hether CT 
scans  should be taken  a f t e r  deep in s p ir a t io n  o r  e x p ir a t io n ,  a lw ays w ith ­
h o ld in g  b re a th in g . In  our d ep artm en t, CT scans a re  perform ed d u rin g  norm al 
b r e a th in g  because t h is  i s  th e  norm al s ta te  d u rin g  i r r a d ia t io n ,  to o . The 
s te a d y  movement o f  organs due to  b re a th in g  is  id e n t ic a l  d u rin g  th e  exam ina­
t io n  and the  i r r a d ia t io n .  CT a llo w s  s im ple  d e te rm in a tio n  o f th e  body con­
t o u r ,  which is  needed fo r  tre a tm e n t p la n n in g , b u t o n ly  i f  th e  g a n try  i s  w ide  
enough even fo r  obese p a t ie n t s .  In  t h is  re g a rd  th e  CT-s o p e ra tin g  in  our 
c o u n try  a re  in s u f f i c ie n t .  F o r t h is  and o th e r reasons i t  i s  recommended to  
e q u ip  ra d io th e ra p y  c e n tre s  w ith  C T 's s p e c ia l ly  designed and produced fo r  
t re a tm e n t  p la n n in g .
CT scans p ro v id e  e x c e l le n t  v is u a l iz a t io n  o f  th e  tumour and n e ig h ­
b o u r in g  organs; th e  a b s o rp tio n  d if fe re n c e s  between s o f t  t is s u e s  can be i n ­
c re a s e d  by in tra v e n o u s ly  a d m in is te re d  c o n tra s t  m a t e r ia l .  I t  is  y e t  unknown
F ig . 2 , CT scan demonstrates an enlarged lymph node in  the ré tro c ru ra l area (arrow ), r ig h t  
to  the aorta (A ). This region remains hidden when conventional imaging methods or u ltrasono­
graphy is  used
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F ig . 3a. CT scan shows tumour o f the nasopharynx as asymmetry on the le f t  s ide  o f the
poste rio r w all
F ig. Tb. Dose d is tr ib u tio n  in  the ta rge t volume
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F ig . 3c. CT scan made 2 years fo llow ing  radiotherapy demonstrates complete regression o f the
tumour
whether MRI w il l  bring about a revolutionary change in  th is  area, s im ila r to 
th a t caused by the in troduction  of the CT. I t  can reasonably be expected 
th a t in  certain loca tions  (brain stem, poste rio r fossa, spinal canal, bone 
marrow, etc.) MRI w i l l  allow more precise recognition of the tumour and tu ­
morous in f i l t r a t io n .
Delineation o f the ta rg e t volume and a l l  s truc tu re s  to  be shielded can p rec ise ly  be 
performed on the CT scan (F ig . 3a-b-c). The examination must be made in  the same p o s itio n  o f 
the  pa tien t in which ir ra d ia t io n  w i l l  be performed. I t  has been w e ll knovn since the in troduc­
t io n  o f CT that organs which had been thought as fix e d  made s ig n if ic a n t movements depending on 
the body's position.
The computer a llow s reconstructions in  s a g it ta l ,  f ro n ta l or any other plane. This 
frequen tly  improves the determ ination of the shape o f the ta rg e t volume and i t s  re la tio n  to  
surrounding organs (F ig . 4 a -b ). In  each scan we can de lineate  the shape o f the tissu e  to  be 
ir ra d ia te d . I t  is  also poss ib le  to  sum up a l l  these marked areas and, a fte r  processing, to  
p ro je c t the resu lting  area to  the  topogram. The p ro je c tio n  o f the volume to  be ir ra d ia te d  made 
v is ib le  on the body w ith  w e ll recognizable re la tio n sh ip  to  fixed  anatomical landmarks, is  o f 
g re a t value in ra d ia t io n - f ie ld  arrangement (F ig . 5 ). Using spec ia lly  developed sophisticated 
software programs we can perform  a three-dimensional reconstruction  of the ta rge t volume, thus, 
make treatment planning more accurate. Not in fre q u e n tly , the scan showing the tumour sur­
p r is in g ly  discovers tumorous manifestation in an other lo ca tio n , too, which in  lack o f c l in ic a l 
symptoms could have been completely hidden (F ig . 6 ).
The CT scan can accu ra te ly  evaluate tumour regression, which is ,  as mentioned above, 
o f  great importance in  shaping correctly  the s ize o f  the rad ia tio n  f ie ld s  to  be decreased
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F ig . 4a. CT scan d isp lays recurrent tumour in  the le f t  p rasternal area fo llow ing  mastectomy. 
There is  a small fa t  l in e  between the in tra tho rac ic  p a rt o f the tumour and the pericardium, 
thus a gross tumorous in f i l t r a t io n  o f the pericardium is  improbable
F io. 4b. The reconstruction in  the s a g itta l plane demonstrates the size and the shape o f the
tumour more accurately
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F ig . 6. The large m ediastinal tumour caused by Hodgkin's disease was w e ll seen on conventional 
X -ray examination. CT discovered su rp ris ing ly  the l y t i c  destruction o f the costotransversal 
process o f the V lth  thoracic  vertebra w ith an adjacent part o f the r ib
F ig . 5. The s ize  o f the tumour as pro jected to  the topogram
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F ig . 7a. CT scan demonstrates b ila te ra l o rb ita l involvement caused by non-Hodgkin lymphoma. 
On the r ig h t  side the tumour is  engulfing the op tica l nerve, on the le f t  there is  an in f i l t r a ­
t io n  ly in g  medially to  the globe
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F ig . 7b. The dose d is tr ib u tio n  in  the ta rge t volume seems to  be appropriate by using 3 f ie ld s
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F ig . 7c. Two years fo llo w in g  radiotherapy the regression o f both tumours is  complete, only 
minimal scar tissue  is  seen around the r ig h t  op tic  nerve
(F ig . 7a-b-c). The CT scans provide information not only fo r treatment planning, but also in  
determ ining whether the tumour is  su itab le  fo r radiotherapy. Necrotic areas in  the tumour are 
w e ll seen as hypodensities on the scans. I f  the volume o f these areas is  extensive, the tumour 
is  mostly not suitable fo r  ra d ia tio n  therapy as a f i r s t  step and other methods o f therapy might 
f i r s t  be applied. I f  th is  form o f  therapy is  o f success, radiotherapy may be ind ica ted  la te r .
The CT made ir ra d ia t io n  possible even in  locations in  which radio­
therapy had mostly been avoided because the protection of neighbouring, by 
conventional imaging methods in v is ib le  organs could not be accurately car­
r ie d  out.
I t  is  questionable whether i t  is  indicated, or is  necessary, to  per­
form CT examination when the aim of radiotherapy is  simply p a llia t io n . In 
our opinion, th is  should always be ind iv idua lly  decided; however, when bone 
métastasés are treated, CT can provide important information about the real 
s ize  and local extension o f bone involvement. In our experience the meta­
s ta s is  demonstrated by a CT scan is  always larger than that shown on conven­
t io n a l X-ray film s.
Summarizing of the above-mentioned facts and experiences makes i t  ob­
vious that CT should be regarded as a routine examination in  every centre of 
oncoradiology. Standard and appropriate application of CT is  mandatory fo r 
ind ica tion  of radiotherapy as well as i t s  ind iv idua l use fo r adequate tre a t­
ment plans. Without the application of CT in  the treatment planning as well 
as before and during rad ia tion  treatment the chances of curing the patient 
are s ig n ifica n tly  decreased. Proper education of oncoradiologists can only
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be complete and adequate i f  they possess complete knowledge of how to  per­
form CT examinations and how to read the p ic tu res . The twin brothers of 
radiology: diagnostics and therapy — frequently opponents — can peacefully 
give hands and unite in  a fr ie n d ly  manner in  th is  f ie ld  of d isc ip line .
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SIGNIFICANCE OF THREE-DIMENSIONAL RADIATION TREATMENT PLANNING
G . NÉMETH, OLGA É S IK
H aynal Im re U n iv e r s ity  o f  H e a lth  S c ie n c e , C h a ir  o f  R a d io th erap y  and
N a t io n a l I n s t i t u t e  o f O ncology, Departm ent o f R ad io therap y , B u dap est,
Hungary
(R e ce iv e d : September 2 3 , 1994)
A tumour and i t s  environment constitu te  a three-dimensional (30) phenomenon. Conse­
quently , adequate management o f the ta rge t volume (tumour + safety zone) is  fe a s ib le  on ly  w ith 
a 3D treatment planning and ir ra d ia tin g  system. The more precise planning and dose de live ry  
involved in  such a 3D treatment lead to  an improved therapeutic effectiveness.
Keywords: 3D. treatment planning, dynamic treatment planning
Survey
A t p resen t th r e r e  a re  some 200 000 m a lig n a n t tumour p a t ie n t  in  Hun­
g a ry . Some type o f io n iz in g  i r r a d ia t io n  (gamma, photon o r e le c t r o n  i r r a d i a ­
t io n )  i s  re q u ire d  d u rin g  th e  c l i n i c a l  course  o f  th e  d isease in  n e a r ly  tw o - 
t h i r d s  o f  th e  cases. T h e ir  reco very  depends, among o th e rs , on th e  a c cu racy  
o f  tre a tm e n t p lan n in g  and on i t s  accom plishm ent. S ince a tumour i s  a t h r e e -  
d im e n s io n a l (3D ) phenomenon, adequate management o f th e  t a r g e t  volume  
(tum our + s a fe ty  zone) i s  fe a s ib le  o n ly  w ith  30 tre a tm e n t p la n n in g . E f f e c ­
t i v e  ra d io th e ra p y  th e r e fo r e  has two p r e r e q u is ite s :
1 . Homogeneous and com plete coverage o f th e  ta r g e t  volume w ith  a 
g iv e n  dose.
2 . Maxim al s p a rin g  o f  the  t is s u e s  o u ts id e  th e  ta r g e t  volum e.
These c r ite r ia  are met by 3D treatment planning. The f i r s t  step in  such treatment 
planning is  to  obtain s e r ia l computer tomographic (CT) images in  p a ra lle l planes on the volume 
o f in te re s t.  The d ig ita liz e d  in form ation is  then transfe rred  d ire c tly  to  the treatm ent planning
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F ig . 1. Target volume (3 .1  cnr5) in  the midline o f the b ra in  and the re la tiv e  (80%) isodose 
d is tr ib u t io n  o f  photon beams (15 MV) : 8 windows were used
softw are /2 , 4 /. Following the removal o f the CT data outside the body contour, 3D e lec tron  
d e n s ity  matrices can be generated fo r dose ca lcu la ting  a lgorithm . The next step is  3D s i ­
m ulation o f the radiotherapy to  be delivered. Simulation is  conducted according to  the p r in ­
c ip le  o f the "beam's eye v iew ". With th is  technique, the anatomic s itua tion  and rad ia tio n  
parameters are displayed on the screen as an eye would see them when looking out from the 
ra d ia t io n  source. In 3D treatm ent planning, a v isua l and numerical display o f dose c a lcu la tio n  
is  a lso  possible.
Image e v a lu a tio n  i s  p os s ib le  by d is p la y in g  th e  r e la t iv e  absorbed  
volum e dose d is t r ib u t io n s  in  the  a x ia l ,  s a g i t t a l  and co ro n a l p la n e s  and 3D 
p e rs p e c t iv e s  (F ig .  1 ) .
Num erical e v a lu a t io n  means the  r e p re s e n ta t io n  o f  dose d is t r ib u t io n  
p ara m e te rs  in  th e  system  o f  c o -o rd in a te s , th e  r e l a t i v e  dose on th e  a b s c is s a  
and th e  number o f volum e elem ents or volume p ercen tage  on th e  o r d in a te .
S oftw are developm ents  have re s u lte d  in  dynam ic 3D tre a tm e n t p la n n in g  
c a p a b le  o f c o n t in u a l a d ju s tm e n t o f a l l  r a d ia t io n  p aram eters . P r im a ry  and 
secon dary  c o ll im a to r  system s have been d ev is e d  to  re -sh ap e  th e  i r r a d i a t i o n  
f i e l d s  / 1 ,  3 / .
The f i e l d  c o n f ig u r a t io n  appearing in  a r b i t r a r y  arrangem ents in  th e  8 
windows o f the  m u lt i - c c l l im a to r r in g  (MCR) corresponds to  th e  p ro je c te d  
t a r g e t  volume seen fro m  th e  ra d ia t io n  source  ( F ig .  2 ) .  Comparison o f  the
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F ig . 2. Scheme o f a n u lt i-c o ll im a to r- r in g  (MCR); overhead and operating board
F ig . 3. Changes in ta rge t volumes w ith in  the 60 to  804 isodose range: d if fe re n t ir ra d ia t io n
teclnigues were used
ar
ea
156 G. NÔCTH, OLGA ÉSIK
d a ta  presented in  F ig .  3 c le a r ly  dem onstrates t h a t  th e  best s p a rin g  o f  th e  
i n t a c t  t is s u e s  o u ts id e  th e  ta r g e t  volume i s  f e a s ib le  w ith  i r r a d ia t io n  
th ro u g h  the MCR.
The in tr o d u c t io n  o f  3D trea tm ent p la n n in g  in  Hungary has c o n tr ib u te d  
to  more p re c ise  r a d io th e r a p y  trea tm en t p la n n in g  and accom plishm ent. The im ­
p ro ved  ra d io th e ra p y  re d u c e s  th e  inc id ence  o f  re c u rre n c e s , th e  th e ra p y  o f  
w h ich  i s  more e x p e n s iv e  th a n  th e  prim ary tre a tm e n t  i t s e l f .
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THE ROLE OF BRACHYTHERAPY IN THE RADIATION TREATMENT OF 
MALIGNANT TUMOURS
A . MAYER
C e n te r o f  O nco rad io lo g y , Uzsoki H o s p ita l ,  Budapest, Hungary
(R ece ived : September 2 3 , 1994)
The magnitude o i brachytherapy doses depends on the applied dose rates: h igh-dose-rate 
or low-dose-rate techniques. Brachytherapy is  usua lly  performed as a complementary m odality 
w ith  megavoltage external beam therapy, but i t  is  also used preoperatively fo r cancers o f the 
u te rine  cerv ix  and corpus. The most common lo c a liz a tio n  is  reviewed in  th is  paper w ith  
specia l regard to the ind ica tions , treatment methods and prognosis o f curing fo r  re c ta l and 
breast cancer.
Keywords: Brachytherapy, breast cancer, re c ta l cancer, organ-conserving cancer treatm ent
In t ro d u c t io n
B rach yth erap y  is  one o f th e  forms o f th e  s o -c a lle d  sm a ll-vo lum e  i r r a ­
d ia t io n ,  which i s  done by p la c in g  a p p lic a to r  w ith  n u c lid  source in  a c a v it y  
o r in  th e  in t e r s t i t iu m .  Depending on w hether th e  r a d ia t io n  source is  a p p lie d  
m a n u a lly , o r  th rough  a f te r lo a d in g  in to  th e  a p p l ic a to r ,  we d is t in g u is h  th e  
manual and th e  a f te r lo a d in g  techniques form s o f  b rachytherapy w h ith in  th e  
l a t t e r ' s  com puter-gu ided  form . Depending on th e  a p p lie d  dose r a t e s ,  th r e e  
form s a re  b e in g  used, such as: lo w -d o s e -ra te , m ed ium -dose-rate  and h ig h -  
d o s e -ra te  form s and t h e i r  more advanced form  i s  th e  p u ls e d -d o s e -ra te  form  
w hich may be used w ith  low o r h ig h  a c t iv a t in g  r a d ia t io n  source . T e c h n ic a l  
developm ent i s  n o t a c r i t e r io n  in  using th e  d i f f e r e n t  a c t i v i t i e s .  The f o r ­
m e rly  used lo w -d o s e -ra te  (LDR) te c h n ic s  have been re p la ce d  by th e  h ig h -d o s e -  
r a t e  (HDR) one in  th e  m eantim e, b u t , due to  o u r re c e n t knowledge in  r a d ia -
Abbrevlatlons: low-dose-rate: LDR, high-dose-rate : HDR
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t i o n  b io lo g y  — depend ing  on tumour c e l l  k in e t ic s  o r th e  g ra d in g s , e i t h e r  
o f  th e  o th e r b ra c h y th e ra p ic  forms is  b e in g  p r e fe r r e d  /1 2 ,  1 3 / .
Advantages o f  b rac h y th e rap y  can be sum marized as fo llo w s :
1 .  L o c a lly  h igh  dose, w i th in  f a i r l y  s h o rt  t im e ;
2 .  Due to  a ra p id  d o s e - f a l l ,  the  surrounding  t is s u e s  w i l l  not be exposed to  
r a d ia t io n .
The main d is a d v a n ta g e s  o f b rachytherap y  a re  as fo llo w s :
1 .  I t  always means lo c a l  i r r a d ia t io n  th e r a p y , in  p re o p e ra tiv e — p o s to p e r­
a t i v e ,  p rim a ry , p e r io p e r a t iv e  forms;
2 .  I t  has not c u r a t iv e  e f f e c t  when a p p lie d  f o r  re g io n a l m e ta s ta s is ;
3 .  T h ere  i s  inhom ogenity  w ith in  the  s o -c a l le d  r a d ia t io n  th e ra p e u t ic  t a r g e t  
volume;
4 .  The r a d ia t io n - b io lo g ic a l  e f f e c t  o f LDR and HDR a re  d i f f e r e n t .
In  primary ir ra d ia t io n  in  case o f ce rv ica l and endometrial tumours we apply the HDR 
brachytherapy a fte rload ing  technics fractionated o f 30-50 Gy (Dose-unit) to  the to ta l  dose o f 
adequate dose-depths, which is  completed percutaneously by the so-called megavolt therapy fo r 
re g io n a l supply /7 , 10/. A fte r  an organ-preserving operation, in  case of breast tumour, the 
LDR brachytherapy is  completed by percutaneous megavolt therapy in a so-called "boost" form.
T h is  is  a s im i la r  procedure as th e  b ra c h y th e ra p e u tic  method a p p lie d
in  case o f p ro s ta te  tum ours , where th e  s o -c a l le d  permanent b ra c h y th e ra p y  
125c o u ld  be done w ith  I  n u c lid  seeds, w hich  re p re s e n t th e  lo c a l  t o t a l  dose 
in  th e  LDR form , and s im i la r ly  to  th e  above-m entioned b re a s t tum ou r, th e  
m e g a v o lt th e ra p y 's  b oo st form  w ith  HDR te c h n ic s  is  being g e n e r a lly  a p p lie d  
w ith  192I r  n u c lid  / 5 ,  1 1 , 1 4 / .
The s p e c ia l fo rm  o f  brachytherapy i s  an in t r a o p e r a t iv e  tu b e -g u id e d  
r a d io th e r a p y , o f  w hich  q u ite  good p a l l i a t i v e  success i s  b e in g  n o t ic e d ,  
e s p e c ia l ly  in  th e  s m a ll p e lv is  re la p s e s  and in  the  re g io n a l m étas tasés  
/ 3 ,  4 / .
• S p e c ia l a t t e n t io n  should  be paid  to  p a l l i a t i v e  b rachy therap y  w ith  th e  
HDR a f te r lo a d in g  te c h n ic s  / 2 ,  4 /  in  case o f  m a in ly  e n d o lu m in a lly  p ro g r e d ie n t  
in o p e r a b le  o b s tru c t iv e  tum ours o f esophagus and bronchus.
Methods
In  the Oncoradiological Center working at the "Uzsoki" Hospital, we have achieved an 
im portant experience w ith  the c u ra tive -p a llia tive  form o f brachytherapy in  gynaecological 
carcinomas. Our re su lts  have already been published / 6 , 9 /.  Reductive-radical surgery — in  
onco log ica l means: i t  is  ra d ic a l —, and could be c a lle d  as "minimal surgery", which is  com­
p le te d  by rad ia tion therapy w ith  percutan megavolt therapy, furthermore w ith brachytherapy.
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We have sa tis fa c to ry  experience o f brachytherapy technic when applying the ea rly  stage tumours 
o f the rectum's middle or lower th ird  and tumours o f outer-upper breast quadrant. I t  w i l l  be 
below the b r ie f  summary o f the therapy resu lts  of the applied ir ra d ia tio n  technics and ind ica­
tio n s  o f the two lo ca liz a tio n s .
R esu lts
I .  B re a s t tumours
In d ic a t io n :  p o s s ib ly  in  the  o u te r-u p p e r b re a s t quadrant s i tu a te d  so­
l i t a r y  tumour carcinom a in tr a d u c ta le  o r carcinom a d u c ta le  in v a s iv u m  h is ­
to lo g y ,  n o t la r g e r  than  20 mm ( T ^ - T ^ )  r e g io n a l ly  n e g a tiv e , o r  w i th  lymph 
node m e ta s ta s is  — re a c h in g  maximum 2 /1 0 :  (N l g ) ;  th e  s u r g ic a l r a d i c a l i t y  is  
co n firm e d  in  2 cm to  a l l  d ir e c t io n s , and endolym phatic  sp read in g  cann ot be 
shown.
The in d ic a t io n  i s  com pleted by p r e d ic t iv e  fa c to r s ,  such as NK a c t i v i t y  
EIC ’ (e x te n s iv e  in t r a d u c ta le  in  s i tu  component) hormone re c e p to r  s ta tu s ,  
e t c .  w hich is  im p o rta n t when con s id e rin g  w hether to  app ly  b r a c h y - te le th e ra p y  
or perhaps chem otherapy.
ve ly :
In  our p ractice , two forms o f brachytherapy are being applied at present postopera ti-
N=111
*No evidence of disease
F ig . 1, Recurrence ana lysis o f 111 women with breast tumour, w ith quandrantectomy and brachy­
therapy, based on the condition o f the operation-margin
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1. LDR brachytherapy o f tumour-bed, manually w ith 50-60 Gy t o ta l  dose, or perhaps the reg ions' 
megavolt therapy.
2. Tumour-bed-whole breast i n i t i a l  megavolt therapy w ith 50 Gy dose, and the tumour-bed boost 
in t e r s t i t ia l  HOR a fte rload ing  technics with 10 Gy dose, o r perhaps by megavolt therapy o f 
the  region.
Between Janu ary , 1987 and December, 1992 we a p p lie d  b ra c h y th e ra p y  in  
111 p a t ie n ts  w ith  b re a s t  tum our. We analyzed  th e  re c u rre n c e s  form  many a s ­
p e c ts .  We p resen t our r e s u l t s  through th e  s id e -e x c is io n  — f r e e  o f  tum our.
I I .  R e c ta l tumours
In d ic a t io n s :  a p p l ic a t io n  in to  the  re c tu m 's  m id d le  o r lo w e r - t h i r d ,  th e  
s iz e  o f  th e  tumour does n o t reach  one q u a rte r  o f  th e  rec tum 's  in n e r  c irc u m ­
fe r e n c e  and i t s  depth  o f  expansion  is  t i l l  Dukes B^ d i f f e r e n t ia t e d  adeno­
c a rc in o m a , e x c lu d in g  d is t a n t  m e ta s ta s is .
P a tie n t-c r ite r ia  should be done a fte r a through examination, which means th a t besides 
the  t ra d it io n a l examination, an in tra lu m in a l sonography and CT check are done.
In  our p re s e n t p r a c t ic e  — p o s s ib ily  w i th in  fo u r  weeks a f t e r  th e  p r i ­
m ary tumour lo c a l e x c is io n  —  th e  fo llo w in g  a re  a p p lie d :
1. Tumour bed HOR a fte rload ing  — w ith  weekly breaks — w ith  6 x 5  Gy to ta l dose.
2. A dd itiona l megavolt therapy, ca lcu la ted fo r the rectum 's region up to  24 Gy to ta l  dose.
Between Janu ary , 1990 and December, 1992 we com pleted b ra c h y /m e g a v o lt  
th e r a p y  on 20 rectum  lo w e r t h i r d  carcinomas w hich meant 60Co te le th e r a p y  
w it h in  our p resent number o f  p a t ie n ts .
Our therapy r e s u l ts  a re  shown in  F ig . 2 .
N=20
*No evidence o f disease
F ig . 2 . Actual su rv iva l prognosis o f 20 rectum low e r-th ird  pa tien ts  a fte r  loca l excis ion and
brachy/megavolt therapy
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D is c u s s io n  and C onc lus ions
B rachytherapy in  s o l id  tum ou r's  ra d ia t io n  th e ra p y  was f i r s t  in tro d u c e d  
in  th e  1930s. Because o f  th e  te c h n ic a l c o n d it io n s  o f th a t  t im e s , th e s e  were 
a p p lie d  in  a manual fo rm , co n s e q u e n tly , th e  r a te s  o f r a d ia t io n  exposures  o f  
th e  s t a f f  were h ig h . The a f te r lo a d in g  tech n iq u e  p u t a s to p  to  th e  s t a f f 's  
r a d ia t io n  exposure and in  th e  com puter-techn ique an o u ts ta n d in g  method in  
r a d ia t io n  p ro te c tio n  has been in v e n te d . W ith  th e  a s s is ta n c e  o f  th e s e  moni­
to r in g  equipm ents (CT— U H ), we a re  a b le  to  reach  th e  o p tim a l d o s e -d is t r ib u ­
t io n  and to  m in im a liz e  th e  r is k  o f th e  surround ing  o rgans ' r a d ia t io n  in ju r y .  
For t h i s  purpose we a re  in  th e  possession o f s p e c ia l ly  developed  a p p lic a to r s  
and m o n ito r in g  dos im eters  f o r  i r r a d ia t io n .  B rachytherapy is  one o f  th e  used 
form s o f  th e  s o -c a lle d  "s m a ll volume" i r r a d ia t io n .  To have a r e l i a b l e  c l i n ­
i c a l  ro u tin e -w o rk , th e  c o -o p e ra tio n  o f th e  p h y s ic ia n  and r a d ia t io n - p h y s i ­
c i s t ,  and sometimes c o -o p e ra t io n  w ith  a r a d ia t io n  b io lo g is t ,  may a ls o  be 
e s s e n t ia l .  These c o n d it io n s  may assure c u r a t iv e  and p a l l i a t i v e  tre a tm e n t o f  
th e  tu m o u r-typ e  and i t s  s p re a d in g .
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THERAPIES AVAILABLE FOR HEAD AND NECK TUMOURS
F . BÁNHIDY
Departm ent o f Flead and Neck S u rg ery , N a t io n a l I n s t i t u t e  o f  O nco logy,
Budapest, Hungary
(R e ce iv e d : September 2 3 , 1994)
Treatment m odalities o f head and neck tumours such as cancers o f the sk in , l ip s ,  o ra l 
c a v ity , sinuses, e p i-, meso- and hypopharynx, larynx and ce rv ica l so ft tissues are discussed. 
C ervica l cysts, thyro id  tumours and sa liva ry gland a lte ra tio n s  are also examined from the 
therapeutic po in t o f view. Therapeutic advices are given fo r  the treatment o f regional 
métastasés.
Keywords : Head and neck tumours, ce rv ica l cysts, sa liva ry  gland metastasis, s o ft tissue 
tumours, thyro id  tumours
In t ro d u c t io n
In  t h is  paper th e ra p ie s  a v a ila b le  fo r  tumours o f  th e  s k in ,  l i p s ,  o r a l  
c a v i t y ,  n asa l and p ara n a s a l s in u s e s , e p i - ,  meso- and hypopharynx, la ry n x ,  
c e r v ic a l  s o f t  t is s u e  (c y s ts  in c lu d e d ), th y r o id ,  s a l iv a r y  g lan d s  and t h e i r  
re g io n a l m étastasés a re  d e a l t  w ith .
Our p a t ie n ts  a re  u s u a lly  sent to  us from  d i f f e r e n t  o u tp a t ie n t  d e p a rt­
ments o f derm ato logy, oph thalm ology, d e n ta l s u rg e ry , o to -r h in o - la ry n g o lo g y  
o r by g en e ra l p r a c t i t io n e r s .  Very o fte n  th e y  a re  a d m itte d  in  advanced c l i n ­
i c a l  s tag e  due e i th e r  to  t h e i r  too  la t e  f i r s t  appearance o r  to  an inad equ a te  
a t t i t u d e  o f  the  f i r s t  exam ining p h y s ic ia n , who may happen to  b e l i t t l e  th e  
p a t ie n t 's  symptoms.
E a r ly  d ia g n o s is , how ever, i s  o f v i t a l  im portance fo r  th e  p a t ie n t .  We 
p ro fe s s  and avow th e  p r in c ip le  th a t  tumour d iseases  can be cu red  p ro v id e d  
th e  p a t ie n t  appears in  e a r ly  c l i n i c a l  s ta g e , d ia g n o s is  is  e s ta b lis h e d  w ith in  
a reaso nab ly  s h o rt t im e  and th e  b est complex th e ra p y  c u r r e n t ly  a v a i la b le  is  
g iv e n .
O ffp rin t requests should be sent to : F. Bánhidy, Department o f Head and Neck Surgery, 
National In s t itu te  o f Oncology, H-1122 Budapest, Ráth György u. 7—9, Hungary
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E f fo r ts  have to  be made to  e x p lo it  th e  e n t i r e  s to reh ou se  o f  d ia g ­
n o s t ic  f a c i l i t i e s ,  such as d ir e c t  and in d i r e c t  e x a m in a tio n s , endoscopy, 
X - r a y ,  US, CT, MR, a s p ir a t io n  cy to lo g y  and an g io g ra p h y . These a re  h e lp fu l  
in  d e te c t in g  prim ary  tum ours and re g io n a l m étas tasés .
L as t but not l e a s t ,  comes h is to lo g y  to  id e n t i f y  th e  v e ry  ty p e  o f  th e  
tu m o u r. Treatm ent m o d a l i t ie s  th a t  may be s u rg e ry , r a d io -  o r chem otherapy o r  
t h e i r  com bination , have to  be ev a lu a te d  in  v iew  o f  th e  p re c is e  d ia g n o s is . In  
c a s e - o f  s u rg ic a l th e ra p y  th e  o p e ra t iv e  tech n iq u e  may be c la s s ic a l  o r c ry o ­
th e r a p y  as i t  is  w ith  th e  T^ l i p  cancers . W ith  tum ours o f th e  la ry n x  and 
s in u s e s  endoscopic s u rg e ry  is  perform ed.
Laser s u rg ic a l in t e r v e n t io n  w ith  an endoscope o r an e x te r n a l  manual 
l a s e r  s c a lp e l may a ls o  be j u s t i f i e d .  W ith  tum ours o f  th e  head and neck we 
u s u a l ly  app ly  CC  ^ la s e r  b u t  f ib e r o p t ic  Nd LAG la s e r  may a ls o  be c o n s id e re d .
S ince 1980, th e  A m erican  C o heren t-type  CO2  la s e r  equipm ent has been 
a v a i l a b le  fo r  us. S in ce  th e n , we have perform ed a m u lt itu d e  o f  endo- and 
e x tr a la r y n g e a l  o p e ra tio n s  w ith  h igh success r a t e  f o r  e a r ly  squamous c e l l  
c a rc in o m a s .
In  o rder to  p ro v id e  an a ccep tab le  q u a l i ty  o f  l i f e  to  p a t ie n ts  who have 
undergone major re s e c t io n s  we have to  perfo rm  re c o n s tru c t iv e  s u rg e r ie s  as 
w e l l .  For th is  purpose, we can use lo c a l ,  q u i l t e d  s p l i t - s k in  g r a f t s ,  vas ­
c u la r  p e d ic le d  myocutaneous com posite f la p s ,  f r e e  t is s u e  t r a n s fe r s  and sem i­
t h i c k  f la p s  as w e ll as p ro s th e s e s  (e .g .  m an d ib u lar re c o n s tru c t io n )  and endo­
p ro s th e s e s  (e .g .  t ra c h e o m a la c ia )  and com posite g r a f t s  adapted  w ith  m ic ro -  
v a s c u la r  anastomosis ( e . g .  g r a f t s  w ith  in c o rp o ra te d  f ib u la  fo r  re c o n s tru c ­
t i o n  o f  th e  m a n d ib le ).
A r ic h  storehouse o f  tre a tm e n t m o d a lit ie s  i s  a t  our d is p o s a l. Care  
m ust, be taken  to  choose th e  most exped ien t one th a t  would p ro v id e  th e  fa s ­
t e s t  reco very  and would n o t  cover an e v e n tu a l r e s id u a l  tum our. S im i la r ly ,  
th e  h is to lo g ic  e x a m in a tio n  o f  th e  " in ta c t  m argins" must n o t be sk ip p e d .
In  the  fo l lo w in g , th e  is s u e  o f r a d ic a l i t y  ve rsu s  p re s e rv a tio n  o f  fu n c ­
t i o n  i s  d iscussed.
R e s u lts  and D iscuss ion
We have to  make i t  c le a r  th a t  th e  p re s e rv a tio n  o f  fu n c tio n  may n o t  
happen to  the  d e tr im e n t o f  a b la t io n .  Forced p a r t i a l  re s e c t io n s  may in c re a s e  
th e  number o f e a r ly  re c u rre n c e s  th a t  may become f a t a l .
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C o n s e rv a tive  s u rg e r ie s  re q u ire  an e a r ly  d ia g n o s is  s in c e  c e r t a in  f a c ­
to r s  such as tumour s iz e  and lo c a l iz a t io n  ( e . g .  w ith in  th e  la r y n x )  have a 
b a s ic  e f f e c t  on the  accom plishm ent o f fu n c tio n  sav in g  o p e ra tio n s .
The p r e r e q u is ite  o f  e a r ly  d iag n o s is  i s  s c re e n in g . S creen ing  i s  to  be 
p erfo rm ed  by the  most experie n c e d  p h y s ic ia n s  who work c irc u m s p e c tly  and w ith  
due c o n s id e ra t io n  o f  a l l  f a c to r s .  I t  happens p r e t ty  o fte n  th a t  p a t ie n t s  must 
be exam ined in  a n a e s th e s ia . Anyway, the  q u a l i t y  o f screen ing  shou ld  be p r e ­
fe r r e d  to  th e  com pliance o f p a t ie n ts .  T h is  i s  th e  o n ly  way to  d is c o v e r  e a r ly  
carc ino m a.
R eg u la r ups c o n tro l exam ination  a re  e s s e n t ia l  even a f t e r  e f f e c t i v e  
t re a tm e n ts .
As long as th e  a e t io lo g y  o f a g iven  tumour is  not c le a r ,  th e  p a t ie n t  
who has undergone e f f e c t iv e  tre a tm e n t fo r  a v e r i f ie d  tumour has a h ig h e r  
p r o b a b i l i t y  to  develop  a second tumour than an o th e r w ith o u t p re v io u s  tum our. 
T h is  e x p la in s  th e  im portance o f c o n tro l exam ina tion s  as p re v e n t iv e  m easures  
f o r  a second tum our.
In  re c e n t years  we have diagnosed more and more synchronous tum ou rs . 
T h is  makes com prehensive p re d ia g n o s tic  exam ina tion s  necessary .
S k in  tumours in  th e  head and neck re g io n  a ls o  belong to  o ur f i e l d  o f  
a c t i v i t i e s .  U n fo r tu n a te ly , many p a t ie n ts  a re  se n t to  us as h av in g  a "s im p le  
b a s a lio m a " . I t  is  t r u e  th a t  basaliom a is  a b a s a l c e l l  carcinom a b u t i t  may 
m e ta s ta s iz e  to  the  re g io n a l c e r v ic a l  lymph nodes and then i t  i s  by f a r  n o t a 
"s im p le  b asa liom a".
N a tu r a l ly ,  o th e r  h is t o lo g ic a l  types o f  s k in  carcinom as may a ls o  o ccur 
in  t h i s  an atom ica l re g io n . They have to  be removed by r a d ic a l  s u rg e ry  w ith  
" in t a c t  m argins" and fo llo w e d  by re c o n s tru c tiv e  s u rg e ry . There a re  many p a­
t i e n t s  whose surgery  was n o t r a d ic a l  enough and lo c a l re c u rre n c e s  became 
h idden  by f la p s  o f re c o n s tru c t iv e  s u rg e ry . In  such a s i tu a t io n  th e  p a t i e n t 's  
f a t e  has been s e a le d .
Removal o f  s k in  a l te r a t io n s  w ith  in t a c t  m argins is  o f v i t a l  im p o rtan c e  
in  cases o f  m a lig n an t melanoma, which r e q u ir e  a complex th e ra p y . S u r g ic a l  
rem oval i s  fe a s ib le  b u t c o n s u lta t io n  w ith  a d e rm a to lo g is t b e fo re  s u rg e ry  is  
h ig h ly  recommended.
L ip  cancer is  a fre q u e n t d isease in  re c e n t tim e s . In  s p i te  o f  b e in g  a 
c l e a r l y  v is ib le  a l t e r a t io n  to  both  the  p a t ie n t  and the  p h y s ic ia n , p a t ie n ts  
o fte n  p re s e n t w ith  v e ry  n e g le c te d  l i p  can cer.
Therapy i s  s u rg e ry , b u t no q uadra te  o r wedge re s e c t io n  is  a l lo w e d . I f  
needed, p la s t ic  su rg e ry  o f  th e  ang le  o f th e  mouth o r ,  w ith  extended  tum ours , 
co sm etic  re c o n s tru c tio n  i s  to  be perform ed.
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Cancers o f  th e  o r a l  c a v ity  a lso  b e lo n g  to  our f i e l d .  Depending on 
s i z e ,  the  l in g u a l  tum ours a re  removed e i t h e r  by s u r g ic a l d ia th e rm ia  o r  
l a s e r .  In  the  presence o f  m etas tas is  monoblock d is s e c t io n , i . e .  rem ova l o f  
th e  p rim ary  tumour and c e r v ic a l  lymph nodes i s  to  be c a r r ie d  o u t .  The same 
i s  v a l id  fo r  tum ours o f  th e  f lo o r  o f th e  m outh, th e  m andible and th e  to n ­
s i l l a r - l i n g u a l  re g io n . In  cases o f m ajor s u r g ic a l  d e fe c ts  p la s t ic  re c o n ­
s t r u c t io n  is  to  be p e rfo rm e d . In  such s i tu a t io n s  we use PM ( p e c to r a l is  
m a jo r )  o r o th e r  f la p s  l i k e  m icrovascu lar myocutaneous ones. For th e  re c o n ­
s t r u c t io n  o f th e  m a n d ib le , p a t ie n ts  a re  managed using  m ic ro v a s c u la r f r e e  
t is s u e  t r a n s fe r  w ith  in c o rp o ra te d  f ib u la .
The s o -c a lle d  "sandw ich  th e ra p y ", i . e .  p re o p e ra t iv e  i r r a d ia t io n ,  s u r ­
g e ry  and p o s to p e ra tiv e  i r r a d ia t io n ,  i s  s t i l l  p o p u la r w ith  tum ours o f  th e  
s in u s e s . Th is  may in v o lv e  th e  p a r t ia l  o r  com ple te  rem oval o f  th e  m a x i l la  
w ith  e n u c le a t io n , i f  n e c e s s a ry .
We must n o t f o r g e t  about the v a r io u s  endoscopic te c h n iq u e s , even i f  
th e y  have but d ia g n o s t ic  power w ith  these tum ours . Com bination o f la s e r  w ith  
endoscopy seems to  be a p ro m is in g  th e ra p e u t ic  means.
The s a l iv a r y  g lan d s  a re  a lso  to  be m entioned  in  t h is  c o n te x t . We have 
to  d is c r im in a te  m ajo r and m inor s a l iv a r y  g la n d s  and t h e i r  m a lig n a n t and 
b en ig n  a l t e r a t io n s .
Biopsy from  th e  p a r o t id  gland is  a m a lp ra c t ic e .  We can p erfo rm  o n ly  
a s p ir a t io n  c y to lo g y  o r  s u rg e ry  i f  lobectom y o r  com plete p aro tid e c to m y  is  
f e a s ib le .  In  f a c t ,  th e  h is to lo g y  o f th e  in t r a o p e r a t iv e  fro z e n  s e c tio n s  de­
te rm in e s  th e  degree o f  r a d i c a l i t y .
We th in k  th a t  th e  t ru n k  o f the n . f a c i a l i s  is  alw ays to  be p rep ared  
a lo n g  i t s  branches in  o rd e r  to  avoid  th e  in ju r y  o f  th e  n e rv e . D u rin g  th e  
re m o v a l o f  a subm andibu lar g lan d u le  the  r .  m a n d ib u la r is  is  to  be saved . In  
c ase  o f  m a lignan t tum our o f  th e  s a liv a r y  g la n d  b lo c k  d is s e c tio n  i s  to  be 
c o n s id e re d .
E p ipharyngeal tu m o u rs ; out o f th e  m a lig n a n t forms th e  t r a n s i t io n  c e l l  
and th e  squamous c e l l  carc inom a are  th e  most f re q u e n t v a r ia n ts .  In  cases o f  
t r a n s i t io n a l  c e l l  carc ino m a e i th e r  w ith  o r  w ith o u t re g io n a l c e r v ic a l  m éta­
s ta s é s  th e  the ra p y  i s  i r r a d ia t io n  a t  c u r a t iv e  dosage. W ith  squamous c e l l  
c a rc in o m a , however, th e  p rim a ry  tumour i s  to  be managed w ith  ra d io th e ra p y  
and th e  re g io n a l m é ta s ta s é s  have to  be removed w ith  r a d ic a l  b lo c k  d is s e c ­
t i o n .  U n fo r tu n a te ly , i t  may happen th a t  e p ip h a ry n g e a l tumours a re  d e te c te d  
i n  a re tro g ra d e  way, i . e .  f i r s t  a c e r v ic a l  lymph node is  removed and i t s  
h is to lo g y  makes th e  exam in er search fo r  th e  p rim a ry  tum our. T h is  o rd e r o f  
in te r v e n t io n s  i s  f a t a l  f o r  th e  p a t ie n t 's  l i f e .
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In  case o f ju v e n ile  a ng io fib rom a  r a d ic a l  su rgery  w ith  p re o p e ra t iv e  em­
b o l iz a t io n  i s  th e  th e ra p y  o f c h o ic e .
More than  90% o f th e  m esopharyngeal tumours are  carcinom as. Depending  
on th e  e x te n s io n  and lo c a l iz a t io n  o f  th e  le s io n  th e y  are  managed e i t h e r  by 
s u rg e ry  o r  ra d io th e ra p y  o r by t h e i r  co m b in a tio n . R ad ica l s u r g e r ie s  have to  
be fo llo w e d  by re c o n s tru c tiv e  su rg ery  to  r e s to r e  sw allo w ing . M yocutaneous PH 
and m uscle f la p s  and t h e i r  d i f f e r e n t  v a r ia n ts  a re  used fo r  t h i s  p u rp o se .
Among th e  hypopharyngeal tum ours, th e  I^ -s ta g e  ones r e q u ir e  r a d io ­
th e ra p y . U n fo r tu n a te ly , tumours o f  t h is  s iz e  a re  b ut seldom d e te c te d  because  
a t  t h i s  s ta g e  symptoms are  m in im al and p a t ie n ts  a re  seldom seen by a d o c to r .
Ih e  Ï 2 _ ^ 4  tum ours a re  to  be t r e a te d  by surgery com plem ented w ith  
r a d ic a l  c e r v ic a l  b lo ck  d is s e c t io n , i f  needed, and by p o s to p e ra tiv e  i r r a d i a ­
t io n .  Some o f the  hypopharyngeal tumours which m eta s ta s ize  in t o  th e  p a r a -  
t r a c h e a l  lymph nodes, to o , a re  h a rd ly  a c c e s s ib le  fo r  surgery  o r f o r  r a d io ­
th e ra p y  r a d ic a l  enough. C onsequently , s u r v iv a l  r a t e  o f p a t ie n ts  w ith  such 
hypopharyngeal tumours is  ve ry  poor, a 5 -y e a r  s u rv iv a l r a t e  o cc u rs  in  
19-22% .
L ary n g e a l carc inom as. Ih e  1^ carcinom as can be t re a te d  w ith  m ic ro s u r­
g ery  and CO2  la s e r ,  ra d io th e ra p y  and c la s s ic a l  chordectomy from  e x te r n a l  
e x p o su re . The T2 tum ours, be e i th e r  o f s u p r a g lo t t ic ,  g lo t t i c ,  o r s u b g lo t t ic  
o r ig in ,  can be removed p a r t i a l l y  o r ,  in  case o f w ider e x te n s io n , w ith  
la ryn gecto m y complemented w ith  b lo ck  d is s e c t io n  in  the  presence o f  c e r v ic a l  
m e ta s ta s is  accord ing  to  th e  "monoblock" p r in c ip le .
P a r t i a l  re s e c t io n  re q u ire s  e a r ly  d ia g n o s is . As a r u le ,  p a t ie n ts  
p re s e n t w ith  a p a in le s s  s w e llin g  on one s id e s  o f th e  neck o r  b o th :  th e  
s w e llin g  keeps grow ing . In  t h is  case we have to  search fo r  th e  p rim a ry  
tumour from  th e  ep ipharynx to  th e  hypopharynx. I f  the  f in d in g s  a re  n e g a t iv e ,  
th e  e x am in a tio n s  have to  be extended to  th e  lu n g , stomach and k id n e y s , u s in g  
US, CT, th y ro id  s c in t ig ra p h y  and s im u ltan eou s  a s p ir a t io n  c y to lo g y . When a l l  
th e s e  exam in a tio n s  happen to  y ie ld  n e g a tiv e  r e s u l ts ,  we a re  a llo w e d  to  p e r ­
form  c e r v ic a l  e x p lo ra t io n  complemented w ith  r a d ic a l  b lock  d is s e c t io n  i f  th e  
in t r a o p e r a t iv e  fro z e n  s e c tio n s  o f  th e  lymph nodes a re  p o s it iv e .
I t  may happen th a t  an e p ip h a ry g e a l tumour is  d ete c te d  a t  a l a t e r  t im e .  
The th e ra p y  is  then i r r a d ia t io n .  In  t h is  c a s e , th e  o rd er o f in te r v e n t io n s  is  
n o t to  th e  d isad van tag e  o f th e  p a t ie n t ,  on th e  c o n tra ry , i t  is  to  .h is  bene­
f i t .  The rem oval o f  a s in g le  lymph node, however, would be d e t r im e n ta l  be­
cause i t  would make fu tu r e  b lo c k  d is s e c tio n  u s e le s s .
Most o f the th y ro id  carcinom as re p re s e n t s u rg ic a l in d ic a t io n s .  We 
d is c r im in a te  r e la t iv e  in d ic a t io n s  ( e .g .  n o d u la r g o ite r  and tra c h e o m a la c ia )
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and ab so lu te  ones ( e . g . ,  suspect m a lig n an cy ). Thyro idectom y and o th e r s u r ­
g e r ie s  may in ju r e  th e  n . re c u rre n s . In  such cases th e  g lo t t i s  has to  be d i ­
la t e d  s u r g ic a l ly .  D epending  on the h is to lo g y  o f  th e  s u rg ic a l p re p a r a t io n ,  
s u rg e ry  is  complemented w ith  ra d io - ,  c ry o - and is o to p e  th e ra p y . The p rim a ry  
t re a tm e n t  o f re g io n a l c e r v ic a l  m étastasés i s  b lo c k  d is s e c tio n  th a t  may be 
p r e v e n t iv e ,  e i th e r  e l e c t i v e  or c o n s e rv a tiv e , i f  a chain  o f n o n -p a lp a b le  
lym ph nodes is  removed from  the c l i n i c a l l y  n e g a tiv e  neck le a v in g  o th e r  
s tr u c tu r e s ,  such as th e  v .  ju g u la r is  in te rn a  and th e  m. s te rn o c le id o m a s -  
to id e u s ,  in ta c t .
When accom plish ing  r a d ic a l  b lock d is s e c t io n  we e x t ir p a te  th e  lymph 
nodes on the fa s c ia  c o l l i  profunda from th e  s u p ra c la v ic u la r  fossa to  th e  
subm andibular re g io n  on one s id e  or both o f th e  n eck , in c lu d in g  th e  m. s t e r -  
n oc le ido m asto ideu s  and th e  v .  ju g u la r is  in te r n a .  T h is  o p e ra tio n  may be c a r ­
r i e d  out according to  th e  "monoblock" p r in c ip le  o r as a secondary b lo c k  
d is s e c t io n .
A f te r  b i l a t e r a l  o n e -s ta g e  block d is s e c t io n  c lo s e  o b serva tio n  o f  th e  
p a t ie n t  is  necessary th ro u g h o u t the  p o s to p e ra tiv e  p e r io d .
Our o p e ra tio n s  a re  conducted in  in t r a t r a c h e a l  n arc o s is  w ith  in tu b a t io n  
e i t h e r  through th e  tra c h é o to m ie  o r i f ic e  o r th ro u g h  th e  mouth. A n a e s th e s io l-  
o g is ts  have a g re a t s h a re  in  th e  success o f  our work d urin g  the  whole p r e - ,  
i n t r a -  and p o s to p e ra tiv e  p e r io d s . W ithout them and t h e i r  most v a lu a b le , un­
s e l f i s h  work we were n o t a b le  to  perform  th e s e  o p e ra t io n s .
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THE NEUROSURGICAL ASPECTS IN  THE TREATMENT OF 
CEREBRAL TUMOURS
S . C Z IR J Á K , B . BÁBEL
N a tio n a l I n s t i t u t e  o f N eurosu rg ery , Budapest, Hungary 
(R ece ived : September 2 3 , 1994)
Experience w ith more than 500 tumour cases operated in  one year in  the National 
In s t i tu te  o f Neurosurgery and the relevant oncological lite ra tu re  point to  an im portant ro le  
o f neurosurgery in  the treatment o f cerebral tumours. A fte r reviewing the dramatic advances o f 
neuroimaging and neurosurgical methods the main problems o f neurooncology w i l l  be brought to 
l ig h t  and the new d irec tions o f bra in  tumour research w i l l  be shown.
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In t r o d u c t io n
B ra in  tumours re p re s e n t a s m a ll b u t very  s p e c if ic  p a r t  o f  o nco lo gy . 
T h e ir  problem s correspond to  th e  la rg e  s u b je c t o f  g en era l o n co lo g y . Even th e  
f a c t  th a t  th e  tumour lo c a l iz e s  in  h ig h ly  organ ized  t is s u e , in  th e  b r a in ,  
w hich i s  found in  a c lo sed  bony space and is  subm itted  to  th e  fu n c t io n  o f  a 
b lo o d -b r a in  b a r r ie r  and to  a c o m p lic a te d , p o o rly  understood a u to r e g u la t io n  
mechanism r a is e s  new aspects  fo r  c o n s id e ra t io n .
The tre a tm e n t o f c e re b ra l tum ours i s  m u lt id is c ip l in e d . In  t h i s  a s p e c t, 
neurosurgeons have to  ta k e  most but n o t a l l  r e s p o n s ib i l i ty  fo r  t h i s  and t h is  
i s  a h ig h ly  im p o rtan t ta s k  fo r  them. For t h is  purpose, ta s k s , o p p o r tu n it ie s  
and some o f  th e  r e la te d  problem s a re  e x p lo re d  in  th is  paper.
O ffp r in t requests should be sent to : S. C z ir já k , National In s t itu te  o f Neurosurgery, 
H-1145 Budapest, Amerikai ú t 57, Hungary
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M a te r ia ls  and Methods
In  the National In s t i tu te  o f Neurosurgery there were more than 500 cerebral tumour 
cases were operated in  one year. In  1992, 553 cerebral tumours were treated s u rg ica lly ; 246 
cases o f these proved to  be h is to lo g ic a lly  benign, 229 cases malignant and 78 cases were tra n ­
s i t io n a l .
R e s u lts  and D iscu ss io n
The way in  which c e r e b r a l  tumours a r is e  i s  n o t known. The r o le  o f  
g e n e t ic s  is  c le a r  in  R e c k lin g h a u s e n 's  and L in d a u 's  d is e a s e ; t h e i r  autosom ic  
d om in an t o r dominant ty p e  has been v e r i f ie d .  In  e x p e r im e n ta l t r i a l s  c e re b ra l  
tum ours  have been t r ig g e r e d  w ith  exogenous e f f e c t s  o r in tra v e n o u s ly  a d m in is ­
t e r e d  chem ical agents ( i . e .  e th y l  n itro s o u re a ) / 8 /  and v i r a l  in fe c t io n  / 1 / .  
I n  th e  o r ig in  o f human b r a in  tumours the c l i n i c a l  in v e s t ig a t io n s  have f a i l e d  
t o  dem onstrate  any r e g io n a l ,  d ie t e t ic  o r o th e r  exogenous fa c to r  / 1 0 / .  How­
e v e r ,  th e re  are re p o r ts  a b o u t meningiomas d e v e lo p in g  a f t e r  i r r a d ia t io n .  The 
p a th o lo g y  o f c e re b ra l tum ours  i s  to  c l a r i f i e d .
Dramatic advances in  c e l l  b io logy and molecular genetics, emerging from u t i l iz a t io n  o f 
recoirbinant deoxyribonucleic a c id  (DNA) technologies, have provided t r u ly  novel opportun ities 
fo r  characterization o f malignancy. We have recognized th a t cancer arises as a series o f 
m olecular a lte ra tions th a t converge to  give the c e l l  malignant properties. W hilst many more 
im portant de ta ils  s t i l l  need to  be e lucidation, i t  is  possib le , fo r  the f i r s t  time in  the h is ­
to ry  o f cancer research to  id e n t i f y  spec ific  molecular changes th a t account fo r  id e n tif ia b le  
c e l lu la r  behaviors. In  the la s t  several decades, genes c o n trib u tin g  to the development o f 
pathogenesis have been id e n t if ie d .  Widely investigated s tru c tu ra l a lte ra tio n  and disturbances 
in  the  regulation o f genes encoding growth factors and th e ir  receptors are c le a rly  important 
in  th a t  they closely re la te  to  in  appropriate c e llu la r  p ro li fe ra t io n ,  the pathologic feature  
o f b ra in  tumours /3 / .
Modem neuroimaginq (CT, MR) allows an early de tection  o f the in tra c ra n ia l space oc­
cupying lesions in the l iv in g  sub ject before the true  symptoms appear. Apart from the e a rly  
d e tec tio n , these new methods make possible an exact lo c a liz a t io n  o f the tumour and the re la ­
t io n s h ip  between the neighbouring structures and the tumour. So the management o f the p a tie n t 
is  more d e fin ite  because the in tra c ra n ia l conditions are w e ll known. The c is te rns , s u lc i,  g y r i ,  
s iz e  and s h ift in g  o f the v e n tr ic le s  can be seen. W hilst the development of the neuroradiolog- 
i c a l  to o ls  simultaneously decreases the invasiveness so we are g e ttin g  more sophisticated in ­
fo rm a tion . The MR angiography and the 3D technique enables us to  understand the nature o f the 
pa tho log ica l course and th e ir  re la tio n s h ip  to  the in ta c t s truc tu re s .
The new diagnostic procedure, PET, serves besides, fo r  determination o f the anatomical 
fe a tu re s , fo r revealing d e ta ils  about th e ir  functional s ta te  and metabolism.
In  addition to  the neuroradiology, the e lectrophysica l (evoked p o ten tia l, mapping) and 
la b o ra to ry  (tumour markers) methods allow  us to determine
( i )  the b io lo g ica l ch a ra c te r is tic s  of the tumours
( i i )  th e ir  secondary change
( i i i )  the optimal management o f the patient / 6/
( iv )  possible com plications o f the neurosurgical in te rve n tio n
(v ) outcome
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Not o n ly  th e  b io lo g ic a l  fe a tu re s  o f  th e  tumour but a ls o  t h e i r  l o ­
c a l i z a t io n  is  an im p o rtan t fa c to r  o f th e  outcom e.
Widely used CT guided s te ro ta c tic  machinery allows us to  obtain a biopsy w ithou t the 
r is k  o f an operation. There is  not only the p o s s ib il ity  o f d if fe re n t ia l diagnosis bu t a lso  the 
method has a great therapeutic value fo r  puncturing the abscess and cysts and fo r  brachy- 
therapy. Deep loca lized  tumours and angiomas have been targeted ra d io lo g ic a lly  w ith  success 
/4 , 9/ .  Such an in tervention contained endoscopy should be able to  remove some sm all in t r a ­
v e n tr ic u la r  tumours or to  fenestrate the ve n tric les .
P r in c ip a l ly  benign tum ours should be t r e a te d  s u r g ic a l ly .  The d e v e lo p ­
ment o f  s u r g ic a l p rocedure  made th e  c h a lle n g e  o p e ra t in g , w ith o u t dam aging  
th e  surro un d in g  s tr u c tu r e  as any m inor c o m p lic a tio n  cou ld  have f a t a l  o u t ­
come. In  th e  la s t  two decades th e  s u r g ic a l tech n iq u e  has p resen ted  and e x ­
c e l l e n t  advance. Using m o b ile  s u r g ic a l m icroscopes we are  a b le  to  rem ove a l l  
tum ours in  r e a l l y  unique lo c a l iz a t io n .  The areas  not approached b e fo re  th e  
m icroscope e ra  a re  o pera te d  v ia  t in y  approaches e .g .  t r a n s n a s a l ly , o r a l l y .  
U sing  la s e r ,  CUSA, fo r  rem oval o f  th e  hard substance le s io n s  m ight be e a s ie r  
w ith o u t p u l l in g  im p o rtan t s tr u c tu r e s . In t r a o p e r a t iv e  sonography makes a 
r ig h t  p la c e d  in c is io n  p o s s ib le  / 5 / .  W ith  th e  h e lp  o f the  in t r a o p e r a t iv e  
evoked p o te n t ia l  t h is  c o n t r o l l  fu n c t io n a l charge p re v e n tin g  f u r th e r '  com­
p l i c a t io n .
The modern neuro im aging b rin g s  to  l i g h t  many new problem s. W h ils t  a 
check-up  fo r  o th e r co m p la in ts  o fte n  d iagnoses benign asym p to tic  c e r e b r a l  
le s io n s .  The n e c e s s ity  o f  th e  s u r g ic a l in te r v e n t io n  has alw ays been a h ard  
q u e s tio n . The rem oval o f  b ra in  tumours nowadays has rem ained a dangerous i n ­
t e r v e n t io n ,  and th e  r is k  o f  m alignancy and in tra tu m o ra l haemorrhage i s  h ig h .  
A r ig o ro u s  form u la  cannot be ru le d  o u t. The g en e ra l c o n d it io n  o f  th e  pa­
t i e n t ,  h is  expected s o c ia l  s u r v iv a l ,  neu ro surgeo n 's  experien ce  and h is  a t ­
t i t u d e  a re  th e  main asp ec ts  o f th e  d e c is io n .
The benign tumours can be o pera ted  r a d ic a l ly .  The rem oval o f  th e  
a x ia l  and c r a n ia l  base tumours is  c om plica ted  because o f th e  p o s s ib le  c lo s e d  
s i t u a t io n  to  im p o rtan t la r g e  v e s s e ls  and c r a n ia l  nerves a t  th e  b as e . The e x ­
te n s io n  o f  th e  rem oval should  be decided d u rin g  th e  s u rg ic a l in t e r v e n t io n .  
N e v e rth e le s s , th e  com pleteness improves th e  c l i n i c a l  outcome. On th e  o th e r  
hand, th e  re o p e ra tin g  o f  s u b to ta l removed tumours m ight be more d i f f i c u l t  
because o f  adherence. The o p tim a l s tra te g y  must be found to  s o lv e  th e s e  two 
p ro b lem s . So f a r  th e  g re a te s t  neurosurgeons a re  not a b le  to  fo r m u la te  an 
a l l -p o w e r fu l  r u le  o f  th e  management. They alw ays m ention d i f f i c u l t i e s  in  
re a c h in g  a d e c is io n . N o tic e a b le  the  d ir e c t io n  o f th e  d iscu ssed  p o in ts  
r e la t e s  to  a r a d ic a l  o p e ra tio n  p ro v id in g  th e  s o c ia l outcome.
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In  s p ite  o f t h i s  th e  m alignant c e r e b r a l  tumours have rem ained i n ­
c u r a b le .  There a re  n o t  o n ly  s u rg ic a l,  b u t a ls o  ra d io -im m u n o -ch em o th erap ica l 
m ethods. The a u th o rs  a g re e  about the p r i o r i t y  o f  s u r g ic a l in te r v e n t io n  in  
re q u ir e d  lo c a l i z a t io n .  A t th e  same tim e th e y  d is a g re e  about th e  e x te n s io n  o f  
th e  rem oval. Some o f  them  /1 2 ,  1 3 / th in k  th e  m a lig n a n t astrocytom as in  90% 
o f  cases are  lo c a l  p ro c e s s  so the  extended r e s e c t io n  improves th e  s u r v iv a l  
( f i v e  ye a rs ' s u r v iv a l  4 .7 % ) .  The in v e s t ig a t io n s  / 7 /  have dem onstrated p o s i­
t i v e  c o r re la t io n  betw een  th e  le s s  re s id u a l tum our mass and th e  s u r v iv a l  
lo n g .  O ther in v e s t ig a to r s  con s ider g lio b la s to m a  to  be a d if fu s e ,  i n f i l t r a t ­
in g  tum our. T h e re fo re , th e y  only  do b iopsy a n d /o r  reduce th e  tumour mass. 
I t  has been shown t h a t  th e  tumour c e l ls  have m ig ra te d  along o f  th e  w h ite  
m a tte r  t r a c ts ,  p e n e tr a t in g  b lood v e s s e ls , n eu ro n es , ependyma o r th rou gh  CSF 
pathw ays by th e  t im e  o f  d ia g n o s is  / 2 ,  1 1 / .
T h is  tw o -s id e d  v ie w  is  r ig h t  because th e  m a lig n a n t g liom a is  c o n s i­
d e re d  as a two com partm ent d isease: a lo c a l  tum our mass w ith  d en se ly  packed  
tum our c e l ls  w ith  b roken-dow n b lo o d -b ra in  b a r r i e r  and a d if fu s e  d is e a s e  com­
posed o f tumour c e l l s  lo c a te d  w ith in  d is ta n t  norm al b ra in  parenchyma h id in g  
b e h in d  an in ta c t  b lo o d -b r a in  b a r r ie r .  T h e ra p e u tic  s t r a te g ie s  should c o n tin u e  
to  focus on both  s id e s .  The n eu ro o n co lo g ica l re s e a rc h  i s  t r y in g  to  c o n firm  
th e s e  two mechanisms. How th e y  in flu e n c e  each o th e r  on th e  m o lecu la r le v e l?  
The process o f in v a s io n  and i t s  in f lu e n c in g  must be d ec id ed .
Also the  c l i n i c a l  ex p e rie n c e s  correspond to  th e  above m entioned . A f te r  
th e  more extended re m o v a l adm in is te red  r a d io -  a n d /o r  chemotherapy r e s u l ts  in  
th e  lo n g e s t s u r v iv a l .
The developm ent o f  th e  s u rg ic a l methods advances the  more r a d ic a l  
n e u ro s u rg ic a l in t e r v e n t io n .  W ith  the aim o f  th e  in t r a o p e r a t iv e  te c h n iq u e s  
and th e  in trod uced  r e a l - t im e  c o n tro ll in g  methods we w i l l  be a b le  to  remove 
more extended m a lig n a n t c e r e b r a l  tumours.
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The success o f surgery performed fo r  pulmonary carcinoma is  based an the se le c tio n  o f 
the pa tien ts  fo r  operation. C yto logica l or h is to lo g ic a l v e rific a tio n  of the tumour p r io r  to  
surgery is  important as concerns the choice o f the type o f surgery and the complex antitumour 
therapy. I t  is  cu rren tly  considered th a t pa tients w ith  tumours in stages I ,  I I  and I l i a  are 
su itab le  fo r  surgery. Operations are also performed in  cases involving s o lita ry  ce re b ra l méta­
stasés, and c e n tra lly - ly in g  tumours vtfiich reach the b ifu rca tio n  carina or the lower p o rtio n  of 
the trachea (Тд) are s im ila ry  ra re ly  resectable.
The basic operation fo r pulmonary carcinoma is  lobectomy. In selected cases o f  squamous 
c e l l  carcinomas in  stage TjNq , a typ ica l wedge resection too may be considered. Extended surgery 
is  also performed, depending on the size o f the tumour. For a l l  types o f tumours, i t  is  es­
s e n tia l to  take a sample from the lymph nodes fo r  accurate staging. Prospective randomized 
c l in ic a l  t r ia l s  on 288 pa tients  undergoing resection fo r  pulmonary cancer revealed th a t ex­
tended m edistina l lymphadenectomy improved the 5-year su rv iva l rate in cases o f adenocarcinomas 
and squamous c e ll carcinoma, invo lv ing  lymph node métastasés. In traoperative  c y to lo g ic a l 
examinations or frozen sections are extremely im portant as concerns the in d ica tio n  o f extended 
m ediastinal lymphadenectomy and adjuvant antitumour treatment.
Keywords: Patient se lection , staging, lung resection, lymphadenectomie, complex 
treatment
Survey
The success o f o p e ra tio n s  perform ed f o r  lung cancer depends c o n s id e r ­
a b ly  on th e  s e le c t io n  o f  th e  p a t ie n ts  f o r  s u rg e ry . This s e le c t io n  in v o lv e s  
th r e e  main asp ec ts :
1 . th e  h is t o lo g ic a l  o r c y to lo g ic a l  v e r i f i c a t io n  o f the  tum our,
2 . th e  e x a c t  knowledge o f th e  an a to m ica l e x te n t  o f the  tum our, t h a t  i s  th e  
p re o p e ra t iv e  s ta g in g , and
3 . th e  p h y s io lo g ic a l s ta tu s  o f  th e  p a t ie n t ,  th a t  is  the assessm ent o f  th e  
s u i t a b i l i t y  fo r  su rg e ry  / 1 / .
O ffp r in t requests should be sent to : I .  Tró ján, Department of Surgery, A lb e rt Szent- 
Györgyi Medical U n ive rs ity , H-6720 Szeged, Pécsi ú t 4, Hungary
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Table I
Place o f  surgery In the treatment o f lung cancer as 
a function of the d iffe re n t stages
T N M Consider 
surgery?
Occult carcinoma Tx N0 Mg Yes
Stage I T l N0 Mg Yes
T2 No Mo Yes
Stage I I T1 N l Mq Yes
T2 N l Mo Yes
Stage I I I  A T3 N0 Mq Yes
T3 N1 Mo Yes
Tl - 3 N2 Mq Yes
В Tl —4 N3 m0 No
T4 N l-3 Mq No
Stage IV Tl —4 N l-3 Ml No
The p re o p e ra tiv e  know ledge o f the h is t o lo g ic a l  s tru c tu re  o f th e  tum our 
i s  a b s o lu te ly  j u s t i f i e d  in  p a t ie n ts  who a re  t o  undergo surgery fo r  lu n g  
c a n c e r .  I t  is  e x tre m e ly  im p o r ta n t to  know p r e o p e r a t iv e ly  whether s m a ll c e l l  
o r  non sm all c e l l  c a rc in o m a is  invo lved . H ow ever, th e  s t a t is t ic s  from  Hun­
g a r ia n  th o ra c ic  s u rg e ry  c e n tre s  in d ic a te  th a t  th e  ty p e  o f tumour i s  known 
in  o n ly  50-80% o f p a t ie n t s  undergoing su rg ery  f o r  carcinom a.
Up to  the mid-1980's, th e re  was a wide debate as concerns the staging o f lung cancer. 
In  1986, Mountain reported a s tag ing system which was accepted by the Union In te rn a tio n a l 
Contre Cancer and vrfiich has become general among thoracic surgeons since 1987 /10 /.
The essence o f th is  system is  that there is  no lymph node metastasis in  the f i r s t  
s tage. The T3 tumours belonging here are smaller than 3 cm and do not reach the v is c e ra l 
p leu ra ..The  T2 tumours s im ila r ly  in  stage I  only reach the v isce ra l pleura and at most cause 
segment ate lectasia; they approach to  w ith in 2 cm o f the b ifu rc a tio n . Stage I I  is  e s s e n tia lly  
characterized by métastasés o f  these same tumours in  the lobes and the h ila r  lymph nodes.
The th ird  stage is  d iv id e d  in to  two groups. The T3 tumour appears in  stage I I I / A ;  th is  
reaches the wall o f the thorax o r  approaches the b ifu rc a tio n  and in f i l t r a te s  certa in  s truc tu re s  
o f  the  mediastinum. Another im portan t c r ite r io n  o f stage I I I / A  is  the N2 metastasis, th a t is  in  
the  m ediastinal lymph nodes. Since 40-60% of the operated lung cancer patients belong in  th is  
group, I  sha ll return to  a d e ta ile d  discussion of th is  stage /9 / .
In  stage I I I /B ,  the T4 tumour extends to the arch o f the aorta or to  the common p u l­
monary trunk or to  the a t r ia l  w a l l ,  and hence means te ch n ica l in o p e ra b ility . In  the same group, 
N3 im p lies  tha t the c o n tra la te ra l or supraclavicular lymph nodes are affected, th a t is  a s i ­
tu a t io n  o f oncological in o p e ra b il ity  ex is ts .
In  stage IV, the d is ta n t М3 métastasés c lea rly  make the lung cancer inoperable.
The use of lymph node maps is  of v i ta l  importance fo r  an accurate in tra o p e ra tive  
s ta g in g  c la s s ific a tio n . The system most frequently app lied , th a t  proposed by Naruke, groups the
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Table I I
Course o f treatment o f lung cancer. I
Squamous Adeno CA Resect At thoracotomy At mediastinoscopy
1
Segmentectomy
1
Chest wall 
Pancoast 
Diaphragm
Lobectomy Lobectomy B ifurcation
Pneumonectomy
1
Pneumonectomy
Pericardium
Resect Neoadjuvant
C ytosta tic  therapy 
Resect i f  response
N2 lymph nodes from 1 to  9, and the chain from 10 to  13 /1 1 /. The loca tion  o f the lymph node 
métastasés is  not only o f prognostic s ign ificance, but is  also an important guide to  the com­
plex a n ti-lu n g  cancer therapy / 12/ .
The s u r g ic a l s o lu tio n s  o f lung cancer is  a fu n c tio n  o f th e  d i f f e r e n t  
s ta g e s .
Segmentectomy can be c a r r ie d  out in  s ta g e  I ,  and lobectom y may be s a id  
to  be a s ta n d a rd  o p e ra t io n . R e c e n tly , in  p la c e  o f  segmentectomy, we p erfo rm  
a ty p ic a l  m echanical wedge re s e c tio n s  w ith  s ta p le rs  in  h ig h - r is k ,  m a in ly  
e ld e r ly  p a t ie n ts  and e s p e c ia l ly  in  cases o f  squamous c e l l  ca rc in o m as . These  
o p e ra tio n s  must d e f i n i t e l y  be avoided in  cases o f adenocarcinom as, because  
o f  th e  h ig h  r a te  o f  lo c a l  re c u rre n c e . In  g e n e ra l,  segmentectomy o r  mechan­
ic a l  wedge re s e c t io n  i s  employed in  1-5% o f re s e c tio n s  perform ed because o f  
lun g  c a n c e r. W ith  more e x te n s iv e  tum ours, we c a rry  out b ilo b e c to m y  o r  p u l -  
monectomy. S leeve  re s e c t io n s  have become g e n e ra lly  accepted d u r in g  th e  p a s t  
te n  y e a rs , and we have used t h is  tech n iq u e  in c re a s in g ly  more f r e q u e n t ly  in  
lun g  cancer p a t ie n ts .  80-90% o f  the  s le e v e  re s e c tio n s  a re  c a r r ie d  o u t b e ­
cause o f lu n g  cancer and t h e i r  number has quadrup led  in  th e  p as t seven y e a rs  
/ 6 / .  The H ungarian  th o ra c ic  surgeons Ungar and K e s z le r earned w id e -ra n g in g  
in t e r n a t io n a l  re c o g n it io n  fo r  t h e i r  good r e s u lts  w ith  p arench ym a-sp arin g  
s le e v e  re s e c t io n s  / 3 ,  1 5 / .
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F ig . 1. Course of treatment o f lung cancer. I I
SEGMENTECTOMY
OR
WEDGE RESECTION
LOBECTOMY
BILOBECTOMY
SLEEVE
LOBECTOMY
PNEUMONECTOMY
SLEEVE
PNEUMONECTOMY
BIFURCATION
F ig . 2 . Types o f operations performed fo r  lung cancer
In  cases o f tum ours or Pancoast tum ours , we perform  r e s e c t io n  o f  
th e  w a l l  or o f th e  apex o f  th e  th o ra x , r e s p e c t iv e ly .  W ith  c e n t r a l ly  lo c a te d  
tu m o u rs , in  many cases we p ro vid e  the  v e s s e ls  i n t r a p e r ic a r d ia l ly , and in  
f a c t  re s e c tio n  o f p a r t  o f  th e  l e f t  a tr iu m  may a ls o  o ccu r. In  th e  e v e n t o f  
tum ours i n f i l t r a t i n g  th e  tra c h e a  b ifu r c a t io n ,  we c a r r y  o u t some ty p e  o f  b i ­
f u r c a t io n  re s e c t io n  o r  s le e v e  pulmonectomy.
An in te r e s t in g  change may be observed as concerns th e  s u r g ic a l  con­
c e p t io n  fo r  N2  tum ours . I f  the  p re o p e ra tiv e  s ta g in g  suggests t h a t  th e  supe­
r i o r  m e d ia s tin a l lymph nodes a re  a ffe c te d , we a lw ays  employ m ed ias tin o sco p y . 
I n  th e  event o f a p o s i t iv e  b io psy , combined n eo ad ju van t c y to s ta t ic  tre a tm e n t
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5 -y e a r  s u r v iv a l T o ta l
S tage I 83%
T2N0 65% 72%
S tage I I T1N1 56%
T2N1 48%
49%
S tage I I I  A T3N0 Chest w a ll 56%
Vo
T1 - 3 N2
P ro x im ity  
to  c a r in a
36%
20%
1 9 -2 3
F ig . 3. F ive-year su rv iva l ra tes o f patients resected because of non-small c e l l  carcinoma 
o f the lung as a function o f the d iffe re n t stages
i s  begun and, i f  th e  le s io n  e x h ib its  a re g re s s io n , re s e c t io n  s u rg e ry  is  
perform ed / 8 / .
In  s ta g e  I I I / B ,  re s e c t io n  can be c a r r ie d  o u t o n ly  very  r a r e ly  in  cases  
o f  p h re n ic  p a r a ly s is .  W ith  Pancoast tumours o r tumours causing  cava s u p e r io r  
syndrome, p a l l i a t i v e  s u rg e ry  comes in to  c o n s id e ra tio n  to  a l l e v i a t e  th e  com­
p la in t s .  In  cases o f d is ta n t  m étas tasés , o n ly  a s o l i t a r y  c e re b ra l m e ta s ta s is  
com prises an ex c ep tio n  to  th e  in o p e r a b i l i ty  / 5 / .
A fe a tu r e  c le a r ly  a s s o c ia te d  w ith  s u rg e ry  f o r  lung cancer i s  lym pha- 
denectom y.
The s u r v iv a l  r a t e  i s  b e s t in  cases o f  T^ e p i t h e l i a l  carc ino m as in  
s ta g e  I ,  where more than  80% o f th e  p a t ie n ts  s u rv iv e  fo r  f i v e  y e a r s .  W ith  
th e  appearance o f th e  lymph nodes in  s tag e  I I ,  the  r a t e  f a l l s  to  40%. 
Only 10-15% o f  th e  p a t ie n ts  a re  in  t h is  s ta g e .
In  s ta g e  I I I / A ,  th e  f iv e - y e a r  s u r v iv a l  r a t e  is  on average abo ut 20%, 
o r somewhat lo w e r, I t  i s  notew o rth y  th a t  in  t h is  s tag e  a s u r v iv a l  r a t e  o f  
50% is  ach ieved  i f  tum ours th a t  reach  th e  w a ll  o f  th e  th o rax  b u t do n o t g iv e  
lymph node m étastasés a re  removed to g e th e r w ith  th e  w a ll fo  th e  th o ra x  / 2 ,  
1 3 / .  The s u r v iv a l  r a te  is  a ls o  b e t te r  in  cases o f  tumours where b i f u r c a t io n  
r e s e c t io n  i s  perform ed and th e re  a re  no lymph node m étas tasés . H ere  th e  
f iv e - y e a r  s u r v iv a l  r a t e  is  above 30%.
For a g iven  lymph node s ta tu s , one fa c to r  in f lu e n c in g  th e  s u r v iv a l  
r a t e  i s  th e  s iz e  o f th e  tum our. Thus, fo r  N2  cases the  f iv e - y e a r  s u r v iv a l  
r a t e  i s  30% fo r  T . , b u t o n ly  12% fo r  T^ / 6 / .
A f u r th e r  such fa c t o r  i s  whether th e re  were m étastasés in  o n ly  one 
lymph node o r  in  s e v e r a l ,  and w hether th e s e  o ccurred  a t one o r more le v e ls ,  
and w hether th e  m e ta s ta s is  p e n e tra te d  through  th e  lymph node w a l l .
1 8 0 I .  TR 0JÄ N , К .  KOVÄCS, 3 .  CSANÁDI
*/.
100-1
80-
БО-
40-
20-
I__
T1-3 N1 N2
MEDIASTINAL LYMPHADENECTOMY Nr = 38 
---------- LYMPHADENECTOMY Nr = 35
40V. 
26 V.
— I—
4812 24 36
M O N T H S
60
Fig. 4, S urviva l o f squamous c e ll carcinoma cases (U .I.C .C . 1987 stages)
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Fig. 5. S u rv iva l o f  adenocarcinoma cases (U .I.C .C . 1987 stages)
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An improvement o f  th e  s u r v iv a l r a te  in  these cases i s  to  be expected  
o n ly  from  complex a n t i- tu m o u r tre a tm e n t. The p ro s p e c tiv e  random ized s tu d y  by 
M a r t in i  re v e a le d  th a t  th e  s u r v iv a l r a te  o f  p a t ie n ts  w ith  adenocarcinom as and 
la r g e  c e l l  carcinom as was s ig n i f ic a n t ly  improved by p o s to p e ra tiv e  i r r a d i a ­
t io n  o f th e  m ediastinum  and subsequent combined c y to s ta t ic  t re a tm e n t  / 7 / .
A few words about lymphadenectomy and extended mediastinal lymphadenectomy. Watanabe 
processed the data on 2000 lung cancer patients and concluded a f a i r l y  large p roportion  o f such 
tumours do not metastasize in  accordance w ith the regional lymph process. A d d it io n a lly , jumping 
or skipping métastasés too may be observed, »Wien a lymph node step or le v e l is  om itted from the 
m etastasization. On th is  basis , he recommended systematic exstirpa tion  o f the m ediastina l lymph 
tissue  in  a l l  lung cancer cases /1 6 /. Indeed, in  a paper published one year la te r ,  fo llow ing  
to ta l exs tirp a tio n  o f the mediastinal lymph nodes in  cases o f N2 e p ith e lia l carcinomas o r i ­
g ina ting  from the le f t  superior lobe, Watanabe also removed the con tra la te ra l lymph nodes v ia  a 
median sternotomy /1 7 /.
To dem onstrate  th e  p la c e  o f extended m e d ia s tin a l lym phadenectom y, I  
should  l i k e  to  g iv e  an account o f our own random ized p a t ie n t  m a t e r ia l .  D uring  
288 lung re s e c t io n s  which we c a r r ie d  o ut because o f n o n -sm all c e l l  pulm onary  
carcinom a in  a th r e e -y e a r  p e r io d , extended m e d ia s tin a l lym phadenectomy was 
perform ed in  every  second case. In  th e  t r a d i t io n a l l y  o p e ra te d  g ro u p , o n ly  
th e  re g io n a l lymph nodes were removed, o r th e  lymph node c h a in  around the  
main b ro n ch i and tho se  lymph nodes th a t  were suggested by p a lp a t io n  to  be 
e n la rg ed  o r  p a th o lo g ic a l.  The s u rg ic a l m o r ta l i ty  in  th e  t r a d i t i o n a l  group  
was 1.62% , w h ile  th a t  in  th e  extended m e d ia s t in a l lymphadenectomy group was 
2.45% . P e r io p e ra t iv e  c o m p lic a tio n s  o ccurred  in  g re a te r  number in  th e  ex­
tended g ro u p , and th e  average amount o f  b lood  used was about d o u b le  in  t h is  
group . The extended m e d ia s t in a l lymphadenectomy in c reased  th e  d u r a t io n  o f 
th e  o p e ra tio n  by 4 0 -5 0  m in u te s . The f iv e - y e a r  s u r v iv a l r a te s  in  th e  two 
groups were 42% and 38%, in  favo u r o f extended m e d ia s t in a l lym phadenectom y. 
The d if fe r e n c e  was n o t s ig n i f ic a n t .
When th e  d a ta  were fu r th e r  broken down accord ing  to  h is t o lo g ic a l  ty p e ,  
and th e  lymph n o d e -p o s it iv e  cases were examined s e p a r a te ly ,  a n a ly s is  o f  th e  
two K aplan—Meyer curves  fo r  th e  lymph n o d e -p o s itiv e  squamous c e l l  c a r c i ­
nomas in d ic a te d  a s ig n i f ic a n t  r e s u lt  in  favo u r o f extended  m e d ia s t in a l  
lymphadenectomy, w ith  r a te s  o f 40% and 26%.
A s tu d y  o f th e  s u r v iv a l  r a te  in  cases o f adenocarcinom as g iv in g  lymph 
node m étastasés a ls o  re v e a le d  a s ig n i f ic a n t  d if fe r e n c e  in  fa v o u r  o f  m edia­
s t in a l  lymphadenectomy, w ith  f ig u re s  o f 34% and 22%.
In  consequence o f  th e s e  d a ta , i t  has become our p r a c t ic e  in  re c e n t  
y ears  to  fo l lo w  th e  d e c is io n  concern ing r e s e c t a b i l i t y  by rem ova l o f  th e  
lymph nodes from  th e  upper m ediastinum , from  th e  b if u r c a t io n ,  fro m  b es id e
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th e  main brochi and from  th e  pulmonary lig a m e n t. I f  th e  in t r a o p e r a t iv e  cy ­
to lo g y  or a fro zen  s e c t io n  shows a m e ta s ta s is  in  any lymph node, then  ex­
te n d e d  m e d is tin a l lym phadenectomy is  perform ed / 1 4 / .
The p lace o f s u rg e ry  in  th e  trea tm en t o f pulm onary carcinom a is  c le a r -  
c u t .  The re s u lts  cannot be im proved, or o n ly  p a r t i a l l y ,  by th e  s u r g ic a l  
r a d i c a l i t y .  A fa c to r  t h a t  d e c is iv e ly  in f lu e n c e s  th e  s u r v iv a l r a t e  is  b e t t e r  
p a t ie n t  s e le c t io n .
T h is  begins w ith  th e  p re o p e ra tiv e  s ta g in g , c o n tin u es  w ith  th e  i n t r a ­
o p e r a t iv e  cyto logy o r f ro z e n  s e c tio n s , and is  com pleted w ith  th e  d e ta i le d  
p o s to p e ra tiv e  h is t o lo g ic a l  exam ination . The in t r a o p e r a t iv e  s ta g in g  i s  ex­
t r e m e ly  im portan t as con cern s  th e  s e le c t io n  o f th e  typ e  o f o p e ra tio n  o r  o f  
lymphadenectomy, and a ls o  d eterm ines  the  m o d if ic a tio n s  o f th e  complex a n t i ­
tum our th e rap y .
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CHEMOTHERAPY OF ADVANCED BREAST CANCER
ű. SZÁNTÓ
N a tio n a l I n s t i t u t e  o f Oncology, Budapest, Hungary
(R e ce iv e d : September 2 3 , 1994)
The treatment o f c l in ic a l ly  overt metastatic breast cancer, despite several treatment 
m odalities (b io log ica l response m odifie rs, megatherapy w ith  autologous bone marrow trans­
p la n ta tio n , growth fa c to rs , new agents, e tc .)  is  in  a s ta t ic  phase. In  the decision-making 
one has to consider the p a tie n t's  age, her menstrual s ta te , the m etastatic s ite ,  previous ad­
juvant and/or postoperative treatment m odalities. Roughly there are two treatment forms, the 
hormonal and the c y to s ta tic  ones. Endocrine therapy should be given as fo llow s: 1. only fo r  
low r is k  group, 2. gestagen or antiestrogen therapy is  the choice fo r the f i r s t  step, 3. i f  
there  is  a progression in  3 months, the hormonal treatment should be changed to  cy to s ta tic  
con tina tion , 4. i f  there is  a progression beyond 3 months fu rth e r hormonal therapy can be 
considered. The e ffica cy  o f endocrine therapy is  30%. In pa tien ts  w ith advanced breast cancer 
chemotherapy provides a response ra te  o f 30 to 60%, however to ta l su rv iva l o f the patients 
does not improve s u b s ta n tia lly . Doxorubicin containing regimens are more e ffe c tiv e , however no 
response in  to ta l su rv iva l can be obtained. New plant a lka lo id s  and a lte red  treatment forms 
w i l l  probably influence s u rv iv a l. Taking a l l  these in to  consideration one has to  decide on the 
q u a lity  o f l i f e  o f the breast cancer pa tients .
Keywords: Advanced breast cancer, decision-making, hormonal treatment, chemotherapy, 
q u a lity  o f l i f e
In tro d u c t io n
Both the  in c id e n c e  and m o r ta l i ty  o f b re a s t  c a n c e r, a re  in c re a s in g  in  
in d u s t r ia l iz e d  c o u n tr ie s  / 1 3 / .  The Hungarian s t a t i s t i c a l  d a ta  a re  shown in  
T ab le s  I — I I — I I I .  I t  i s  supposed from the  o ccurrence  r a te  th a t  th e  d isease
Abbreviations: ER = estrogen receptor, PGR = progesteron receptor, CPA = Cyclophos­
phamide, Mitox. = Mitonzantron, PMC = Mitomycin C, ADM = Adriamycin, MTX = Metothrexate, 
5-fU = 5-Fluorouracyl, OOP = c is -P la t in , IFO = Ifosfam ide, CMF = Cyclophosphamide + Meto­
threxate  + F luorouracyl, FAC = F luorouracyl + Adriamycin + Cyclophosphamide, AC = Adriamycin + 
+ Cyclophosphamide, PfM = M itozantron+ Metothrexate+ Mitomycin C, VACMFP = V in c r is t in  + Adria­
mycin + Cyclophosphamide + Metothrexate + F luorouracil + Prednisolon, MVAC = Metothrexate + Vin­
c r is t in  + Adriamycin + Cyclophosphamide, VCFP = V in c r is t in  + Cyclophosphamide + Fluorouracyl + 
+ Prednisolon, AV = Adriamycin+ V in c r is t in
O ffp rin t requests should be sent to : I .  Szántó, National In s t itu te  o f Oncology, 
H-1122 Budapest, Ráth György и. 7a, Hungary
0236-5286/94/ff 4 .00©  Akadémiai Kiadó, Budapest
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Table I
M o rta lity  data
Year Total Breast
1980 279Î7 1800
19B5 28893 1990
1990 31221 2097
1992 32676 2232
Table I I
Effectiveness o f cy to s ta tic  drugs in  advanced breast cancer
Name o f the drug Response (4) Surviva l (mos.)
CPA 33 12
MIT0X. 35 14
№C 28 10
ADM 38 15
MTX 28 11
5-FU 27 10
D0P 20 15
IF0 20 17
Table I I I
Combined chemotherapy o f advanced breast cancer
Name o f 
the drug
Response rate
(4)
Response duration 
(months)
CMF 48 11
FAC 60 21
AC 44 24
l*M 51 16
VACMFP 46 19
MV AC 57 17
VCFP 51 17
AV 58 12
w i l l  be presumably observed  in  one case o f 10 to  12 newborn fe m a le s . De­
s p i t e  s o p h is tic a te d  a d ju v a n t chemotherapy t r i a l s  in  p a t ie n ts  w ith o u t c l i n ­
i c a l l y  reco g n isab le  m é ta s ta s é s , in  th re e  q u a rte rs  o f th e  p a t ie n ts  o v e r t  
m é ta s ta s é s  w i l l  develop  in  2 to  10 years and th e  p a t ie n t  d ie s  in  a r a th e r  
s h o r t  p e r io d  / 3 / .
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The treatment o f c l in ic a l ly  overt m etastatic breast cancer is  in  a s ta t ic  phase and 
w ith ra re  exceptions, the disease is  considered fa ta l in  outcome /1 8 /. Despite innumerable 
m odalities (using hormonal agents, cy to s ta tic  drugs, high dose chemotherapy w ith  autologous 
bone marrow transp lan ta tion , b io lo g ica l response m od ifie rs, e tc .)  the cure ra te  has no t changed 
s u b s ta n tia lly , however, the disease free su rv iva l, and, which is  more important, the q u a lity  of 
l i f e  o f the pa tients  has improved dram atica lly.
In  t r e a t in g  p a t ie n ts  w ith  m e ta s ta t ic  b re a s t  cancer i t  is  im p o r ta n t  to  
c o n s id e r th e  fo llo w in g  components: th e  p a t ie n t 's  age, her m e n s tru a l s t a t e ,  
th e  m e ta s ta t ic  s i t e ,  p rev io u s  ad ju v a n t a n d /o r p o s to p e ra tiv e  t re a tm e n t  mo­
d a l i t i e s .  Roughly th e re  a re  two subgroups in  th e  tre a tm e n t fo rm s , th e  h o r­
monal and th e  c y to s ta t ic  tre a tm e n ts .
Survey
Endocrine  th e ra p y
M a n ip u la tio n  o f  th e  endocrine  system has been th e  cho ice  o f  t re a tm e n t  
fo r  s e v e r a l  years  in  premenopausal women w ith  m e ta s ta t ic  d is e a s e . D e c re a s in g  
th e  le v e l  o f  endogenous es trog en  perform ed e i t h e r  by s u rg ic a l ocophorectom y  
o r w ith  o v a r ia n  i r r a d ia t io n  has le d  to  a th e ra p e u t ic  r e s u lt  o f  a p p ro x im a te ly  
30% / 8 / .  The d is c o v ery  o f  s te r o id  re c e p to rs  c o n tr ib u te d  to  th e  s e le c t io n  o f  
p a t ie n ts  f o r  end ocrine  t re a tm e n t. The o b je c t iv e  response r a te  i s  50 to  60% 
in  p a t ie n ts  o f es trog en  p o s it iv e  (ER + ) tum ours and t h is  r a te  f u r t h e r  in ­
c re a s e s  by 10% i f  th e  p ro gesteron  re c e p to r  (PGR) is  a lso  p o s i t iv e .  Tum ours/ 
m étastasés  having  ER va lu e s  le s s  than 3 -1 0  fm ol/m g respond to  e n d o c rin e  
t re a tm e n t in  le s s  than 20% compared w ith  n e o p la s ia  o f 70% response r a t e  w ith  
more th an  30 fm ol/m g o f p r o te in .  The PGR le v e l  seems to  be even more im por­
ta n t  th a n  ER p o s i t i v i t y  / 6 ,  2 1 / .
S u rg ic a l ocophorectomy in  m en s tru a tin g  women w ith  ER + tum ours causes  
an o b je c t iv e  response o f  more than 30% la s t in g  fo r  ap p ro x im a te ly  8 m onths. 
R a d ia t io n  c a s tr a t io n  w ith  2000 cGy shows th e  same e f f e c t ,  however i t s  r e s u l t  
appears 8 to  10 weeks l a t e r  / 5 / .
As p a t ie n ts  w ith  ER-tumours respond to  these  procedures r a r e l y ,  such 
in te r v e n t io n s  a re  n o t in d ic a te d  in  t h is  g roup . The c o n s id e rab le  e x c e p tio n  in  
th e  ER-group is :  p a t ie n t  more than 35 y e a rs  o f  age, slow growing m étas tasés  
and lo n g  d is e a s e -f re e  in t e r v a l .
O th e r end ocrine  m an ip u la tio n s  as adrenalectom y o r hypophysectom y a re  
doubted in  th e  presence o f novel medicaments as a m in o g lu té th im id e  o r  LHRH 
analogues / 1 6 / .
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A n tie s tro g e n s
The n o n s te ro id a l a n tie s tro g e n  tam ox ifen  has become the  most w id e ly  
used hormonal th e ra p y  f o r  p a t ie n ts  w ith  m e ta s ta t ic  b re a s t cancer and i t  
seems to  be as a c t iv e  as th e  o p e ra tiv e  p ro ce d u re . I t  e x e rts  i t s  main a n t i ­
p r o l i f e r a t i v e  e f f e c t  by com peting w ith  e s tro g e n  f o r  b in d in g  to  ER p r o te in s .  
B e s id e s , i t  a ls o  a l t e r s  th e  mechanism o f s ig n a l  t ra n s d u c tio n  and le a d s  to  a 
c e l l - c y c l e  b lockade / 2 6 / .  In  postmenopausal women tam oxifen  decreases  th e  
n o rm a lly  e le v a te d  g o n ad o tro p in  le v e l  and i t  in f lu e n c e s  th e  p re v io u s  s te a d y  
s t a t e  o f  hormone b a la n c e .
Tamoxifen is  cu rre n tly  recommended fo r postmenopausal pa tients w ith advanced disease 
in  a d a ily  dose o f 20 mg. (Doses exceeding th is  le ve l do not show be tte r re su lts , however the 
to x ic i t y  is  more prominent. ) The drug is  also active  in  ER + premenopausal women, however i t s  
va lue is  less w e ll documented /1 9 /. Among others Buchanan e t a l .  /5 /  compared tamoxifen w ith  
s u rg ic a l oophorrectomy in  1986. The median response du ra tion  and the ove ra ll median su rv iva l 
fa i le d  to  achieve s ta t is t ic a l s ign ificance . However, the side e ffe c ts  were more pronounced in  
the oophorectomized group. Considering th is  the cas tra tion  is  not recommended in  the premeno­
pausal group.
The e ffe c t iv e n e s s  o f  tam oxifen  is  around 30% in  postmenopausal women 
w ith  m e ta s ta t ic  c a n c e r. The median tim e t i l l  p ro gress io n  is  about 5 .4  
months / 6 / .
The t o x ic i t y  o f ta m o x ife n  is  m in im al and t r a n s ie n t  / 2 2 / .  W eight g a in  
due to  f lu id  r e t e n t io n ,  v a g in a l b leed in g  caused by hormonal in b a la n c e ,  
edem a, s k in  ra s h , nausea and v o m itin g , le u k o p e n ia  and th ro m b o p h le b itis , ab­
n o rm a l l i v e r  fu n c tio n  appears  in  le s s  than 3% o f  p a t ie n ts .  H yperca lcaem ia  
and tum our f l a r e  occur in  about 5% o f th e  t r e a te d  p a t ie n ts .
New analogues l i k e  d ro lo x ife n e , to re m ife n e , z in d o x ife n e  and t r i o x i f e n e  
do n o t  show b e t t e r  r e s u l ts  than  the  p are n t compound.
Progestogens
M ed ro x ip rog estero n e  a c e ta te  (P ro v e ra , U p joh n , F a r lu t a l ,  Pharm acia) and 
m e g e s tro l a c e ta te  (M egace, B r is t o l  Myers—S q u ib b ) a re  a v a ila b le .  The a n t i -  
n e o p la s t ic  e f f e c t  o f  th e s e  drugs is  p o o rly  u n d ers to o d . They may cause a n t i ­
tum our e f f e c t  m ed iated  by hormone re c e p to rs . On th e  o th e r hand, th e y  i n ­
f lu e n c e  th e  h yp o th alam ic  — p i t u i t a r y  — a d re a n a l a x is  w ith  r e s u l t in  in su p p ­
re s s io n  o f a d re n a l s te r o id  p ro du ction  / 7 / .
The most f r e q u e n t ly  g iven  dosage is  500 to  1000 mg per os once a day 
f o r  th e  f i r s t  month, th en  tw ic e  a week u n t i l  p ro g re s s io n .
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The drug is  almost exclus ive ly  administered in  postmenopausal women. I t s  e ffec tiveness 
is  about 30% /1 1 /. However, i t  should be noted th a t the greater the PR content the higher the 
response ra te  /2 / .  The response la s ts  about 4 months. The re s u lts  are be tte r in  hormone naive 
pa tie n ts . In  case o f l iv e r  involvement the e ffectiveness is  uncertain. There is  no c le a r cut 
evidence th a t the conbination w ith Tamoxifen shows b e tte r  re su lts  /1 0 /, however, i t  can be 
stressed th a t the re s u lts  are probably be tte r i f  the hormonal treatment had been begun w ith  
progestogens instead o f Tamoxifen /6 / .
The s id e  e f f e c t  o f  th e  tre a tm e n t in c lu d e s  fa c ie s  lu n a r is ,  f in e  tre m o rs  
and le g  cram ps, w e igh t g a in , f lu id  r e te n t io n ,  h y p e rte n s io n , e tc .  in  10 to  
50% o f th e  cases . Worsening o f d ia b e te s  and hyperca lcaem ia  should  a ls o  be 
s tre s s e d  / 2 7 / .
A m in o g lu té th im id e  and arom atase in h ib i to r s
The m ajo r sources o f th e  es trogen  p ro te c t in g  b re a s t cancer c e l l s  a re  
th e  o v a r ie s ,  p i t u i t a r y ,  f a t  and th e  a d re n a ls . The inc id ence  peak o f  b re a s t  
cancer i s  in  th e  7 th  decade, where th e  overw helm ing p ro du ction  o f  e s tro g e n  
i s  lo c a l is e d  to  th e  a d re n a ls . The norm al c e l l s  o f  the  g land  produce a n d ro -  
s te n e d io n e . The l a t t e r  is  converted  by an arom atase re a c t io n  in  p e r ip h e r a l  
t is s u e s  to  e s tro n e  and e s t r a d io l .
Aminoglutéthimide blocks several cleavage enzymes and i t  is  capable o f in h ib it in g  the 
conversion o f cho lestero l to  pregnenolone, blocking a l l  adrenal s tero id  synthesis. Therefore, 
pa tients trea ted  w ith  aminoglutéthimide are usua lly  given g lucocortico ids to  prevent Addisonian 
side e ffe c ts  /15 , 23/.
The treatment w ith  aminoglutéthimide is  as e ffe c tiv e  as other hormonal treatment forms 
and the former can replace the surg ica l in tervention in  postmenopausal women.
The rou tine  dosage is  2 x 250 mg Orimeten (Ciba) tw ice d a ily  conbined w ith  40 mg/day 
hydrocortisone fo r  several months.
The o v e r a l l  response r a te  is  35% in  p re v io u s ly  u n tre a te d  postmeno­
p au sa l p a t ie n t s .  The median d u ra tio n  o f  th e  response is  about 5 m onths; i t  
should  be s tre s s e d  th a t  in  p re v io u s ly  Tam oxifen  t re a te d  p a t ie n ts  th e  r e ­
sponse r a t e  i s  25%. I t  is  im p o rtan t to  m ention th a t  the  drug is  more l i k e l y  
to  induce o b je c t iv e  response in  s i te s  o f o s t e o ly t ic  m étastasés.
Most o f  th e  s id e  e f fe c ts  can be observed in  th e  f i r s t  6 w eeks. They 
c o n s is t  o f  s k in  ra s h , which d isap pears  spontaneous ly  d u rin g  th e  tre a tm e n t  
and doses n o t need th e  c e s sa tio n  o f th e  m e d ic a tio n , a ta x ia ,  d iz z in e s s  and 
le th a r g y ,  and h yp e rte n s io n  / 1 2 / .
L u te in iz in g  hormone re le a s in g  hormone analogues
These a g o n is ts , in c lu d in g  b u s e re lin ,  g o s e re lin ,  le u p ro lid e  d ecrease  
FSH and LH s e c re t io n  and a re  recommended fo r  premenopausal b re a s t  c a n c e r
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p a t ie n ts  w ith  in t a c t  o v a ria n  fu n c tio n . The response r a te  is  30 to  40% fo r  
p re v io u s ly  u n tre a te d  women. In t e r e s t in g ly ,  th e r e  a re  some d ata  w hich  show 
th e  e f fe c t iv e n e s s  o f  th e  drug a ls o  in  postm enopausal cases / 1 7 / .
Amenorrhoa p e r s is ts  as long  as th e  p a t ie n t  is  on tre a tm e n t.
S id e  e f f e c ts  a re  m in im al and they  c o n s is t  m a in ly  o f hot f lu s h e s  which  
do n o t need to  s to p  m e d ic a tio n .
Combined end ocrine  th e ra p y
Combining s e v e ra l hormones does n o t seem to  be s u p e rio r to  s in g le  
horm onal th e ra p y .
G u id e lin e s  fo r  en d o c rin e  therap y
R egarding s u r v iv a l ,  b re a s t cancer p a t ie n ts  can be d iv id e d  in t o  two 
g ro u p s , a lo w - r is k  and h ig h - r is k  groups. P a t ie n ts  above 35 years  w ith  h ig h  
ER and PR c o n ten t th o s e , w ith  m onolocalised  bone o r p le u ra  o r s o f t  t is s u e  
m étas tasés  and th o se  in  whom m étastasés appears  as la t e  as beyond 2 y e a rs ,  
a re  ass igned  to  th e  low  r is k  group. In  prem enopausal p a t ie n ts  w ith  low  ER 
a n d /o r  PR c o n te n t , in  those w ith  one o r  more v is c e r a l  m étastasés and where  
th e  m étastasés a p p e a rin g  w ith in  2 years  a f t e r  th e  d iag n o s is  th e  e n d o c rin e  
t re a tm e n t  i s  in e f f e c t iv e :  a l l  these  p a t ie n ts  a re  in  th e  h igh  r i s k  g ro u p .
The b est r e s u l ts  o f  hormonal tre a tm e n t can be seen in  s o f t  t is s u e  
m étas tasés  fo llo w e d  by p le u ra  and bone m é ta s ta s é s . P r a c t ic a l ly  no response  
can be seen in  v is c e r a l  le s io n s  and th e re  i s  a r is k  o f w orsening in  l i v e r  
m étastasés  t r e a te d  w ith  hormones.
R egarding th e s e  o b s e rv a tio n s  th e  recom m endation o f hormonal th e ra p y  is  
as fo l lo w s :
1 .  hormonal tre a tm e n t o n ly  fo r  low r i s k  p a t ie n ts  is  recommended,
2 . gestagen o r  a n t ie s tro g e n  th e ra p y  i s  th e  cho ice  fo r  th e  f i r s t  s te p  
o f horm onal th e ra p y ,
3 . i f  th e re  is  a p rogress ion  in  3 m onths, th e  hormonal tre a tm e n t  
sho u ld  be changed to  c y to s ta t ic  drug co m b in a tio n ,
4 .  i f  th e re  i s  a p ro gress io n  beyond 3 months o f hormonal t r e a tm e n t ,  
f u r t h e r  hormonal th e ra p y  can be co n tin u e d .
Chemotherapy
In  p a t ie n ts  w ith  advanced b re a s t c an cer chem otherapy evokes a response  
r a t e  o f  30 to  60%, however lo n g -te rm  re m is s io n s  o r cure  occur r a r e l y  / 1 / .
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T ak in g  t h is  in to  c o n s id e ra t io n , th e  aim  o f th e  m edical o n c o lo g is t o f te n  r e ­
m ains improvement o f q u a l i ty  o f l i f e  in s te a d  o f  h e a lin g  o f th e  p a t ie n t .  The 
in c re a s in g  enthusiasm  re g a rd in g  th e  success o f  ad ju van t the ra p y  has le d  to  
fo r c e  c y to s ta t ic  tre a tm e n t even in  advanced cases .
Many drugs are e ffe c tiv e  in  the treatment o f breast cancer. The medicaments most com­
monly used are lis te d  in  Table I I .  However, current t r ia l s  indicate th a t polychemotherapy is  
superior to  monotherapy regimens in  disease-free s u rv iv a l. I t  is  also known, th a t doxorub ic in - 
containing protocols y ie ld  a 10 to  204 higher response ra te  than polydrug regimens w ithout 
doxorubicin. Unfortunately, improvement in  general su rv iva l has not been demonstrated. The same 
applies to  OFVP when compared w ith O f . V in c r is t in  and prednisolon does not improve s u rv iv a l, 
but these drugs provoke more side e ffe c ts . The cu rre n tly  used polychemotherapy p ro toco ls  are 
l is te d  in  Table I I I .  The d ifferences came from the p a tie n t selection, tumour lo c a lis a t io n , 
stage, e tc . The response ra te  is  higher among p a tie n t who present w ith  disease predominantly 
in  s o ft tissues than those w ith bone or v isce ra l métastasés. On the other hand, one should not 
be neglect the con tribu tion  o f lo ca l treatment is  c e rta in  s itua tions. I f  there appears fo r  
example a lo c a l relapse 4 years a fte r  the diagnosis has been made, the c y to s ta tic  treatm ent is  
not ind ica ted, but i t  can be e ffe c tiv e ly  treated w ith  lo ca l excision and ir ra d ia t io n  when 
restaging excludes d is tan t metastasis /1 5 /.
The o p tim a l d u ra tio n  o f th e  tre a tm e n t i s  c o n tr a v e r s ia l .  C u rre n t  t r i a l s  
in d ic a te  t h a t . a  con tinuous use o f  chem otherapy re s u lts  in  a tw o fo ld  lo n g e r  
d is e a s e - f r e e  in t e r v a l  than  polychem otherapy in  s ix  courses, however no d i f ­
fe re n c e  can be observed in  t o t a l  s u r v iv a l t im e  / 2 4 / .  As th e re  i s  no c le a r  
c u t ev iden ce  on th e  s u p e r io r i ty  o f e i th e r  fo rm , the  m edical o n c o lo g is t  has 
to  fo cu s  on th e  q u a l i ty  o f  l i f e  in s te a d  o f causing  more s id e  e f f e c t s .  Com­
p a r in g  d o x o ru b ic in  c o n ta in in g  regim ens to  m ito xan tro n e  po lychem otherap y , i t  
can be concluded th a t  th e  an titu m o u r e f f e c t  is  the  same, however th e  t o x ic  
e f f e c t s  a re  reduced in  th e  l a t t e r  form  o f  tre a tm e n t / 2 0 / .
A nother im p ortan t q ues tio n  is  com bin atio n  o f polychem otherapy w ith  
e n d o c rin e  tre a tm e n t. T h e o r e t ic a l ly ,  th e  tumour may c o n ta in  s e v e r a l  c lo n e s  
w hich a re  d i f f e r e n t ly  s e n s it iv e  to  a l te r e d  m a n ip u la tio n s . U n fo r tu n a te ly ,  
th e r e  i s  no ev idence th a t  com bining th e  two m o d a lit ie s  r e s u l ts  in  b e t t e r  
s u r v iv a l .
Recommendations fo r  chem otherapy in  advanced b re a s t cancer p a t ie n ts
H igh r is k  group p a t ie n ts  should be t r e a te d  w ith  m u ltid ru g  chem othera ­
p y . I t  i s  necessary to  c o n s id e r th e  ty p e  o f  ad ju van t tre a tm e n t. I f  i t  has  
been made by using  CMF, an a n th ra c y c lin  d e r iv e d  com bination shou ld  be con­
s id e re d  e i t h e r  w ith  o r w ith o u t hormonal tre a tm e n t fo r  a minimum p e r io d  o f  
6 m onths.
I f  p ro gress io n  appears th e  fo rm e rly  used polychem otherapy sh o u ld  be 
stopped  and re p la ce d  w ith  an o th er reg im en . The b est re s u lts  can be reach ed
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by using  V in b la s t in e  + Mytomycin C in  p r e v io u s ly  a n th ra c y c lin  t r e a te d  
p a t ie n ts .
New drugs and t re a tm e n ts
The taxus b r e v i f o l i a  d erived  ta x o l i s  th e  most p rom ising  new d ru g  in
th e  tre a tm e n t o f  advanced b re a s t cancer be i t  p re v io u s ly  t re a te d  o r  n o t.
2
The recommended s t a r t in g  dose is  225 mg/m e v e ry  3 weeks / 4 / .  The 30 to  50% 
response r a te  seems to  be o f  g re a t im p ortan ce  in  p re v io u s ly  t r e a te d  pa­
t i e n t s .  S ide e f f e c t s  l i k e  n eu tro p e n ia , asym ptom atic  ta c h y c a rd ia , m y a lg ia s ,  
a lo p e c ia ,  v o m itin g , d ia r r h o e a ,  e tc .  should be c o n s id e re d .
Other p la n t -d e r iv e d  drugs l ik e  to p o s ta t in  and p o d o p h y llo to x in s  a re  
a ls o  o f  s c ie n t i f i c  im p o rta n c e , however no random ized  s tu d ie s  a re  a v a i la b le  
t o d a te .  Bone marrow t r a n s p la n ta t io n ,  h a e m a to p o ie tic  growth fa c to r s  a re  a ls o  
p ro m is ing  in  the  t r e a tm e n t  o f g en e ra lis e d  b re a s t  c a n c e r. The form er m o d a lity  
makes megatherapy p o s s ib le  and p revents  d e a th  from  m yelosuppression / 2 8 / .  
The l a t t e r  a llo w s  us to  a l t e r  the p ro to c o ls  u s in g  4 week courses. U n fo r tu ­
n a t e ly ,  i t  is  n o t unan im ously  confirm ed, t h a t  th e  2 weeks c y c le  i s  s u p e r io r  
to  th e  c la s s ic a l 4 week courses / 2 5 / .
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NEW TREWJS IN  THE SURGERY OF GYNAECOLOGICAL TUMOURS
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Operative treatment o f gynaecological tumours includes exploration, staging and removal 
o f tumour fo r  both therapeutic and diagnostic purposes fo r  advanced processes the optimum con­
d it io n s  o f postoperative supplementary treatment are to  be developed. In  con tras t w ith  the 
e a r lie r  view suggesting th a t a malignant tumour o f a given organ is  always the same in  every 
case, nowadays tumour heterogeneity is  emphasized. M ilt ic e n tr ic a l co-operative su rg ica l 
research should widen our knowledge. Well-designed and well-equipped centres should be made 
a va ilab le  fo r  our patients su ffe rin g  from gynaecological malignancies; gynaecological oncology 
needs well-planned function ing specia l c lin ics/w ards.
Keywords : Surgical treatment, gynaecologic malignancy, cancer ce rv ica l, endom etrial, 
ovarian, vu lvar
In t r o d u c t io n
Our aim in  th e  su rg e ry  o f g y n a e c o lo g ic a l tumours i s  to  d e v e lo p  — in  
accordance w ith  modern p r in c ip le s  o f su rg ery  — in te rv e n tio n s  more and more 
r a d ic a l  in  re s p e c t o f  c u r in g  o f th e  a f fe c te d  organ; th e  organ l e f t  b eh ind  
a f t e r  o p e ra tio n  should  c o n ta in  h e a lth y  and a c t iv e  t is s u e  as much as pos­
s ib le .  For th is  purpose, th e  tumour should  be removed c o m p le te ly  w ith  
grow ing  accuracy .
The prognosis o f a p a t ie n t  w ith  m a lig n a n t tumour depends on th e  s ta g e  
o f  m alig nan cy  and on th e  th e ra p y  in  use / 1 5 / .  The modern tumour s u rg e ry  ad­
ju s ts  to  th e  s tage o f m alignancy as f a r  as p o s s ib le . In  p ro g n o s t ic a t io n  o f  
b en ign  cases , th e  in te r v e n t io n  should n o t be r a d ic a l ;  th e  a f f e c te d  organ  
sho u ld  keep most o f i t s  fu n c tio n s . In  m a lig n a n t cases on th e  o th e r  hand th e  
o p e r a t iv e  a re a  should be ex ten ded , i . e .  th e  o p e ra tio n  should be more r a d ic a l .
O ffp r in t requests should be sent to : A. Szánthő, 1st Department o f O bs te tr ics  and 
Gynaecology, Semmelweis U n ive rs ity  Medical School, H-1088 Budapest, Baross u. 27, Hungary
0236-5286/94/8' 4.00 © Akadémiai Kiadó, Budapest
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The therap y  i s  th e  more successfu l th e  b e t t e r  th e  p ro g n o s tic  fa c to r s  
a r e  known. T h e re fo re , i t  i s  im portant to  e s ta b l is h  th e  r is k  groups w ith  pa ­
t i e n t s  who — because o f  h av in g  m alignant tum our —  need in c re as e d  s c re e n in g  
t e s t s  and care / 1 2 / .
The FIGO S tage A rrangem ent (1 9 8 8 ), w hich was b u i l t  up in  th e  l a s t  one 
o r  two decade's e x p e r ie n c e s , is  also  im p o rta n t / 8 / .  A c c o rd in g ly , in  th e  
judgem ent o f g y n a e c o lo g ic a l tumours, a g a in s t a l l  o th e r  c r i t e r i a  we should  
d e c is iv e ly  r e ly  on h is to p a th o lo g ic a l f in d in g s ,  as c l i n i c a l  d e t a i ls  may n o t  
a g re e  w ith  the  r e s u l t  o f  th e  d ia g n o s tic  e x a m in a tio n .
The h igh numbers o f  th e ra p e u tic a l f a i l u r e s  r e f e r  to  th e  f a c t  t h a t  
g y n a e c o lo g ic a l oncology i s  s t i l l  in  p ro g res s . F a i lu r e  i s  o fte n  caused by a 
w rong judgement —  t h a t  was based — b e fo re  th e ra p y  on th e  s iz e  and e x te n ­
s io n  o f the tumour / 1 7 / .  To develop a r ig h t  o p in io n  about the  success o f  th e  
th e ra p y  is  s tro n g ly  in f lu e n c e d  by c e r ta in  tu m o u r-s p e c if ic  p r o p e r t ie s .  The 
g e n e ra l stage o f  th e  p a t i e n t 's  h e a lth , h is  s ta t e  o f  nourishm ent and h is  
c u r r e n t  immune s ta tu s  a f f e c t  th e  s u c c e s s /fa i lu r e  o f  th e  th e ra p y .
There is  no doubt t h a t  th e  rap id  developm ent o f s c re e n in g , d ia g n o s tic s  
and the ra p y  has n ot overshadowed o p e ra tiv e  g y n a e c o lo g ic a l approach; in s te a d ,  
i t  becomes more and more in d is p e n sa b le . (S ta g in g  o p e ra t io n s , r a d ic a l  o p e ra ­
t i o n s ,  e t c . )  Removal o f  th e  tumour t is s u e ,  and a ls o  o f p o te n t ia l  tum our 
t is s u e s  by e x c is io n  has rem ained the  key o f  th e ra p y . M oreover, i t  shou ld  be 
n o te d  th a t  th e re  e x is t s  no v irtu o u s  s u r g ic a l s o lu t io n  th a t  cannot be com­
p le t e d  by ra d io -  a n d /o r  chemotherapy in  a fa v o u ra b le  manner. So we do n o t  
s p e c i fy  the  e x c lu s iv e n e s s  o f  th e  s u rg ic a l a p p ro ach , in s te a d  we s p e c ify  i t s  
p la c e  in  the  th e ra p y  a r s e n a l .  That is  th e  p r in c ip le  th a t  should  le a d  us 
g y n a e c o lo g ic a l o n c o lo g is ts  —  in  every c a s e , even when we e s ta b l is h  th e  
th e ra p y  p lan .
The s u rg e ry  o f c e r v ic a l  can ce r
In  cu ring  o f i n t r a e p i t h e l i a l  carcinom a, in s te a d  o f  using th e  e a r l i e r  
g e n e r a l ly  accepted cone b io p s y , some a u th o rs  suggest c o lp o s c o p ic a lly  aimed  
punch b iopsy , an in t e r v e n t io n  th a t  they  c o n s id e r le s s  a g g ress ive  th an  cone 
b io p s y  i s .  In  t h is  r e s p e c t ,  however th e  l i t e r a t u r e  i s  in c o n s is te n t ;  we un­
am biguously p r e fe r  cone b io p s y . Of course, in  th e  judgem ent, fa v o u ra b le  o r  
u n fa v o u ra b le  e x p e rie n c e s  in  using  c o n iz a tio n  p la y  a s ig n i f ic a n t  r o le .  We a re  
s u re  th a t  our own o p e r a t iv e  technique is  n o t "a g g re s s iv e " . By th e  w ay, a 
b a r e ly  or le s s  " a g re s s iv e "  in te rv e n tio n  has to  be combined w ith  a c lo s e r  and
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more a c c u ra te  fo llo w -u p  method. The aimed b io p s y 's  concept does n o t reckon  
w ith  th e  p o s s ib i l i t y  o f  an in t r a c e r v ic a l  process and d e l ib e r a t e ly  o r  not 
d e l ib e r a t e ly ,  does n o t th in k  o f th e  th e r a p e u t ic a l  and p re v e n t iv e  im p ortan ce  
o f c o n iz a t io n  / 6 / .
The prerequis ite  o f a correct judgement a r ig h t  operative approach o f c e rv ic a l cancer, 
is  a c le a r survey o f the possible ways o f the metastasis-forms o f the tumour. As i t  is  known 
the tumour f i r s t l y  in f i l t r a te s  the cerv ix  and i t  is la te r  tha t i t  breaks in to  the lynphatic  
vessels. I t  is  yet unknown how deep the stroma invasion must be to cause such break in .  Several 
observations whos th a t even a minimal stroma invasion can cause spreading in to  lymphatic 
vessels. From tha t moment on, the r is k  o f ex trace rv ica l spreading is  h igh. The re s u lts  o f 
morphometrical measuring re fe r  to  the fa c t,  th a t there is  a connection between tumour size and 
the incidence o f lymph node metastasis /1 2 /.
Furthermore, we should not leave out o f consideration that the tumour can break in to  
blood-vessels: a problem th a t was undeservedly avoided before. There are three ways fo r  spread­
ing in  the lymphovascular system. 1. la te ra l in f i l t r a t io n  through the paracerv ica l lymphatic 
vessels towards the parametriums and the w a ll o f the p e lv is ; 2. caudal spreading: the tumour 
may break in to  the stroma o f the vagina or can even take over the place o f the stroma. In  case 
o f major spreading the tumour can spread to  the lower pa rt o f the vagina and to  the ingu ina l 
lymph nodes; 3. c ran ia l spreading: the ce rv ica l cancer takes over the endocervix and the lower 
p a rt o f the uterus. The FIGO d id  not take th is  often occurring spreading in to  consideration w 
when he developed h is  Stage Arrangement. This way o f spreading can contain the major p a rt o f 
the lower pa rt o f the u te rus. In  case o f primary ir ra d ia t io n , a certa in  part o f the tumour is  
stay ing  out o f the isodose lin e s . In  the cases reported by Janish and Kübli /1 2 / th is  type of 
c e rv ic a l cancer was apparent in  304.
The inc id ence  and th e  r is k  o f th e  lymph node m e ta s ta s is  i s  s ta g e -d e -  
p en d e n t. In  stage lb  i t  i s  2 04 , whereas in  I I l b  o r IVa i t  i s  a lr e a d y  604 . 
The f u r th e r  spread ing  through  th e  p a r a -a o r t ic a l  lymph node c h a in  can spread  
as f a r  as th e  s u p ra c la v ic u la r  re g io n .
For a long tim e  th e re  was no c o n s is te n t  o p in io n  about c e r v ic a l  m ic ro -  
carc in o m a . The d e f in i t io n  has changed d u rin g  th e  p ast few y e a rs . A cco rd in g  to  
th e  new arrangem ent to  d is t in g u is h  s tag e  I a l  from Ia 2  is  based on th e  f in d ­
in g s  t h a t  was th e  g rade o f th e  in v a s io n  from  the  base o f  th e  e p ith e liu m  
w ith in  5 mm, and th e  h o r iz o n ta l  sp read in g  w ith in  7 mm. A tumour la r g e r  than  
t h is  b elongs to  s tag e  lb .
The c l in ic ia n 's  dilemma is  about th e  f a c t  th a t  the  d i f f e r e n c e  between  
I a l  and Ia 2  is  based n o t on an e x a c t measurement, but on th e  p a t h o lo g is t 's  
d e f i n i t i o n .  D e te rm in a tio n  o f  th e  depth o f  tumour in vas io n  i s  im p o r ta n t  o n ly  
when i t  e x e r ts  an in f lu e n c e  on prognosis  and th e ra p y . L i t e r a r y  d a ta  and our 
own o b s e rv a tio n s  show th a t  in  s tag e  I a l  we can be s a t is f ie d  w ith  a s im p le  
h ys te re c to m y , whereas in  s ta g e  Ia 2  we have to  in te rv e n c e  as in  s ta g e  lb .  
T h e re fo r e ,  th e re  is  a need fo r  p re -  and p o s to p e ra tiv e  i r r a d i a t i o n  and 
W e rth e im 's o p e ra tio n , fo r  in  case o f a 3 to  5 mm i n f i l t r a t i o n  th e  r i s k  o f  
m e ta s ta s is  is  54 / 1 5 / .
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Up to  stage l i b  o f  c e r v ic a l  cancer W e rth e im 's  o p e ra tio n  has rem ained  
t h e  s tan dard  t re a tm e n t. In  case o f advanced p ro cesses  ( I l i a  and I l l b )  on 
t h e  o th e r  hand, o n ly  r a d ia t io n  th e ra p y , comes in t o  c o n s id e ra t io n .
The o p e ra tiv e  th e r a p y  o f  c e rv ic a l cancer has to  be com pleted w ith  
r a d io th e r a p y . We have no f i n a l  v iew po in t about a d ju v a n t and n eo a d ju v an t  
chem otherapy.
The surgical so lu tion  o f  a recurrent ce rv ica l cancer is  a major challenge fo r  on­
c o lo g ic a l gynaecologists, as the  recurrencies in  most cases grow slowly and appear lo c a lly .  
There can only be one aim a t th e  so lu tio n  o f the surgery o f relapses i . e .  to  remove the e n tire  
tumour. Therefore, in  case o f  c e n tra lly  located recurrence mainly p a rt ia l or e n tire  exen­
te ra t io n  is  the so lu tion o f cho ice . I f  the recurrences touch the w a ll o f the p e lv is  and bone 
m etastasis has developed, the prognosis does not leave much hope.
The l i f e  chance o f  a p a t ie n t  w ith  c e r v ic a l  cancer depends on th e  
tu m o u r s iz e ,  the  typ e  o f  h is to lo g y  and th e  lymph node m étastasés. An im p or­
t a n t  fa c to r  is  the  h is to lo g y  o f  the  s u r g ic a lly  removed lymph nodes. In  case  
o f  p o s i t iv e  f in d in g  th e  chan ce  fo r  a f iv e -y e a r  s u r v iv a l  i s  about 60%, w here­
as  in  case o f n eg a tiv e  f in d in g  i t  is  85%.
The s u rg e ry  o f  e n d o m e tr ia l can ce r
The combined s u r g e r y -p a th o lo g ic a l s tag e  arrangem ent o f e n d o m e tr ia l 
ca rc in o m a  had been used u n t i l  a couple o f y e a rs  ago / 8 / .  The reason  f o r  
c h a n g in g  the stage a rra n g e m e n t has been th e  re c o g n it io n  o f s e v e ra l p ro g ­
n o s t ic  fa c to rs  which d e c is iv e ly  in flu e n c e  th e  l i f e  chance o f th e  p a t ie n t  
/ 2 1 / .  The most im p o rta n t changes happened in  e a r ly  c a s e s , where th e  ju d g e ­
m ent o f  the myometrium i n f i l t r a t i o n  p layed  a s ig n i f i c a n t  r o le .  The dep th  
o f  th e  invas ion  shows a good c o r re la t io n  w ith  th e  r i s k  o f th e  developm ent 
o f  lymph node m e ta s ta s is  an d , th e re fo re , w ith  th e  s u r v iv a l  chances o f  pa­
t i e n t s  w ith  e n d o m e tria l c a n c e r / 7 / .  The i n f i l t r a t i o n  o f th e  tumour can be 
w e l l  judged by a t r a n s v a g in a l  u ltraso un d  e x a m in a tio n  as w e l l .
In  the  o ld  t im e s  p r im a ry  i r r a d ia t io n  was th e  tre a tm e n t o f c h o ic e  o f  
u t e r in e  cancer. Nowadays, how ever, in  most cases th e  p a t ie n ts  w ith  in c re a s e d  
s u r g e r y  r is k s  can be o p e ra te d  w ith ou t any p a r t i c u la r  danger. The advantage  
o f  th e  o p e ra tiv e  s o lu t io n  i s  th a t  i t  m oderates th e  d eve lo p ing  o f lo c a l  r e ­
c u r re n c e s  and — by p r e c is e  exam ination  o f th e  abdom inal c a v ity  — assures  
a m qre exact s ta g in g .
Operative so lu tion has made i t  c lear that in  pa tien ts  a t stages I  and I I  the is thm ica l 
re g io n  is  affected in  about 23%, the  adnexal structures in  5 to  6%; the pe lv ica l lymph nodes in
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10 to  11%; the peritoneal f lu id  contains tumour c e lls  in  12-13% o f the cases /4 / .  These fa c to rs  
s trong ly  influence the prognosis. Besides a ffec tion  o f the blood vessels, find ing  o f the lymph 
node is  p a rt ic u la r ly  im portant. We have the worst prognosis when metastasis can be shown a t 
pa ra -ao rtic  lymph node /1 4 /.
Oust l ik e  the in f i l t r a t io n  depths o f the tumour, the recognition o f the type o f h is ­
to logy in  p a rticu la r o f the malignant serous and clear c e ll tumours, and the grade o f d if fe re n ­
t ia t io n  (greading: p lo idy , the ra te  o f the S-phase) are to  be specified  and the receptor con­
ten t. is  to  be determined. These fac to rs  can be w e ll examined in  the uterine cu re tte  from an 
abrasion even a t the p rice  o f repeating the curettage.
The presence o f the node métastasés shows a good co rre la tio n  w ith the other prognostic 
fa c to rs . In  case o f favourable and unfavourable prognosis the presence the node metastasis is  
<  10%, and 40%, respective ly / 7 / .
Of a l l  e n d o m e tria l m a lig nan cies  2 /3  a re  re p re s e n te d  by lo w - r is k  c a r ­
cinom as. T h is  means carcinom as o f h igh  p ro g e s te ro n e -re c e p to r  c o n te n t ,  d i ­
p lo id  chromosome c o m p o s itio n , g la n d u la r o r g la n d u la r -s o lid  e n d o m e tr io id  
ty p e , which i n f i l t r a t e s  on th e  end om etria l s u r fa c e  o r i n f i l t r a t e s  th e  myo­
m etriu m , to o , maximum to  i t s  50% (s tag es  IA  and I B ) .  R isk fo r  th e  a f f e c t io n  
o f  th e  lymph nodes i s  below  5%, th e re fo r e ,  th e re  i s  no need fo r  lym phadenec- 
tomy o r  p o s to p e ra tiv e  i r r a d ia t io n .  P e c u lia r  f o r  th e  h ig h - r is k  tumour i s ,  th e  
la c k  o f p ro gesterone re c e p to rs ,  the  a n e u p lo id y , an u n favo u rab le  ty p e  o f  h is ­
to lo g y ,  th e  s o lid  typ e  o f  growing and a s tro n g  i n f i l t r a t i o n  o f  th e  myo­
m etrium . I f  the  carcinom a i n f i l t r a t e s  more than  50% o f the  myometrium ( IC  
s ta g e )  then i t  is  j u s t i f i e d  to  remove th e  lymph nodes o f th e  p e lv is  and 
— in  case o f m acroscopic su s p ic io n  o f m e ta s ta s is  — to  remove th e  p a ra ­
a o r t ic  lymph nodes, too  / 7 / .
In  th e  " h ig h -r is k "  group , th e  a f fe c t io n  o f  th e  p e lv ic  o r p a r a - a o r t ic a l  
ly m p h a tic  node is  > 5 4 .
. As in  the treatment o f u te rine  cancer, the su rg ica l so lu tion is  s t i l l  a t the f i r s t  
place /1 7 /; in  our own p ractice  i t  is  performed a fte r preoperative ir ra d ia tio n . Looking a t the 
recovery ra te  fo r patients a t the same stage, omission o f surgery acts against s u rv iv a l by 
10 to  25%. Twice as much is  the incidence o f recurrence in  pa tients w ith primary ir ra d ia t io n ,  
than in  those w ith primary operation /1 7 /. Thus the two procedures should be combined, not 
contrasted.
In  the knowledge o f the r is k  factors, in  cases o f stage IA and IB , we do not have to  
reckon w ith  pos itive  lymph node find ings ; therefore, there is  no need fo r Wertheim's operation; 
a simple hysterectomy by keeping the p rinc ip le  o f a b la s t ic ity  in  view is  s a tis fa c to ry . (Imme­
d ia te ly  before operation we close the cerv ica l canal and during the operation we do not grasp 
the corpus, but fo r example, we p u ll the uterus w ith s titch e s  placed in  the ligamenta rotunda, 
we hold the in fundibu lope lv ic  ligament w ith  broad c u ff ,  e tc .)  /1 5 /.
The l i t e r a t u r e  is  in c o n s is te n t  about u te ru s  rem oval w ith  v a g in a l  c u f f .  
C a re fu l s u rg ic a l c lo s in g  o f  th e  c e r v ic a l c a n a l in  case o f p a t ie n ts  o p e ra te d  
w ith  u te r in e  cancer is  im p o r ta n t , as i t  can reduce th e  number o f  th e  r e c u r ­
re n c ie s  in  th e  vag in a  stum p, and th e re  w i l l  be no need fo r  h ys te rec to m y  to  
be made by c u f f .  Tumour spread in g  in to  the  v a g in a , on th e  o th e r hand , makes 
th e  rem oval o f  th e  a f fe c te d  p a r ts  in d is p e n s a b le .
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O varian cance r
I t  is  g e n e ra lly  acc ep ted  th a t  rem oving o f  th e  whole tumour ind uces  a 
p ro lo n g e d  s u r v iv a l .  I f  th e  re s id u a l tumour i s  s m a ll-s iz e d , o r  reduced  in  
m ass, th e  g en era l c o n d it io n  o f the  p a t ie n t  can c o n s id e rab ly  im p ro ve . Ih e  
success o f  an o p e ra t io n , re s u lt in g  in  a r e s id u a l  tumour s m a lle r  th a n  2 cm 
depends on the  tum our lo c a l i z a t io n  and th e  e x te n s io n  o f th e  tum our in t o  th e  
u p p er abdom inal a re a  / 1 1 ,  1 3 / .
According to  th e  g e n e r a l ly  accepted v ie w , th e  l i f e  chance o f  a p a t ie n t  
o p e ra te d  w ith  o v a r ia n  c a n c e r depends on th e  s ta g e  o f  th e  tum our, th e  h is ­
t o lo g ic a l  d i f f e r e n t ia t io n  and on re s id u a l tum our / 1 8 / .
The corners to ne  o f  th e  trea tm en t o f  o v a r ia n  cancer is  tum our re d u c t io n  
d u r in g  prim ary  o p e ra t io n  and s tag ing  / 3 / .  O p e ra tiv e  in te r v e n t io n  w ith  keep­
in g  o f  th e  conception  i s  o n ly  ju s t i f i e d  in  cases o f young women who a re  a t  
s ta g e  l a  and who s t i l l  w ant to  g ive  b i r t h .  Ih e  p r e r e q u is ite  o f  t h i s  i n t e r ­
v e n t io n  is  th a t  th e  tum our is  o n e -s id ed , w ith o u t  adhesions and r u p tu re  o f  
th e  ca p s u le , and i t  i s  h is t o lo g ic a l ly  h ig h ly  d i f f e r e n t ia t e d .  I f  fa m ily  
p la n n in g  has been f in is h e d ,  th e  le f to v e r  o v a r ie s  should be removed even by a 
subsequent o p e ra tio n  f o r  i t  cannot be exc lu d ed  th a t  tumour is  b i l a t e r a l  and, 
i f  so th e  consequences on th e  le f to v e r  o va ry  a re  u nes tim a b le . I t  i s  a ls o  
j u s t i f i e d  to  remove th e  u te r u s , and an omentectomy is  recommended.
Ih e  aim o f th e  s u r g ic a l  s o lu tio n  o f  th e  advanced o v a ria n  c a n c e r i s  to  
rem ove th e  tumour as e x te n s iv e ly  as p o s s ib le ,  f o r  th e  s u r iv a l  t im e  i s  p ro ­
p o r t io n a l ly  reduced by th e  re s id u a l tumour q u a n t i t y .  B urghard t e t  a l .  / 5 /  
recommend p e lv ic  and p a r a -a o r t ic a l  lymph node d is s e c tio n  as w e l l .  In  s p ite  
o f  t h i s  rem oval o f  lymph nodes in  cases o f  o v a r ia n  cancer cannot be made 
o b l ig a t o r y ,  y e t i t  seems th a t  i f  i t  i s  p o s s ib le  through th e  open abdomen 
( f o r  example: th e  o p e ra t in g  surgeon i s  —  o c c a s io n a lly  — f a m i l i a r  w ith  
lymphadenectomy) i t  can be done / 2 / .
The lite ra tu re  is  incons is ten t about the ro le  o f the so-called "second look" operation 
in  the surgery o f ovarian cancer. Today the second-look operation is  recommended p r im a r ily  fo r 
d iagnostic  purposes, when the aim o f the success o f th is  treatment method is  the ob jec tive  
judgement and the planning o f the fu rthe r therapy cannot be reached w ith not invasive methods. 
During the second operation the supplementary tumour reduction does not necessarily add to  the 
leng th  o f the su rv iva l tim e; however, there are experiences showing the contrary. We agree w ith 
the  la te s t  establishment, which suggests that the laparoscopy and the laparotomy con tribu te  
o n ly  l i t t l e  to  the prognosis, and strongly reduces the q u a lity  o f the remaining l i f e  o f the 
p a tie n t 111.
Tumours o f low malignancy (borderline tumours) o f the ovary deserve p a rt ic u la r  judge­
ment. The lite ra tu re  is  con trad ic to ry  about the prognosis o f patients w ith  th is  k ind  o f 
tumour. In  our own experience the prognosis o f the il ln e s s  is  good compared w ith  the prognosis 
o f  o the r malignant tumours, even i f  transperitoneal metastasis is  present.
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Chemotherapy s u c c e s s fu lly  com pletes th e  su rg e ry  o f o v a ria n  c a n c e r .  
The tre a tm e n t method w hich f i t s  to  the  s ta g e  arrangem ent is  fo llo w e d  by a 
t re a tm e n t method th a t  a d ju s ts  to  the  p a t ie n t  m ore. I t  is  c h a r a c t e r is t ic  o f  
t h is  tendency th a t  many — e a r l ie r  thought in o p e ra b le  — prim ary  o p e ra t io n  
o f e ld e r ly  p a t ie n ts  can be done w ith  success. The in d iv id u a l t re a tm e n t  a ls o  
means th a t  th e  s u rg e r ie s  made today are  more r a d ic a l  than the e a r l i e r  ones 
w ere , w ith o u t a h ig h e r s u rg e ry  r is k  o f th e  p a t ie n t s .  Th is  can happen because  
o f  th e  h ig h e r le v e l  o f p o s to p e ra tiv e  t re a tm e n t , th e  modern a n a e s th e s ia , and, 
f i n a l l y ,  th e  r ic h e r  e x p e rie n c e  o f surgeons. The te c h n ic a l developm ent a ls o  
su p p o rts  th e  c y to re d u c t iv e  surgery  tre a tm e n t.
The f i r s t  a r t i c l e s  about the  u ltra s o u n d  s u rg e ry  appeared in  th e  second  
h a l f  o f  th e  '8 0 s . The CUSA (C a v itro n  U lt r a s o n ic  S u rg ic a l A s p ira te )  has an 
o p e ra t in g  head made o f  t i ta n iu m  th a t  v ib r a te s  w ith  23 000 h e r tz  f i x  fre q u e n ­
c y ; by changing th e  a m p litu d e , th e  high w a te r -c o n ta in in g  and th e  low  c o l l a ­
g e n -c o n ta in in g  t is s u e s  a re  s h u tte re d  and washed away. In  our own e x p e r ie n c e s  
w ith  th e  h e lp  o f t h is  machine i t  is  p o s s ib le  to  reduce o va rian  tum ours in  
s iz e  and to  remove lymph nodes ly in g  n e x t to  v e s s e ls  and nerves / 1 9 / .  I t  
needs s p e c ia l a t t e n t io n  th a t  — by g e t t in g  to  know more and more p ro g n o s tic  
f a c to r s  — th e  v iew  th a t  ta k e s  the  r e s t r i c t io n  o f  r a d ic a l i t y  and th e  k e e p in g  
o f th e  organ in to  c o n s id e ra t io n .
The su rg e ry  of vulvar can ce r
In  th e  d ia g n o s is  and trea tm en t o f v u lv a r  c a n c e r, we can w itn e s s  an im­
provem ent re g a rd in g  th e  e a r ly  re c o g n itio n  and th e  chances o f s u r v iv in g .  
There  a re  some changes in  trea tm en t in tro d u c e d  in  th e  la s t  10 y e a rs  / 1 0 / .  
The tre a tm e n t became p a r t ic u la r ly  in d iv id u a l ,  e s p e c ia l ly  a t  th e  tu m o u r's  
e a r ly  s ta g e .
Looking at e a r lie r  s ta t is t ic  data, the proportion o f the incidence was about 4% fo r  a l l  
malignant gynaecological tumours. In  the la s t years the nuirber o f vulvar in tra e p ith e lia l neo­
p las ia  (VIN) has grown, espec ia lly  in young people /1 / .
The reason fo r  th is  is  probably tha t the population undergo more in fec tions w ith  onco­
genic v iruses. Just l ik e  in  the case of pre-invasive changes o f ce rv ica l cancer, we d is tin g u is h  
the stages I ,  I I  or I I I  o f vu lvar in tra e p ith e lia l neoplasia (VIN). The basis o f c la s s if ic a t io n  
— in  th is  case too — is  the r ig h t  sample and r ig h t  h is to lo g ic a l processing.
R e c e n tly  an in d iv id u a l  surgery te c h n iq u e  has been in trod uced  in t o  th e  
tre a tm e n t o f  v u lv a r  c a n c e r, th a t  e q u a lly  in c lu d e s  amended r a d ic a l v u lvec to m y  
and —  in  case o f  e a r ly -s ta g e d  tumours — lo c a l  rem oval o f th e  tu m o u r. I t
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seems th a t  th e  2 cm h e a lth y  e x c is io n  o f th e  tum our im pairs  n e ith e r  th e  s u r ­
v i v a l ,  nor the  r is k  o f r e la p s e . But even th e  new organ-keeping id e a s  do n o t  
g iv e  up lymph node d is s e c t io n  / 1 6 / .
By th e  rem oval o f  th e  in g u in a l and fem o ra l lymph nodes th e  tum our 
s i z e ,  th e  depth o f  in v a s io n  and the a f f e c t io n  o f  the  vessels  has t o  be no­
t i c e d .  In  th e  tre a tm e n t o f  tumours the  rem oval o f  the  in g u in a l and fe m o ra l 
lym ph nodes and th e  i r r a d ia t io n  o f th e  in g u in a l  reg ion  are th e  most common 
in te r v e n t io n s .
I n  our d ep artm en t, we have found o u t from  the h is to lo g y  t h a t  th e  
tum our can spread to  th e  o p p o s ite  s id e . So th e  lymph node d is s e c t io n  i s  es ­
s e n t i a l  and the  p o s to p e ra tiv e  i r r a d ia t io n  has to  be done in  e v e ry  c a s e .
System ic tre a tm e n t o f  th e  tumour has n o t y e t been so lved . The reaso n  
f o r  th a t  is  th a t  we do n o t have enough e x p e rie n c e  about the  t re a tm e n t  o f  
r a r e  tum our. Very l i t t l e  l i t e r a t u r e  is  known th a t  would évalué m ethods com­
b in e d  w ith  chem otherapy. So nowadays i t  i s  h ard  to  have a f i n a l  v ie w p o in t  
a b o u t s y s te m ic a l t re a tm e n t .
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Based on li te ra ry  data and h is  own p rac tica l experience the author summarizes the short 
h is to ry  and p o s s ib il it ie s  fo r  su rg ica l therapy o f the esophageal and g a s tric  cancer diseases.
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On th e  s u r g ic a l th e ra p y  o f  esophageal cancer
M a lig n a n t esophageal tumours make some 2% o f  th e  t o t a l  number o f  can­
c e rs  and 4% o f th e  tum ours o f  th e  g a s t r o in te s t in a l  t r a c t  / 1 5 / .  I t s  in c id e n c e  
is  v a r ia b le :  in  N o rth ern  China 100 , in  Japan 50 whereas in  th e  s o - c a l le d  
w estern  c o u n tr ie s  4 to  5 cases p er a 100 000 p o p u la tio n  a re  re v e a le d  e v e ry  
y e a r.
In  Hungary, s im ila r ly  to  many other countries, tumours o f the d igestive  t ra c t  belong to  
the ra re ly  occurring diseases. Oue to  th e ir  la te  recognition , incurable cases are o fte n  en­
countered, and a considerable p a rt o f the operated cases show a rather high postoperative mor­
t a l i t y  because o f th is  reason and due to the unfavourable s u rv iv a l, esophageal cancer is  one o f 
the most problematic f ie ld s  o f oncological surgery.
The esophageus is  located in  three parts o f the body, v iz .  in  the cervix in  the thorax 
and in  the abdomen. I t  is  c lose ly  connected w ith organs o f l i f e  importance. This is  why eso­
phageal surgery belongs to  the category o f major operations. The treatment o f esophageal 
tumours may be o f m u ltid is c ip lin a r approach, but the primary ro le  o f su rg ica l in te rve n tio n  is  
beyond g e s t io n .
I t  was in  1913 th a t Franz Torek, a surgeon o f Hungarian o r ig in , operated a 60-year-o ld  
women fo r  tumour o f the m id -th ird  o f the esophagus. He removed the tumorous esophagus, then made 
an esophagostomy a t the neck and made a gastrostomy. He repaired the con tinu ity  o f the in te s ­
t in a l  t r a c t  by a rubber pipe /4 5 /. The pa tient survived the in te rven tion  by more than 10 years 
and d ied o f an in te rcu rren t i l ln e s s .  The f i r s t  in tra tho raca l replacement a fte r  removing the
O ffp r in t requests should be sent to : 3. K iss, "Imre Haynal" U n ivers ity  o f  Health 
Sciences, Postgraduate Medical School, Department o f Surgery, H-13B9 Budapest, Szabolcs u. 33, 
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esophagus was performed by Ohsawa in  1933 /3 2 /. Thus, in  1913, and again in  1933, i t  was shown 
th a t  esophageal carcinoma was not an incurable disease and th a t even a reconstruction is  
poss ib le  viiich improves the p a t ie n t 's  postoperative q u a lity  o f l i f e .
Pastorino /3 5 / processed the data of 4930 esophageal resections from the li te ra tu re  of 
th e  years 1955 to  1985. He found th a t between the f i r s t  and the la s t th ird  o f th is  period the 
mean value o f postoperative m o rta lity  f e l l  from 30% to  9% while  the 5 -year-surv iva l ra te  rose 
from . 8% to 19%. He found s im ila r ,  but more expressed, trends in  the Chinese and Japanese l i ­
te ra tu re . In  those coun tries  the  surviva l ra te  fo r  unselected patients rose from 9% to  23%. 
T h is  ra te  attained even 90% when only operations performed in  an early  phases o f the disease 
were taken in to  account.
The r e s u lts  can n o t y e t  be g e n e ra liz e d  y e t .  In  the  m a jo r ity  o f th e  cases  
th e  d iseases a re  a lr e a d y  in  advanced s ta te  when th e  d ia g n o s is  i s  e s ta b l is h ­
e d . Due to  th e  w ide e x te n s io n  o f the tumour a n d /o r  e x is te n c e  o f  rem ote  m éta­
s ta s é s ,  the d isease  i s  in c u ra b le .  In  advanced c a s e s , lo n g -te rm  s u r v iv a l  can­
n o t  be expected , th e  e f f o r s t s  a re  m ain ly  o f  p a l l i a t i v e  c h a ra c te r  and th e y  
a r e  aimed a t  r e s to r in g  o f  sw allow ing . T h is  i s  th e  p rim ary  g o a l o f  tre a tm e n t  
o f  p a t ie n ts  w ith  esop hag ea l carcinom a, b e s id e s , p re v e n tio n  o f c o m p lic a t io n s ,  
p ro lo n g a tio n  o f l i f e  and i f  p o s s ib le , t o t a l  h e a lin g  a re  aimed a t .
R a d ic a l surgery o f  esop hag eal tumours
A nalyzing  th e  f a c t o r s  o f p o s to p e ra tiv e  s u r v iv a l  S k in ner / 4 0 /  concluded  
t h a t  th e  s u r v iv a l i s  in f lu e n c e d  by tra n s m u ra l tumour ex te n s io n  and by lymph 
nodes m étastasés. I t  seems to  be w e ll-fo u n d e d  th a t  th e  s ta te  o f  th e  lymph 
nodes is  the  most r e l i a b l e  p ro gn ostic  f a c t o r  f o r  esophageal re s e c t io n  / 3 ,  5 , 
2 0 ,  2 2 / .  In  th e  s u rg e ry  o f  esophageal tum ours th r e e ,  p a r t i a l l y  a n ta g o n is t ic ,  
a t t i t u d e s  can be d is t in g u is h e d ,  we h a llm a rk  th e s e  by th e  names o f  O r r in g e r ,  
S k in n e r  and Akiyama'.
Orringer /3 3 / recommends transh ia ta l removal o f the esophagus, w ithout opening the 
th o ra x . In  h is  opinion long-term  su rv iva l is  not in fluenced by the degree o f lymph node dissec­
t io n  i f  so i t  is  not ju s t i f ie d  to  make e ffo rts  fo r removing lynph nodes tha t may be burdened by 
métastasés. For th is  reason the surg ica l in terventions performed as "b lunt-b ind" d issection are 
p re fe rred  by th is  author.
According to  Skinner /3 8 / ,  who makes e ffo r ts  to  remove the tumour ra d ic a lly ,  by en bloc 
d issec tion  o f the esophagus and the surrounding tissu e s  being under favourable cond itions, 
i . e .  when preoperative s tag ing  promises curative surgery, uses th is  technique and thus enables 
to  cure a part o f the p a tie n ts  even i f  lymph nodes are being affected in  the remaining cases 
lo c a l recurrence occurs most ra re ly  i f  th is  method is  app lied . However, postoperative mobidity 
and m orta lity  are not n e g lig ib le  in  such cases /4 1 /.
Akiyama / 1 /  p erfo rm e d  s u b to ta l rem oval o f  th e  esophagus and recommend­
ed re s e c tio n  o f th e  stom ach which he approached from  th e  s id e  o f  th e  le s s e r  
c u r v a tu r e ,  he combined t h is  in te rv e n t io n  w ith  standard  lymphadenectomy 
( F i g .  1 ) .  (A cco rd ing  to  th e  in te r p r e ta t io n  o f  th e  p resen t t im e  s tan d ard
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Fig. 1. Typical lymph nodes positions around the esophagus
lymphadenectomy means a d o u b le - f ie ld  lymphadenectomy which e x te n d s  to  th e  
m ediastinum  and th e  upper h a l f  o f  th e  abdomen.) In  Akiyam a's o p in io n ,  gas­
t r i c  re s e c t io n  from th e  s id e  o f  th e  le s s e r  c u rv a tu re  is  n ecessary  from  the  
o n c o lo g ic a l p o in t o f  v iew  because lymph node m étastasés (som etim es s o -c a l le d  
jum ping m étastasés) o fte n  occur in  t h is  p o s it io n  which in  case o f  tum ours in  
th e  m idd le  t h i r d  may even jump over in te rm e d ia ry  lymph nodes, t r a n s f e r r in g  
m étastasés  to  the  c e l ia c  tru n k  lymph nodes.
For in t r a th o r a c a l  carcinom as a l l  th e  th re e  methods accep t th e  n e c e s s i­
t y  o f  s u b to ta l esophagectomy because o f  th e  in tra m u ra l ten d en cy  o f  eso­
phagea l tumours and t h e i r  m u lt ifo c a l  appearance.
Replacement can be made on the s ite  o f the esophagus, i .e .  in tra p le u ra lly  o r re tro -  
s te rn a lly ,  and an antethoracal replacement is  also possible. I t  may be an advantage o f the 
re tro s te rn a l replacement th a t possib ly developing lo c a l recurrence cannot "ca tch" the organ 
used fo r  reconstruction o f the in te s t in a l t r a c t 's  con tin u ity  and a postoperative ir ra d ia t io n  
o f the esophageal bed remains possible. Insu ffic ience  o f the sutureline o f c e rv ic a l anastomosis 
is  followed by a reduced r is k  i f  the replacement is  re tros te rna l.
Wong /50 / in  h is  operations signed the a lt itu d e  o f the anastomosis before examining how 
ra d ica l the esophageal resection from a transthoracic approach may be. He found th a t in  an 
anastomosis prepared in  the ce rv ica l esophagus enables the surgeon to extend resection  by less 
than 2 cm. With postoperative randomized examinations, Chasseray /8 /  showed th a t in  case o f an 
anastomosis prepared in  the ce rv ica l esophagus tha t the distance between the resection  lin e  
and the tumour was twice but such an extension o f the operation was not fo llowed by a reduced 
number o f perioperative complications or by a more favourable long-term prognosis.
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Out o f the  n e o p la s t ic  d iseases o f th e  th o r a c ic  esophagus th e  above- 
m en tio ned  Akiyama o p e r a t io n  i s  performed most commonly a l l  over th e  w o r ld .  
I n  th e s e  o pera tion s  th e  lym ph node d is s e c tio n  i s  p y ra m id a l in  shape, i t  is  
t h e  most ex ten s ive  in  t h e  abdomen and the  lo w e r m ediastinum  and th e  le a s t  
r a d i c a l  in  the  upper m ed ias tin u m  and a t  th e  c e r v ic a l  le v e l .  The in te n s iv e  
developm ent o f the  s u r g ic a l  techniques and th e  h ig h - le v e l  p e r io p e r a t iv e  i n ­
te n s iv e  therapy have made i t  p ossib le  fo r  Akiyam a e t  a l .  / 4 /  to  recommend 
e x te n d e d  lymphadenectomy a t  le a s t  fo r  s e le c te d  c a s e s .
E xtend ed  — s o -c a lle d  t h r e e - f i e l d  — lymphadenectomy
D issem ination  i s  much more ty p ic a l  o f  esophageal carcinom a th a n  o f  
g a s t r i c  cancer. The s tom ach  has a network o f  ly m p h a tic s  around i t s e l f  w hich  
may s e rv e  as a p r o te c t iv e  f a c t o r  against tumour m é ta s ta s é s . In  th e  submucous 
l a y e r  o f the esophagus, t h e  lym phatics run lo n g i t u d in a l ly ,  th e r e fo r e ,  e . g . ,  
i n  case  o f a m id d le - th ir d  tum our, tumour c e l l s  may a r r iv e  a t  th e  c e r v ic a l  o r  
c e l i a c  trunk lymph nodes e a r l i e r  than th o se  ru n n in g  in  th e  ly m p h a tic s  
th ro u g h  in  esophageal m u s c u la r la y e r  a r r iv e  a t  th e  lymph nodes lo c a te d  a t  
t h e i r  own le v e l .  When th e  esophagus is  a f f e c te d ,  lymph node m étastasés may 
a p p e a r f a r  from th e  r o u t in e  areas o f s u r g ic a l r e s e c t io n s .  T h is  may be why 
t h i s  tim e  more and more su rg e o n s , m ainly Japanese ones, recommend an e x te n ­
s io n  o f  the o p e ra t io n , i . e .  performance o f  a t h r e e - f i e l d  lymphadenectomy.
The extended surgery i s  approached with thoracotomy from the r ig h t s ide , the fa t ty  
t is s u e  is  to ta lly  removed from th e  upper part o f the mediastinum en b loc. The lymphnode chains 
have to  be dissected and removed which adjacent to  the recu rren t nerves, to  the a r t .  bronchio- 
cepha lica , to  the sup. ven. cava as w e ll as to  the r ig h t  and l e f t  paratrachéal region. In  the 
neck, the supraclavicular reg ion  is  approached from both sides to  remove the in te rn a l jugu la r 
v e in  as w e ll as the paraesophageal lymph nodes and the lymph nodes adjacent to  the n. recurrens 
a re  to  be removed. These considerab ly prolonged operations are accompanied by preoperative and 
postoperative complications which are d e fin ite ly  elevated in  nunber. I t  has been reported 
se ve ra l times that also m o r ta lity  is  higher. Further s tud ies  and a care fu l evaluation is  
needed u n t i l  i t  w i l l  be c la r i f ie d  when and on what kind o f se lec tion  is  i t  possible to  choose 
an operation of higher r is k  in  the  hope o f prolonged s u rv iv a l.
In  case o f tumour lo c a te d  in  the low er p a r t  o f  th e  esophagus P e ra c c h ia  
/ 3 6 /  recommends rem oval o f  th e  esophagus th ro u g h  a r ig h t -s id e d  thoracotom y  
com bined w ith  s tan dard  lymphadenectomy, he p re p a re s  th e  anastom osis in  th e  
th o r a x  a t  a high l e v e l .  E x tended  ( t h r e e - f i e ld )  lymphadenectomy seems to  be 
in d ic a te d  when tumours o f  h ig h  segment o f th e  esophagus a re  to  be removed o r  
i n  s e le c te d  cases when t h e  m id -p a rt o f th e  esophagus is  to  be rem oved. The 
same au th or perform ed re m o v a l o f  the esophagus w ith o u t  thoracotom y. Such an
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in te r v e n t io n  does n ot make p o s s ib le  a c o r r e c t  lymph node d is s e c t io n .  P e - 
ra c c h ia  s e le c ts  t h is  o p e ra tio n  o n ly  in  cases in  which an o p e ra t io n  perfo rm ed  
w ith  thoracotom y is  c o n tra in d ic a te d .
We a t  our U n iv e r s ity  C l in ic  o f  S u rg ery  s e le c t  th e  ty p e  o f  s u rg e ry  on 
p r a c t i c a l l y  s im i la r  in d ic a t io n s . In  case o f  m id d le - th ird  tum ours, w hich  make 
th e  m a jo r i ty  o f  th e  cases , we choose th e  c la s s ic  Akiyama o p e ra t io n  as a 
r o u t in e  p ro ced ure , th e  same in te r v e n t io n  i s  p re fe r re d  by us f o r  s o -c a l le d  
e a r ly  carc inom as.
P a l l i a t i v e  o p e ra tio n s  in  the  tre a tm e n t o f  esophageal tumours
Many surgeons suggest th a t  th e  r o le  o f  th e  surgeon in  th e  t re a tm e n t  o f  
esop hag eal carcinom a is  o n ly  p a l l i a t i v e  / 2 9 ,  3 3 / .  Belsey / 6 /  i s  o f  th e  same 
o p in io n  excep t th a t  he s tre s s e s  th e  surgeons have an a c tiv e  r o le  in  p ro lo n g ­
in g  th e  p a t ie n t 's  l i f e  and a l l e v ia t in g  h is  s u f fe r in g .  Belsey says t h a t  such 
a c o r r e la t io n  i s  more im p o rtan t th an  th e  s t a t i s t i c a l  a n a ly s e s . The age o f  
l i f e  and th e  r is k  o f c o m p lic a tio n s  cann ot c o n tra in d ic a te  o p e ra t io n .
In  a h ig h  p er c e n t o f  the  p a t ie n ts  p re s e n tin g  w ith  c o m p la in ts  th e  
tum our has a lre a d y  broken through th e  w a l l  o f  th e  esophagus and has d e v e l­
oped rem ote  m étas tasés . Oysphagia appears  d r a m a t ic a l ly ,  i t s  cause can e a s i ly  
be p ro v e d , however, i t  should be known t h a t  two th ir d s  o f th e  esophageal 
c irc u m fe re n c e  has a lre a d y  been i n f i l t r a t e d  b e fo re  dysphagia m a n ife s ts  i t ­
s e l f .  Developm ent o f  a tumours f i s t u l a  tow ards th e  a irw ays may be fo llo w e d  
by r a p id  and c a ta s tro p h a i consequences f o r  th e  p a t ie n t  / 1 8 / .  The s u r v iv a l  
t im e  o f  th e  u n tre a te d  p a t ie n t  la s ts  n o t lo n g e r than s e v e ra l m onths. A g lu t i -  
t io n ,  a s p ir a t io n s  and th e  consequent c o n d it io n s  c re a te  in t o le r a b le  c ircu m ­
s ta n c e s  fo r  s u r v iv o rs .
Although pa tients w ith  hopeless esophageal carcinoma have already t r ie d  to  heal by 
other procedures (cy to s ta tic s , ir ra d ia tio n , la se r, e tc . ) ,  surg ica l solutions occupy the f i r s t  
place even in  the p a ll ia t iv e  therapy /19, 46, 50/. The goal o f treatment should be worthy sur­
v iv a l,  not a simple one (McKeon /2 8 /) .  Resection is  the best p a llia t io n  not on ly  from on­
co lo g ica l but also from functiona l view.
When metastasis is  to  be found preoperative ly in  a l l  the three regions (c e rv ic a l,  media­
s t in a l and abdominal reg ion), long-term su rv iva l cannot be expected even a fte r  complete lymph 
node d issec tion . I f  the tumour belongs to the h ig h ly  malignant cases, long-term s u rv iv a l cannot 
be expected even i f  the microscopic find ing  is  negative fo r  métastasés. In  such cases, extended 
lymphadenectomy is  not ju s t i f ie d .  There is  no doubt th a t remote métastasés and lo c a lly  invasive 
tumours need only p a ll ia t iv e  resection, the usual type o f lymph node removal is  no t ind icated 
in  such cases /4 / .  Many authors have suggested th a t out o f the p a llia tio n s  the resection  should 
be p re fe rred  when the operation is  aimed at the recovery o f o ra l n u tr it io n  /6 ,  10/.
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I f  an esophageal tum our cannot be re s e c te d , e s p e c ia l ly  i f  t h is  c o n d i­
t io n  i s  m a n ife s t and a s s o c ia te s  to  e s o p h a g o -tra c h e a l/b ro n c h ia l f i s t u l a  th e  
s u r g ic a l  "bypass s u rg e ry "  may be the s o lu t io n  o f  ch o ic e . A f i s t u l a  as ­
s o c ia t in g  to  se v ere  dysphag ia  may be accompanied by continuous a s p i r a t io n ,  
th u s , i t  may be in t o le r a b le .  I f  the  g e n e ra l c o n d it io n  o f  the  p a t ie n t  i s  good 
enough to  a llo w  a m ajo r o p e ra t io n , r e s t i t u t io n  o f  a b i l i t y  o f sw a llo w ing  w ith  
b yp ass in g  o f  th e  esophagus is  a r ig h t  method f o r  e l im in a t io n  o f  an im m inent 
f i s t u l a .  The stomach i s  used fo r  th is  purpose th e  most fa v o u ra b ly . I f  th e  
stom ach is  n o t a c c e s s ib le  f i t  fo r  rep lacem ent e .g .  in  case o f a p re v io u s  
g a s t r ic  re s e c t io n , an i s o p e r is t a l t i c  co lon  segment can be used in s te a d . In  
th e  absence o f f i s t u l a  between th e  esophagus and th e  a irw a y s , one shou ld  
ta k e  c a re  o f u nburdening  o f  th e  rem ain ing  esophagus segment. I f  th e  tum our 
has • caught th e  r e c u r r e n t  n erve  and the  p a t ie n t  c o n tin u o u s ly  a s p ir a te s  be­
cause o f  a d e fe c t iv e  mechanism o f sw allow ing  th e n  even "bypass s u rg e ry "  w i l l  
have no r o le  in  th e  p a l l i a t io n  s e r ie s  / 2 ,  4 7 / .
P a r t  o f th e  p a t ie n ts  cannot be s u b je c t to  p a l l i a t i v e  bypass s u rg e ry  
because i t  needs s a t is f a c t o r y  g en era l c o n d it io n  o f th e  p a t ie n t .  In  such 
cases r e s t i t u t io n  o f  s w a llo w in g  can be ach ieved  by in s e r t io n  o f  an eso­
p h a g e a l e n d o p ro th e s is . In  cases o f tumours e x te n d in g  to  high le v e ls  th e  in ­
tro d u c e d  en d o p ro th es is  sometimes g ets  d is p la c e d  and thus the  p ro x im a l p a r t  
o f  th e  p ro s th e s is  may s l i p  in to  the  pharynx. T h is  is  p os s ib le  because in  
th e s e  cases th e  esophageal segment over th e  tum our i s  not long enough to  
push back the  tub e  in to  th e  tumorous segment. In  b o rd er cases th e  o p e ra t io n  
can be com pleted by th e  c e r v ic a l  approach. S l ip p in g  up o f the p ro s th e s is  is  
p re v e n te d  by loo se  n arro w ing  th read  loops im m e d ia te ly  below th e  p h a ry n x -  
esophagus b o rd e r.
In  cases in  w hich  even th e  in tr o d u c t io n  o f  th e  end op ro thes is  i s  im­
p o s s ib le  (tum ours in  a h ig h  c e r v ic a l  l e v e l ) , th e  c a th e te r  pharyngo-esophago- 
(g a s tro )-s to m a  may be in d ic a te d  / 4 8 / .
The e a r ly  esophageal carcinom a and th e  s o -c a l le d  B a r r e tt  m a lfo rm a tio n  
w i l l  be d iscussed in  th e  fo llo w in g  s e p a ra te ly .
On th e  s u rg ic a l t re a tm e n t o f e a r ly  esophageal carcinom a
In  th e  l a s t  few  y e a rs , owing to  th e  im provem ent o f  d ia g n o s tic  f a c i l i ­
t i e s  and very  c a r e f u l ly  perform ed s tu d ie s  about p a t ie n ts  w ith  e a r ly  com­
p la i n t s ,  th e  number o f  e a r ly  d iscovered  carcinom as has c o n s id e rab ly  been in ­
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c re ased  e s p e c ia l ly  in  Japan. At p re s e n t, we have an a v a ila b le  number o f  d a ta  
on .the c h a r a c te r is t ic s  o f the  s o -c a lle d  e a r ly  carcinom a /1 1 ,  3 1 / .
I t  i s  j u s t i f i e d  to  d iv id e  in to  th r e e  subgroups th e  tumours q u a l i f i e d  
as T1 acco rd in g  to  th e  TNM c la s s i f ic a t io n  o f  1 9 8 7 . These are i n t r a e p i t h e l i a l  
(E P ) ,  mucous typ e  (MM) and submucous typ e  (SM ) carcinom as. Lymph node m éta­
s ta s é s  do not d evelop  from  EP tum ours, so d eve lo p  but r a r e ly  (5%) from  MM 
tum ours and d evelop  a t  a h igh  frequency (a b o u t 40%) a f t e r  th e  changes have  
exten ded  to  th e  submucosa / 1 1 / .
The typ e  o f in te rv e n t io n s  to  be s e le c te d  depends on th e  f a c t s ,  nam ely  
end osco p ic  mucosectomy o r rem oval o f  th e  esophagus w ith o u t thoracotom y is  
th e  in te r v e n t io n  o f ch o ic e  when the  tumour i s  o f  subgroup EP o r MM. In  case  
o f MM carcinom a o p e ra t io n  w ith o u t thoracotom y o r th a t  w ith  r ig h t - s id e  th o r a ­
cotom y, may be p o s s ib le .
When th e  tumour is  o f th e  SM ty p e , thoracotom y to  be approached from  
th e  r i g h t  s id e , to g e th e r  w ith  r a d ic a l  lym phadenectom y, is  s ug ges ted , how­
e v e r ,  th e re  a re  surgeons who a re  s a t is f ie d  w ith  rem oval o f  th e  esophagus  
w ith o u t opening th e  th o ra x  / 3 4 / .
□n th e  s u r g ic a l tre a tm e n t o f endobrachiesophagus — B a r r e t t 's  esophagus
When endobrachiesophagus is  p re s e n t , th e  d is t a l  segment o f  th e  eso­
phagus i s  covered by colum nar e p ith e liu m . F or t h is  reason the  esophagus ap­
p e a rs  to  be s h o rt  from  th e  in n e r  s id e . T h is  p ic tu r e ,  which was f i r s t  d e ­
s c r ib e d  by Norman B a r r e t t  in  1950, i s  th o u g h t to  be an acqu ired  phenomenon 
a t  p re s e n t . To make th e  v a lu a t io n  more a c c u r a te , th e re  is  a w id e ly  a c cep ted  
r u l e ,  v i z .  we speak o f  B a r r e t t 's  esophagus o n ly  in  cases in  which i t  app ears  
as an a t  le a s t  3 cm long  fo rm atio n  as a c o n t in u in g  o f the  g a s t r ic  mucosa. 
A ccord in g  to  B rem ner's  th e o ry  111 the  s i t e  o f  th e  esophageal mucosa d is a p ­
p e a rs  as a r e s u l t  o f  gastroesophageal r e f lu x  and i t s  s i t e  becomes c o v e red  by 
colum nar e p ith e liu m , which is  growing more r a p id ly .  S k inner / 3 9 /  sug gests  th a t  
r e f lu x  and B a r r e t 's  m e ta p la s ia  a re  p a r a l l e l  phenomena, t h e i r  c o -e x is te n c e  
shows a r a th e r  h ig h  c o r r e la t io n ,  however, c a u s a l re la t io n s h ip  betw een th e  
two c o n d it io n s  cou ld  n o t be e s ta b lis h e d . I t  i s  o f  im portance th a t  m a lig n a n t  
t ra n s fo rm a t io n  occurs 30 to  125 tim es as f r e q u e n t ly  in  cases o f  e n d o b ra c h i­
esophagus than  in  th e  in t a c t  esophagus; th e  cases have been in c r e a s in g  in  
num ber. A ccording to  DeMeester / 9 /  each d iagnosed  case in  th e  in d ic a to r  o f  
20 non-d iagnosed  ones, fu rth e rm o re , 40% o f  th e  p a t ie n ts  have no c o m p la in ts  
s u g g e s tiv e  o f r e f lu x .
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The s u r g ic a l tre a tm e n t in c lu d e s  t re a tm e n t o f the  c o m p lic a tio n s  and  
p re v e n t io n  o f m a lig n a n t m a lfo rm a tio n . A lthough  i t  has not u n e q u iv o c a lly  been  
p ro v e d , fo rm a tio n  o f  d y s p la s ia  in  th e  B a r r e t t  e p ith e liu m  can be p re v e n te d  by 
a n t i r e f l u x  s u rg e ry  o r  th e  m e ta p la s ia  re g re s s e s  fo llo w in g  s u r g ic a l  t r e a t ­
ment / 3 9 / .
What is  to  do when B a r r e t t 's  anomaly has been diagnosed?
Medication should be in it ia te d  even in  u n in te n tio n a lly  recognized cases which are free  
from complaints. In  such cases the condition should be checked a t 6 to  12 month in te rv a ls .  For 
th is  purpose m u ltis ite  biopsy m ateria l should be taken from the m etaplastic-dysplactic area in  
o rder to  determine the degree o f dysplasia and, i f  i t  is  ju s t if ie d ,  to  judge the possib le 
progress and, thus to  recognize the possibly carcinomatous character. Regular checking is  ju s ­
t i f i e d  even a fte r  a n t ire f lu x  surgery and the so-ca lled brush cyto log ica l te s t should be per­
formed yearly  to  demonstrate possibly appearing malignant c e lls .
The in d ic a t io n  o f  th e  c o n s e rv a tiv e  s u r g ic a l  tre a tm e n t i s  s im i la r  to  
t h a t  o f  th e  o p e ra tio n s  perform ed fo r  g as tro esop hag ea l r e f lu x ,  nam ely a r e ­
f l u x  r e s is t in g  in t e r n a l  tre a tm e n t a n d /o r a se v ere  ( u lc e r a t iv e )  n o n h e a lin g  
B a r r e t t 's  u lc e r  c o m p lic a ted  by s t r ic t u r e .  S u rg ic a l s o lu tio n  may be n e c e s s a ry  
when s e r ia l  a s p ir a t io n s  occur in  a c o n d it io n  p r a c t ic a l ly  f r e e  from  com­
p la i n t s  o r when th e  p a t ie n t  o b je c ts  lo n g -te rm  m ed ica tio n . The c o n s e rv a t iv e  
t re a tm e n t  u s u a lly  means some form o f fu n d o p lic a t io n , however, F é k é té  / 1 4 /  
s u g g es ts  to  p erfo rm  t o t a l  duodenal d iv e rs io n  aimed a t  p re v e n tin g  r e g u r g i t a ­
t io n  o f  duodenal c o n te n ts  in to  the  esophagus.
R a d ic a l s u r g ic a l tre a tm e n t ( r e s e c t io n )  may be in d ic a te d  in  s e v e re  
cases  o f  d y s p la s ia  and h is t o lo g ic a l ly  proved carcinom a in  which th e  changes  
a re  p ro g res s in g  in  s p i t e  o f a c o r re c t  c o n s e rv a tiv e  therap y  / 2 3 ,  4 2 / .  I t  
sh o u ld  be noted t h a t  a t  p re s e n t p a th o lo g is ts  and c l in ic ia n s  a g re e  w e l l  in  
t h a t  h ig h -g ra d e  carcinom a and in  s i tu  carcinom a a re  synonymous d e s ig n a t io n s ,  
and a ls o  in  th a t  r e s e c t io n  i s  th e  method o f  c h o ic e  / 4 3 / .
B a r r e t t 's  carcinom a has a bad p ro gn os is  and th e  s u r v iv a l shows a c lo s e  
c o r r e la t io n  w ith  tum our s ta g e . I t  seems to  be w id e ly  accepted t h a t  d y s p la s ia  
—  h ig h -g ra d e  d y s p la s ia  — is  th e  b est in d ic a to r  o f  m alignant m a lfo rm a tio n  
in  cases  o f B a r r e t t 's  esophagus / 2 5 / .
The re s e c t io n  s u rg e ry  o f th e  esophagus is  a m ajor s u r g ic a l in t e r v e n ­
t i o n .  N e v e rth e le s s , i t  may load  to  fa v o u ra b le  r e s u l ts  (reduced m o rb id ity  and 
m o r t a l i t y )  in  c e n te rs  in  which the  team is  w e l l - t r a in e d  in  o rg a n iz in g  b o th  
th e  p re o p e ra t iv e  and p o s to p e ra tiv e  work w e l l  / 3 0 / .
SURGERY OF ESOPHAGEAL AND GASTRIC CANCER 213
On th e  s u r g ic a l tre a tm e n t o f  g a s t r ic  cancer
Carcinom a, th e  g a s t r ic  tumour o f e p i t h e l i a l  o r ig in  makes 95% o f  th e  
tumorous d is eases  o f  th e  stomach. I t  occurs most f re q u e n tly  in  Japan and in  
C h ile .  I t s  y e a r ly  in c id e n c e  in  these c o u n tr ie s  ranges between 7 and 1 0 /1 0 0 0 0  
p o p u la tio n . In  th e  USA and in  Canada the  co rresp o n d in g  frequency ran g ed  b e­
tween 0 .8  and 1 .4 /1 0 0 0 0 .  In  Hungary, about 4000 p a t ie n ts  d ied  o f  g a s t r ic  
cancer y e a r ly .
The incidence o f th is  disease shows as downward trend a l l  over the world. I t  i s  o f 
in te re s t th a t the lo c a liz a tio n  o f the primary a ffe c tio n  is  changing. In  the USA two th ird s  o f 
these tumours appeared in  the antrum prim arily  and only 104 were recognized around the ca rd ia . 
According to a recent study published by the American College o f Surgeons (ACS) /4 9 / 31 and 14% 
occurred in  the upper and middle th ird s  o f the stomach, respective ly , and the changes extended 
to  the e n t ire  stomach in  10%, only 26% occurred in  the lower th ird .
I t  is  o f importance th a t the cardia cancers are more aggressive than the tumours oc­
cu rring  elsewhere in  the stomach, and i t  should be stressed th a t the treatment o f proximal 
tumours is  te ch n ica lly  more complicated than the changes appearing in  an an tra l p o s it io n . The 
former need wider circumspection, more intense tra in in g  and experience.
G a s tr ic  cancer needs s u rg ic a l t re a tm e n t , t h is  p r in c ip le  has g e n e r a l ly  
been a c c p e te d . The re c e n t  development o f a n e s th e s ia , the  h ig h - le v e l  d i r e c ­
t io n  o f  th e  p e r io p e r a t iv e  p e r io d  and th e  r e f in e d  s u rg ic a l te c h n iq u e s  have  
made i t  p o s s ib le  to  p erfo rm  r a d ic a l  o p e ra t io n s . As th e  typ e  o f s u rg e ry  and 
th e  d eg ree  o f  r a d i c a l i t y  th e re  a re  c o n tro v e rs ie s  in  th e  w orld  o f  s u rg e o n s .
The f i r s t  s u c c c e s s fu l g a s t r ic  re s e c t io n  was perform ed by Theodor B i l l ­
ro th  on 29 Janu ary , 1881. H is  p a t ie n t  s u rv iv e d  th e  in te rv e n tio n  by 14 months 
and d ie d  o f  d is s e m in a tio n  o f tum our.
In  th e  '40s  and '5 0 s  o f the  p resen t c e n tu r y ,  t o t a l  gastrectom y was th e  
o p e ra t io n  o f  ch o ice  in  th e  th e rap y  o f g a s t r ic  cancer / 2 6 / .  Th is  r a d ic a l  ap­
proach abandoned l a t e r ,  because i t  seemed to  be u n d es ira b le  in  in c r e a s e  
g a s t r ic  c r ip p le s  in  number. S t i l l  l a t e r ,  i t  became apparent t h is  c o n d it io n  
was n o t a consequence o f th e  a g a s tr ic  s ta t e ,  and i t  was a lso  proved t h a t  t h is  
u nd ou bted ly  p o o rly  to le r a t e d ,  c o n d itio n  can be avoided  on the  b a s is  o f  fu n c ­
t i o n a l l y  a p p lie d  p r in c ip le s .
The studies d irected  to the lymph c irc u la tio n  o f the stomach were in it ia te d  e a r ly  in  
the century /2 1 / (F ig . 2 ). Spreading of gastric  tumours through the lymphatic system was f i r s t  
described in  d e ta il by Sunderland et a l.  /44 / in  1953. Radical dissection became a standard 
component o f g a s tric  cancer surgery soon. G ilbertsen /1 7 / stated in  1969 tha t m orb id ity  and 
m o rta lity  increased and the 5 year surv iva l was reduced a f te r  extended surgery. Subsequently, 
in  the USA and in  a great pa rt o f the Western world — except fo r certa in  centerns — the 
p r in c ip le  and p ractice  o f rad ica l lymph dissection was suppressed w ile  elsewhere, f i r s t  o f  a l l  
in  Japan, i t  has remained an indispensable component o f surgery, i t s  gradually re f in in g  p r in ­
c ip les  and techniques are being applied w ith favourable re s u lts .
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F ig . 2. Typica l lymph nodes pos itions  around the stomach
The 5 -y e a r  s u r v iv a l  r a te  c a lc u la te d  f o r  a l l  types o f re s e c t io n  p e r ­
form ed fo r  g a s t r ic  ca n c e r is  f lu c tu a t in g  betw een 1 2 .6  and 32.4%  ( i f  p a l ­
l i a t i v e  and r a d ic a l  re s e c t io n s  are not s e p a ra te d  from each o th e r ) .  The e x ­
c lu s iv e  s u r v iv a l  f o r  r a d ic a l  re s e c tio n s  ra n g e s  between 1 8 .6  and 8 3 .5% . The 
com bined re s e c t io n  r a t e  (w ith o u t reg ard  to  th e  typ e  o f re s e c t io n )  a t  th e  
C l i n i c  o f Surgery  o f  th e  A lb e r t  S z e n t-G y ö rg y i U n iv e rs ity  M e d ic a l S choo l 
(SZOTE) was p u b lis h e d  by I .  P e t r i  / 3 7 /  was 25.7%  fo r  5 -y e a r s u r v iv a l  and 
18.3%  fo r  10 y e a r s u r v iv a l .  The re s p e c t iv e  s u r v iv a l  ra te s  fo r  r a d ic a l  s u r ­
g e ry  were 3 9 .1  and 28 .1% .
In  an e x te n s iv e  s tu d y  o f the ACS two t h i r d s  o f th e  cases b e lo ng ed  to  
s ta g e s  I I I  and IV  w h ile  th e  5 -y e a r s u r v iv a l  1 3 .6  and 3%, r e s p e c t iv e ly  / 4 9 / .
I t  is  a balanced standpoint tha t the lo ca tio n , the stage and Lauren's h is to lo g ic a l 
scoring  present the nest important data fo r se lecting  the type o f surgery /1 3 /. The h is to lo g ­
ic a l  type and the degree o f d iffe re n tia tio n  are fu rth e r important facto rs.
Subtotal g a s tr ic  resection is  performed when a sm all d is ta l carcinoma is  located in  the 
antrum and the tumour belongs to Lauren's in te s t in a l type . In  these cases the lymph nodes o f
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the greater omentum, those o f the lesser omentum and the lymph nodes o f compartment I  are re ­
moved. Splenectomy is  om itted. Ihe lymphadenectomy is  extended to  compartment I I  provided there 
is  no remote metastasis.
We ind ica te  to ta l gastrectomy when the tumour is  in  the upper-middle th ir d .  With re ­
spect to  the rap id  spread o f the tumour, the d is ta l 3 to  5 cm o f the segment o f the esophagus 
is  removed, ju s t l ik e  the lymph nodes o f the omentum maius and minus as w e ll as those o f 
compartment I .  ( In  ra d ic a l surgery even the lymph nodes o f compartment I I  are removed.) Of 
course, in  surgery performed w ith p a ll ia t iv e  purpose lymphadenectomy and splenectomy should 
be omitted.
I f  th e  tumour i s  adherent to  rem ovable organ — o r p a r t  o f  an o rgan  — 
th e  a f fe c te d  organ ( p a r t  o f  o rgan) (c r u r a  o f  diaphragm , h e p a tic  lo b e ,  ad­
r e n a l  g la n d , p an creas , co lon  tra n s v e rs  c o lo n , e t c . )  may be rem oved. T h is  is  
th e  s o -c a l le d  combined s u rg e ry .
Combined su rg ery  does not c o n s id e ra b ly  in c re a s e  th e  m o r t a l i ty  b u t th e  
chance o f s u r v iv a l .  The 5 -y e a r s u r v iv a l r a t e  f o r  combined o p e ra t io n s  was 
14.2% (5 -y e a r  s u r v iv a l )  and 9.6*5 (10  y e a rs  s u r v iv a l )  / 3 7 / .  A c c o rd in g ly  i t  is  
j u s t i f i e d  to  p erfo rm  combined surgery  in  e v e ry  case in  which i t  i s  t e c h n i ­
c a l l y  p o s s ib le  /1 6 ,  3 7 / .
In  advanced cases, p a ll ia t iv e  resections are the most e ffe c tive  symptomatic treatm ent, 
too . Resection is  o f no reason in  case o f ca rc inos is  pe ritone i and extensive hepatic  méta­
stasés. In  such cases resection may be the in te rven tion  o f choice only excep tiona lly .
On th e  s u r g ic a l tre a tm e n t o f " e a r ly "  g a s t r ic  carcinom a
The d e s ig n a tio n  " e a r ly "  is  t y p ic a l  o f  th e  p o te n t ia l  c u r a b i l i t y  o f  th e  
tum our, i t  i s  le s s  c h a r a c te r is t ic  o f th e  tu m o u r's  s iz e  and e x te n s io n . Ac­
c o rd in g  to  a recomm endation o f th e  Japanese S o c ie ty  o f G a s tr o e n te r o lo g ic a l  
Endoscopy (1 9 6 2 )  a cancer l im ite d  to  th e  g a s t r ic  mucosa and submucosa is  
c a l le d  e a r ly  w ith o u t re g a rd  to  lymph node m étas tasés .
A lthough e a r ly  cancers a re  o fte n  m u l t ic e n t r ic ,  lymph node m é ta s ta s é s  
occur as c o n s id e ra b ly  h ig h  frequ ency . N e v e rth e le s s , the  tumours a re  m o s tly  
c u ra b le  i f  an adequate tre a tm e n t is  a p p lie d . The 5 -y e a r s u r v iv a l r a t e  ranges  
between 60% and 100%. However, th e re  a re  d e b a ta b le  questio ns  r e f e r r i n g  to  
s u r g ic a l t re a tm e n t. To inc re as e  r a d i c a l i t y ,  many authors in d ic a te  t o t a l  
gastrec tom y combined w ith  lymphadenectomy. O th e rs  a re  s a t is f ie d  w ith  p a r t i a l  
r e s e c t io n  a p p lie d  w ith  zone s e c u r ity .
Most o f the surgeons performing d is ta l resection  recommend resection o f a 5 cm healthy 
segnent  o f the stomach while  others perform a more extensive resection. Recurrence, though rare 
in  occurrence, is  fa ta l in  outcome. Most o f the recurrences occur w ith in  f iv e  years. They are more 
common (B.4%) i f  "early " carcinoma has already extended in to  the submucosa than i f  i t  is  
lim ite d  to  the mucosa (2.2%). On the Western hemisphere, recurrence is  not a t tr ib u te d  to 
operations performed w ith  in s u ff ic ie n t ra d ic a lity  (resection  and removal o f lymph nodes). Ihe 
recurrence ra te  is  sometimes elevated i f  a non-early cancer is  considered to  be e a rly  /1 2 /.
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When ea rly  changes have been demonstrated in  the proximal segment o f the stomach, 
p roxim al resection is  taken in to  account. However, such an in tervention may be fo llow ed by 
unfavourable event. The p ro b a b ility  o f the "pos itive  resection  lin e "  and of carcinoma remaining 
in  the  d is ta l g a s tric  stump is  h igh . I t  is  more d i f f i c u l t  to  prepare a correct lyitphadenectomy, 
and an esophagogastrostomy a f te r  proximal resection is ,  so-to-say, always followed by (A io - 
deno)-gastro-esophageal re f lu x  and a consequent severe esophagitis. Maruyama /27 / recommends 
t o t a l  gastrectomy w ith  preserved pancreas.
The p rognosis  o f  th e  " e a r ly  g a s t r ic  c a n c e r" , e s p e c ia l ly  o f th o s e  w ith  
tum ou r l im ite d  to  th e  mucosa, is  very  good. K u r i t a  e t  a l .  / 2 4 /  p u b lis h e d  
d a ta  o f  520 cases, lymph node m etas tas is  was found  in  2.1% o f 291 cases  o f  
m ucosa l cancer and in  15.7%  o f  299 cases o f  submucosal cancer. N e ith e r  lym ph  
node m e ta s ta s is  nor p erm e a tio n  o f th e  ly m p h a tic s  o ccurred  unless  th e  le s io n  
was la r g e  than 10 mm in  d ia m e te r . In  case o f  such c ircu m scrib ed  e a r ly  c a r c i ­
nom as, l im ite d  r e s e c t io n ,  in c lu d in g  endoscopic r e s e c t io n , can be p erfo rm ed  
w ith o u t  any r i s k .  There i s  no doubt th a t  an a c c u ra ta  judgement o f  th e  d ep th  
o f  - th e  tumour is  o f b a s ic  im portance when t h i s  tre a tm e n t is  to  be chosen . 
Today th e  endoscopic u lt r a s o n ic  mucosectomy p ro v id e s  th e  most r e l i a b l e  ap­
p ro a c h . However, even such a method f a i l s  t o  p ro v id e  an answer o f  f u l l  
v a lu e .  Perhaps t h is  i s  why Watanabe e t  a l .  / 5 1 /  recommended a co m b in a tio n  o f  
mucosectomy w ith  la s e r  t re a tm e n t .
S u rg ic a l tre a tm e n t o f  th e  e a r ly  cancer needs th e  most r a d ic a l  i n t e r ­
v e n t io n  fo llo w e d  by th e  lo w e s t r is k :  p o s to p e ra tiv e  l i f e  q u a l i ty  sho u ld  a ls o  
be ta k e n  in to  c o n s id e r a t io n .
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LYVPHADENECTOMY IN GASTROINTESTINAL CANCER SURGERY
ö . P . HORVÁTH
1 s t  S u rg ic a l C l in ic ,  U n iv e r s ity  M e d ic a l School o f Pécs, Hungary  
(R ece ived : September 2 3 , 1994)
Extended lymph node dissection is  an important part o f the surg ica l treatm ent fo r  
cancer o f the esophagus, stomach, colon and rectum. With an appropriate lymphadenectomy a more 
precise tumour-staging, an increase in  re s e c ta b ility ,  a r is e  o f the rate  o f Rg-resections, 
fu r th e r  a decrease in  lo c a l tumour recurrences and an improvement of prognosis can be achieved.
Keywords: Lymphadenectomy. gas tro in te s tin a l cancer
Survey
Lymphadenectomy is  a w e ll known and proved th e ra p e u tic  p ro ce d u re  in  
o n c o lo g ic  s u rg e ry . About 100 years  ago, i t  was in i t i a t e d  as an o p e ra t io n  f o r  
c u re  o f  b re a s t  carcinom a by H a ls te d t  / 6 / ,  15 y ears  l a t e r  by M ile s  / 1 4 /  f o r  
r e c t a l  carcinom a and by T u rn b u ll as Non-Touch Is o la t io n  Technique f o r  co­
lo n ic  carcinom a / 2 0 / .  Lymphadenectomy in  g a s t r ic  and oesophageal c a n c e r was 
s ta n d a rd iz e d  in  Japan a few years  ago and i t  is  in c re a s in g ly  perfo rm ed  
w o rld w id e  / 1 ,  1 2 , 1 3 / .
The th e ra p e u t ic  aim o f lymphadenectomy is  as fo llo w s :
1 . To assess th e  e x a c t tumour s ta g e .
2 .  To in c re a s e  th e  r e s e c t a b i l i t y  due to  g r e a te r  e x tra lu m in a l r a d i c a l i t y .
3 .  To enhance th e  r a t e  o f  Rg re s e c t io n s  (no m icroscop ic  and m acroscop ic  r e ­
s id u a l  tumour accord ing  to  th e  UICC 1987 c la s s i f ic a t io n )  / 7 / .
4 .  To decrease  lo c a l  re c u rre n c e s .
5 . The u lt im a te  purpose o f lymphadenectomy is  to  improve th e  p ro g n o s is .
O ffp r in t rquests should be sent to : Ö. P. Horváth, University Medical School o f Pécs, 
1st Surg ica l C lin ic ,  H-7624 Pécs, Ifjú ság  u. 13, Hungary
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F ig . 1. Nuntier o f reroved lymph nodes in  patients w ith  co lon ic  and re c ta l cancer trea ted  w ith  
standard and extended lymphadenectomy
ad 1 . The assessm ent o f tumour s ta te  i s  m andatory fo r  cure  in  onco­
lo g ic  s u rg ery . O th er p ro g n o s tic  fa c to r s ,  p a r t i c u la r ly  the  nodal s ta tu s  a re  
a ls o  re la te d  to  tum our s ta g e . For pN a r e l i a b le  tumour s tag in g  i s  o n ly  pos­
s ib le  w ith  an adequate  lymphadenectomy. The number o f lymph nodes removed 
can be increased  by a more extended lymphadenectomy in  esophageal, g a s t r ic ,  
c o lo n ic  and r e c t a l  c an cer s u rg e ry . In  F ig .  1 th e  d a ta  o f th e  S u rg ic a l C l in ic  
E rla n g e n  are  shown, th e  number o f lymph nodes can be doubled by lym phadenec­
tomy in  case o f c o lo n ic  and rectum  cancer / 5 / .
The same increase can be achieved in  esophageal cancer (F ig . 2 ). There is  a new trend 
in  esophageal cancer surgery, according to  which some surgeons perform, instead o f a tw o -f ie ld  
lymphadenectomy, a so -ca lled  th re e - f ie ld  lymphadenectomy. The former includes lymphadenectomy 
o f  .the lower mediastinum and the suprapancreatic area. The th re e - f ie ld  operation extends the 
removal o f lymph nodes above the azygos vein on both sides o f the trachea along the recu rren t 
nerves as w e ll as in  the region o f the vessel sheets to  d issect the ce rv ica l lymph nodes, 
too /10 , 11, 21/.
According to  recent reports  /10, 11/ the ra te  o f ce rv ica l lymph node metastasis in  
cases subjected to  nodal d issection in  three regions was almost the same, about 30%. Akiyama 
/ 1 /  also reported th a t lymph nodes in  the superior mediastinum were metastatic in  36% o f the 
tumours o f the upper th o ra c ic  oesophagus, in  12% o f mid tho rac ic  oesophageal tumours and in  
11% o f lower tho rac ic  oesophageal tumours. Therefore, a th re e - f ie ld  lymphadenectomy is  advised 
n o t on ly  fo r  tumours o f the upper oesophagus, but a lso fo r  middle and lower tho rac ic  oeso­
phageal tumours.
The s ig n if ic a n c e  o f  an a p p ro p r ia te  lymphadenectomy fo r  s ta g in g  p u r­
poses i s  in d ic a te d  by th e  fa c t  th a t  the  more lymph nodes are  removed d u r in g  
s u rg e ry  the  more i s  th e  number o f lymph nodes found  p o s it iv e  a t  h is to lo g y .
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F in . 2. Number o f removed lymph nodes a fte r tw o -fie ld  and th re e -fie ld  lymph node d issection
fo r oesophageal cancer
In  S ie w e r t 's  s e r ie s  53.6% o f lymph nodes were p o s it iv e  when le s s  th an  20 
m e d ia s t in a l and p e r ig a s t r ic  nodes were exam ined, and 70.4% were p o s i t iv e  
when more than  20 nodes were examined / 1 8 / .  T h e re fo re , the s tag e  o f  p a t ie n ts  
w ith o u t a c o r re c t  lymphadenectomy can be u n d eres tim ated  and hence th e  p ro g ­
n o s is  w i l l  be m is judged.
An a p p ro p r ia te  example was g iv e n  by G a l l  / 4 /  in  con nection  w ith  co­
lo n ic  c a n c e r, th a t  lymph node m e ta s ta s is  was p re s e n t in  18% even t h e r e  from  
where i t  co u ld  n o t have been removed by c o n v e n tio n a l re s e c t io n .
ad 2 .  Lymphadenectomy in c re as e s  th e  r e s e c t a b i l i t y  r a t e .  S ie w e r t  and 
G a ll  / 4 ,  5 ,  1 7 / dem onstrated  a 10% in c re a s e  o f  r e s e c t a b i l i t y  in  p a t ie n ts  
w ith  g a s t r ic  and c o lo n ic  cancer. R e s e c ta b il i t y  is  a surgeon-dependent sub­
je c t i v e  c a te g o ry . Lymphadenectomy demands good s u r g ic a l s k i l l s  and w ith  th e  
im provem ent o f s u r g ic a l tech n iq ues  th e re  w i l l  be le s s  and le s s  tum ours th a t  
a re  th o u g h t as lo c a l ly  in re s e c ta b le .
ad 3 .  The most im p o rtan t consequence o f lymphadenectomy i s  t h a t  i t  
s i g n i f i c a n t ly  in c re a s e s  th e  r a te  o f R g -re s e c t io n . S ie w e rt and G a l l  / 5 ,  1 7 /  
re p o r te d  a 8-15% growth in  th e  r a te  o f R g -re s e c tio n s  in  case o f  stom ach, 
c o lo n ic  and rectum  cancer s in th e  th e  i n i t i a t i o n  o f lymphadenectomy. Akiyama 
/ 1 /  dem onstrated  s im i la r  re s u lts  in  c o n n e c tio n  w ith  the  oesophageal c a n c e r.
In  the German G astric Cancer Study, conta in ing the data of 2394 pa tients  w ith  g a s tr ic  
cancer, the prognostic relevance o f systemic lymph node dissection was evaluated /1 9 / .  Of 1654 
pa tien ts  undergoing resection, 558 had a standard lymph node dissection, defined as fewer than
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Table I
Tumour recurrence a fte r standard and extended 
lymphadenectomy fo r oesophageal, g a s tr ic  and rec ta l 
cancer
Standard Extended
Siewert: g a s tr ic  cc 20% 6.9%
Enker: rectum cc 
Dukes C 60% 30.8%
Ho jo :  rectum cc 
Dukes В 21.8% 6.3%
Dukes C 32.9% 23.6%
Isono—Barbier
esophageal cc 50%* 5.3%
*Transmediastinal oesophagectomy
26 nodes in  the specimen. 1096 underwent rad ica l lymphadenectomy w ith 26 or more nodes in  the 
specimen. The Rg-resection was one o f the strongest prognostic facto rs on m u ltiva ria te  analy­
s is .  The frequency o f Rg-resections in  patients undergoing standard or rad ica l lymph node d is ­
se c tio n  re la ted  to the pT and pN categories were examined. Radical lymphadenectomy s ig n if ic a n t­
l y  increased the ra te  o f Rg-resections in  patients w ith  pT2 , pTj or pT^ tumours and in  those 
w ith  pNg, pNj or pN2 lymph node s ta tus .
ad 4 . Lymphadenectomy as p ro p h y la x is  o f lo c a l  re c u rre n c e s .
There i s  a g re a t  chance fo r  a lo c o ré g io n a l re cu rren ce  i f  lymph nodes 
i n f i l t r a t e d  by carcinom a a re  l e f t  .behind. These p o s it iv e  lo c o ré g io n a l lymph 
nodes a f f e c t  th e  q u a l i t y  o f  l i f e  and an a d d i t io n a l  aggressive  th e ra p y  i s  
o f te n  re q u ir e d . C o n s id e rin g  t h is  asp ec t, a lymphadenectomy appears to  be in ­
d ic a te d  a ls o  fo r  advanced s ta g e s , because i t  w i l l  h e lp  to  ach ieve  r e g io n a l  
tum our c le a ra n c e  which i s  p ro g n o s tic a lly  i r r e le v a n t  y e t is  im p o rta n t fo r  
l o c a l  re c u rre n c e .
T ab le  I  shows t h a t  tumour recu rren ce  a f t e r  rectum o p e ra tio n s  w ith  
lym phadenectom y was reduced  to  i t s  h a l f  / 3 ,  8 / .  The rec u rre n c e  a f t e r  RQ 
o eso ph agea l re s e c t io n s  was 5.3% in  S ie w e r t 's  m a te r ia l  / 1 8 / .  T h is  low  lo c a l  
re c u rre n c e  r a te  is  e s p e c ia l ly  re le v a n t  i f  compared w ith  the  r a t e  o f  lo c a l  
re c u rre n c e  fo llo w in g  t ra n s m e d ia s tin a l b lu n t  d is s e c t io n  o f the  oesophagus. 
B a r b ie r  / 2 /  found lo c a l  re c u rre n c e s  in  more th a n  50% o f cases fo l lo w in g  an 
in c o m p le te  lymphadenectom y. S ie w e rt and Lange / 1 7 /  re p o rte d  on a d ecrease  o f  
l o c a l  re c u rre n c e  from  20% to  6.9% in  p a t ie n ts  w ith  g a s t r ic  cancer t r e a te d  
w ith  an adequate lym phadenectom y.
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Table I I
5-year surv iva l a fte r  standard and extended 
lymphadenectomy in  patients w ith re c ta l cancer
Standard
n:245
Extended
n:192
Dukes A 87% 95%
Oukes В 61% P <  0.05 88%
Dukes C 43% P <  0.05 74%
Nakayama and N is h i / 1 5 /  analysed th e  ty p e  and inc idence  o f  re c u rre n c e s  
in  2523 p a t ie n ts  who d ie d  o f stomach cancer a f t e r  su rgery . The most common 
typ e  o f  re la p s e  was p e r ito n e a l d is s e m in a tio n  (43% ), fo llo w ed  by haem ato- 
genous m e ta s ta s is  (2 4 .9 % ). S u rg ic a l f a i l u r e  accounted fo r  32%, lo c a l  r e c u r ­
ren ce  f o r  18.6%' rem ote lym p hatic  spread fo r  11%, and stump re c u rre n c e  fo r  
2.4% o f  th e  le t h a l  outcome. These d ata  a re  p ro m is ing  from th e  s u r g ic a l  p o in t  
o f v ie w , f o r  w ith  adequate lymphadenectomy and r a d ic a l i t y  an im provem ent in  
p ro g n o s is  can be ach ieved  in  30% o f a l l  ca s es .
ad 5 . The main purpose o f th e  lymphadenectomy is  to  im prove th e  prog ­
n o s is . G a l l  / 5 /  compared th e  5 -y e a r s u r v iv a l  r a te s  a f t e r  extended and s ta n ­
dard  lymphadenectomy in  p a t ie n ts  w ith  c o lo n ic  and r e c ta l  cancer ( F i g .  1 ) .  
The 5 -y e a r  s u r v iv a l was 80.9% versus 64.3%  fo r  c o lo n ic  cancer and 66.3%  
versu s  48.6%  fo r  rectum  can cer. Hojo / 8 /  dem onstrated  a s ig n i f ic a n t  im prove­
ment in  s u r v iv a l  fo r  p a t ie n ts  w ith  Dukes В and C r e c t a l  cancer (T a b le  I I ) .
Maruyama / 1 3 /  j u s t i f i e d  th e  u s e fu ln e s s  o f lymphadenectomy in  a b ig  
stomach cancer p a t ie n ts  c o l le c t iv e .  In  th e  German G a s tr ic  Cancer S tu d y  / 1 9 /  
r a d ic a l  d is s e c tio n  s ig n i f ic a n t ly  improved th e  s u r v iv a l ra te  in  p a t ie n t s  w ith  
UICC s ta g e s  I I  and I I I A .  R ad ic a l lymphadenectomy co n ferred  no s u r v iv a l  ad­
vantage  in  p a t ie n ts  w ith  pN£ tum ours.
Ison o  / 1 0 /  has re c e n t ly  analysed in  a Japanese c o l la b o r a t iv e  n a t io n ­
wide s tu d y  to  show w hether th e re  is  a p ro g n o s tic  b e n e f it  by th e  t h r e e - f i e l d  
lymphadenectomy as compared to  th e  2 - f i e l d  lymphadenectomy (F ig .  2 ) .  Out o f  
4590 re s e c te d  p a t ie n ts  1791 were t r e a te d  w ith  t h r e e - f ie ld  lym phadenectom y, 
2799 by a t w o - f ie ld  lymphadenectomy. O v e ra ll  th e  t h r e e - f ie ld  lym phadenectomy  
im proved th e  5 -y e a r  s u r v iv a l  r a te  up to  10% as compared to  t w o - f ie ld  lym pha­
denectom y. W ith in  th e  s in g le  subgroups i t  seems th a t  a p ro g n o s tic  b e n e f i t  
can be ach ieved  fo r  e a r ly  stages o f lymph node m étastasés b u t n o t  f o r  pa­
t i e n t s  w ith o u t o r w ith  advanced nodal m é ta s ta s é s .
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Table I I I
Operating time, blood loss and complications a fte r 
standard and extended lymphadenectomy fo r  re c ta l cancer
Standard
n:245
Extended
n:192
Operating time 288 min 312 min
Blood loss 1500 ml 1900 ml
Anast. in s u f f . 16.9% 22.8%
In fe c tio n 8.2% 6.8%
Ile u s 4.1% 4.1%
U rinary-vo id ing  fa ilu re 8.8% 39.4%
Impotency 40% 75%
I t  seems th a t  a number o f p a t ie n ts  w ith  lymph node invo lvem ent can be 
c u re d  by these te c h n iq u e s  and, a lso  when cu re  i s  n o t o b ta in e d , th e s e  p ro ­
c e d u re s  o f f e r  th e  b e s t lo c a l  c o n tro l o f  c a n c e r w ith  a low er in c id e n c e  o f  
r e g io n a l  re c u rre n c e s . However, using these  te c h n iq u e s , p o s to p e ra tiv e  m o rb i­
d i t y  and m o r ta l i ty  a re  n o t n e g l ig ib le ,  e s p e c ia l ly  in  p a t ie n ts  w ith  oeso­
p h a g e a l and r e c t a l  c a n c e r. The o p e ra tin g  tim e  o f  a t h r e e - f ie ld  lym phadenec- 
tomy is  7 -8  h . The in c id e n c e  o f la ry n g e a l n e rv e  p a ra ly s is  and t ra c h e o ­
b r o n c h ia l  ischaem ia i s  v e ry  h ig h  / 1 6 / .  The p o s to p e ra tiv e  m o rb id ity  and mor­
t a l i t y  r a t e  is  a ls o  h ig h e r  in  p a t ie n ts  w ith  r e c t a l  cancer t r e a te d  w ith  w ide  
i l e o p e lv ic  lymphadenectomy (T a b le  I I I ) .  Hojo / 8 /  re p o rte d  th a t  th e  r a d ic a l  
i l i o p e l v i c  lymphadenectomy was successfu l as f o r  as decreasing  th e  in c id e n c e  
o f  lo c a l  re c u rre n c e  and a ls o  in  p ro lo ng ing  s u r i v a l ,  th e re  were in c re a s e d  i n ­
c id e n c e s  o f u r in a r y -v o id in g  f a i lu r e  and s e x u a l im potency. Extended lym pha­
denectom y does n o t in c re a s e  th e  m o rb id ity  and m o r ta l i ty  a f t e r  r e s e c t io n  o f  
g a s t r ic  and c o lo n ic  c a n c e r / 9 ,  1 9 / .
P re lim in a ry  r e s u l t s  suggest th a t  a more a c c u ra te  s u rg ic a l s ta g in g  and , 
c o n s e q u e n tly , a more r e a l i s t i c  lo n g -te rm  p ro g n o s is  i s  p rovided  by ex ten d ed  
lym phadenectom y. These reasons emphasize th e  im portance o f ex tended  lymph  
node d is s e c tio n  a t  le a s t  fo r  s e lec te d  ca rc in o m a s , depending upon th e  s ta g e  
and th e  lo a d -b e a r in g  c a p a c ity  o f the  p a t ie n t .
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BONE TUMOURS IN  CHILDHOOD
T .  V IZ K E L E T Y
O rth op aed ic  Departm ent o f Semmelweis U n iv e r s ity  M ed ica l S c h o o l, 
Budapest, Hungary
(R ece ived : September 2 3 , 1994)
The author gives a survey o f lite ra tu re  on bone tumours in  childhood and a comparison 
w ith  h is  own work. Introducing four cases he concluded, th a t the surv iva l ra te  o f malignant 
bone tumours are increasing, the autologous bone transp lan ta tion  seems to take p r io r i t y  against 
p rosthesis in  childhood, and the autologous bone transp lan ta tion  is  more re lia b le  method, than 
the homologous one.
Keywords : Bone tumours, autologous bone g ra f t ,  homologous bone g ra ft
In t r o d u c t io n
Because o f  t h e i r  more fre q u e n t appearance in  c h ild re n  th e  im p o rtan c e  
o f  bone tumours is  much h ig h e r in  c h ild re n  then in  a d u lts . The in c id e n c e  o f  
th e  m a lig n a n t bone tumours is  in  g e n e ra l 0 . 5 4 ,  and i t  is  5.6% under 15 y e a rs  
o f  age / 1 ,  2 ,  5 , 8 , 9 / .  5% o f th e  s o l id  tum ours in  ch ildhood and 60% o f  th e  
m a lig n a n t bone tumours a re  osteosarcom a, which occurs most o fte n  / 1 0 / .  The 
n e x t  la r g e s t  group is  Ewing sarcom a, w ith  3-6% in  s o lid  tumours and w ith  30% 
in  m a lig n a n t bone tumours / 1 ,  1 1 / .
The appearance o f the malignant bone tumours is  d iffe re n t in  childhood from those en­
countered in the adulthood. Meanwhile the malignant tumours in  adulthood are mainly carcinomas 
and th e ir  lo c a liza tio n  is  lung, kidney, breast and digestion system in  order, the p a e d ia tr ic  
tumours are mainly sarcomas in  the haemopoietic, re ticu loendo the lia l and nervous system, in  the 
muscles, bones and kidneys. In  childhood the lo c a liz a tio n  and the development o f the tumour is  
m ainly a t the place and in  the time o f the in tensive growth.
The age d is t r ib u t io n  ( i n  y e a rs ) o f  osteosarcom a is  as fo llo w s :
O ffp r in t requests should be sent to : T. V izkeley, Orthopaedic Department o f Semmelweis 
U n ive rs ity  Medical School, H-1113 Budapest, Karolina ú t 27, Hungary
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8% in  th e  f i r s t  decade, from age 1 to  9 ,
60% in  th e  f i r s t  tw en ty  years ( 1 -1 9 )  and
32% la t e r .
Concerning th e  lo c a l i z a t io n ,  osteosarcom as a re  very  near to  th e  grow th  
p la t e  in  the  m etaph ys is  o f  long bones, where th e  growth is  f a s t  ( d i s t a l  f e ­
m o ra l and p ro x im a l t i b i a l  end, p roxim al p a r t  o f  th e  humerus and d is t a l  end 
o f  th e  fo rearm ) / 6 / .  The osteosarcoma occurs  e a r l i e r  in  g i r l s  th an  in  boys 
as i t  happens w ith  bodygrow th as w e l l .  The c h i ld r e n  w ith  osteosarcom a a re  
much t a l l e r  than th e  h e a lth y  ones / 4 / .
I t  is  a s p e c ia l  problem  in  ch ildhood  t h a t  h e r e d ita ry  bone d y s p la s ia s ,  
w hich are  tu m o u r - l ik e  la e s io n s  (m u lt ip le x  and s o l i t a r y  enchondroma, o s te o ­
chondroma, f ib r o u s  d y s p la s ia )  can be tra n s fo rm e d  m a lig n a n tly . B enign bone 
tum ours and tu m o u r - l ik e  la e s io n s  in  ch ild h o o d  in  th e  agg ress ive  s ta g e  may 
r e q u ir e  s u rg ic a l in te r v e n t io n  s im ila r  to  th e s e  re q u ire d  by m a lig n a n t d is ­
e a s e s . Bone tum ours in  ch ild ho od  are  b io lo g ic a l ly  more a c t iv e  and may show 
f a s t  c e l lu la r  g ro w th . The s o ft  t is s u e  i n f i l t r a t i o n ,  th e  m e ta s ta s is  and th e  
d e te r io r a t io n  in  g e n e ra l h e a lth  a re  th e  main c h a r a c te r is t ic s .
The success in  th e  tre a tm e n t o f m a lig n a n t tumours in c lu d in g  bone t u ­
m ours, has im proved w i th in  the  la s t  5 y e a rs . The s u r v iv a l r a te  fo l lo w in g  pure  
s u r g ic a l  in te r v e n t io n  in  th e  e a r ly  years  was around 20%, but th e  in t r o d u c t io n  
o f  r a d io -  and chem otherapy ra is e d  th e  s l i g h t l y  more than  5 -y e a r s u r v iv a l  up to  
65%. Limb saving  s u rg e ry  has become a r e a l i t y .  C h ild re n  w ith  m a lig n a n t bone 
tum ours have more chance to  s u rv iv e , th e r e f o r e ,  th e  s e le c t io n  o f  s u r g ic a l  
method is  im p o r ta n t , p ro v id in g  a good q u a l i t y  o f  l i f e  fo r  y e a rs . The tumour 
s u rg e ry  in  ch ild h o o d  may be le s s  a g g ress ive  when i t  is  aimed a t  e r a d ic a t in g  
th e  tumour: t h is  i s  e q u a l ly  v a l id  fo r  r a d io - ,  chemo- and s u r g ic a l th e ra p y .  
I t  should be keen to  r e s to r e  the  a na tom ica l and fu n c t io n a l c o n d it io n .
Concerning the p o s s ib i l i t ie s  in reconstruction the bone transplantation and the tumour 
prosthesis are very good examples. The reconstruction could be achieved fo r ever w ith  a good 
bone transplantation, but the implanted tumour prosthesis in  childhood requires rev is io n  in  the 
successfully treated cases.
M a t e r ia ls ,  o b s e rv a tio n s , case re p o r ts
The H ungarian  Bone Tumour R e g is te r i s  o p e ra tin g  in  th e  O rth o p ae d ic  
Departm ent o f o ur U n iv e r s it y :  80% o f th e  p rim a ry  tumour cases a re  t r e a te d  
th e r e .  The d is t r ib u t io n  o f  the re g is te re d  tum ours is  shown in  T ab le  I .
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Fig. 1, a. A 3-year-old boy. Benign osteoblastoma w ith  secondary aneurysmal bone cys t in  the 
proximal metaphysis o f the r ig h t  humerus, b. Following the metaphysis was resected, the contra­
la te ra l f ib u la  segment was transplanted, c. Three months postoperatively. The f ib u la  was 
incorporated, d. Six and e ig h t years postoperatively.The appearance is  the same on both sides
As i t  was m entioned b e fo re , in  some cases o f benign tum ours and 
tu m o u r- lik e  d is e a s e s , r a d ic a l  s u rg ic a l in te r v e n t io n  may be r e q u ir e d .  The 
chem otherapy as recommended by COSS fo r  p a t ie n ts  w ith  osteosarcom a and by 
CESS f o r  Ewing sarcoma cases was perform ed in  th e  U n d  P a e d ia tr ic  D epartm ent 
o f our U n iv e r s it y .  R ad io th erap y  was perfo rm ed  in  the  Ewing sarcoma cases in  
a d d it io n .  Our s u r g ic a l  o p p o r tu n it ie s  a re  dem onstrated  in  th e  fo l lo w in g  case  
re p o r ts .
Case 1. A 3-year-o ld  boy suffered from a spontaneous fractu re  of the proximal metaphy­
s is  o f h is  r ig h t  humerus (F ig . 1 ). Aneurysmal bone cyst was suspected, there fore  segment re ­
section was performed and con tra la te ra l autologous f ib u la  g ra ft  a successful reconstruc tion  
was achieved by. The bone incorporated w e ll, healed w ith  minimal abbreviation and the f ib u la  
was regrown from the periosteum. The histology showed benign osteoblastoma w ith  secondary 
aneurysmal bone cyst.
Case 2. A 12-year-old boy had centra l chondroma in  the proximal th ird  o f the l e f t  femur, 
i t  tended to transfrom m alignantly (Fig. 2 ). The femur was resected, and we were able to  
preserve the proximal metaphysis, assuring the autologous f ib u la r  transplantation s ta b ile .  F o l­
lowing the postoperative procedure, orthesis was app lied . Playing foo tba ll a fte r  the o rthes is  
was unlocked and the f ib u la r  g ra ft  was fractured (F ig . 3 ). The fracture  was healed in  p la s te r. 
The c h ild  grew t a l l  and the a ffected  l in t  was 5 cm shorte r than the opposite one, consequently, 
the r ig h t  leg was shortened. The f in a l resu lt was a 175 cm t a l l  ch ild , w ith the same leg leng th.
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F ig . 2 . a. A 12-years-old boy. Chondroma in  the proximal metaphysis of the l e f t  femur, 
b . Resection, fib u la  tran sp la n ta tio n , c. Three months postoperatively.S igns o f inco rpo ra tion , 
d. One year postoperatively.Remodellation, thickened fibu la
Case 3. A 13-year-old boy w ith  in tra c o rt ic a l osteosarcoma in  the d is ta l and la te ra l 
p a r t  o f  the le f t  t ib ia  (F ig . A ). Following enlarged resection  the bone was healed and the re ­
m ode lla tion  was complete. A fte r 8 years surgery the p a tie n t was symptomfree. This was the case, 
in  which the moderate a g g ress iv ity  lead to  success.
Case 4. A 14-year-old g i r l  w ith  osteosarcoma in  the d is ta l th ird  of the l e f t  t ib ia  
(F ig .  5 ) .  Unfortunately the case due to  enlarged tumour was not suitable fo r limb saving su r­
g e ry , bu t because o f the paren ts ' objection against amputation, rad ica l resection and f ib u la  
tra n sp la n ta tio n  were ca rried  o u t. The fib u la  incorporaiton was good, but, due to  recurrency in  
the  c o n tra la te ra l knee and lung metastasis, the p a tie n t was lo s t  2 years a fte r the opera tion .
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F ig , 4, a. A 13-year-old boy. In tra c o rt ic a l osteosarcoma in  the d is ta l metaphysis o f the le f t  
t ib ia ,  b. Large resection, c —d. One and two years postop. Fast re s t itu t io n
F ig . 3. The same pa tie n t, a. Fractured transplanted f ib u la ,  b. Healing in  p la s te r, c—d. Two 
and fou r years postop. The transplanted fib u la  is  enlarged, complete recana liza tion
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F ig . 3. a. A 14-year-old g i r l .  Osteosarcoma in  the d is ta l metaphysis o f the l e f t  t ib ia ,  
b . Radical resection, f ib u la  transplantation, c . Good incorporation, f u l l  weight-bearing
D iscuss io n
According to  th e  l i t e r a t u r e  and c o n c e rn in g  our re s u lts  th e  s u r v iv a l  
r a t e  o f  th e  m a lig n a n t bone tumours has been in c re a s e d  due to  th e  modern m u l­
t i d i s c i p l i n a r y  c o -o p e ra t io n  in  the  tre a tm e n t .
In  p a e d ia tr ic  c a s e s , s u r v iv a l tim e  has been p ro longed, so th e  p re s e n t  
p ro b le m  to  be so lved  has been s h if te d  to  th e  o ld  age. The bone t r a n s p la n t a ­
t i o n ,  which re q u ire s  more c o -o p e ra tio n  and more t im e , seems to  ta k e  p r i o r i t y  
a g a in s t  p ro s th e s is .
In  the  m eantim e, p ap ers  have been p u b lis h e d  about success w ith  homo­
lo g o u s  bone and c a r t i la g e -b o n e  t r a n s p la n ta t io n ,  and th e  au to lo g o u s  bone 
t r a n s p la n ta t io n  seems to  be a more r e l i a b le  m ethod. F o r tu n a te ly , we have two  
f i b u la e ,  so , us in g  e i t h e r  one or b o th , augmented w ith  ca n c e llo u s  bone fro m  
th e  i l i a c  c re a s t ,  we a re  a b le  to  so lve  most o f  th e  problems.
The problem  c o u ld  be so lved  fo r  e v e r u s in g  autologous bone t r a n s p la n ­
t a t i o n ,  and th e  chance d o in g  any o th e r c o r r e c t io n  ( e .g .  e lo n g a t io n )  i s  s t i l l
t h e r e .
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NEW ASPECTS IN THE TREATMENT OF BONE SARCOMAS
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O rth op aed ic  Departm ent o f th e  Semmelweis M ed ica l U n iv e r s it y ,  
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(R ece ived : Septem ber 2 3 , 1994)
The author reports on the progress made in  the treatment o f bone tumours in  the la s t 
two decades. There is  a short descrip tion o f new e n t it ie s  l ik e  the so lid  form o f  aneurysmal 
bone cys t; ded iffe ren tia ted  and c le a r-c e ll chrondrosarcoma; low malignant cen tra l osteosarcoma; 
pe rio s te a l and high-grade surface osteosarcoma, which have recently been reported in  the 
l i te ra tu re .  The response to  the chemotherapy in  osteosarcoma and the problems o f lim b-saving 
surgery in  bone tumours are discussed.
Keywords : Bone tumours, chemotherapy, lin b  saving surgery
Survey
Bone tum our c e n tre s , in te r n a t io n a l  c o l la b o r a t io n s
The la s t  two decades have brought s ig n i f ic a n t  changes in  th e  t re a tm e n t  
o f  bone sarcom as. In  th e  p a s t, th e  h is to lo g y  and the  s u rg ic a l t r e a tm e n t  o f  
bone tum our p a t ie n ts  w ere perform ed in  th e  p a th o lo g ic a l and s u r g ic a l  d e p a r t ­
ments o f  g e n e ra l h o s p ita ls .  C o ns idering  th e  m oderate ly  fre q u e n t o c c u rre n c e  
o f  th e s e  tumours — e .g .  th e  inc id ence  o f  osteosarcom a is  about 1 . 5 / m i l l i o n /  
y e a r — o ur e f f o r t s  f a i l e d  in  th e  d ia g n o s t ic  procedure and t r e a tm e n t .  T h is  
problem  was f i r s t  reco g n ize d  by Codman, who founded subsequently  th e  Bone 
Sarcoma R e g is try  in  1920 in  th e  USA. The aim  o f  t h is  R e g is try  was th e  h is ­
t o lo g ic a l  c la s s i f ic a t io n  o f  tumours b e s id e s  re c o rd in g  d ata . G re a t p e r s o n a l i ­
t i e s ,  l i k e  P h em is ter, who d is t in g u is h e d  th e  chondrosarcomas from  o s te o s a r ­
comas; P a rk e r and Jackson, who d es c rib e d  th e  r e t ic u lu m -c e ll  sarcom a o f  th e  
bone in  1939; o r Ew ing, who c h a ra c te r iz e d  h is  ro u n d -c e ll  sarcoma on b a s is  o f  
2000 r e t r o s p e c t iv e ly  ana lysed  bone tum ours, h a ll-m a rk e d  th is  w ork.
O ffp r in t requests should be sent to : M. Szendrói, Orthopaedics Department, Semmelweis 
Medical U n ive rs ity , H-1113 Budapest, Karolina ú t 27, Hungary
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F ia , la .  Solid form o f aneurysmal bone cyst. Pure l y t i c  le s io n  w ith  pathologic fra c tu re  o f the
humerus (anteroposterior view)
Bone tumour r e g i s t r i e s  were founded l a t e r  in  many c o u n tr ie s ; s p e c ia l ­
iz e d  r a d io lo g is ts ,  p a th o lo g is ts  and o n co lo g ic  surgeons have been w o rk in g  in  
c lo s e  c o lla b o r a t io n  in  B o log na , V ienna, P a r is ,  Birmingham and P ragu e , o n ly  
to  m ention the  g r e a te s t  c e n tre s  in  Europe.
Considering the low number o f the newly-recognized bone tumour cases (5-9 Ewings' sa r­
comas, 1-3 malignant fib ro u s  histiocytomas of the bone a year in  a 10 m illio n  popu la tion ), 
the re  has been an increasing demand to establish in te rn a tio n a l working-groups. This is  how the 
Arbeitsgemeinschaft fü r  Knochentumoren was founded in  the German-speaking world twenty years ago 
and the European Musculoskeletal Oncology Society (E.M.S.O.S.) in  1987. The Bone Tumour Regis­
t r y  o f our University is  founding renter in both o f the working-groups. The aim o f the in te r ­
n a tio n a l co llaboration is  to  characterize the c lin ico p a th o lo g ica l features o f ra re  bone 
tumours, to  elaborate new d iagnos tic  and therapeutic schedules and to evaluate the treatm ent 
re s u lts  on the basis o f u n if ie d  c r i te r ia .
W ith in  th e  in t e r n a t io n a l  c o lla b o r a t io n  th e  A rb e its g e m e in s c h a ft f ü r  
Knochentumoren re p o r te d  on 25 adamantinoma cases  and th e  E .M .S .O .S . e v a lu ­
a te d  th e  tre a tm e n t r e s u l t s  o f 677 g ia n t - c e l l  bone tum ours / 2 / .
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F ig , lb .  The cut surface o f the resected specimen presents a so lid  tumour
P rogress  in  th e  c la s s i f ic a t io n  o f bone tumours
The im p lem en ta tio n  o f new im m unohistochem ical tech n iq ues  and th e  c a re ­
f u l  e v a lu a t io n  o f la rg e  s e r ie s  o f  bone tum ours re s u lte d  in  d e s c r ip t io n  o f  
new tum our e n t i t ie s .
R e c e n tly , th e  s o l id  form  o f aneurysm al bone c ys t has been d e s c r ib e d  
/ 1 0 / .  The X -ra y  appearance o f  th e  pure l y t i c - c y s t i s  le s io n  i s  n o t c h a r a c te r ­
i s t i c  ( F ig .  l a ,  b ) ,  i t  i s  e a s i ly  m istaken  fo r  a g ia n t - c e l l  tum our o r  a t  
l e a s t  fo r  an osteosarcom a. The s o l id  v a r ia n t  o f  th e  aneurysm al bone c y s t  is  
composed o f  a f ib r o b la s t ic  pseudosarcom atous and f ib r o h is t io c y t ic  s trom a in  
w hich abundant o s te o c la s ts  and n ew ly-fo rm ed  bone tra b e c u le s  a re  p re s e n t .
V ery  r a r e  types o f th e  chondrogenic bone tumours a re  th e  d e f i f f e r e n -  
t i a t e d  and th e  c le a r - c e l l  chondrosarcom a, both  o f which were f i r s t  re v ie w e d  
in  th e  e a r ly  s e v e n tie s  / 1 ,  3 / .  The ra d io g ra p h ic  and h is to lo g ic  app earance  o f  
th e  l a t t e r  form  is  ve ry  s im i la r  to  th a t  o f  th e  chondroblastom a. Among th e  
c h a r a c t e r is t ic  tumour c e l ls  w ith  c le a r  cytoplasm a and s m a ll round  d ark
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n u c le i  s itu a te d  c e n t r a l l y  th e re  a re  numerous m u lt in u c le a te d  g ia n t  c e l l s  
s c a t te r e d  through th e  s tro m a . M étastasés occur seldom , s u r v iv a l is  fa v o u r ­
a b le .
A new e n t i t y  o f  th e  o s te o g e n e tic  bone tum ours i s  low m alig nan t c e n t r a l  
osteosarcom a / 1 4 / .  T h is  r a r e  form  o f osteosarcom a is  w e l l - d i f f e r e n t ia t e d ,  so 
t h a t  i t  is  o fte n  m is ta k e n  f o r  a benign process such as f ib ro u s  d y s p la s ia  o r  
n o n -o s s ify in g  fib rd m a  ( F i g .  2 ) .  The lo c a l  re c u rre n c e  r a te  is  h ig h , m éta­
s ta s é s ,  however, ap p ear r a r e l y .  Only th e  more c e l l u l a r  f ib ro u s  strom a and 
m ito s e s  r e fe r  to  th e  m a lig n a n cy  o f the  tum our.
The s o -c a lle d  p e r io s t e a l  osteosarcoma is  o fte n  not easy to  d i s t i n ­
g u is h  from  p a ro s te a l osteosarcom a / 1 3 / .  Both o f  them grow on th e  s u r fa c e  and 
d e s tro y  the  c o r t ic a l  bone in  an advanced s ta g e . In  c o n tra s t  to  th e  p a r o s te a l  
osteosarcom a, which a f f e c t s  th e  m etaphysis o f  lo n g  bones and grows s lo w ly ,  
p ro d u c in g  a la rg e  amount o f  bone, the  p e r io s te a l  osteosarcom a occurs on th e  
s u r fa c e  o f the  d ia p h y s is  and i t  is  composed o f  lo b u le s  o f c a r t i la g e  w ith
F in . 2. Low malignant c e n tra l osteosarcoma; fibrous d ysp la s ia -like  ly t ic -s c le ro t ic  destruction
o f the proximal t ib ia
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F in . За. P eriosteal osteosarcoma : minimal destruction o f the c o r t ic a l bone and wide s o ft- t is s u e  
extension (anteroposterior and la te ra l view)
c e n t r a l  bone fo rm a tio n . The p ro gn os is  is  b e t t e r  than  in  c o n v e n tio n a l o s te o ­
sarcoma b u t worse than in  p a r o s te a l osteosarcom a ( F ig .  3 a , b ) .
The h ig h -g ra d e  s u r fa c e  osteosarcoma is  th e  le a s t  common o f th e  o s te o ­
sarcom as. I t  occurs in  young p a t ie n ts  and p re s e n ts  th e  same h is t o lo g ic a l  
fe a tu r e s  as th e  c o n v e n tio n a l osteosarcom a. The p ro gn os is  i s  p o o r, th e  s o f t  
t is s u e  in v a s io n  is  u s u a lly  e x te n s iv e  even i f  th e  c o r t i c a l  bone i s  le s s  in ­
v o lv e d .
Response to  chem otherapy in  osteosarcoma
Some decades ago osteosarcom a was tho ug ht to  be a tumour r e s is t a n t  to  
chem otherapy. Rosen e t  a l .  / 7 /  f i r s t  re p o r te d  on th e  e f f ic a c y  o f  chemo­
th e ra p y  in  osteosarcom a based on h igh-dose m e th o th rex a te  and a d ria m y c in  in  
1 9 7 4 . The r a t i o  o f lung  m étas tasés  decreased and th e  f iv e - y e a r  s u r v iv a l  r a t e  
changed from  20% to  70%, even when lim b -s a v in g  s u rg e ry  was p e rfo rm e d . A lso
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F in . 3b. The surface o f the h a lf-c u t specimen: the intram edullar cav ity  is  not invaded
by the tumour
Rosen e t  a l .  / 8 /  p o in te d  to  th e  b e n e f ic ia l  e f f e c t  o f  th e  p re o p e ra t iv e  (n e o ­
a d ju v a n t )  chem otherapy. S hrinkage  and d em arca tio n  o f  th e  tum our o cc u rre d ;  
m e ta s ta s is  fo rm a tio n  due to  th e  procedure o f  th e  b iopsy was p re v e n te d ; the  
c h e m o th e r a p y -s e n s it iv ity  o f  th e  osteosarcoma can be e s tim a te d  by h is to lo g ­
i c a l  e v a lu a tio n  f o l lo w in g  th e  d e f in i t iv e  s u rg e ry .
The chem otherapy w i l l  be e f f e c t iv e  i f  more than  90% o f  th e  tumour 
c e l l s  appeare to  be d e s tro y e d  h is t o lo g ic a l ly .  Our Departm ent has been u s in g  
th e  m o rp h o log ica l e v a lu a t io n  o f the  c h e m o th e ra p y -s e n s it iv ity  in  osteosarcom a  
s in c e  1984. A ccording  to  l i t e r a r y  d ata  / 4 ,  1 2 /  we found a c lo s e  r e la t io n  be­
tw een  th e  h is t o lo g ic a l  s u b typ e s , the response to  chemotherapy o f  th e  o s te o ­
sarcom as and th e  f i v e - y e a r  s u r v iv a l r a t e .  F i f t y  to  60% o f th e  osteosarcom as  
a r e  w e ll-re s p o n d e r and have a s ig n i f ic a n t ly  b e t t e r  p rognosis  / 9 /  th an  th e  
non -resp on der ones.
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Changes in  th e  s u r g ic a l s tr a te g y  o f  bone tum ours
Some decades ago a b la t iv e  su rg e ry  p la y e d  the  main r o le  in  th e  t r e a t ­
ment o f  bone sarcomas. In  s p ite  o f  t h i s ,  n o t more than 20% o f th e  p a t ie n t s  
s u rv iv e d  th e  f i r s t  5 y e a rs . Due to  th e  e f f e c t i v e  chem otherapy, 50 to  75% o f  
th e  osteosarcom a and E w ing 's  sarcoma p a t ie n ts  have a chance f o r  s u r v iv a l  
/ 6 ,  1 1 / ,  even in  lim b -s a v in g  s u rg e ry . In  50 to  70% o f the  cases , l im b -s a v in g  
s u rg e ry  has became a r e a l  a l t e r n a t iv e  f o r  am putation . The b a s ic  c o n d it io n
ê
f o r  lim b -s p e a r in g  was th e  developm ent o f re c o n s tru c tiv e  s u r g ic a l te c h n iq u e s .  
B a s ic a l ly ,  th e  la rg e  d e fe c ts  o f th e  bone fo llo w in g  tumour re s e c t io n  can be 
re c o n s tru c te d  e i th e r  by a u to -  o r hom ografts  o r by tumour e n d o p ro s th e s e s . The 
in c o rp o r a t io n  and union o f (v a s c u la r iz e d )  a u to g ra fts  a re  s u p e r io r  t o  a l l  
o th e r  m ethods, th e y , however, can o n ly  be used as in te r c a la r y  g r a f t s  f o r  r e ­
p la c in g  d ia -m e ta p h y se a l d e fe c ts  in  most cases .
J o in t  s u rfa c e s  can be re p la c e d  by o s te o a r t ic u la r  hom og rafts . Many d i f ­
f e r e n t  p re s e rv in g  methods ( i r r a d i a t i o n ,  a u to c la v e  procedures, d e e p - f r e e z in g  
in  g ly c e r o l ,  e t c . )  a re  used in  bone banks — th a t  means th a t  no one s in g le  
p ro ced ure  a llo w s  e i t h e r  com plete in c o rp o r a t io n  o f th e  g r a f t  in t o  th e  host  
bone o r com plete s u r v iv a l o f  th e  c a r t i la g e  c e l ls  a t  the  s u r fa c e . These mas­
s iv e  o s te o a r t ic u la r  g r a f ts  alw ays rem ain  "dead" bones and, as a consequence, 
c o m p lic a tio n s  l i k e  m alun ion , fa c tu r e  o r in fe c t io n  occur in  a h ig h  p e rc e n ta g e  
o f th e  ca s es .
Tumour endoprostheses can a ls o  s e rv e  th e  re c o n s tru c tio n  o f  j o i n t  and 
bony d e fe c ts  / 5 / .  They a re  custom-made o r  m odular ty p e . The l a t t e r  one has  
th e  advan tage th a t  th e  e x a c t s iz e  o f th e  p ro s th e s is  can be e s t im a te d  ju s t  
a f t e r  th e  re s e c t io n  o f the  tumour a t  th e  o p e ra tio n  ta b le .  M odular ty p e s  o f  
endoprostheses  were developed in  th e  l a t e  s e v e n tie s  / 5 / ;  we have been  u s in g  
our own d es ig n  fo r  5 y e a rs . Tumour endoprostheses have th e  a d v a n ta g e  t h a t  
th e y  a llo w  a f u l l - r a n g e  m otion o f th e  j o i n t  and the  e x tr e m ity  can be 
w eigh ten ed  ju s t  a f t e r  th e  im p la n ta t io n . U n fo r tu n a te ly , however, th e  r i s k  o f  
th e  p ro s th e s is  loo sen in g  in c re a s e s  r a p id ly  a f t e r  the  f i r s t  y e a r s ,  and an 
e a r ly  re o p e ra tio n  is  n ecessary .
I t  is  s t i l l  an open q u e s tio n  w hether bone g r a f ts  o r tumour e n d o p ro s ­
th e s e s  shou ld  be used fo r  th e  r e c o n s tru c t io n . As mentioned above b o th  o f  
them have many advantages and d is a d v a n ta g e s , to o . The s u rg ic a l s t r a te g y  de­
pends on many fa c to r s ;  e .g .  on h is t o lo g ic a l  g rad ing  o f the tum ou r, on th e  
s u r g ic a l  s ta g e  o f th e  tum our, on the  lo c a l i z a t io n ,  on the  age and g e n e ra l  
c o n d it io n  o f  th e  p a t ie n t ,  on th e  p o s s i b i l i t i e s  and experience  o f  th e  s u r -
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g eo n . According to  o u r e x p e rie n c e , we r e p la c e  th e  d e fe c t by b o n e g ra ft  in  
young p a t ie n ts  w ith  fa v o u r a b le  l i f e  e x p e c ta n c ie s  and we use tumour endo­
p ro sth es e s  in  o ld e r  p a t ie n t s  w ith  less  fa v o u r a b le  s u r v iv a l  chances.
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OSTEOPOROSIS — A MODIFYING FACTOR OF SURGICAL 
TREATMENT
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Increasing knowledge o f f ra g ile  bone has been gained by non-invasive m ineral assess­
ments. I t s  fu tu re  importance seems to be twofold. F irs t  by, i t  seems l ik e ly  th a t pa tie n ts  w ith 
low bone mineral w i l l  be treated to  t r y  to  increase th is  bone mineral or a t le a s t to  keep i t  
steady. Secondly, in  the presence o f osteoporosis special s trag ies nust be taken in to  consi­
de ra tion . In  many locations osteoporotic fractures may need special so lu tions . I t  seems th a t 
osteosynthesis with plates and screws vbich have th e ir  d e fin ite  ind ica tions in  younger pa tients  
may be replaced by a lte rn a tive s , such as cerclage w ireing and intram edullary im plants. Poly- 
methylmetacrylate has been a good adjunct to  strengthen screw fix a tio n  and to  f i l l  defects 
a f te r  compression o f f ra g ile  cancellous bone.
Keywords: Osteoporosis, fra c tu re , operative procedure
In tro d u c t io n
T h is  rev iew  focuses  on th e  r o le  o f bone f r a g i l i t y  in  th e  tre a tm e n t  o f  
f r a c tu r e s  and o th e r o rth o p a e d ic  phenomena. There a re  d i f f e r e n t  a e t io lo g ie s  
o f  bone f r a g i l i t y ,  n o ta b ly  f a c to r s ,  such as age, sex , ra c e , l i f e  h a b i ts ,  
f a l l i n g  tendency and d i e t .  N o n -in v a s iv e  assessment o f bone m in e ra l i s  as ­
s ig n e d  in c re a s in g  im p ortan ce  in  th e  u nd erstand ing  o f o ste o p e n ic  f r a c tu r e s .  
Bone is  c a l le d  f r a g i l e  when i t  b reaks under le s s  than  a norm al lo a d .  In  t h is  
re v ie w , bone f r a g i l i t y  and o ste o p o ro s is  a re  used synonymously.
Two types o f in v o lu tio n a l osteoporosis have been delineated. Postmenopausal osteo­
porosis  is  designated Type I ,  whereas senile  osteoporosis occurring in  women and men a lik e , 
Type I I .  A combination o f the two types a ffec ts  d ra s tic a lly  the frac tu re  epidemiology dras­
t ic a l ly .
O ffp rin t requests should be sent to : M. Szendrói, Orthopaedics Department, Semmelweis 
Medical U n ivers ity , H-1113 Budapest, Karolina út 27, Hungary
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S evera l s tu d ie s  have shown th a t  th e  s tr e n g th  o f bone is  r e la te d  to  i t s  
m in e r a l c o n ten t. Reduced bone m in era l in  o s te o p o ro s is  reduces th e  h o ld in g  
pow er o f im p lan ts . Bones a re  e la s t ic  and th e y  adap t to  th e  lo a d s  o f  d a i ly  
l i f e  by r e c o i l in g .  I f  th e  lo a d  exceeds th e  y ie ld in g  p o in t ,  permanent d e fo r ­
m a tio n  and f r a c tu r e  e n s u re . However reduced bone m in e ra l is  th e  main cause  
o f  s u s c e p t ib i l i t y  to  f r a c t u r e  in  the  e ld e r ly .  In  a g e -re la te d  o s te o p o ro s is  
b o th  c o r t ic a l  and c a n c e llo u s  bone m in era l a re  reduced / 2 ,  4 , 6 / .
Problem s o f  th e  tre a tm e n t o f  o s te o p o ro t ic  p a t ie n ts
The trea tm en t p rob lem  in  an o s te o p o ro s is  f r a c tu r e  i s  tw o fo ld . Bone 
f r a g i l i t y  reduces th e  p o s s i b i l i t i e s  o f secure  f i x a t io n  and th e  o ld  p a t ie n t  
may be d e b i l i t a t e d ,  th u s  th e  r is k s  o f o p e ra tio n  w i l l  be in c re a s e d . T h e re fo re  
o s te o p o ro t ic  f r a c tu r e s  i n  th e  e ld e r ly  a re  o f te n  t r e a te d  by sed m ethods. The 
l i t e r a t u r e  is  poor in  s y s te m a tic  c l in ic a l  s tu d ie s  o f  th e  e f f e c ts  o f  o s te o ­
p o r o s is  on in te r n a l  f i x a t i o n ,  and s p e c ia l s t r a te g ie s  fo r  t r e a t in g  f r a g i l a  
s tr u c tu r e s  are seldom a p p lie d  in  p re o p e ra tiv e  p la n n in g . Extreme bone f r a g i ­
l i t y  is  o fte n  e x p e rie n c e d  as an unexpected, d is a s tro u s  s i tu a t io n  i n t r a -  
o p e r a t iv e ly ;  screws do n o t h o ld , bone i s  s p l in te r e d  d u rin g  re d u c t io n  and 
f i x a t i o n  a tte m p ts . S p e c ia l  s o lu tio n s  have been suggested fo r  such s i tu a ­
t i o n s .  Screws can be f i x e d  w ith  n u ts , c e rc la g e  w ire in g  may hold  where screws  
lo o s e  t h e i r  g r ip s . In  ex trem e  s itu a t io n s  p o ly m e th y lm e ta c ry la te  cement has 
been  suggested / 5 .  8 / .  The problem is  th e  same w ith  im p a ired  im p la n t f i x a ­
t i o n  in  o s te o p o ro tic  b o n e . Reduced bone m in e ra l in  o s te o p o ro s is  reduces the  
h o ld in g  power o f im p la n ts  / 8 / .  There is  a r e la t io n s h ip  between th e  s e v e r i ty  
o f  osteop oros is  and th e  f i x a t io n  s tre n g th  o f  p e d ic le  screw s. The p u llo u t  
f o r c e  i s  doubled by bone cem ent.
S u rg ic a l p rocedures  m o d ified  by o s te o p o ro s is
The o p e ra tio n s  on th e  upper e x tr e m it ie s  n ever cause d i f f i c u l t i e s ,  l i k e  
th o s e  on the o th e r p a r ts  o f  the body. There i s  no w e ig h tb e a rin g  a t  th e  
f r a c t u r e  o f the  d is t a l  end o f  the  ra d iu s . However d i f f e r e n t ia t e d  tre a tm e n t  
o f  th e  ra d iu s  i s  o b v io u s ly  re q u ire d .
The most common ty p e s  o f  osteop oros is  f r a c tu r e  a re  th e  f r a c tu r e s  o f  
th e  h ip . S ta b le  f r a c tu r e s  may be t re a te d  more s im p le  than  communited ones.
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a
Fig, la . Gravis osteoporosis o f the dorsal vertebras
F ig, lb . Avascular necrosis o f the head o f the le f t  hip
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Fig. 2a. Osteoporosis o f vertebrae
F in , le .  Total cemented h ip  replacement
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Fig. 2c. Hip endoprosthesis was inserted
F ig. 2b. O s te o a rth ritis  o f the hip
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In  communited h ip  frac tu res  intramedullary polymethylmetacrylate has been used fo r  
f ix a t io n  o f the endoprosthesis and the resu lts  seem favourable, therefore endoprosthetic 
replacement has been recommended, even in  young pa tie n ts . Besides early weightbearing i t  a llows 
good periostea l healing (F ig . la ,  b, c, Fig. 2a, b, c ) .
The in tram edullary loca tion  o f cement also allows good periosteal healing. I t  seems 
th a t  fractu res o f the d is ta l  end o f the femoral sha ft in  the e lde rly  may do b e tte r  a f te r  
in tram edullary n a ilin g  than a f te r  an angled bladeplate osteosynthesis.
In  knee s u rg e ry  th e  presence o f o s te o p o ro s is  must be a lso  ta k e n  in t o  
c o n s id e ra t io n . Reduced bone m in era l c o n te n t in  o steop oros is  may cause d e­
f e c t s  — e .g .  com pression o f f r a g i le  c a n c e llo u s  bone. In  one o f our tum our­
l i k e  cases bone d e fe c t  was detected  in  th e  r i g h t  l a t e r a l  t i b i a l  c o n d y le . 
H is to lo g ic a l  e x a m in a tio n  re v e a le d  the presence o f  o s teo p o ro s is . For such a 
good a lignm ent o f th e  fe m o r o - t ib ia l  a x is  v a ru s  fe m o ra l osteotomy was c a r r ie d  
o u t ( F ig .  3a , b ) . On th e  o th e r hand, a t  th e  p ro ce d u re  o f replacem ent i t  seems 
to  us reaso nab le  to  use b ic o n d y la r r a th e r  th a n  u n ic o n d y la r p ro s th e s is , th e  
u n ic o n d y la r typ e  can s in k  more e a s ily  in to  th e  p a r o t ic  u nd erly ing  bone.
F ig . За. Tumour-like cond ition  o f the r ig h t la te ra l t i b i a l  condyle. H isto log ica l examination
revealed osteoporosis
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In  th e  o th e r case b ic o n d y la r  knee p ro s th e s is  was loosened w i th in  ten  
months fo l lo w in g  o p e ra tio n  (F ig .  4 a , b ) .
In  sp ine  surgery  o f o s te o p o ro s is  s p e c ia l s tr a te g ie s  must be taken  
in to  c o n s id e r a t io n . The s p e c ia l n a tu re  o f  o s te o p o ro tic  bone t h a t  l i m i t s  the  
ch o ic e  o f  f ix a t io n  methods should be c le a r ly  understood. The f i x a t i o n  o f  
s h o rt segments by p e d ic u la r  screws and p la t e  seems to  be r i s k f u l  in  o s te o -  
p o r a t ic  p a t ie n ts .  S t a b i l i t y  in  p o r o t ic  v e r te b r a l  coloumn can be o n ly  
a c h ie v e d  by f ix a t io n  o f lo n g er segments (CD o r USIS in s tru m e n ta t io n , e t c . )  
( F ig .  5 a , b , c , d ) .
Fig. 3b. Varus femoral osteotomy was carried out
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F ig . 4b. Loosening o f the prosthesis
F in. 4a. B icondylar knee prosthesis in  good position
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F ig . 5a. S te ife  instrumentation fo r s ta b il iz a t io n  o f the lurrbar spine 
(anteroposterior view)
C o n c l u s i o n s
The p a t ie n ts  w ith  low m in e ra l c o n te n t sho u ld  be tre a te d  to  t r y  to  in ­
c rease  t h e i r  bone m in e ra l .  O rthopaed ic p ro ced ures  may need s p e c ia l s o lu t io n s  
acco rd in g  to  th e  extrem e bone f r a g i l i t y .  In t e r n a l  f ix a t io n  should  be com­
b in ed  w ith  a d ju v a n ts  as bone cement o r c e rc la g e .
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Fig. 5b. La te ra l view
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F ig . 5c. The f ix a tio n  o f pedicular srews is  poor (anteroposterior view)
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CYTOKINES IN  TEE TREATftNT OF MALIGNANCIES
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(R e ce iv e d : September 2 3 , 1994)
Cytokines are p le io tro p ic  peptides produced by lymphoid c e lls  tha t play im portant ro les  
in  c e llu la r  p ro life ra tio n  and m u ltip lic a tio n . Diminished or enhanced production or c o n s titu t iv e  
secretion o f cytokines contributes to  the aetiology and pathogenesis o f several diseases. They 
are so luble mediators e l ic i t in g  s p e c ific  responses o f d iffe re n t ta rge t c e lls  o f paracrine, 
autocrine and cascade systems o f the organism. Their secretion is  regulated a t the molecular 
genetic le v e l.  Gene rearrangements o f cytokines and th e ir  receptors have been demonstrated in  
several diseases. As means o f s p e c ific  or supportive therapy, cytokine treatment has been used 
both in  neoplastic and other p ro li fe ra t iv e  diseases. Lymphokines and in te rfe rons comprise the 
f i r s t ,  whereas colony s tim ula ting  fac to rs  and growth fa c to rs  y ie ld  the second group o f  cyto­
k ines. Most s c ie n t if ic  experience is  w ith  in te rfe ron-a lpha . I t s  a n t i-v ira l mechanism o f action 
has been extensively studied and c la r if ie d ,  vLiereas i t s  antitumour e ffe c t is  more obscure and 
is  a re s u lt  o f many simultaneous b io lo g ic  events.
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I n t r o d u c t i o n
C ytokines a re  p r o t e i n - l i k e  sm all m o lecu les  produced by lym phoid  and 
n on -lym p ho id  c e l l s .  By mechanism o f a c tio n  th e y  a re  s o lu b le  m e d ia to rs  e l i ­
c i t i n g  s p e c if ic  responses in  v a rio u s  c e l l s  in  p a ra c r in e  and a u to c r in e  sys­
tem s o r  both and in  pathw ays o f the  cascade r e a c t io n s .  The f i r s t  g roup  o f  
c y to k in e s  is  com prised o f  th e  lym phokines and in te r fe r o n s  ( IF N s ) ,  w hereas  
th e  second group in c lu d e s  th e  c o lo n y -s tim u la t in g  f a c to r s .  C ytok ines  a re  used 
in  d is e a s e s  c h a r a c te r iz e d  by m alignan t c e l l  o r r a th e r  m alig nan t t is s u e  p ro ­
l i f e r a t i o n  p a r t ly  as c a s u a l th e ra p e u tic  agen ts  and p a r t ly  as s u p p o rt iv e  
th e ra p y  a p p lie d  in  o rd e r  to  a l le v ia t e  u n d e s ira b le  s id e -e f fe c ts  r e s u l t in g  
fro m  o th e r th e ra p ie s . A ltho ug h  re p o rts  on t h e i r  e f f ic a c y  as c a s u a l th e r a ­
p e u t ic  agents a re  h ig h ly  c o n tro v e r s ia l and th e re  a re  c o n tro v e rs ie s  as fo r  
th e  l a t t e r  a p p l ic a t io n ,  we may g iv e  account o f  c o n s id e ra b ly  good r e s u l t s  in  
th e  l a t t e r  f i e l d  to o .
S u b je c ts
C ytokines a re  a c t u a l l y  s p e c ia l form s o f  p le io t r o p ic  proteohorm ones  
e x e r t in g  t h e i r  a c tio n  w i t h in  a "comm unication n e tw o rk " , th u s , p la y in g  an im ­
p o r ta n t  r o le  in  th e  com plex system o f c e l l  grow th  and c e l l - f u n c t io n in g .  
U n d e r- o r o v e r -p ro d u c tio n  o f  cy to k in e s  r e s u l ts  in  v a rio u s  p a th o lo g ic a l con­
d i t i o n s .  T h e ir  r e g u la t io n  is  m ediated v ia  g e n e t ic  fa c to r s  hence in  v a r io u s  
p a th o lo g ic a l s ta te s  th e  g e n e t ic  t ra n s p o s it io n  has been proved , nam ely, genes  
o f  a lp h a  and b eta  IFN  g e t  wiped o f f  /1 2 ,  3 4 / .
Inadequate  t r a n s c r ip t io n a l  a c t i v i t y  ( IRF 1 ) o f  th e  IF N -in d u c in g  gene 
seen in  leukaem ia and m ye lo d y s p la s ia  (p re le u k a e m ia !)  could  be t ra c e d  to  an 
a b n o rm a lity  in  chromosome 5q.
U n t i l  today about a hundred such m o lecu les  — corresponding  in  s t r u c ­
t u r e  and fu n c tio n  to  th e  above — have been d e s c r ib e d . Tab le  I  g iv e s  a c la s ­
s i f i c a t i o n  from th e  p o in t  o f  view  o f c l i n i c a l  p r a c t ic e .
C ytokines as l ig a n d s  and inducers  can e x e r t  t h e i r  in f lu e n c e  o n ly  in  
th e  presence o f t h e i r  r e c e p to rs  to  which th e y  g e t  a tta c h e d . The mode o f  t h is  
a tta c h m e n t is  n o t i n d i f f e r e n t  and as a consequence i t  in flu e n c e s  t h e i r  me­
chan ism  o f a c tio n  / 4 1 / .  A ccording to  our p re s e n t  knowledge, i t  works as a 
s ig n a l in g  system a f f e c t in g  u lt im a te ly  c e l l - l e v e l  processes.
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Table I
C lass ifica tion  o f in te rleuk ines
In terleukines IL 1-12
Cytotoxic
fac to rs TNF-a,e
In te rfe rons IFN-a, ß, у, ш /22, 23/
Colony-
s tim ula ting
facto rs
G-CSF, GM-CSF, M-CSF, EPO, IL-3
Growth factors EGF (EGF, TGF-a, VGF),
FGF-a,
FGF-ß,
TGF-ß (TGF-ß-1, TGF-ß-2, TGF-ß-3, Inhibines, MDIP, BMP), 
PDGF-1,
PDGF-2,
FGF-a, IL -2 ,
FGF-ß,
I1GF-1,
I1GF-2,
IL -1  ( IL - l - a ,  IL - l-ß ) ,
HST-2 ,
Boutes ui
A p art from  a few excep tio n s  ( I L - 1 ,  TNF, IF N -a lp h a , IF N -b e ta ) ,  a l l  
c y to k in e s  have t h e i r  own s p e c if ic  re c e p to rs  to  which they w i l l  a t t a c h  them ­
s e lv e s  and th e y  w i l l  n o t compete w ith  o th e r  c y to k in es  fo r  b in d in g  s i t e s .  
T h e ir  b in d in g  a f f i n i t y  i s  u s u a lly  h igh  (Kd = 10“ 11— lC f 10 m o l / l i t r e ) .  Due to  
t h is  h ig h  a f f i n i t y ,  10 -1 0 0  lig a n d s  a tta c h e d  to  re c e p to rs  a re  s u f f i c i e n t  to  
produce an a c t i v i t y  / 3 3 / .
There a re  two im p o rta n t c h a r a c te r is t ic s  o f  these re c e p to rs , i . e .  t h e i r  
ex p re ss io n  co u ld  be induced and they  have th e  a b i l i t y  to  m odulate upon th e  
e f f e c t  o f  t h e i r  own o r o th e r  lig a n d s . R e s tin g  lymphocytes e x h ib i t  e i t h e r  few  
( e .g .  IL -4 R )  o r u n d e te c ta b le  number ( e . g .  p 55 , IL -3 R ) o f v a r io u s  c y to k in e  
re c e p to rs , how ever, th e s e  cou ld  in c re a s e  in  number upon th e  e f f e c t  o f  c y to ­
k in e s  / 4 7 / .
The re c e p to r  found on th e  s u rfa c e  o r on th e  membrane o f th e  s u b c e l lu la r  
o rg a n e lle  i s  n o t id e n t ic a l  in  th e  case o f  many lig a n d s . For e x a m p le , IL -2  
may be bound by th re e  m o lecu les , how ever, th e  a f f i n i t y  o f each m o le c u le  is
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d i f f e r e n t .  As a con sequence, we may say t h a t  th e  f a c t  o f b in d in g  in  i t s e l f  
w ould not always r e s u l t  in  an id e n t ic a l  e f f e c t .  A t th e  same t im e , genomes 
o f  th e  m olecules a c t in g  as recep to rs  (p .  5 5 , p . 7 0 , and th e  two to g e th e r )  
seem to  be e n t i r e ly  d i f f e r e n t  from each o th e r  / 3 1 ,  3 6 / .
IL -4  and IL - 5  p la y  an im portant r o le  in  th e  express ion  o f re c e p to r  mo­
le c u le s .  These w ere exam ples  to  show th a t  even th e  re c e p to r i t s e l f  i s  n o t  
n e c e s s a r ily  a homogenous m olecule and th e  e x te n t  o f i t s  exp ress io n  i s  a 
fu n c t io n  o f th e  p re s e n c e  o f  o th er c y to k in e s . However, th e re  is  an o b s e rv a ­
t io n  th a t  in  case IL - 4  b in d s  to  i t s  own r e c e p to r ,  IL -2 R  express io n  i s  n o t  
enhanced f u r th e r ,  in  f a c t  i t  is  ra th e r d ec re as e d .
The fo reg o in g  a l lo w  us a glim pse in to  t h i s  com plicated  system w o rk in g  
in  a p a ra c rin e  fa s h io n  whereas the te c h n iq u e s  accum ulated in  m o le c u la r  
b io lo g y  a llow  i t  to  be in f lu e n c e d . The use o f  p u r i f i e d  recom binant c y to k in e s  
in  in fe c t io n s  and m a lig n a n t d iseases o r p a th o lo g ic a l  c o n d itio n s  w ith  bone 
marrow f a i lu r e  and immune d e fic ie n c y  is  n o t unan im ou sly , but w id e ly  a c c ep ted  
/ 6 ,  3 5 / .
S p e c if ic  a c t io n s  o f  a n t i-c y to k in e  a n t ib o d ie s  prompt us to  lo o k  f o r  
th e ra p e u t ic  p e r s p e c t iv e s . I t  has been p roven  t h a t  g en e ra lize d  e n d o th e l ia l  
a c t iv a t io n  is  th e  r e s u l t  o f  cy to k in e  a c t io n .  T h is  s ta te  has been c a l le d  SIRS  
(s y s te m ic  in fla m m a to ry  response syndrome). I t  shou ld  be noted th a t  c y to k in e s  
have no ro le  in  th e  m ain ten ance  o f normal hom eo stas is  / 1 3 / .  At th e  same t im e  
th e  above d es c rib e d  syndrome can be p re v e n te d  by TNF, IL -1  / 1 3 /  and a n t i ­
b o d ie s  to  IL -8  / 2 / .
B locking o f  TNF by monoclonal a n t ib o d ie s  / 1 ,  1 6 /  fo r  the  p re v e n t io n  o f  
E . c o li- in d u c e d  e n d o to x ic  shock has been t r i e d .  However, fo r  p r a c t ic a l  use  
s o lu b le  TNF re c e p to rs  w ou ld  have a more p ro m is in g  fu tu r e  — though i t  s h o u ld  
be emphasized h ere  t h a t  th e  in te rv e n tio n  i s  o f  use o n ly  p r io r  to  TNF b in d in g  
as  a fte rw a rd s  th e  c h a in  re a c t io n  cannot be s topped  any more / 3 ,  4 6 / .  U n fo r ­
tu n a te ly ,  i t s  use f o r  p re v e n tio n  has n o t been approved even though i t  i s  
known th a t  c y to k in e s  p la y  no r o le  in  norm al h om eo stas is . In  case o f  g e n e r a l­
l y  decreased immune re s p o n s e , p re v e n tive  a d m in is t r a t io n  o f s o lu b le  TNF r e ­
c e p to r  p re p a ra tio n  may le a d  to  death / 8 / .
Concluding from  th e  above we may say t h a t  th e re  a re  mechanisms to  
enhance both th e  p a r a c r in e  and, in  some r e s p e c t ,  th e  a u to c rin e  re a c t io n s  
(c y to k in e  synerg ism , c ascad es , enhanced e x p re s s io n  o f homologous and non - 
homologous re c e p to rs ,  an tigen -d epen den t c y to k in e  sy n th e s is  fo r  r e s t r i c t i o n  
o r  c o n tro l o f a l l ,  d ecreased  recep to r e x p re s s io n , c y to k in e  antagonism  o r  
s w itc h -c o n t r o l) .  I t  i s  a g re a t c h a llen g e  f o r  th e  c l in ic a l  p r a c t ic e  w hich
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r a t io n a le  to  fo llo w : enhance o r decrease im m u n o re a c tiv ity  by in f lu e n c in g  th e  
endogenous c y to k in e  s y n th e s is  o r c y to k in e  a d m in is tra t io n ?  Anyhow, g a in in g  
more exp e rie n c e  is  e s s e n t ia l .  Most e m p ir ic a l d a ta  round th e  w orld  have been 
c o l le c t e d  re g a rd in g  IF N -a lp h a . We, to o , f e e l  e n t i t le d  to  express o ur o p in io n  
in  t h i s  c o n te x t.
I t  was 37 years  ago th a t  a s ig n i f ic a n t  b io lo g ic a l  a c t i v i t y  o f  IF N -  
a lp h a  was f i r s t  d escrib ed  in  case o f m a lig nan t p ro cesses , n e v e r th e le s s , th e  
mode o f  a c tio n  o f t h is  c y to k in e  s t i l l  rem ains unknown / 1 1 / .  B est r e s u l t s  
w ere seen in  connection  w ith  h ae m a to lo g ica l d is o rd e rs  / 4 8 / .
The a n t i v i r a l  p ro p e rty  o f  IF N -a lp h a  has been more o r le s s  c l a r i f i e d  
/ 2 9 /  by now. IF N -a lp h a  prom otes th e  endonucleases and th e  p ro d u c tio n  o f  2 -5  
o lig o a d e n y la te  s y n th e ta s e , and these  p ro te in s  in  tu rn  le a d  to  th e  d e s tru c ­
t io n  o f  RNA-neg v i r io n .  On th e  o th e r hand, i t  h in d e rs  p ro te in  c o lo n iz a t io n ,  
e .g .  th e  p ro du ction  o f cytochrom e p. 450 enzyme 42 .
Many papers have been p u b lis h e d  in  o rd er to  c l a r i f y  th e  mechanism o f  
a c t io n  o f  IF N -a lp h a , how ever, p u t t in g  to g e th e r th e  p u z z le  b i t s  s t i l l  does 
n o t a llo w  us to  o b ta in  a c o h e re n t view  o f th e  s u b je c t . D ecreasing  o r  i n h i ­
b i t i n g  and in c re a s in g  o r  augm enting e f fe c ts  a re  summarized under " la t e s t  
r e s u l ts "  in  Tab les  I I  and I I I .
The two ta b le s  which a re  f a r  from com plete p re s e n t c l i n i c a l l y  s ig ­
n i f i c a n t  con c lu s io n s , f a r  from  being  com plete. L ik e  o th e r th e r a p ie s , IFN  ad­
m in is t r a t io n  has s id e  e f f e c t s .  However, to  la b e l  i t  as having " u n d e s ira b le  
s id e  e f fe c ts "  would not be c o r r e c t ,  as , in  case o f a b io lo g ic a l ly  a c t iv e  na­
t u r a l  substance, i t s  s id e  e f f e c ts  a re  in  f a c t  a p ro o f o f i t s  a c t i v i t y  / 2 4 / .
The expected b e n e f i t  o f  IF N -a lp h a  in  m a lig n an c ies  cannot be a t t r ib u t e d  
to  a s in g le  cause but r a th e r  to  a cha in  o f b io lo g ic a l  even ts  n o n -re d u c e a b le  
to  th e  same denom ination (T a b le  I V ) .
The most pronounced s t r u c t u r a l  change seen in  HCL fo llo w in g  IF N -a lp h a  
a d m in is t r a t io n  (F ig s  1 , 2 ) .
F o llo w in g  IF N -a lp h a  a d m in is tra t io n  not o n ly  e x te r n a l ly  v is ib le  changes  
—  te n d in g  towards r e v e r t in g  to  normal — a re  n o t ic e a b le  b u t b o th  in  th e  
h e a lth y  and p a th o lo g ic a l lym phocytes th e re  is  a s p e c ia l h is t o lo g ic a l  change  
in  th e  form  o f a tu b o r e t ic u la r  in c lu s io n  w ith in  th e  s u b c e llu la r  o r g a n e l le s .  
T h is  l a t t e r  o b s e rv a tio n  i s ,  how ever, not in  accordance w ith  th e  l i t e r a r y  
f in d in g s  where these changes a re  presumed to  occur o n ly  in  th e  c e l l s  a f f e c t ­
ed by th e  d isease  ( F ig .  3 ) / 1 8 / .
A c l in ic ia n  o fte n  enco un ters  immunosuppressive sequelae  o f m a lig n a n t  
d is e a s e s  in  th e  form  o f h erpes z o s te r  s k in  e ru p t io n s . The course  o f  th e
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Table I I
"Decreasing". " In h ib itin g " e ffe c ts  o f IFN-a
Features
Blocking o f DTH 
Antagonism against PDGF 
B locking o f growth increasing e f fe c t  o f IL -6  
Decreasing o f expression o f IgE-FcR I I .  (?)
Decreasing p a rt ic le  nunbers o f CD^  w ith  HIV in fec tion  
Down regulation o f oncogene expression 
IFN-y could defend a n tip ro life ra tiv e  e ffe c t on neuroblastic c e l l- l in e  
Decrease a c t iv ity  o f DNA-polymerase
Table I I I
" In c re a s in g ", "stim ulating" e ffe c ts  o f IFN-a
Features
Stim ulates thymocyte b la s t transformation 
Stimulates formation o f IFN-y 
Increases concentration o f IgE 
Increases t i t r e  of progesterone receptor 
Stim ulates formation o f IL-1 in  GM-CSF induced macrophages 
Increases t i t r e  o f ICAM-1
Increases expression of CD3 , CDg, CO2 3 , CD25 and CQ^ 
Increases t i t r e  o f anti-HBc Ag
Table IV
E ffe c t o f IFN-a in  tumourous diseases
Features
D irect cyto toxic e ffe c t
A n t ip ro life ra t iv e  e ffec t — by way tumour suppressor gene 
Decrease tumour c e ll s e n s it iv ity  against NK c e lls  
A c tiv a tio n  NK c e ll receptors through TAC antigens 
Change pharmacokinetics o f Alkeran 
Activation o f LAK c e lls
Synergism w ith  cy to to x ic  e ffec t o f a lk y la tin g  agents and Prednisolone
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F ig . 2. Lymphocyte In HCL, a fte r  the treatment
d is e a s e  cannot be in f lu e n c e d  much by IF N -a lp h a  th e ra p y . I t  should  be em­
p h a s iz e d , how ever, th a t  w h ile  g iven  c o n c o m ita n tly  w ith  the  s k in  e r u p t io n s ,  
p o s th e rp e tic  ro o t  p a in s  cou ld  be a b o lis h e d  and g en e ra lize d  spread  o f  th e  
le s io n s  was p re v e n te d  (F ig s  4 , 5 ) .
F ig . 1. Lymphocyte in  HCL, p r io r  to  treatment
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F ig . 3. T ubore ticu lar inclusions in  the cytoplasm o f lymphocyte
Based on our e x p e rie n c e s  we may say t h a t  a s h o rt term  ( 1 - 2  m onths) 
IF N -a lp h a  th e ra p y  w i l l  n o t  lead  to  u n d e s ira b le  s id e  e f fe c ts  a p a rt  fro m  th o s e  
m entioned  above, w hereas a long term , co n tin u o u s  IF N -a lp h a  a d m in is t ra t io n  
r e q u ir e s  fu r th e r  o b s e rv a t io n s , fo llo w -u p  and i s  d is p u ta b le  from th e  f o l lo w ­
in g  p o in ts  o f v ie w .
1 . In  th e  p resence  o f autoimmune d is e a s e  m arkers th e  a d m in is tra t io n  o f  
IF N -a lp h a  is  r is k y  as e .g .  in  C v iru s  c a r r i e r  CAH cases i t  may w orsen an 
imm une-m ediated h e p a to c y te  damage / 3 0 / .  T h is  p o s s ib i l i t y  should be k e p t  in  
m ind w ith  r is e  in  th e  am in o tra n s fe ras e  l e v e ls .  Even th e  in flam m ato ry  e x a c e r ­
b a t io n  may be o f  such a h ig h  degree in  p a t ie n ts  w ith  c ir r h o s is  o f  th e  l i v e r  
t h a t  u lt im a te ly  a h e p a t ic  f a i lu r e  may d eve lo p  /1 5 ,  2 6 / .
Data from l i t e r a t u r e  a re  c o n tro v e r s ia l in  t h is  re s p e c t, s in c e  enzyme 
l e v e ls  o f p a t ie n ts  in fe c te d  w ith  the  d e lta -a g e n t  r e v e r t  to  normal fo l lo w in g  
IF N -a lp h a  a d m in is t r a t io n .  Although a f t e r  d is c o n t in u a tio n  o f th e  tre a tm e n t  a 
re la p s e  may occur / 5 / .
2 . IF N -a lp h a  a d m in is t ra t io n  is  c o n tra in d ic a te d  in  p a t ie n ts  w ith  c h ro n ic  
a c t iv e  h e p a t i t is  (n o n -c a r r ie r s )  and autoimmune d iseases  in  re m is s io n  phase  
as t h i s  may le a d  to  e x a c e rb a tio n  o f th e  p ro cess  / 3 9 / .
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F ig . 5, Herpes zoster in  healing stadium
3 . 1% o f p a t ie n ts  who have undergone IF N -a lp h a  th e ra p y  have n e u t­
r a l i z i n g  a n t ib o d ie s , a lth o u g h , a n t ib o d ie s  may be found even in  cases  w ith  
no p r io r  h is to r y  o f tre a tm e n t / 4 9 / .  In  c l i n i c a l  p ra c tic e  one sh o u ld  th in k  
o f  the  presence o f a n tib o d ie s  when lo s s  o f  a p p e t ite  and weakness d is a p p e a r  
d u rin g  th e  t re a tm e n t. There a re  some p u b lic a t io n s  presuming a 30-60%  i n ­
c id e n c e  / 5 0 / .  The la t e s t  p u b lic a t io n s  c o n s id e r t h is  h igh  p e rc e n ta g e  to  be 
f a ls e  and d i f f e r e n t ia t e  between th e  im m unogenicity o f IF N -a lp h a -2 a  and
F ig . 4. Herpes zoster fa c ie i in  flo rib u s
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A-IgG
A-IgG
F ig. 6 . Patient sera (PS) a fte r  the treatment o f reconbinant in terferon-a lpha, 
w ith  antibody (IgG) against rIFN-alpha
A-lgA
A-lgA
Fig. 7, Patient sera (PS) a fte r  the treatment o f reconbinant in terferon-a lpha, 
w ith  antibody (IgA) against rIFN-alpha
IF N -a lp h a -2 b . In  th e  l a t t e r ,  the  in c id en ce  i s  < 3 %  as seen from th e  r e s u l ts  
p u b lis h e d  in  /4 3 ,  4 4 / .  We d etec ted  IgG and IgA  ty p e  a n tib o d ie s  in  HCL pa­
t i e n t s  on lo n g -te rm  ( 4 ,  5 y e a rs ) p e r io d ic  t re a tm e n t  w ith  our own a u to ra d io ­
g ra p h ic  technique (F ig s  6 ,  7 )  / 2 5 / .
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In  th e  fo l lo w in g , we summarize our p re s e n t knowledge.
P rod uction  o f a n t ib o d ie s  capab le o f complex fo rm a tio n  w ith  IF N -a lp h a  
is  dependent upon:
— th e  method and ty p e  o f IFN p ro d u c tio n  (b io lo g ic a l  o r reco m b inan t 
o r i t s  s u b ty p e s ),
— th e  dose o f  IFN  g iv e n ,
— th e  tim e p e r io d  o f  IFN tre a tm e n t,
— th e  ro u te  o f  a d m in is tra t io n  (sub cu tan eou s , in tra c u ta n e o u s , i n t r a ­
m u s c u la r, e t c . ) ,
— th e  typ e  o f  g e n e tic  background re p re s e n te d  by th e  p a t ie n t .
4 .  Upon fo llo w -u p  o f  69 p a t ie n ts  w ith  h a ir y  c e l l  leukaem ia — d ia g n o s ­
ed between 1983 and 1986 — we found th a t  13 o f them had some ty p e  o f  ma­
lig n a n c y  7 .5  years  l a t e r .  S ix  cases out o f  th e  13 developed a h a e m a to lo g ic a l 
m alig nan cy  / 2 7 / .
I t  has been proposed th a t  the  m a lig n an t change m ight be a r e s u l t  o f  
th e  decreased  im m unity fo l lo w in g  IF N -a lp h a -2 b  tre a tm e n t as w e ll  as o f  o th e r  
d i r e c t  e f f e c ts  o f IF N -a lp h a -2 b  on c e l l  p r o l i f e r a t io n  and m etabo lism . These 
a l t e r n a t iv e s  m ight be b ro ug ht to g e th e r even in  a s in g le  p ro cess . IF N -a lp h a  
i s  a b le  to  b lock  th e  p ro d u c tio n  o f  growth fa c to r s  in v o lv e d  in  th e  a u to c r in e  
r e g u la t io n  — a t th e  same tim e  enhancing th e  p ro d u c tio n  o f 2 -5  A s y n th e ta s e  
w h ic h , in  tu r n , reduces th e  le v e ls  o f TN F-alpha c o n c e n tra tio n  a f f e c t in g  n ot 
o n ly  th e  c e l l  m etabolism  o f tumour c e l ls  b u t a ls o  th a t  o f  th e  o th e r  c e l l s  
and th u s  c e l ls  hav ing  a p o t e n t ia l  fo r  m a lig n an t d i f f e r e n t ia t io n  w ould be r e ­
l ie v e d  o f  t h e i r  c o n tr o l e x e rte d  by TN F-alpha / 2 0 / .  One may n ot be a b le  to  
e x c lu d e  th e  above-m entioned d e tr im e n ta l e f f e c t  o f  IF N -a lp h a  on th e  chromo­
somes /2 1 ,  4 5 / .  L a s t ly ,  we should  touch upon a p r a c t ic e  which does n o t seem 
to  d ecrease  a t  a l l ,  nam ely th a t  many papers have been p u b lis h e d  re g a rd in g  
IF N -a lp h a  th e ra p y , in v o lv in g  s m a ll groups o f p a t ie n ts ,  having  v a r io u s  d ia g ­
n o s e s , using  d i f f e r e n t  doses fo r  tre a tm e n t g e t t in g  v a ry in g  r e s u l ts  le a d in g  
to  v a r io u s  co n c lu s io n s .
On a n a ly s is  o f  th e s e  p u b lic a t io n s  a q u e s tio n  a r is e s  as to  th e  c o s t /b e -  
n e f i t  r a t i o :  w hether i t  i s  p e rm is s ib le  to  spend huge amounts o f  money a t  
such f in a n c ia l ly  c r i t i c a l  tim es on in d ic a t io n s  having  no u n e q u iv o c a l 
s u p p o rt.
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In  summary: in  s p i t e  o f  th e  many decades, e x p e rim e n ta l work and o b ser­
v a t io n s  we a re  s t i l l  u n a b le  to  answer th e  fo l lo w in g  fo u r  b a s ic  q u e s tio n s  
c la im e d  fo r  by th e  o u t l in e  o f  in d ic a tio n s  f o r  th e ra p y :
1 . how much is  to  be g iven?
2 . when should  i t  be g iven?
3 . th e  ro u te  o f  a d m in is t ra t io n ;
4 .  th e  tim e  p e r io d  o f  tre a tm e n t.
( 1 )  In trav e n o u s  a d m in is t ra t io n  o f IF N -a lp h a  w i l l  r e s u l t  in  a 500 -600  
IU /m l peak le v e l  w ith in  1 5 -3 0  m in. I t s  h a l f  l i f e  i s  2 hours and th e  plasma 
IFN  t i t e r  w i l l  r e v e r t  to  th e  b a s a l le v e l  by th e  end o f  th e  4 th  h o u r.
On in tra m u s c u la r o r  subcutaneous a d m in is t ra t io n  peak le v e ls  w i l l  be 
re a c h e d  in  4 h , and f o r  th e  n e x t 8 -12  h a 100 -2 0 0  IU /m l c o n c e n tra t io n  w i l l  
be reco rd ed  /1 9 ,  4 0 / .  A d a i l y  dose o f 1 to  9 x 10^ IU /d o s e  o f  IF N -a lp h a ,  
g iv e n  in tra m u s c u la r ly , i s  f a i r l y  w e ll t o le r a t e d  in  r e la t io n  to  adverse  
e f f e c t s .
Severe t o x ic i t y  i s  encountered  w ith  in tra m u s c u la r  a d m in is t ra t io n  a t  a 
d a i l y  dose o f 10 to  18 x ID 6 IU /d o s e . I r r e v e r s ib le  sequelae  fo l lo w  th e  d a i ly  
a d m in is t ra t io n  o f a 20 to  30 x 10^ IU /d o s e . I r r e s p e c t iv e  o f th e  in d ic a t io n  a 
dose o f  1 x 10^ to  3 x 10^ IU /d a y  i s  g iven  u s u a l ly .  The dose o f recom binan t 
IF N -a lp h a  should be d e te rm in e d  a t  2 -  to  3 - f o ld  le v e ls .
( 2 )  V i r a l  and m a lig n a n t d iseases should  be managed d i f f e r e n t l y  re g a rd ­
in g  th e  i n i t i a t i o n  o f t r e a tm e n t .  In  case o f  v i r a l  in fe c t io n s  i t  should  s t a r t  
as e a r ly  as p o s s ib le . The r a t io n a le  behind t h i s  is  to  m in im ize  th e  chances  
o f  d ev e lo p in g  c o m p lic a tio n s  and a b o lis h  th e  p a in ,  e .g .  in  herpes z o s te r ,  as  
IF N  bound to  o p ia te  re c e p to rs  p revents  p a in  / 3 7 /  as w e ll  as g e n e r a l iz a t io n  
o f  th e  d isease p ro ce s s .
In  our o p in io n  th e  use o f IF N -a lp h a  in  m a lig n a n c ie s  i s  j u s t i f i e d  o n ly  
/ 1 7 /  in  c o n ju n c tio n  w ith  an in d u c tio n  th e ra p y  / 2 7 /  o r in  o rd e r to  keep th e  
d is e a s e  " s ta t io n a r y " ,  i . e .  in  rem iss io n , by a d m in is te r in g  i t  a lo n e  o r in  com­
b in a t io n  w ith  s te r o id s  / 7 ,  9 / .  I t s  use i s  n o t j u s t i f i a b l e  as p a r t  o f  a p o s t-  
r e la p s e  combined tre a tm e n t  / 1 0 / .
( 3 )  How should  IF N - t  be a d m in is te re d , c o n s id e rin g  i t s  s h o rt  h a l f  
l i f e ,  p o s s ib le  s id e  e f f e c t s  and the  c h a r a c te r is t ic s  o f th e  p re p a ra tio n s  c u r ­
r e n t l y  a v a ila b le  in  th e  m arket?  These a re  g iv e n  in  th e  form  o f s low  i n t r a ­
venous in fu s io n s  / 3 8 / .  A subcutaneous in fu s io n  ( l i k e  th e  in s u l in  pump) cou ld  
p re v e n t  th e  s id e - e f f e c ts  a f f e c t in g  the  c e n t r a l  nervous system /1 4 ,  3 2 / .  In  
c a s es  o f lo n g -te rm , re p e a te d  a d m in is tra t io n s , t h is  is  th e  most accep ted  
r o u te .  For s h o r t - te r m , h o p e fu lly  s in g le  use —  th e  in tra m u s c u la r ro u te  i s  
p r e fe r r e d .
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A few a tte m p ts  have been made to  g iv e  IF N - t  d i r e c t ly  in to  th e  le s io n .  
I t  would be r a th e r  d i f f i c u l t  to  comment on th ese  on the b a s is  o f  l i t e r a r y  
d a ta .  I t s  com bination  w ith  o th er drugs i s  s t i l l  debated. T h e re  a re  no 
a u th e n t ic  data  so f a r  re g a rd in g  the  p aram ete rs  determ in ing  th e  d o s e - r a t io  
and th e  p lace  o f IFN in  th e  com bination  (s y n e r g is t ic ,  a d ju v a n t ,  p o ten ­
t i a t i n g ,  e t c . ) .  I t  i s  w e ll  known th a t  IFN  s e n s it iz e s  c e l ls  to  th e  e f f e c t s  
o f  c y to s ta t ic  agents  co n co m in tan tly  b lo c k in g  th e  microsomal enzymes in  th e  
l i v e r  in  v i t r o  as w e ll  as in  anim al e x p e rim e n ts . T h is  f a c t  sho u ld  draw  our 
a t t e n t io n  to  p o s s ib le  unwanted o r expected  drug in te ra c t io n s  e .g .  P la c y ly l  
(A b b o tt  L a b o ra to r ie s  C h icago) g iven  to g e th e r  w ith  IFN re s u lte d  in  a r e ­
v e r s ib le  comatose s ta t e .  N eu ro to x ic  e f f e c t  o f  V in b la s t in  is  p o t e n t ia t e d  by 
IF N , R a d ia t io n  th e ra p y  + IFN cause s e r io u s  mucous membrane in f la m m a tio n . We 
a re  f a r  from s o lv in g  th ese  randomly b rought up questions and c a n n o t coming 
n ear to  answer them by lo g ic  o r e x p e r ie n c e . For the  fu tu r e ,  h ow e v e r, th e  
fo l lo w in g  p o in ts  should be ke p t in  mind:
V ery  few a n t i-c a n c e r  drugs — i f  IFN  cou ld  be regarded as an a n t i ­
tum our drug a t  a l l  — would y ie ld  f a s t ,  c le a r - c u t ,  w e ll-a n a ly s a b le  r e s u l ts  
upon t h e i r  te s t in g  o r in  th e  e a r ly  phase o f  tre a tm e n t. There i s  no doubt 
t h a t  many years  and decades have passed w h ile  tumour d ia g n o s tic s  em erged and 
d e v e lo p e d . I t  is  u n fo r tu n a te  to  accept o n ly  prompt r e s u l ts ,  and n o t pay 
a t t e n t io n  to  th e  lo n g -te rm , slow changes, t h e i r  o b serva tio n s  and r e g i s t ­
r a t io n .
I t  is  d eb a ta b le  w hether c y to to x ic i ty  s tu d ie s  o f b io lo g ic a l  su b s ta n c es
—  in  c u r r e n t ly  used systems — would y ie ld  r e l i a b le  data and r e s u l t s .  I t  
has been noted th a t  IFN  tre a tm e n t w ith in  g iv e n  c o n d itio n s  in v o lv in g  d ia g n o ­
s is  and s ta g e in g  (u n d er more or le s s  s ta n d a rd iz e d  c o n d itio n s ) p ro ve d  to  be 
e f f e c t i v e  in  one p a t ie n t  and in e f f e c t iv e  in  a n o th e r. T h is  o b s e rv a t io n  le a v e s  
th e  q u e s tio n  o f s e n s i t i v i t y  as w e ll as th e  s ig n if ic a n c e  o f re s e a rc h  o f  th e  
i n t r a c e l l u l a r  and membrane e f fe c ts  o f IFN  open. I t  should be s t r e s s e d ,  how­
e v e r ,  t h a t  a re s is ta n c e  d eve lo p ing  to  IFN  co u ld  be th e  r e s u lt  o f  p ro p a g a t io n  
o f  a n o th e r m a lig nan t c lo n e  and n ot th e  one fo r  which the  i n i t i a l  t re a tm e n t
—  th e  f i r s t  ty p e  o f IFN  was g iv e n .
L a s t but not le a s t ,  the  most im p o rta n t o b s tac le  is  t h a t  we la c k  
th e  means o f fo llo w in g  th e  IFN -in du ced  e v e n ts . In  s p ite  o f t h i s  " la c k  o f  
know ledge" the  fu tu r e  would be th e  com bin atio n  o f IF N -a lp h a  w ith  o th e r  c y to ­
k in e s .
( 4 )  How long  should  th e  tre a tm e n t la s t?  Our answer would be based  on 
c l i n i c a l  em p iric ism  in c o rp o ra tin g  s u b je c t iv e  r a th e r  than o b je c t iv e  e le m e n ts .
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The g o a l should be re a c h in g  a rem ission p h ase . As a r e s u lt  o f  IF N -a lp h a  
th e ra p y  in  m a lig n a n c ie s  c o m p le te  rem ission  (A )  does not r e s u lt  in  c u r e ,  th e  
t im e  o f  re la p se  i s  n o t  much prolonged (B ) th e  mean s u r v iv a l r a t e  does n o t  
in c r e a s e  and a t  th e  same tim e  the  im m ediate and l a t e  adverse e f f e c t s  o f  
th e r a p y  (C ) cannot be n e g le c te d . T h erap eu tic  use  o f  IF N -a lp h a  would le a d  to  
im m edia te  ( fo l lo w in g  th e  a d m in is tra t io n )  and l a t é  adverse re a c t io n s .  In  
la c k  o f  adequate in fo r m a t io n  one should n o t comment on whether th e s e  symp­
tom s a re  a t t r ib u ta b le  t o  th e  e f f e c t ,  s id e  e f f e c t  o r  t o x ic i t y  o f  th e  d ru g .  
However t h e i r  r e g i s t r a t i o n  i s  mandatory, so t h a t  a l l  those who em ploy i t  
w ou ld  know /2 4 / .
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CISPLATIN CONTAINING COMBINATION CHEMOTHERAPY OF 
ADVANCED GERM CELL LINE TESTICULAR TUMOURS
I .  BO DRO G I, M . B A K I,  J .  H O R T I, L .  G É C Z I, G . L IS Z K A , S .  O T T Ú , 
I .  H IN D Y , S . ECKHARDT, 3 .  SUGÁR
N a t io n a l I n s t i t u t e  o f O ncology, Budapest, Hungary
(R e ce iv e d : September 2 3 , 1994)
One hundred n ine ty pa tien ts  w ith  germ c e ll l in e  te s t ic u la r  tumours were trea ted  accord­
ing to  the modified Einhorn scheme. The response ra te  was 67.9%. The most favourable re su lts  
were found in the embryonal h is to lo g ic  type (RR = 76.9%) in  the b io lo g ica l markers (&-HCG and 
AFP) negative (RR = 97.4%) and in  the minimal pulmonary extent group (RR = 94.1%). The authors 
treated 112 patients w ith  inc lud ing  these VPB-resistant germ c e ll te s tic u la r  tumour and those 
w ith  recurrence a fte r th is  treatm ent. The pa tients ' mean age was 28.8 ( l im its  19 to  44) years. 
Patients were given Vepeside (100 mg/m in in fusion fo r  days 1 -5 ), A driab lastin  (40 mg/m in  in ­
fusion on day 1) and C is p la tin  (20 mg/m in  in fusion) fo r  day 1-5. The treatment resu lte d  in  CR 
w ith  18 pa tients (16.1%) and PR w ith  42 (37.5%) (RR = 53.6%). The best re su lts  were obtained 
w ith  the seminoma pa tien ts  who were marker-negative and had small-volume m etastasis. CR devel­
oped in  4 o f 7 seminoma pa tien ts  (57%) and in  7 o f 25 marker-negative in d iv id u a ls  (28%), and 
PR developed in  11 pa tie n ts  (44%) (RR = 72%). Out o f 12 pa tients w ith small volume m etastatis 
four (33%) showed CR and f iv e  revealed PR (41.7%), th e ir  RR turned out to  be 74.6%. The average 
remission period was 37 (range 4-70) months in  CR but merely 6.1 (range 2-38) months in  PR. I t  
can be stated th a t f a i r l y  good re su lts  can be achieved w ith  second-line VpAP treatm ent in  case 
o f resistance developed to  primary VPB therapy or subsequent relapse. The e ffica cy  o f combined 
chemotherapy o f Vepesed + Holoxan + /-  Adriab lastin  as th ird -cho ice  was studied in  advanced te s ­
t ic u la r  cancer patients re fra c to ry  to , or recurrent a fte r ,  f i r s t -  and second-line c y to s ta tic  
therapy. Between September 1981 and January 1988 49 evaluable patients were treated w ith  Vepe- 
s id  (VP-16213 — 100 mg/m2 days 1 -5 ), Holoxan (40 ml/kg days 1-5), hydration, u rin e -a lk y la ­
tio n  + Uromi texan + /-  A d ria b la s tin  (40 mg/m day 1). The s ing le  dose o f Uromitexan was 20% o f the 
d a ily  dose o f Holoxan, and the pa tients received i t  i . v .  ju s t p r io r  to  Holoxan adm in is tra tion  
(h 0 ), then 4 and 8 h la te r .  Two patients got in to  CR and 10 to  PR. The ra te  o f rem ission was 
24.5%. The most severe side e ffe c t was leukopenia. The e levation o f BUN and se. c re a tin in e  was 
tran s ie n t and m ild. In  those cases where Holoxan was not included in  the f i r s t -  o r second-line 
regimens, when conbined w ith  Vepesid and A driab lastin  as th ird -cho ice  therapy one could achieve
Abbreviations: CT = computer tomography, WBC = white blood c e l l ,  HCG - human chorion 
gonadotrophin, AFP = a lpha -fe top ro te in , RR = response or remission ra te , adv. = advanced, 
abd. = abdominal, pulm. = pulmonary, hep. = hepatic, cereb. = cerebra l, médiást. = m ed iastina l, 
tu . = tumour, supraclav. = supraclavicu lar, DDP = c is p la t in ,  Vp = Vp-16213, Vepesid, Etoposid. 
ACM = adriamycin, a d r ib la s tin , BLM = bleomycin
O ffp r in t requests should be sent to : I .  Bodrogi, Department of Uro-Oncology, National 
In s t itu te  o f Oncology, H-1525 Budapest, P.0. Box 22, Hungary
0236-5286/94/# 4.00 © Akadémiai Kiadó, Budapest
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fu r th e r  improvement. In  case o f  CR the prolongation o f l i f e  is  also noteworthy. The f i r s t - ,  
second- and th ird - lin e  therapy p lus salvage RLA and/or pulmonary metastasectomy achieved long­
term  su rv iva l only in  one quarte r o f the patients.
Keywords : Advanced germ c e l l  l in e , te s tic u la r  cancer, c isp la tin -co n ta in in g  chemo­
therapy
F i r s t  l i n e  c h e m o t h e r a p y  w i t h  v i n b l a s t i n e ,  
b l e o m y c i n ,  c i s p l a t i n  ( V B P )
T e s t ic u la r  can c e rs  do n o t belong to  th e  tum ours o f h ig h  in c id e n c e ,  
th e y  t o t a l  to  m ere ly  1 to  2% o f a l l  male m a lig n a n c ie s . T h e ir  g r e a t  s ig ­
n i f ic a n c e  is  a t t r ib u te d  to  th e  fa c t  th a t  in  th e  age group o f  15 to  35 y e a rs  
th e y  occupy th e  t h i r d  p la c e  in  the cancer m o r ta l i ty  s t a t i s t i c s ,  a f t e r  
le u k e m ia s  and lymphomas.
A pproxim ate ly  95% o f  th e  te s t ic u la r  tum ours a re  o f germ c e l l  ty p e , o f  
them  two th ir d s  b e in g  nonseminomatous. W h ile  in  S tage I  and I I  seminomas 
ra d io th e r a p y  is  v e ry  s u c c e s s fu l,  the  nonseminomatous tum ours show r e s i s t ­
a n c e , which e x p la in s  th e  e a r ly  choice o f chem otherapy in  t h is  f i e l d .  L i  / 1 0 /  
r e p o r te d  on n o tew o rth y  r e s u l t s  obta ined  by th e  com bin atio n  o f a c tio n o m y c in -  
D , m e th o tre x a te  and c h lo ra m b u c il.  A g re a t s te p  fo rw ard  was taken  by Samuels 
e t  a l .  /1 9 ,  2 0 / ,  whose p u b lic a t io n  on th e  co m b in a tio n  o f v in b la s t in e  (VBL) 
and b leom ycin f i r s t  a p p eared  in  1973. The n e x t advance was h a ll-m a rk e d  by 
th e  team  o f Higby and W a lla c e , who perform ed a phase I  s tu d y  w ith  c i s -  
d ia m in e -d ic h lo ro p la t in u m  (c is -D D P ) and found t h i s  drug e f f e c t iv e  in  g e rm in a l 
neoplasm s / 1 0 / ,  In  1 9 7 4 , E in ho rn  / 3 /  s ta r te d  in v e s t ig a t io n s  w ith  VBP (VBL, 
BLM and c is -D D P ), he p u b lis h e d  h is  e x c e lle n t  r e s u l ts  in  1977. T h is  i s  con­
s id e r e d  to  be th e  b e g in n in g  o f  the u p - to -d a te  combined c y to s ta t ic  tre a tm e n t  
o f  t e s t ic u la r  tum ours. A fte rw a rd s  numerous team s /1 3 ,  1 4 , IB , 2 0 /  e la b o ra te d  
e q u a l ly  o r s im i la r ly  a c t iv e  combined c y to s ta t ic  schemes (V A B -V I, PBVcr, ВЕР, 
VPBVe e t c . ) .  In  H ungary> th e  N a tio n a l I n s t i t u t e  o f  Oncology has made a v a i l ­
a b le  to  a l l  our t e s t i c u l a r  cancer p a t ie n ts  th e  p la t in u m -c o n ta in in g  combined 
c y t o s t a t ic  tre a tm e n t s in c e  1979. When we s ta r te d  our in v e s t ig a t io n s ,  th e  
r e s u l t s  o f VPB were th e  most fa v o u ra b le , in  o ur In s t i t u t e  we a p p ly  th e  mo­
d i f i e d  VPB as f i r s t - l i n e  th e ra p y . In  th e  l a s t  5 y ears  we have g iv e n  a more 
advantageous ВЕР (B le o m y c in , Etoposid  and C is p la t in )  schedule as a f i r s t -  
c h o ic e  tre a tm e n t f o r  advanced d isease . By th e  p re s e n t t im e , t h is  m a te r ia l  
has n o t been e v a lu a te d .
CHEMOTFERAPY OF ADVANCED TESTIC ULAR TUMOURS 2 7 7
P a t i e n t s  a n d  M e t h o d s
Between Oecenber 1979 and Duly 1986, 190 germ -cell-type nonseminomatous te s t ic u la r  
cancer pa tients were trea ted . The ir average age was 2B years ranging from 16 to 56 years. H is­
to logy was determined according to  the WHO recommendation o f 1981. Out o f the 190 pa tie n ts  78 
had embryonal carcinomas, 1 yo lk  sac tumour, 13 teratomas, 6 choriocarcinomas and 92 mixed-type 
tumours. For restaging and measurements o f the resu lts  physica l examination, haemogram, 12- 
channel screening p ro f i le ,  serum beta subunit HCG, a lpha -fe top ro te in , chest X-ray, abdominal 
ultrasound and/or CT-scan were used. Brain, bone and l iv e r  is o to p ic -  or CT-scan were performed 
when c l in ic a l ly  warranted. Of the 190 patients 43 were in  Stage I I /B ,  3 in  I I I /A  and 144 in  
I I I /B .  The modified Einhorn scheme (VPB) was applied:
The patients неге p re - and posthydrated w ith 500 ml o f 5% glucose, and c is p la t in  was 
administered in  500-1000 ml Rindex or physiological sa lin e . The courses of treatment were re ­
peated every 4 weeks. P a tien ts progressing despite therapy a f te r  the second cycle were taken 
o f f  the study and were given second-line (vepeside, a d ria b la s tin , c is p la tin ) treatm ent. The 
evaluation o f response and to x ic i t y  was performed according to  the as recommended by the WHO. 
Complete response (CR) means th a t the c l in ic a l symptoms, the ra d io lo g ica l, abdominal u l t r a ­
sound, CT, b ra in , l iv e r  and bone iso to p ic - or CT-scan les ions had completely regressed, and the 
increased le ve ls  o f radioimmunoassay, a lpha-fetoprotein and beta-HCG serum observed p r io r  to  
the s ta r t  o f treatment f u l ly  normalized. P a rtia l response (PR) was considered to be a 50% or 
more decrease in  the diameter o f measurable lesions. A 25% or greater increase in  the diameter 
o f measurable lesions was regarded as progression (Porg). Between PR and Prog there were pa­
t ie n ts  w ith  no response (NR).
Of th e  190 p a t ie n t s ,  70 (36 .8% ) showed CR and 39 (31 .1% ) showed PR. 
The t o t a l  response r a t e  (CR + PR, i . e .  RR) was 67 .9% . The c o r r e la t io n  be ­
tween h is to lo g y  and response  i s  shown in  T a b le  I .  Out o f 78 p a t ie n ts  w ith  
em bryonal carc inom a, CR was achieved in  32 (4 1 .0 % ).  PR was observed in  28 
p a t ie n ts  (3 8 .9 % ). The r e s p e c t iv e  f ig u re s  fo r  th e  6 NR and 12 Prog p a t ie n t s  
a re  7.7% and 15.4% . The y o lk  sac tumour group was n o t e v a lu a b le , due to  th e  
low number o f  cases. T h ir te e n  p a t ie n ts  belonged to  th e  teratom a h is t o lo g ic a l  
group , 1 o f them (7 .7 % ) ach ieved  CR: in  4 cases PR (3 0 .8 % ), in  3 cases  NR 
(2 3 .1 % ), and in  5 cases Prog (38 .5% ) was o b s e rv e d . In  th e  cho rio carc ino m a  
group o n ly  1 o f the  6 (1 6 .7 % ) p a t ie n ts  developed  CR. PR was seen in  2 cases  
(3 3 .3 % ). H a lf  o f  th e  choriocarc inom a p a t ie n ts  f a i l e d  to  respond to  th e  
th e ra p y , th e y  had a v e ry  h ig h  l i t e r  o f beta-HCG and were in  a f a r  advanced  
s ta g e . In  th e  group o f  m ixed typ e  tumours 35 p a t ie n t s  o f th e  t o t a l  92 (38% ) 
ach ieved  CR, 26 (2 8 .2 % ) had PR, in  15 (16 .3 % ) NR, and in  17 (18 .5 % ) Prog
v inb las tine  6 mg/m2 
c is p la tin  20 mg/m2 
bleomycin 30 mg
i . v .
infusion
i.m .
on days 1 and 2 
on days 1-5 
on days 2, 9 and 16
R e s u l t s
was seen.
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Table I
C orre la tion between h is to logy  and response
Histology CR PR NR PROG Total No.
Embryonal carcinoma 32 28 6 12 78
Yolk sac tumour 1 1
Teratoma 1 4 3 5 13
Choriocarcinoma 1 2 3 6
Mixed type 35 25 15 17 92
T o t a l 70 59 24 37 190
Table I I
C orre la tion  between b io lo g ica l markers and response
B io log ica l marker CR PR NR Prog Total No.
Elevated AFP 27 12 9 13 61
44% 20% 15% 21%
Elevated HCG 7 9 3 8 27
26% 33% 11% 30%
Elevated AFP+HCG 13 23 12 15 63
21% 36% 19% 24%
Normal AFP+HCG 23 15 1 39
59% 38% 2%
T o t a l 70 59 24 37 190
com paring th e d if f e r e n t g ro up s, we found RR (CR + PR)
th e  embryonal carc inom a g roup , 38.5% in  te ra to m a , 50% in  c h o rio c a rc in o m a  and 
65.4%  in  the  mixed ty p e  group. W ith  re s p e c t  to  rem iss io n , em bryonal c a r c i ­
noma proved to  be th e  most and tera tom a th e  le a s t ,  fa v o u ra b le .
The response a c c o rd in g  to  h is t o lo g ic a l  markers is  shown in  T a b le  I I .
The response in  fu n c tio n  o f th e  e x te n t  o f d isease was a ls o  s tu d ie d :  
th e  re s u lts  a re  shown on Tab le  I I I .
The most f re q u e n t  s id e  e f fe c ts  were nausea, vom iting  and le u k o p e n ia .  
G e n e r a lly ,  le u k o p e n ia  was th e  most s e v ere  s id e  e f f e c t .  WBC was b e lo w  1000 in  
7% o f  th e  c y c le s . G a s tr o in te s t in a l  t o x i c i t y  occurred  in  s e v ere , m o d era te  and 
m ild  form s. N e p h ro to x ic ty  appeared in  4% o f  c y c le s , w ith  an in c r e a s e  in  the  
l e v e l  o f b lood u rea  n it r o g e n  and s e ru m -c re a t in in e . Th is  phenomenon, how ever, 
was o f moderate d eg ree  and t r a n s ie n t ,  and cou ld  be t re a te d  by h y d ra t io n .
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Table I I I
C orrelation between extent o f disease and response
Histology CR PR NR PROG Total No.
Min. pulm. 30 2 2 _ 34
88% 5% 6% -
Adv. pulm. 17 15 6 8 46
37% 33% 13% 17% -
Abd.+supraclav.
and/or médiást 3
Min. pulm.+min. abd. 5 2 - 7
Min. pulm.+adv. abd. 3 8 1 6 18
17% 44% 6% 33% -
Adv. pulm.+adv. abd. 6 19 4 8 37
16% 51% 11% 22% -
Adv. abd. 8 11 11 13 43
18% 26% 26% 30%
Abd.+liver 1 1 2
T o t a l 70 59 24 37 190
F o llo w in g  t re a tm e n t , a f t e r  th e  2nd o r 3rd c y c le ,  in  58% o f th e  p a t ie n t s  con­
s id e r a b le  h a i r  lo s s  was seen. As a s id e  e f f e c t  o f  b leom ycin h y p e rk e ra to s is  
and desquam ation were observed o n ly  in  5 cases: pulmonary f ib r o s is  was n o t  
seen . As re g a rd s  VBL, in t e s t in a l  p a r a ly t ic  symptoms occurred  in  6.8% (1 3  pa­
t i e n t s ) ,  w hich responded w e l l  to  parasym pathom im etic ag en ts .
D iscu ss io n
The VPB c y to s ta t ic  com bination  is  one o f  th e  most w idespread  a p p ro ­
aches in  th e  tre a tm e n t o f  germ c e l l  t e s t ic u la r  tum ours. The ad van tag es  o f  
t h i s  th e ra p y  a re  h ig h  CR and RR, excep t fo r  th e  f a r  advanced and b u lk y  t u ­
m ours. No expen sive  in s tru m e n ts  ( e .g .  continuous d e l iv e r y  drug pump) a re  ne­
c e s s a ry , th e  perform ance o f  th e  tre a tm e n t is  s im p le , th e  m ye lo su p p res s iv e  
e f f e c t s  a re  c o n s id e ra b le . In  1977, E inhorn  e t  a l .  / 3 /  were th e  f i r s t  to  
p u b lis h  r e s u l ts  o b ta in e d  w ith  th e  VPB c om bin a tio n . Out o f 47 e v a lu a b le  
c a s e s , 35 CR (74% ) and 12 PR (26% ) were ach ieved  (RR = 100%). The r a t e  o f  CR 
a f t e r  th e  s u r g ic a l rem oval o f  th e  re s id u a l tumour was 81%, in  th e  case  o f  
m in im al abdom inal and pulmonary d ise a s e  88%, in  advanced pulm onary and a b -
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dominai disease 67% and 56%. In 1980 Williams and Einhorn et a l.  /30 / re­
ported on a larger group of patients. They applied the VPB treatment to 78 
pa tien ts  and achieved CR in  53 (63%) and PR in  23 (30%) patients. A fte r the 
su rg ica l removal of the residual tumour CR was seen in  82% while the RR was 
98%. I t  was confirmed again that the patients w ith advanced pulmonary and 
abdominal métastasés were worse responders than those having minimal méta­
stasés. CR in the pulmonary metastatic group was 50%, in  the abdominal group 
i t  was 43%.
Bosl /1 / reported tha t in 20 out of 28 patients with metastatic tes­
t ic u la r  cancer chemotherapy was the only treatment that resulted in  CR 
(71%). In 3 patients the residual tumours, fo llow ing surgery, proved to be 
necrosis or f ib ro s is , therefore, these were also regarded as CR, thus 82% 
of the cases showed CR.
The SW0G (Southwest Oncology Group) /6 / described VPB therapeutic re­
s u lts  of 135 patien ts, in  82 patients CR (61%), in  32 PR patients (24%) was 
seen (RR = 85%). In 1984 the SW0G reported from another study including 110 
patien ts with the fo llo w in g  results: CR 60 patients (53%), PR 42 patients 
(37%), RR 90%.
We had an unselected group of 190 patients o f whom 41 had minimal pul­
monary or pulmonary + abdominal métastasés. This is  lik e ly  to explain the 
lower RR of the whole group. The most favourable resu lts approaching the 
best results described in  the lite ra tu re  were seen in  the minimal pulmonary 
and marker-negative cases. Four-fifths of our patients were in  a fa r  ad­
vanced stage, which understandably influenced the to ta l parameters of the 
e n tire  group.
The VPB combination is  a very e ffe c tive  treatment fo r disseminated 
te s tic u la r cancer, but due to i ts  high to x ic ity ,  the patients should be con­
t ro lle d  most c a re fu lly .
S e c o n d -l in e  chemotherapy o f  VBP r e s is ta n t  
m e ta s ta t ic  t e s t i c u la r  cancer
As a ru le , 30-40% of advanced tumour patients require — even accord­
ing to the best s ta t is t ic a l  results — continual therapy fo r progression was 
noted at f i r s t  admission or fo r a relapse developed la te r on. With stage I/B  
or stage I I  patients undergone retroperitoneal lymphadenectomy (RLA) com­
bined with adjuvant C isp la tin  therapy one has to  reckon with a relapse in
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Table IV
Second-line therapy o f VPB-resistant pa tients with Vepesld 
contiined with C isp la tin
Authors Conbinations Pts.No.
CR
No.
PR
No.
RR
W
W illiam s et a l.  /3 0 / Vp+DQP+/-BLM 8 5 3 100
VP+DDP+ADM+/-BLM 20 9 9 90
Vogelzang, Kennedy /2 4 / Vp+DDP+A0M+BLM 7 4 4 100
Vp+DDP+AOM 11 1 10 100
Bosl /1 / Vp+DDP 19 0 0 0
Lederman et a l.  /9 / Vp+DDP 12 5 4 75
Haisworth et a l.  /6 / Vp+D0P+/-ADM+/-BLM 45 19 12 70
Hansen e t a l.  /7 / Vp+DDP+BLM 26 6 11 65
T o t a l 158 48 53 64
10 to  15% o f the  c a s e s . T h is  o b s e rv a tio n  speaks in  fav o u r o f  c o n t in u in g  
t h e i r  th e ra p y . W itho u t f u r th e r  e f f e c t iv e  tre a tm e n t these p a t ie n ts  s u r v iv e  not 
lo n g e r th a n  fo r  severe  months / 6 ,  1 5 / .  The p ro m is ing  th e ra p e u t ic  p o t e n t ia ls  
o f c u r re n t  chem otherapy and demands o f c l i n i c a l  p r a c t ic e  a l l  n e c e s s ita te  th e  
developm ent and in t r o d u c t io n  o f new, more p o te n t c y to s ta t ic s .
P o s it iv e  c l i n i c a l  achievem ents were noted  in  th e  th e ra p y  o f  th e  above 
tum ours w ith  Vepeside (V P -16213  o r E to p o s id e ). Even th e  VPB r e s is t a n t  non­
seminoma ty p e  germ c e l l  t e s t ic u la r  cancers were responsive  to  V e p e s id e  in  
phase I  and I I  s tu d ie s  / 5 ,  1 2 , 3 0 / .
In  an im al exp e rim e n ts  Schabel e t  a l .  / 2 1 /  dem onstrated in  1979 syn­
e r g ic  th e ra p e u t ic  e f f e c t s  and enhanced a d d it iv e  t o x ic i t y  o f V e p e s id e  and 
C is p la t in .
A lm ost s im u lta n e o u s ly , s tu d ie s  were s ta r te d  w ith  Vepeside in  combined  
s e c o n d -lin e  th e ra p y  o f  VPB r e s is ta n t  p a t ie n ts  (T a b le  I V ) .
C l in ic a l  r e s u lts  have confirm ed th e  s y n e rg ic  e f f e c t  o f  V e p es id e  and 
C is p la t in ;  t o x ic i t y  has a ls o  proved to  be a d d i t iv e .
P a t ie n ts  and Methods
Altogether 112 VPB re s is ta n t pa tients or those developing relapse a fte r  th is  therapy 
were treated by us during the period from October 1983 to  January 1987. The p a tie n ts ' mean age 
was 28.8 years (range: 19 to  A4 years). D is tr ib u tion  o f pa tien ts  according to tumour type : no
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detectab le  tumour in sp ite  o f h igh  AFP value (1 p a tie n t) ; inoperable I I /B ,  I I I /A  (19 pa tients) 
and I I I / B  stage tumours (89 p a tie n ts ) ; seminoma (4 p a tie n ts ) ; embryonal carcinoma (47 pa­
t ie n t s ) ;  teratoma (6 p a tie n ts ) ; choriocarcinoma (4 p a tie n ts ) ; endodermal sinus tumour (1 pa­
t ie n t ) ;  germinal tumour o f mixed type (47 pa tients). In  30 pa tients  elevated AFP le v e l and in  
20 o thers high beta-HCG le v e l was found. In 37 cases, however, both markers were e levated, but 
in  25 cases, they were found w ith in  the physiological range. As a f i r s t - l in e  therapy a l l  the 
112 pa tien ts  received VPB, two o f  them were given radiotherapy, too before chemotherapy. At our 
Department the second-line chemotherapy was conducted according to the fo llow ing  schedule:
Vepeside 100 mg/m2 in  in fus ion days 1-5
Adriablastin  40 mg/m2 in  in fus ion  day 1
C isp la tin  20 mg/m2 in  in fus ion  days 1-5
I f  laboratory parameters perm itted, th is  therapy wes repeated at 4-week in te rv a ls . Pa­
t ie n ts  receiving minimum 2 cyc les  were evaluated from the therapeutic po in t o f view. Evaluation 
was made according to the in te rn a tio n a l standards.
R e su lts
The Vepeside + A d r ia b la s t in  + C is p la tin u m  (VpAP) com bin atio n  as a 
s e c o n d - lin e  th e ra p y  was a p p lie d  to  112 0VB r e s is t a n t  germ c e l l  t e s t i c u l a r  
c a n c e r p a t ie n ts .
CR was ach ieved  in  IB  p a t ie n ts  (1 6 .1 % ) and PR in  42 (3 7 .5 % ). In  th e  
e v a lu a t io n  o f t e s t i c u l a r  can cers  we reg ard  o n ly  CR and PR as a th e r a p e u t ic  
e f f e c t ,  t h e i r  summarized v a lu e  expresses th e  re m is s io n  r a te  (RR) t h a t  in  our 
c a s e  was 53.6% . T w e n ty - f iv e  p a t ie n ts  d id  n o t respond to  th e  th e ra p y  (2 2 .3 % )  
and w ith  27 p a t ie n ts  (2 4 .1 % ) p rogression  was o bserved .
T hera p e u tic  r e s u l t s  w ere fu r th e r  a n a ly s e d  in  fu n c tio n  o f  h is t o lo g ic a l  
d ia g n o s is ,  b io lo g ic a l  m a rk e rs  and tumour e x te n s io n . The r e la t io n s h ip  between  
h is t o lo g ic a l  s t r u c tu r e  and rem ission  is  dem on stra ted  in  T ab le  V.
Tab le V makes i t  c l e a r  th a t  p a t ie n ts  o c c u rre d  in  h ig h e r number o n ly  in  
th e  groups o f em bryonal carc inom a and mixed tum our. T h e re fo re , we c o u ld  o n ly  
c a lc u la te  rem iss io n  r a t e  o n ly  fo r  these g ro u p s , th e y  were 48.9% and 63 .8% , 
r e s p e c t iv e ly .  I f  th e  seminoma groups and th e  a n a p la s t ic  seminoma groups a re  
com pared to  e a c h -o th e r , i t  i s  conspicous t h a t  in  4 /7  p a t ie n ts  (57% ) CR cou ld  
b e  ach ieved  w ith  s e c o n d - l in e  th e ra p y , to o . In  th e  non-seminoma g ro u p s , how­
e v e r ,  in  cases o f  s t a t i s t i c a l l y  e v a lu a b le  em bryonal carc inom a, o n ly  6 /4 7  
p a t ie n t s  (12 .76% ) showed CR. W ith  p a t ie n ts  h av in g  mixed typ e  tum our CR was 
o bserved  in  7 /4 7  cases (1 4 .8 9 % ).
Because o f d i f f e r e n t  fe a tu re s  th e r a p e u t ic  r e s u lts  r e la t in g  to  th e  
o th e r  groups cannot be sum m arized, and th e  low  case number would n o t p e rm it  
t o  draw an e s ta b lis h e d  c o n c lu s io n . However, CR ach ieved  in  th e  c h o r io c a r ­
cinom a group w ith  v e ry  p o o r prognosis in  n o te w o rth y , ind eed . The c o r r e la t io n  
betw een  b i lo g ic a l  m arkers  and rem ission was a ls o  s tu d ie d  (T a b le  V I ) .
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Table V
C orre lation between h isto logy and remission
H istology CR PR NR PROG Patients
No.
RR
(\>
Seminoma 2 — 1 — 3
Anaplastic seminoma 2 - 1 1 4
Eitbryonal carcinoma 6 17 12 12 47 48.90
Yolk sac tumour - - 1 - 1
Teratoma - 2 3 1 6
Choriocarcinoma 1 - - 3 4
Mixed tumours 7 23 7 10 47 63.8
T o t a l 18 42 25 27 112
Table VI
C orre la tion  between b io log ica l markers and remission
B io lo g ica l
markers
CR PR NR PROG Patients
No.
RR
(4)
Elevated AFP 5 11 7 7 30 53.30
Elevated HCG 2 9 4 5 20 55.00
Elevated AFP+HCG 4 11 9 13 37 40.50
Normal AFP+HCG 7 11 5 2 25 72.00
T o t a l 18 42 25 27 112
A n a ly s is  o f th e s e  d a ta  makes i t  u n e q u iv o c a l th a t  th e  b est th e r a p e u t ic  
e ffe c t iv e n e s s  was observed w ith  those h av in g  norm al b io lo g ic a l m arkers  
(AFP +-HCG), in  t h e i r  group th e  RR was 72%. Of c o u rs e , h ig h e s t CR v a lu e  was 
found a ls o  in  t h is  g roup , t h is  meant 7 /2 5  cases (28% ). RR va lu e s  in  th e  
groups o f h ig h  AFP and h ig h  HCG le v e ls  were a lm o st id e n t ic a l ;  53.3% and 55%, 
r e s p e c t iv e ly .  In  th e  group o f h igh  AFP le v e l  CR cou ld  be dem onstrated  in  
5 /3 0  p a t ie n ts  (1 6 .6 6 % ) in  c o n tra s t to  th e  h ig h  HCG group where CR was id e n ­
t i f i e d  o n ly  in  2 /2 0  p a t ie n ts  (10% ). The lo w e s t rem iss io n  r a te  (4 0 .5 % ) was 
a s s o c ia te d  by th e  e le v a t io n  o f both m arkers , b u t o n ly  4 /3 7  p a t ie n ts  (1 0 .8 % )  
re v e a le d  CR. The r e la t io n s h ip  between d is e a s e  ex te n s io n  and re m is s io n  i s  
re p re s e n te d  in  T ab le  V I I .
In  s p ite  o f  th e  c o n s id e rab le  number o f  p a t ie n t s ,  o n ly  fo u r o f  th e  11 
groups in c lu d e d  more than  10 p a t ie n ts .  For th e s e  fo u r groups th e  RR v a lu e s
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Table V II
Relationship between disease extension and remission
Disease extension CR PR NR PROG PatientsNo.
RR
(4)
High AFP only 1 — — - 1
Min. pulm. 3 1 - - 4
Adv. pulm. 5 6 4 2 15 60.00
Min. abd. - 1 3 - 4
Adv. abd. 3 7 2 6 18 55.60
Min. pulm.+min. abd. - 3 - - 3
Min. pulm.+adv. abd. 2 4 2 3 11 54.50
Adv. pulm.+min. abd. 1 1 - 1 3
Adv. pulm.+adv. abd. 3 18 13 12 46 45.70
Adv. abd. and/or Med. Sup. 1 1 - 2 4
Adv. abd.+adv. pulm. + 
+ other organ
1 - 1 1 3
T o t a l 18 42 25 27 112
Table V I I I
Side e ffec ts  o f VpAP treatment
Side e ffe c ts
WHO grades (%) Total
W1 2 3 4
Vomiting, nausea 52.00 38.30 3.50 - 93.70
Leukopenia - 50.90 15.20 8.00 74.10
Nephrotoxicity 3.60 - - - 3.60
H epatotoxicity - 2.70 - - 2.70
C ard io tox ic ity 2.70 - - - 2.70
Alopecia - 25.00 — - 100.00
w ere  a ls o  in d ic a te d . Of them 46 p a t ie n ts  b e lo n g in g  to  the  group o f  M. pu lm . +
M. abd. invo lvem ent had reached a s t a t i s t i c a l l y  é v a lu ab le  l e v e l .  In  t h is  
h ig h ly  advanced s ta g e  w ith  marked e x te n s io n , CR was observed w ith  as few  as 
3 p a t ie n ts  (6 .5 % ).  When exam ining th e  few  p a t ie n ts  w ith  s l ig h t  tum our e x te n ­
s io n  o r  m e ta s ta s is  to g e th e r  w ith  those o f  p o s it iv e  AFP f in d in g  (h ig h  AFP;
S . p u lm ., S. a b d ., S. pu lm . + s l ig h t  a b d .)  we had 12 p a t ie n ts  o f  whom 4 (33% ) 
showed CR and 5 (4 1 .6 % ) showed PR (RR = 7 4 .6 % ). Out o f 100 p a t ie n t s  w ith  
la r g e  volume m étastasés  14 (14%) re v e a le d  CR and 37 showed PR (3 7 % ). T h e ir
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summarized RR was 52%. The x t e s t  y ie ld e d  P <  0 .1 0  fo r  CR and P <  0 .0 5  fo r  
RR (m e re ly  a v a lu e  o f 0 .2  was m issing  to  reach  th e  le v e l  o f  s ig n i f ic a n c e ) .
The average d u ra tio n  o f was 37 (4 -7 0 )  months fo r  com plete re m is s io n  
and i t  was 6 .1  (2 -3 8 )  months fo r  p a r t i a l  re m is s io n .
D e s c r ip tio n  o f th e  th e ra p e u tic  e f fe c t iv e n e s s  o f t h is  a g g re s s iv e  
th e ra p y  has to  be complemented w ith  i t s  p o t e n t ia l  s id e  e f fe c ts  (T a b le  V I I I ) .
The most common s id e  e f fe c ts  w ere: nausea, v o m itin g , a lo p e c ia  and 
le u k o p e n ia : Leukopenia under 1000 was th e  most dangerous consequence, i t  o c ­
c u rre d  in  8% o f th e  c y c le s . N ad ir was between days 9 and 11 c a lc u la te d ,  from  
th e  f i r s t  day o f t re a tm e n t. N e p h ro to x ic ity  m an ife s te d  in  tem porary  r i s e  o f  
BUN a n d /o r se . c r e a t in in e  le v e ls  th a t  co u ld  be n orm alized  w ith  h y d ra t io n  in  
a few  days. Only 3 p a t ie n ts  had s ign s  o f c a r d io t o x ic i t y ; they  com pla ined  o f  
t r a n s ie n t  ES. H e p a to to x ic ity  was shown as e le v a te d  l i v e r  enzyme a n d /o r  s e . 
b i l i r u b i n  v a lu e s , s ig n s  which n o rm a lized  under c o n s e rv a tiv e  th e ra p y  ( d i e t  
and Reducdyn) in  a few weeks.
D iscu ss io n
F avo urab le  e xp erien ce  has been o b ta in e d  w ith  th e  s e c o n d -lin e  VpAP com­
b in e d  th e ra p y  o f 112 VPB r e s is ta n t  t e s t ic u la r  cancer p a t ie n ts .  In  c o n tr a s t  
to  th e  67.89% rem iss io n  r a t e  o f th e  f i r s t  l i n e  VPB therap y  th e  re m is s io n  
r a t e  o f  s e c o n d -lin e  VpAP th e ra p y  was 53.7% , which is  a f a i r l y  good r e s u l t s .  
D u rin g  p rim a ry  VPB th e ra p y  th e  CR v a lu e  was 36 .8% . A f te r  s e c o n d -lin e  th e ra p y  
i t  decreases  d r a s t ic a l ly  to  16.1% . The low er RR va lu e s  and p a r t i c u l a r l y  th e  
CR ones d u rin g  s e c o n d -lin e  th e ra p y  were n a t u r a l ly  due to  th e  f a c t  t h a t  c e l l s  
s e n s i t iv e  to  chemotherapy had d ie d  d u rin g  p rim a ry  tre a tm e n t and th u s  th e  
s e c o n d -lin e  th e ra p y  ac ted  a g a in s t a much more r e s is ta n t  tumour c e l l  l i n e .  
S ig n s  su g g e s tiv e  o f more fa v o u ra b le  p ro g n o s is , l i k e  the  n e g a tiv e  m arkers  o r  
s m a ll s iz e  m étastasés a re  v a l id  in  second l i n e  th e ra p y , to o . In  many i n ­
s t i t u t e s ,  th e  s e c o n d -lin e  th e ra p y  u s u a lly  c o n s is ts  o f Vepeside + C is p la t in .  
Lederman / 8 / ,  however, th in k  th a t  com bination  o f  Vepeside + A d r ib la s t in  + 
C is p la t in  to  be more p o te n t . We chose t h is  l a t t e r  com bination because in  th e  
e a r ly  80s we succeeded in  a c h ie v in g  CR in  some VPB r e s is ta n t  p a t ie n ts  u s in g  
th e  combined a d m in is tra t io n  o f A d r ib la s t in  and C is p la t in  a lth o u g h  n o t so 
many tim e s  as w ith  th e  com bination  c o n ta in in g  a d d it io n a l V ep esid e . O th e rs ' 
in v e s t ig a t io n s  m entioned in  th e  fo reg o in g  and our own o b s e rv a tio n s  c o n firm  
th e  f a c t  th a t  VpAP is  a p o te n t com bination  th a t  may open new v is ta s  in  
s e c o n d -lin e  th e ra p y .
2 8 6 I .  BODROGI e t  a l .
T h ir d - l in e  chem otherapy o f  r e s is ta n t  advanced t e s t ic u la r  can ce r
In  the  m in o r ity  o f  advanced g e rm -c e ll t e s t i c u la r  cancers th e  above  
f i r s t - c h o ic e  tre a tm e n ts  a re  not e f f e c t i v e ,  th e  d ise a s e  fu r th e r  p ro g res s e s  
and alm ost 15% o f CR p a t ie n ts  develop re c u rre n c e s . Relapse may o ccu r a f t e r  
s t a g e - I I  a d ju v a n t t re a tm e n ts  as w e l l .  In  most p a r ts  o f th e  w o rld , t re a tm e n t  
reg im es  c o n ta in in g  V ep es id e  (V P -16213) and c is p la t in  / 1 ,  6 , 9 , 1 6 , 3 0 /  a re  
w id e ly  used as a s e c o n d -c h o ice . L it e r a tu r e  d a ta  and our own o b s e rv a tio n  sug­
g e s t th a t  in  24 to  43% o f th e  p a t ie n ts  com plete  rem ission  (CR) can be 
a c h ie v e d . The r e s u l ts  o f  h igh-dose chem otherapy (u s u a lly  V epeside a n d /o r  
C is p la t in ) ,  w ith  o r  w ith o u t bone marrow t r a n s p la n ta t io n s ,  show t h a t  d e s p ite  
th e  h ig h e r r a t e  o f  com ple te  rem iss io ns  th e  s u r v iv a l  tim e  is  n o t p ro lo n g ­
ed / 3 / .
P a t ie n ts  r e f r a c t o r y  to  th e  p re v io u s ly  d e s c rib e d  th e ra p ie s  o r r e la p s in g  
a f t e r  second-cho ice  tre a tm e n t need f u r th e r  t re a tm e n t .  On the  o th e r hand , we 
can read  about th e  le s s  fa v o u ra b le  r e s u lts  o f  th ir d -c h o ic e  th e ra p ie s .
I t  seems t h a t  in  those cases where H oloxan ( Ifo s fa m id e )  i s  n o t in ­
c lu d e d  in  the  p r im a ry  o r  secondary tre a tm e n t i t  may be an im p o rta n t compo­
n e n t o f th e  th ir d - c h o ic e  th e ra p y . Ifo s fa m id e  was proved to  be an e f f e c t i v e  
drug  by Weissbach /2 7 ,  2 8 /  and Schmoll / 2 2 ,  2 3 / .
In  c o n s id e ra t io n  o f  a l l  above we t r i e d  to  a p p ly  th e  com bination  o f  V e -  
p e s id  (V P -16213 , E to p o s id e ) + A d r ia b la s t in  + H oloxan as th ird -c h o ic e  tre a tm e n t.
P a tie n ts  and M ethods
Between Septentier 1981 and January 1988, 49 pa tien ts  re s is ta n t to primary and secondary 
treatment or those w ith  recu rren t disease were studied.
The median age o f pa tie n ts  was 28.66 years, ranging from 17 to 66. In  2 pa tien ts  re tro ­
peritonea l lymphadenectomy (RLA), in  9 patients salvage RLA or debulking surgery were perform­
ed, 2 patients w ith  seminoma received radiotherapy as f i r s t - l in e  treatment.
Two pa tients  had seminoma, 2 anaplastic seminoma, 18 had eitbryonal carcinoma, 7 had 
teratoma and 20 suffered from mixed type germ c e l l  te s t ic u la r  tumour. Three pa tien ts  had in ­
operable bulky abdominal i . e .  stage I I /B  disease, 2 pa tien ts  were in  c lin ic a l stage I I I / A  and 
44 in  stage I I I /B .
A ll pa tients received 4 to  6 cycles o f VBP as f i r s t - l in e  therapy, th e re a fte r 2 to  6 
cycles o f VAP (Vepesid, A d ria b la s tin , C isp la tin ) as second-line treatment. Then the fo llow ing  
th ird - l in e  scheme was used:
Vepesid 100 mg/m2 in  in fus ion  on days 1-5
Holoxan 40 mg/kg in  in fus ion  on days 1-5
a lk y la tio n , hyd ra tion , ürömitexan
A driab las tin  40 mg/m2 in  in fus ion  on day 1
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Holoxan was administered in  1000 ml Rindex, prae- and posthydration were applied in  the form 
o f 1500 to  2000 ml glucose o r physiologic sa line. A fte r Holoxan adm inistration the u rin e  pH 
was kept about 7, e ith e r by i . v .  sodium bicarbonate so lu tion  o r peros a lka line  mineral water. 
The dose o f Uromitexan correspond to 20% of the d a ily  dose o f Holoxan and was app lied i . v .  
p r io r  to , and 4 and 8 a f te r ,  Holoxan adm inistration. M icroscopic study o f the urinary sediment 
was performed p r io r  to  therapy, on days 3 and 6, in  case o f microscopic haematuria every 2nd 
or 3rd day u n t i l  e lim ina tion  o f the sediment.
R esu lts
The response was e v a lu a te d  a f t e r  the  second tre a tm e n t c y c le .
Two p a t ie n ts  showed com plete re m is s io n , 10 p a t ie n ts  p a r t ia l  re m is s io n ,  
th e  r a te  o f rem is s io n  was 24.5% . Moderate re m is s io n  (MR) was seen in  7 p a ­
t i e n t s ,  s ta b le  d is e a s e  (SD) in  9 , p ro g res s io n  (PROG) d e s p ite  th e ra p y  in  
21 p a t ie n ts .
In  th e  2 p a t ie n ts  w ith  seminoma and 2 w ith  a n a p la s t ic  seminoma no 
c o n s id e ra b le  e f fe c ts  w ere observed, 1 p a t ie n t  had s ta b le  d isease and in  th e  
o th e r  cases p ro g res s io n  to o k  p la c e . Due to  th e  e a r l i e r  i r r a d ia t io n ,  to  d i ­
m in ish  t o x i c i t y ,  25% dose re d u c tio n  was n e c e s s a ry . CR was seen in  2 o f  18 
p a t ie n ts  w ith  em bryonal carcinom a, 5 PR, 4 MR, 3 SD and 4 PRDG w ere ob­
s e rv e d . The most fa v o u ra b le  response, 38.9% was RR, was seen a ls o  in  t h i s  
group. Of th e  7 p a t ie n ts  w ith  teratom a 1 PR, 2 MR, 2 SD and 2 PROG w ere r e ­
corded . A lthough th e  m a jo r i ty  o f the  p a t ie n ts  w ith  mixed typ e  tumours showed 
p ro g res s io n  (60 % ), 4 PR, 2 MR and 2 SD were a ls o  o bserved .
A lthough th e  number o f  p a t ie n ts  in  th e  in d iv id u a l  groups is  s m a ll to  
d e te c t  s t a t i s t i c a l l y  s ig n i f ic a n t  d if fe r e n c e ,  i t  seems e v id e n t th a t  CR was 
ach ieved  in  a s u p ra c la v ic u la r  and /o r m e d ia s t in a l and in  an abdom inal + p u l ­
monary case. In  th e  f i r s t  4 groups o f Tab le  X I ,  th e r e  were 32 p a t ie n ts ,  none 
o f  whom had c e re b ra l o r  h e p a tic  m e ta s ta s is . In  t h i s  group 2 and 6 p a t ie n t s  
showed CR and PR, r e s p e c t iv e ly .  Seventeen p a t ie n ts  belonged to  th e  o th e r  
4 groups, a l l  o f  them had c e r e b r a l ,  h e p a tic  o r b o th  typ es  o f m é ta s ta s é s , and 
o n ly  4 p a t ie n ts  developed  PR.
S ix te e n  p a t ie n ts  had e le v a te d  AFP serum l e v e l ,  in  1 case CR, in  2 
cases PR, in  4 cases MR, in  4 cases SD and in  5 cases p ro gress io n  was ob­
s e rv e d . In  11 p a t ie n ts  h ig h  serum ß-HCG was fo u n d , in  1 o f them CR, in  2 PR, 
in  1 MR and in  6 p a t ie n ts  p ro gress io n  was d e te c te d . E le v a te d  AFP + ß-HCG was 
reco rd ed  in  16 p a t ie n t s ,  th e  response in  t h is  group was as fo llo w s :  4 PR, 
2 MR, 2 SD and 8 PROG. The AFP + 6-HCG le v e l  was n o t e le v a te d  in  6 p a t ie n t s ,  
2 o f them had PR, 2 SD and 2 PROG.
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Table IX
Therapeutic re s u lts
Number o f 
patients CR PR MR SD PROG
49 2 10 7 9 21
4.1% 20.4% 14.3% 18.4% 42.9%
Table X
C orre la tion between h is to logy and remission
H istology CR PR MR SD PROG
Seminoma 1 12
Anaplastic seminoma 2
Embryonal carcinoma 2 5 4 3 4
Teratoma 1 1 2 2
Mixed type tumour 4 2 2 12
T o t a l 2 10 7 9 21
Table XI
C orre la tion  between disease extension and remission
S ite  o f metastasis CR PR MR SD PROG
Supracav. and/or médiást. 1 1
Adv. púim. 3 2 4
Adv. abd. 2
Pulm. and abd. 1 2 3 7 6
Adv. pulm. and cereb. 2 1
Adv. abd. and cereb. 1 1 1 3
Adv. abd., hep., pulm. 1 1 1 4
Adv. abd., hep., pulm., cereb. 1 1
T o t a l 2 10 7 9 21
The most common s id e  e f fe c ts  were a lo p e c ia ,  le u k o p e n ia , nausea and 
v o m it in g . A lo p ec ia  o cc u rre d  a lre a d y  a f t e r  th e  f i r s t  tre a tm e n t c y c le ,  between  
days 20 and 30 a f t e r  th e  i n i t i a t i o n  o f  th e r a p y . The most severe  s id e  e f f e c t  
was le u k o p e n ia , th e  WBC count was below 1 0 0 0 /p l i t e r  in  17% o f  th e  c y c le s .
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Table X II
C orre la tion  between b io log ica l markers and remission
B io log ica l marker CR PR MR SD PROG
Elevated AFP 1 2 4 4 5
Elevated beta-HCG 1 2 1 1 6
Elevated AFP+beta-HCG 4 2 2 8
Normal AFP+beta-HCG 2 2 2
T o t a l 2 10 7 9 21
Table X I I I  
Toxic ity
Tox ic ity
Total
(%)
WHO grade
1 2 3 4
% o f patients
Nausea and vom iting 40.0 4.0 34.50 1.5
Leukopenia 52.0 21.0 5.0 9.0 17.0
Thrombopenia 14.50 1.50 5.0 8.0
Alopecia 100.0 17.0 83.0
Haematuria 6.0 6.0
Elevated se. c rea tin ine 3.80 3.80
Elevated BUN 1.5 1.50
The n a d ir  was o n ly  day 8 (ra n g e  days 3 to  1 5 ) .  Thrombopenia g e n e r a l ly  as ­
s o c ia te d  w ith  le u k o p e n ia , o ccurred  in  14%. Nausea and v o m itin g  m a in ly  mo­
d e r a te ,  which tended  to  be eased by a n t ie m e t ic s , were r e g is te r e d  in  40% o f  
th e  c y c le s . M icro h a e m a tu ria  developed in  6% o f  th e  c y c le s , b u t macrohaema- 
t u r i a  o ccurred  in  none o f  th e  cases. M ild  and t r a n s ie n t  e le v a t io n  o f  BUN and 
s e . c r e a t in in e  was observed in  1.5%, and 3.8% , r e s p e c t iv e ly ,  b u t th e s e  
le v e ls  f e l l  to  th e  norm al w ith in  a few days by con tinuous h y d ra t io n .
D iscuss io n
The prognosis  o f  p a t ie n ts  re f r a c to r y  to  o r re c u r r e n t  a f t e r  p r im a ry  o r  
secondary tre a tm e n t is  v e ry  poor, in  th e  m a jo r ity  o f cases f u r t h e r  chemo-
2 9 0 I .  BODROGI e t  a l .
th e ra p y  i s  n ecessary . Each in s t i t u t io n  i s  d ete rm ined  to  a p p ly  some i n d i ­
v id u a l  s o lu tio n s , b u t in  such in c u ra b le  cases one can h a rd ly  a c h ie v e  any 
r e s u l t .  T h is  i s  why th e  l i t e r a t u r e  lacks  p u b lic a t io n  on t h is  to p ic .
In  the  p a r t  two y e a rs  E inhorn  e t  a l .  / 3 /  p u b lis h e d  papers  on th e  V IP  
(V P -1 6 , Ifo s fa m id e , C is p la t in )  tre a tm e n t used as th ir d -c h o ic e  approach . They 
fou nd  a RR in  37% o u t o f  which 21% were CR. Between September 1981 and 
Jan u a ry  1988 th e  same a u th o rs  t re a te d  49 e v a lu a b le  p a t ie n ts  w ith  th e  com bi­
n a t io n  o f Vepesid + H o loxan  + / -  A d r ia b la s t in .  ( F i f t e e n  p a t ie n ts  d id  n o t r e ­
c e iv e  A d r ia b la s t in  in  th e  course  o f the t h i r d  c h o ic e  th e r a p y .)  They re p o r te d  
t w ic e  on t h e i r  r e s u l ts  / 5 ,  3 0 / .  Most o f th e  p a t ie n ts  s u f fe r e d  from  f a r - a d ­
vanced  d is e a s e . Out o f  them  17 had c e re b ra l a n d /o r  h e p a tic  m e ta s ta s is  in  ad­
d i t i o n  to  th e  pulm onary and abdom inal ones. The a u th o rs  f a i l e d  to  rep ro du ce  
th e  r e s u l ts  o b ta in e d  by E in h o rn  e t  a l . ,  o n ly  24.8%  RR was re p o r te d . O nly 2 
p a t ie n t s  achieved CR, w hich  la s te d  fo r  36 months in  one o f  th e  p a t ie n t  and 
17 months in  th e . In  th e  fo rm e r case, p r io r  to  tre a tm e n t e x te n s iv e  abdom inal 
o r  pulm onary, in  th e  l a t t e r  o n ly  s u p ra c la v ic u la r  and m e d ia s t in a l m étas tasés  
w ere  d e te c te d . Ten p a t ie n t s  showed PR, w ith  a median d u ra t io n  o f 4 .5  months 
( ra n g e  from 1 to  6 . 5 ) .  The b e s t rem ission  r a t e  was observed in  th e  em bryonal 
c a rc in o m a . The p oo re s t r e s u l t s  were seen in  p a t ie n ts  w ith  th e  e le v a te d  ß-HCG 
and AFP + ß-HCG groups w ith  66% and 50% o f p ro g re s s io n , r e s p e c t iv e ly .  S in ce  
1 9 8 9 , we have a p p lie d  V IP  (V ep es id  + Ifo s fa m id e  + C is p la t in )  com bin atio n  as 
t h i r d - l i n e  th e ra p y , b u t i t  has not been e v a lu a te d  by th e  p re s e n t t im e .
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PDR V o l.  43 c o n s is ts  o f f iv e  e x te n s iv e  survey a r t ic le s  o f pharma­
c e u t ic a l  re s e a rc h . The f iv e  to p ic s  o f th e  c u r re n t  issue a re :
1 . C h o le s te r o l- lo w e r in g  drugs and t h e i r  e f fe c tiv e n e s s  in  th e  p r a c t ic e
2 . A n tih y p e rte n s iv e  drugs in  the  p as t 50 y ears
3 . N a tu ra l polym aines and t h e i r  r o le  in  th e  immune system
4 . Summary o f b io lo g ia l ly  a c tiv e  q u in a zo lo n e s
5 . In te r fe r o n s  — gene re g u la tio n  and express io n
A l l  f i v e  to p ic s  o f th e  c u rre n t issue a re  rev iew ed  by w id e ly -re c o g n iz e d  ex­
p e r ts .  The is s u e  is  h ig h ly  recommended fo r  p r a c t i t io n e r s  d e a lin g  w ith  h y p e r­
te n s io n  in  th e  everyday h e a lth -c a re  ( to p ic  2 ) ,  and c l in ic ia n s  s p e c ia l iz e d  in  
m e ta b o lic  d is o rd e rs  (h y p e r lip id a e m ia , to p ic  1 ) .  The o th er th re e  to p ic s  a re  
u s e fu l fo r  s p e c ia l is ts  and research ers  w ork ing  in  the  f i e l d  o f e x p e r im e n ta l 
immunology ( to p ic s  3 and 5 ) and to p ic s  4 .  e x te n s iv e  co u s is ts  and re v ie w  o f  
quinazo lon es  used in  human th erap y .
Is s u e  4 3 , 1994 c o n s is ts  o f 336 pages in c lu d in g  index fo r  v o l .  43 . 
P r ic e  SF 2 9 8 .-
SUMMARIES AND COMMENTS
T op ic  1 . Drugs f o r  tre a tm e n t o f p a t ie n ts  w ith  h ig h  c h o le s te ro l le v e ls  and 
o th e r  d y s lip id a e m ia s .  Bays, H. E. and D u jovene , C. (32  pages in c lu d in g  101 
re fe re n c e s  and 13 ta b le s )
Summary: Recommendations fo r  a r th e r o s c le r o t ic  coronary a r te r y  d is e a s e  
(ASCADl th e ra p y  should begin w ith  e v a lu a tio n  and trea tm en t o f th e  u nd er­
ly in g  c o n d it io n s  th a t  may c o n tr ib u te  to  h y p e r lip id a e m ia , use o f p o s s ib le  
a l te r n a t iv e s  to  drugs th a t  may worsen d y s lip a e m ia , encouragement f o r  a 
h e a lth y  l i f e  s ty le  d ie t  and p h y s ic a l e x e rc is e . I f  dys lipaem ia  p e r s is t s ,  th e  
most c o s t -e f f e c t iv e  approach towards recommending the  most a p p ro p r ia te  l i ­
p id -a c t in g  drug is  to  reserved  fo r  tre a tm e n t o f  p a t ie n ts  w ith , o r a t  h ig h  
r is k  f o r ,  ASCAD whose expected b e n e fit  o u tw e ig h ts  the p o te n t ia l  r is k s  and 
excess ive  c o s ts .
Comments: The a u th o r has succeeded in  keep in g  in  balance between th e  
growing amount o f in fo rm a tio n  to  c i t e  and th e  amount o f im portan t message to  
d e l iv e r .  H is  c o n c lu s io n s  are a c c ep tab le . He does not over-em phasize any o f  
the  drugs and s tu d ie s . A l l  c l in ic ia n s  should  read and keep in  mind h is  
message.
T op ic  2 . I n  sea rch  o f  id e a l a n t ih y p e r te n s iv e  d ru g s : P rogress in  f i v e  de­
cades. L ie n ,  E . J . ,  Gao, H. and L ie n , L . L . (4 4  pages, in c lu d in g  6 t a b le s  
and 139 re fe re n c e s )
Summary and comments: The author re v ie w s  a l l  groups o f a n t ih y p e r te n ­
s iv e  drugs used in  th e  p ast 50 years . The re v ie w  serves as a s h o rt c a ta lo g u e  
groups o f d ru gs , l i s t i n g  the  s tru c tu re  a c t i v i t y  re la t io n s h ip ,  b iopharm a­
c e u t ic s  and p h a rm a c o k in e tic s , pharmacology and in d ic a t io n ,  dosage, ad verse
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re a c t io n s  and in te r a c t io n s  w ith  o th er d ru gs . The work is  im p ress ive  and im­
p o r ta n t  in  th e  everyday p r a c t ic e .  T h is  re v ie w  may serve  a lso  s tu d en ts  s tu d y ­
in g  a n t ih y p e r te n s iv e  tre a tm e n t and c l in ic ia n s  who a re  not f a m i l ia r  w ith  new 
f a m i l ie s  o f a n t ih y p e r te n s iv e  drugs.
T o p ic  3 . The n a tu r a l po lym a ines and th e  immune system . S e i le r ,  N. and A ta -  
n as s o v , C . L . (5 6  pages, in c lu d in g  254 re fe re n c e s  and В f ig u re s )
Summary: N a tu ra l po lyam ines, such as p u tre s c in e , sperm id ine and s p e r­
m ine a re  in  may ways in v o lv e d  in  host d efense  mechanisms. They p a r t i c ip a t e  
in  m acrom olecular syntheses , in  the  s t r u c t u r a l  o rg a n iz a tio n  o f numerous c e l l  
com ponents, and th e y  m odulate and re g u la te  enzyme a c t iv i t é s .  The d i f f i c u l t y  
o f  p in p o in t  polyam ine fu n c tio n s  is  due to  t h e i r  low im portance w ith in  c e l l u ­
l a r  m ach inery . A l l  known fu n c tio n s  o f po lyam ines are  review ed in  an e x te n ­
s iv e  manner. T h is  re v ie w  recommended fo r  re s e a rc h e rs  working in  f i e l d  o f  
c e l l u l a r  immunology and b io lo g y .
T o p ic  4 . B io lo g ic a l ly  a c t iv e  q u in a z o lo n e s . S in h a , S. and S r iv a s ta v a ,  M.
(9 6  pages, in c lu d in g  374 re fe re n c e s  and 12 a d d it io n a l pages as addendum)
Summary and comments: Th is  e x te n s iv e  re v ie w  l i s t s  216 q u in a z o lo n e s ,  
p re s e n tin g  t h e i r  chem ica l s tru c tu re s  and known b io lo g ic a l  a c t i v i t é s .  The new 
q u in a zo lo n e s  o f  th e  l a s t  13 years a re  d e a lth  w ith .  (The la s te s t  re v ie w  one 
th e  same to p ic  was p ub lish ed  by Johne S. in  1981 in  PDR.) The la r g e  body o f  
d a ta  proves th e  im portance and e ffe c t iv e n e s s  o f  quinazolones from  a n t i h e l -  
m in t ic  th e ra p y  to  hypoglycaem ic a c t i v i t y .  T h is  a r t i c le  is  suggested  fo r  
s p e c ia l is ts  fo r  q u inazo lon e  re search .
T o p ic  5 . P ro d u c tio n  and a c t io n  o f  in te r fe r o n s :  New in s ig h ts  in to  m o le c u la r  
mechanisms o f  gene r e g u la t io n  and e x p re s s io n . Hayes, M. P. and Zoon, К .  C.
(3 2  pages, in c lu d in g  211 re fe re n c e s )
Summary and comments: New in fo rm a tio n  about in te r fe ro n  ( IF N )  r e g u la ­
t io n  and IF N -c o d in g  genes opened a new in s ig h ts  in to  in t r a c e l lu la r  s i g n a l l ­
in g .  The IFN  system has provided  a model system  fo r  the study o f  c y to k in e s  
and th e  r e g u la t io n  o f gene express io n . U nders tand ing  o f the s t r in g e n t  con­
t r o l s  g overn ing  the p ro d u ctio n  and a c tio n  o f cy to k in es  makes us a b le  to  
u t i l i z e  th ese  agents in  th e  c l in ic  e f f e c t i v e l y .  T h is  a r t i c le  is  u s e fu l  f o r  
re s e a rc h e rs  engaged in  th e  m o lecu lar b io lo g y  and fo r  im m unologists in  b a s ic  
re s e a rc h . A t l a s t  i t  p re s e n ts  an updated summary fo r  c l in ic a l  im m un o lo g is ts  
about th e  gene re g u la t io n  and b as ic  p r in c ip le s  o f in te r fe r o n  b io lo g y .
Z . TULASSAY, M .D .
A c ta  M e d ic a  H u n g a r ic a ,  V o l .  5 0 / 3 — 4 ,  p p . 2 9 5 — 2 9 6  ( 1 9 9 4 )
FAREWELL TO ACTA FEOICA HUNGARICA
THE READER HOLDS THE LAST ISSUE OF THIS PERIODICAL IN H IS  HANDS, A 
VERY SAD ANNOUNCEMENT BY THE EDITO R-IN -CHIEF. OUR ACTA MEDICA HAS COME TO AN 
END WITH ITS VOLUME 50.
ACTA MEDICA, LIKE OTHER PERIODICALS WRITTEN IN FOREIGN LANGUAGES, WAS 
FOUNDED BY THE HUNGARIAN ACADEMY OF SCIENCES SOON AFTER WORLD WAR I I ,  WHEN 
OUR DEVASTATED COUNTRY WAS SLOWLY RECOVERING. IT  STARTED AT A HISTORICAL 
MOMENT WHEN THE DOWNROLLING IRON CURTAIN THREATENED OUR SCIENTIFIC  SCHOOLS 
FROM BEING COMPLETELY ISOLATED FROM ABROAD. OUR JOURNAL WAS AIMED AT AL­
LOWING THE FREE FLOW ORINFORMATION IN SPITE OFAlSTRCNG COUNTERPRESSURE .THUS, 
A WINDOW OF VITAL IMPORTANCE WAS OPENED TOWARDS THE WORLD OF INTERNATIONAL 
SCIENCE.
ALL HUNGARIAN PHYSICIANS WERE AWARE OF THIS FACT, AND SO WERE THE 
EDITORS OF THIS JOURNAL. IN  THE FOLLOWING YEARS BOTH THE AUTHORS AND THE 
EDITORS MADE EFFORTS TO PUBLISH THE BEST RESULTS OF THE HUNGARIAN MEDICAL 
RESEARCH IN ACTA MEDICA. AS A RESULT CRITICALLY REVIEWED, WELL-EIDÏED AND 
WELL-PRESENTED PUBLICATIONS WRITTEN IN ENGLISH AND OTHER LANGUAGES OF 'WIDE 
DISSEMINATION APPEARED IN  IT .
OUR EFFORTS SOON BROUGHT ABOUT AN INTERNATIONAL ACKNOWLEDGEMENT OF 
ACTA MEDICA.
OF COURSE, OUR JOURNAL ENCOUNTERED DIFFICULTIES FROM THE VERY BE­
GINNING. PUBLICATION OF PAPERS IN  FOUR LANGUAGES CAUSED PROBLEMS IN  EDITING  
AND DISTRIBUTION; DUE TO DIFFICULTIES IN OBTAINING PAPER AND PRINTING  
F A C IL IT IE S , THE PUBLICATION OF THE ISSUES WERE OFTEN DELAYED, AND THE 
DISTRIBUTOR ALSO ENCOUNTERED DIFFICULTIES IN  DELIVERING THEM ON TIM E.
THE SITUATION CHANGED IN  THE EARLY ' 8 0 ' S ,  WHEN HUNGARIAN SCIENTISTS  
WERE ALLOWED TO PUBLISH IN  TRADITIONAL INTERNATIONAL JOURNALS, CONSEQUENT­
LY, WE RECEIVED GOOD-QUALITY MANUSCRIPTS IN  AN EVER DECEASING NUMBER. THE 
DECLINING STANDARDS AND THE IRREGULAR APPEARANCE OF THE JOURNAL LED TO 
DELETION FROM CURRENT CONTENTS LIFE SCIENCES AND A CONSEQUENT LOSS OF
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IMPACT FACTOR. UNDER THE CHANGED CIRCUMSTANCES HUNGARIAN SCIENTISTS PREFER 
TO PUBLISH IN WELL-KNOWN TRADITIONAL PERIODICALS WITH HIGH IMPACT FACTORS.
AS EDITOR-IN -CHIEF I  KNOW WELL THAT THE EXISTENCE OF ACTA MEDICA WAS 
NOT WITHOUT SERVICE TO SCIENCE. IT  HELPED TO MAKE FOREIGN REAOERS FAMILIAR 
WITH THE WORK OF HUNGARIAN SCIENTISTS IN  AN ERA WHEN THERE WAS NO OTHER WAY 
OPEN FOR THEM. THUS, IT  CONTRIBUTED TO THE SURVIVAL AND FLOURISHING OF 
HUNGARIAN MEDICINE: THIS SHOULD BE KEPT IN  MIND WHEN DRAWING THE FINAL 
BALANCE.
WE EXPRESS OUR GRATITUDE TO THE HUNGARIAN ACADEMY OF SCIENCES FOR 
FOUNDING AND FUNDING OF OUR DOURNAL AND FOR MAKING FOREIGN-LANGUAGE PUBLICA­
TION POSSIBLE IN  A DIFFICULT HISTORICAL PERIOD.
E. STARK M.D.  
E d i to r - in - C h ie f
MAGYAR
TUDOMÁNYOS AKADÉMIA 
KÖNYVTARA
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